 
Official Title:   
A PHASE III, OPEN -LABEL, MULTICENTER,  RANDOMIZED 
STUDY EVALUATING THE EFFICACY  AND SAFETY OF 
ATEZOLIZUMAB (MPDL3280A, ANTI -PD-L1 ANTIBODY) IN 
COMBINATION WITH CARBOPLATIN +PACLITAXEL OR 
ATEZOLIZUMAB IN  COMBINATION WITH C ARBOPLATIN+ NAB-
PACLITAXEL VERSUS  CARBOPLATIN+ NAB-PACLITAXEL IN  
CHEMOTHERAPY -NAIVE PATIENTS WITH STAGE IV SQUAMOUS 
NON -SMALL CELL LUNG CANCER  
Study ID: [REMOVED]  
Document Date : Protocol  Version 7: 24-October -2018 
 
 
 
PROTOCOL AMENDMENT APPROVA L
CONFIDENTIA L
This clinical study is being sponsored globally by F. Hoffmann -La [COMPANY_002] Ltd of Basel, 
Switzerland. However, it may be implemented in individual countries by [CONTACT_26702]’s local affiliates, 
including Genentech, Inc. in the [LOCATION_002].  The information contained in this document, 
especially any unpublished data, is the property of F. Hoffmann -La [COMPANY_002] Ltd (or under its control) 
and therefore is provided to you in confidence as an investigator, potential investigator, or 
consultant, for review by [CONTACT_10825], your staff, and an applicable Ethics Committee or Institutional 
Review Board.  It is understood that this information will not be disclosed to others without written 
authorization from [COMPANY_002] except to the extent necessary to ob tain informed consent from persons 
to whom the drug may be administered.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
Protocol GO29437 , Version 7PROTOCOL
TITLE: A PHA SE III, OPEN -LABEL, MULTICENTER, 
RANDOMIZED ST UDY EVA LUATING THE E FFICA CY 
ANDSAFETY OF A TEZOLIZUM AB(MPDL3280A , 
ANTIPD-L1 A NTIBODY) IN COMBINA TION WITH
CARBOPLA TINPACLITA XEL OR ATEZOLIZUMA B IN 
COMBINA TION WITH 
CARBOPLA TINNAB-PACLITA XEL VERSUS 
CARBOPLA TINNAB-PACLITA XEL IN 
CHEMOTHERA PY-NAIVEPATIENTS WITH STA GEIV 
SQUA MOUS NON SMA LL CELL LUNG CA NCER
PROTOCOL NUMBER: GO29437
VERSION NUMBER: [ADDRESS_121698] NUMBER: 2014 -003208 -59
IND NUMBER: [ADDRESS_121699]: Atezolizumab (MPDL3280A, RO5541267)
MEDICA L MONITOR: , M.D.
SPONSOR: F. Hoffmann -La [COMPANY_002] Ltd
DATE FINA L: 26 November 2014
DATES A MENDED: Version 2:  29 March 2015
Version 3:  [ADDRESS_121700] 2015
Version 4:  11 November 2015
Version 5:  15 June 2016
Version 6:  1 March 2017
Version 7:  See electronic date stamp below.
24-Oct-2018 09:32:14
Title
Approver's Name
[CONTACT_26862] (UTC)

Atezolizumab —F. Hoffmann -La [COMPANY_002] Ltd
2/Protocol GO29437 , Version 7PROTOCOL A MENDMENT, VERSION 7:
RATIONA LE
Protocol GO29 [ADDRESS_121701] a change in the definition for the end of 
study .  Changes to the protocol, along with a rationale for each change, are summarized 
below:
The end of study definition has been corrected.  This correction ensures that the 
study continues until last patient, last visit or until the Sponsor terminates the study 
(Section 3.2).
The inclusion criterion that addresses female contraception has been modified to 
specify when women must refrain from donating eggs (Section 4.1.1).
Instructions about patient withdrawal from the [COMPANY_002] Clinical Repository after site 
closure have been modified to indicate that the investigator must inform the Sponsor 
of patient withdrawal by [CONTACT_109790]_rcr -[EMAIL_1377] (Section 4.5.1 1.6).
Language has been revised to account for the fact that some sites may not allow 
follow -up on partner pregnancies (Section [IP_ADDRESS]).
Language has been updated to indicate that therapeutic or elective abortions are 
not considered adverse events unless performed becau se of an underlying maternal 
or embryofetal toxicity.  In such cases, the underlying toxicity should be reported as 
a serious adverse event.  Language has also been added to clarify that all abortions 
are to be reported on the paper Clinical Trial Pregnanc y Reporting Form
(Section [IP_ADDRESS]).
Language has been added for consistency with [COMPANY_002]'s current data retention 
policy and to accommodate more stringent local requirements (if applicable)
(Section 7.6) .
Additional minor changes have been made to improve clarity and consistency.  
Substantive new information appears in italics.  This amendment represents cumulative 
changes to the original protocol.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
3/Protocol GO29437 , Version 7TABLE OF CON TENTS
PROTOCOL AMENDMENT A CCEPTANCE FORM .......................................... [ADDRESS_121702]-Line Treatment for Advanced Non Small 
Cell Lung Cancer with an EGFR Mutation or ALK 
Rearrangement ...................................................................... [ADDRESS_121703] -Line NSCLC .................. 34
1.1.4 nab-Paclitaxel Carboplatin for First -Line 
NSCLC .................................................................................. 37
1.1.5 Erlotinib Maintenance Therapy for Squamous 
NSCLC .................................................................................. 38
1.2 Background on Atezolizumab (MPDL3280A) ........................ 39
1.2.1 Summary of Nonclinical Studies ............................................ 39
1.3 Clinical Experience with Atezolizumab .................................. 40
1.3.1 Ongoing Clinical Studies ........................................................ 40
1.3.2 Clinical Safety ........................................................................ 40
[IP_ADDRESS] Single -Agent Clinical Safety in Patients with 
NSCLC in Study PCD4 989g .................................................. 40
[IP_ADDRESS] Single -Agent Clinical Safety in Patients with 
NSCLC in Study GO28753 (POPLAR) .................................. 42
[IP_ADDRESS] Single -Agent Clinical Safety in Patients with 
NSCLC in the Study GO28915 (OAK) ................................... 43
[IP_ADDRESS] Clinical Safety in Combination with B evacizumab 
or Platinum -Based Doublet Chemotherapy ........................... 44
1.3.3 Clinical Activity ....................................................................... 46
[IP_ADDRESS] Single -Agent Clinical Activity in Patients with 
NSCLC in Study PCD4989g .................................................. 46
[IP_ADDRESS] Single -Agent Clinical Activity in Patients with 
NSCLC in Study GO28753 (POPLAR) .................................. 47
[IP_ADDRESS] Single -Agent Clinical Activity in Patients with 
NSCLC in Study GO28915 (OAK) ......................................... 49
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
4/Protocol GO29437 , Version [IP_ADDRESS] Clinical Efficacy in Combination with 
Platinum -Based Doublet Chemotherapy in 
Patients with NSCLC ............................................................. 50
1.3.4 Clinical Pharmacokinetics and Immunogenicity ..................... 50
1.3.5 Rationale for Atezolizumab Dosage ...................................... 50
1.4 Study Rationale and Benefit -Risk Assessment ...................... 51
1.4.1 Rationale for Testing Atezolizumab in 
Combination with Carboplatin/Paclitaxel or 
Carboplatin/nab -Paclitaxel ..................................................... 52
2. OBJECTIVES .............................................................................................. 54
2.1 Efficacy Objectives ................................................................ 54
2.1.1 Co-Primary Efficacy Objectives ............................................. 54
2.1.2 Secondary Efficacy Objectives .............................................. 54
2.2 Safety Objectives ................................................................... 55
2.3 Pharmacokinetic Objectives .................................................. 55
2.4 Exploratory Objectives ........................................................... 56
3. STUDY DESIGN ......................................................................................... 56
3.1 Description of the Study ......................................................... 56
3.1.1 Independent Data Monitoring Committee .............................. 59
3.2 End of Study .......................................................................... 60
3.3 Rationale for Study Design .................................................... 60
3.3.1 Rationale for Testing Atezolizumab in Patients 
with PD -L1Unselected NSCLC ............................................ 60
3.3.2 Rationale for Control Arm ...................................................... 61
3.3.3 Rationale for Open -Label Study ............................................ 62
3.3.4 Rationale for Progression -Free Survival and 
Overall Survival as Co -Primary Endpoints ............................. 62
3.3.5 Rationale for Allowing Patients to Continue 
Atezolizumab Treatment until Loss of 
Clinical Benefit ....................................................................... 63
3.3.6 Rationale for Patient -Reported Outcome 
Assessments ......................................................................... 63
3.3.7 Rationale for Collection of Archival and/or Fresh 
Tumor Specimens and Evaluation of PD- L1 and 
T-Effector Gene Signature ..................................................... 64
3.3.8 Rationale for Blood Sampling for Biomarkers ........................ 65
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
5/Protocol GO29437 , Version 73.3.9 Rationale for the Collection of Mandatory Tumor 
Specimens at Radiographic Progression ............................... 65
3.4 Outcome Measures ............................................................... 66
3.4.1 Efficacy Outcome Measures .................................................. 66
[IP_ADDRESS] Co-Primary Efficacy Outcome Measures ............................... 66
[IP_ADDRESS] Secondary Efficacy Outcome Measures ................................ 66
3.4.2 Safety Outcome Measures .................................................... 66
3.4.3 Pharmacokinetic Outcome Measures .................................... 67
3.4.4 Exploratory Outcome Measures ............................................ 67
4. MATERIALS AND MET HODS .................................................................... 67
4.1 Patients.................................................................................. 67
4.1.1 Inclusion Criteria .................................................................... 67
4.1.2 Exclusion Criteria ................................................................... 70
[IP_ADDRESS] Cancer -Specific Exclusions ................................................... 70
[IP_ADDRESS] General Medical Exclusions .................................................. 71
[IP_ADDRESS] Exclusion Criteria Related to Medications ............................. 73
[IP_ADDRESS] Exclu sions Related to Chemotherapy .................................... 73
4.2 Method of Treatment Assignment and Blinding ..................... 74
4.3 Study Treatment .................................................................... 74
4.3.1 Formulation, Packaging, and Handling .................................. 74
[IP_ADDRESS] Atezolizumab (MPDL3280A) ................................................. 74
[IP_ADDRESS] Carboplatin, Paclitaxel, and nab -Paclitaxel ............................ 74
[IP_ADDRESS] Erlotinib .................................................................................. 75
4.3.2 Dosage, Administration, and Compliance .............................. 75
[IP_ADDRESS] Atezolizumab ......................................................................... 77
[IP_ADDRESS] Paclitaxel, nab -Paclitaxel, and Carboplatin ............................ 79
[IP_ADDRESS] Erlotinib .................................................................................. 81
4.3.3 Additional Required Medication ............................................. 81
[IP_ADDRESS] Prophylactic Measures for Carboplatin .................................. 81
[IP_ADDRESS] Premedication for Paclitaxel .................................................. [ADDRESS_121704]- Study Access to Atezolizumab ...................................... 82
4.4 Concomitant Therapy ............................................................ 82
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
6/Protocol GO29437 , Version 74.4.1 Permitted Therapy ................................................................ .82
4.4.2 Cautionary Th erapy for Atezolizumab- Treated 
Patients.................................................................................. 83
4.4.3 Prohibited Therapy ................................................................ 84
4.5 Study Assessments ............................................................... 84
4.5.1 Informed Consent Forms and Screening Log ........................ 85
4.5.2 Medical History and Demographic Data ................................ 85
4.5.3 Physical Examinations ........................................................... 85
4.5.4 Vital Signs .............................................................................. 86
4.5.5 Tumor and Response Evaluations ......................................... 86
4.5.6 Laboratory Assessments and Biomarker 
Samples ................................................................................. 88
4.5.7 Tumor Tissue Samples .......................................................... 90
[IP_ADDRESS] Archival and Freshly Collected Tumor Tissue 
Samples for Screening .......................................................... 90
[IP_ADDRESS] Tumor Samples at the Time of Radiographic 
Progression ........................................................................... 91
[IP_ADDRESS] Tumor Samples at Other Timepoints ..................................... 91
[IP_ADDRESS] Use and Storage of Remaining Samples from 
Study -Related Procedures ..................................................... 92
4.5.8 Anti-Therapeutic Antibody Testing ......................................... 92
4.5.9 Electrocardiograms ................................................................ 92
4.5.10 Patient -Reported Outcomes .................................................. 92
4.5.11 Samples for [COMPANY_002] Clinical Repository .................................. 94
[IP_ADDRESS] Overview of the [COMPANY_002] Clinical Repositor y............................ 94
[IP_ADDRESS] Approval by [CONTACT_33427] .................................................................. 95
[IP_ADDRESS] Sample Collection .................................................................. 95
[IP_ADDRESS] Confidentiality ........................................................................ 96
[IP_ADDRESS] Consent to Participate in the [COMPANY_002] Clinical 
Repository ............................................................................. 96
[IP_ADDRESS] Withdrawal from the [COMPANY_002] Clinical Repository ..................... 97
[IP_ADDRESS] Monitoring and Oversight ....................................................... 97
4.5.12 Timing of Assessments .......................................................... 97
[IP_ADDRESS] Screening and Baseline Assessments .................................. 97
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
7/Protocol GO29437 , Version [IP_ADDRESS] Assessments during Treatment ............................................. 98
[IP_ADDRESS] Assessments at Study Drug Discontinuation Visit ................. 99
[IP_ADDRESS] Follow -Up Assessments ........................................................ 99
[IP_ADDRESS] Assessments at Unplanned Visits ....................................... 100
4.6 Patient, Treatment, Study, and 
SiteDiscontinuation ............................................................. 101
4.6.1 Patient Discontinuation ........................................................ 101
4.6.2 Study Treatment Discontinuation ......................................... 101
4.6.3 Study and Site Discontinuation ............................................ 103
5. ASSESSMENT OF SAF ETY..................................................................... 104
5.1 Safety Plan .......................................................................... 104
5.1.1 Risks Associated with Atezolizumab ................................... 105
5.1.2 Risks Associa ted with Carboplatin ....................................... 105
5.1.3 Risks Associated with Paclitaxel .......................................... 105
5.1.4 Risks Associated with nab -Paclitaxel .................................. 105
5.1.5 Risks Associated with Erlotinib ............................................ 106
5.1.6 General Plan to Manage Safety Concerns .......................... 106
[IP_ADDRESS] Monitoring ............................................................................ 106
5.1.7 Dose Modification ................................................................ 107
[IP_ADDRESS] General Notes Regarding Dose Modification ....................... 107
[IP_ADDRESS] Atezolizumab Dose Modification .......................................... 107
5.1.8 Management of Atezolizumab -Specific Adverse 
Events.................................................................................. 108
5.1.9 Carboplatin and Paclitaxel Dose Modification and 
Management of Specific Adverse Events ............................ 109
[IP_ADDRESS] Hematologic Toxicity ........................................................... 109
[IP_ADDRESS] Gastrointestinal Toxicity ....................................................... 111
[IP_ADDRESS] Hepatic Toxicity (Paclitaxel Only) ........................................ 111
[IP_ADDRESS] Cardiovascular Toxicity (Paclitaxel Only) ............................. 112
[IP_ADDRESS] Neurologic Toxicity (Paclitaxel Only) ................................... 113
[IP_ADDRESS] Allergic Reaction/Hypersensitivity (Pac litaxel 
Only) .................................................................................... 113
[IP_ADDRESS] Other Toxicities .................................................................... 113
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
8/Protocol GO29437 , Version 75.1.10 Carboplatin and nab-Paclitaxel Dose Modification 
and Management of Specific Adverse Events ..................... 114
[IP_ADDRESS] Hematologic Toxicity ........................................................... 114
[IP_ADDRESS] Gastrointestinal Toxicity ....................................................... 115
[IP_ADDRESS] Neurological Toxicity ........................................................... 116
[IP_ADDRESS] Hepatic Toxicity (nab- Paclitaxel Only) ................................ .117
[IP_ADDRESS] Pulmonary Events and Pneumonitis:  
Atezolizumab with nab -Paclitaxel, or 
nab-Paclitaxel with or without Atezolizumab ........................ 117
[IP_ADDRESS] Other Toxicities .................................................................... 119
5.1.11 Erlotinib Dose Modification and Management of 
Specific Adverse Events ...................................................... 120
5.1.12 Potential Overlappi[INVESTIGATOR_70034] .......................................... 120
5.2 Safety Parameters and Definitions ...................................... 121
5.2.1 Adverse Events ................................................................... 121
5.2.2 Serious Adverse Events (Immediately Reportable 
to the Sponsor) .................................................................... [ADDRESS_121705] (Immediately 
Reportable to the Sponsor) .................................................. 122
5.3 Methods and Timing for Capturing and 
Assessing Safety Parameters .............................................. 123
5.3.1 Adverse Event Reporting Period ......................................... 123
5.3.2 Eliciting Adverse Event Information ..................................... 124
5.3.3 Assessment of Severity of Adverse Events ......................... 124
5.3.4 Assessment of Causality of Adverse Events ....................... 125
5.3.5 Procedures for Recording Adverse Events .......................... 125
[IP_ADDRESS] Diagnosis versus Signs and Symptoms ............................... 125
[IP_ADDRESS] Adverse Events That a re Secondary to Other 
Events.................................................................................. 126
[IP_ADDRESS] Persistent or Recurrent Adverse Events .............................. 126
[IP_ADDRESS] Abnormal Laboratory Values ............................................... 126
[IP_ADDRESS] Abnormal Vital Sign Values ................................................. 127
[IP_ADDRESS] Abnormal Liver Function Tests ............................................ 128
[IP_ADDRESS] Deaths ................................................................................. 128
[IP_ADDRESS] Preexisting Medical Conditions ............................................ 129
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
9/Protocol GO29437 , Version [IP_ADDRESS] Worsening of NSCLC .......................................................... 129
[IP_ADDRESS] Hospi[INVESTIGATOR_109766] ........................ 129
[IP_ADDRESS] Adverse Events Associated with an Overdose or 
Error in Drug Administration ................................................ 130
[IP_ADDRESS] Patient -Reported Outcome Data ......................................... [ADDRESS_121706] ................... 131
[IP_ADDRESS] Events That Occur prior to Study Drug Initiation .................. 131
[IP_ADDRESS] Events That Occur after Study Drug Initiation ...................... 131
5.4.3 Reporting Requirements for Pregnancies ............................ 132
[IP_ADDRESS] Pregnancies in Female Patients .......................................... 132
[IP_ADDRESS] Pregnancies in Female Partners of Male Patients ............... 132
[IP_ADDRESS] Abortions ............................................................................. 133
[IP_ADDRESS] Congenital Anomalies/Birth Defects .................................... [ADDRESS_121707] of Study .......................................... 138
6.3 Summaries of Treatment Group Comparability ................... 138
6.4 Efficacy Analyses ................................................................ 138
6.4.1 Co-Primary Efficacy Endpoints ............................................ 138
6.4.2 Secondary Efficacy Endpoints ............................................. 141
[IP_ADDRESS] Progression- Free Survival and Overall Survival in 
Secondary Populations ........................................................ 141
[IP_ADDRESS] Objective Response Rate .................................................... 141
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
10/Protocol GO29437 , Version [IP_ADDRESS] Duration of Response .......................................................... 141
[IP_ADDRESS] Overall Survival Rate at Landmark Timepoints .................... 142
[IP_ADDRESS] Patient -Reported Outcomes ................................................ 142
6.4.3 Handling of Missing Data ..................................................... 142
6.5 Safety Analyses ................................................................... 143
6.6 Pharmacokinetic Analyses ................................................... 144
6.7 Exploratory Analyses ........................................................... 144
6.7.1 Exploratory Analyses of Progression -Free 
Survival ................................................................................ 144
[IP_ADDRESS] Progression-Free Survival Rate at Landmark 
Timepoints ........................................................................... 144
[IP_ADDRESS] NonProtocol -Specified Anti -Cancer Therapy ..................... 144
[IP_ADDRESS] Subgroup Analysis ............................................................... 144
[IP_ADDRESS] Sensitivity Analyses ............................................................. 145
6.7.2 Exploratory Analyses of Overall Survival ............................. 145
[IP_ADDRESS] Loss to Follow -Up................................................................ 145
[IP_ADDRESS] Subgroup Analysis ............................................................... 145
[IP_ADDRESS] Overall Survival Rate at Three -Year Landmark ................... 145
[IP_ADDRESS] Milestone Overall Survival Analysis ..................................... 145
6.7.3 Exploratory Biomarker Analysis ........................................... 146
6.7.4 EQ-5D-3L Health Status Data ............................................. 146
6.7.5 Patient -Reported Outcome Analyses .................................. 146
6.8 Interim Analyses .................................................................. 146
6.8.1 Planned Interim Analysis ..................................................... 146
6.8.2 Optional Interim Analysis ..................................................... 148
7. DATA COLLECTION A ND MANAGEMENT ............................................. 149
7.1 Data Quality Assurance ....................................................... 149
7.2 Electronic Case Report Forms ............................................. 149
7.3 Electronic Patient -Reported Outcome Data ......................... 149
7.4 Source Data Doc umentation ................................................ 150
7.5 Use of Computerized Systems ............................................ 150
7.6 Retention of Records ........................................................... 151
8. ETHICAL CONSIDERA TIONS .................................................................. 151
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
11/Protocol GO29437 , Version 78.[ADDRESS_121708] or Ethics Committee .................. 153
8.4 Confidentiality ...................................................................... 153
8.5 Financial Disclosure ............................................................ 153
9. STUDY DOCUMENTATI ON, MONITORING, 
AND ADMINISTRATION ........................................................................... 154
9.1 Study Documentation .......................................................... 154
9.2 Protocol Deviations .............................................................. 154
9.3 Site Inspections ................................................................... 154
9.4 Administrative Structure ....................................................... 154
9.5 Publication of Data and Protection of 
Trade Secrets ...................................................................... 154
9.6 Protocol Amendments ......................................................... 155
10. REFERENCES ......................................................................................... 156
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
12/Protocol GO29437 , Version 7LIST OF TA BLES
Table 1 Randomized Phase III Studies in Patients with Previously 
Untreated NSCLC ....................................................................... 35
Table 2 Study PCD4989g:  Adverse Events with Frequency 10% of 
Patients for All Grades ................................................................ 41
Table 3 Study GO28753 (POPLAR):  Adverse Events Reported in at 
Least 10% of Patients ................................................................ .43
Table 4 Adverse Events in Study GO28915 (OAK) with a Between -
Arm Difference in Frequency of at Least 5 Percentage Points ....44
Table 5 Study GP28328:  All Reported Adverse Events .......................... 45
Table 6 Patients with NSCLC in Study PCD4989g:  
Investigator -Assessed Confirmed Objective Response Rate 
by [CONTACT_70108] -L1 Expression, Duration of Response, and 
Six-Month Progression -Free Survival Rates (per RECIST, 
Version 1.1) ................................................................................. 47
Table 7 Efficacy Results in Study GO28753 (POPLAR):  
Intent -to-Treat Population ........................................................... 48
Table 8 Study GO28753 (POPLAR) Efficacy Results by [CONTACT_109791]-L1 Diagnostic Subgroup with Complementary 
Compa rison Subgroupi[INVESTIGATOR_14839]:  Intent -to-Treat Population .............. [ADDRESS_121709] and Subsequent Infusions 
ofAtezolizumab .......................................................................... 78
Table 13 Vital Sign Measurements at Cycle 1 and All Subsequent 
Cycles ......................................................................................... 86
Table 14 Dosing Based on ANC and Febrile Neutropenia—Paclitaxel 
and Carboplatin ................................
......................................... 109
Table 15 Dosing Based on Nadir Platelet Count —Paclitaxel and 
Carboplatin ................................
................................................ 110
Table 16 Carboplatin and Paclitaxel Dose Modification Based on 
Gastrointestinal Toxicities in the P receding Cycle .................... 111
Table 17 Dose Modifications for Paclitaxel for Hepatic Toxicity ............... 112
Table 18 Paclitaxel Dose Modification for Neurologic Toxicity ................. 113
Table 19 nab-Paclitaxel and Carboplatin Permanent Dose Reductions 
Based on Nadir Absolute Neutrophil Count and Platelets ......... 115
Table 20 Carboplatin and nab -Paclitaxel Dose Modification Based on 
Gastrointestinal Toxicities in the Preceding C ycle.................... 116
Table 21 nab-Paclitaxel and Carboplatin Permanent Dose Reductions 
for Neurological Toxicity ............................................................ 117
Table 22 Management Guidelines for Pneumonitis:  Atezolizumab with 
nab-Paclitaxel, or nab -Paclitaxel with or without 
Atezolizumab ............................................................................ 119
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
13/Protocol GO29437 , Version 7Table 23 nab-Paclitaxel and Carboplatin Permanent Dose Reductions 
for Non -Hematologic, Non -Gastrointestinal, Non -Neurologic, 
and Non -Hepatic Toxicity .......................................................... 120
Table 24 Adverse Event Severity Grading Scale for Events Not 
Specifically Listed in NCI CTCAE ............................................. 124
Table 25 Analysis Timing and Stoppi[INVESTIGATOR_109767] B vs Arm C 
Comparison ............................................................................... 147
Table 26 Analysis Timing and Stoppi[INVESTIGATOR_109768]:  Arm A vs. Arm C ...................... [ADDRESS_121710] OF FIGURES
Figure 1 Study Schema ............................................................................. 59
Figure 2 Criteria for Continuing Atezolizumab in the Presence of 
Increased Radiographic Tumor Size (Atezolizumab Arms) ....... 103
Figure 3 Progression-Free Survival and Overall Survival Analysis 
Hierarchy, Allocation, and Recycling .................................. [ADDRESS_121711] OF A PPENDICES
Appendix 1 Schedule of Assessments ......................................................... 164
Appendix 2Schedule of Pharmacokinetic, Pharmacodynamic, Biomarker, 
and Anti -Therapeutic Antibody Assessments ............................ 171
Appendix 3 American Joint Committee on Cancer  Non Small Cell Lung 
Cancer Staging, 7th Edition ...................................................... 174
Appendix 4 Response Evaluation Criteria in Solid Tumors:  
Modified Excerpt from Original Publication ............................... 176
Appendix 5 Modified Response Evaluation Criteria in Solid Tumors ........... 187
Appendix 6 AntiPD-L1 Immunohistochemistry ........................................... 194
Appendix 7 EORTC QLQ -C30..................................................................... 195
Appendix 8 EORTC QLQ -LC13 ................................................................... 197
Appendix 9 EQ-5D-3L.................................................................................. 198
Appendix 10 Eastern Cooperative Oncology Group Performance Status 
Scale ......................................................................................... 201
Appendix 11 Anaphylaxis Precautions ........................................................... 202
Appendix 12 Preexisting Autoimmune Diseases ........................................... 203
Appendix 13 Symptoms in Lung Cancer ........................................................ 204
Appendix 14 Patient Global Impression of Severity ....................................... 207
Appendix 15 Additional Guidance on Chemotherapy Administration ............. 208
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
14/Protocol GO29437 , Version 7PROTOCOL AMENDMENT A CCEPTA NCE FORM
TITLE: A PHA SE III, OPEN -LABEL, MULTICENTER, 
RANDOMIZED STUDY EVA LUATING THE EFFICA CY
AND SA FETY OF A TEZOL IZUMA B (MPDL3280A , 
ANTIPD-L1 A NTIBODY) IN COMBINA TION WITH
CARBOPLA TINPACLITA XEL OR ATEZOLIZUMA B IN 
COMBINA TION WITH 
CARBOPLA TINNAB-PACLITA XEL VERSUS 
CARBOPLA TINNAB-PACLITA XEL IN 
CHEMOTHERA PY-NAIVE PA TIENTS WITH STAGEIV 
SQUA MOUS NON SMA LL CELL LUNG CA NCER
PROTOCOL NUMBER: GO2943 7
VERSION NUMBER: [ADDRESS_121712] NUMBER: 2014 -003208 -59
IND NUMBER: [ADDRESS_121713]: Atezolizumab (MPDL3280A, RO5541267)
MEDICA L MONITOR: , M.D. 
SPONSOR: F. Hoffmann -La [COMPANY_002] Ltd
I agree to conduct the study  in accordance with the current protocol.
Principal Investigator’s Name  (print)
Principal Investigator’s Signature [CONTACT_33505].  Please return a copy to 
the Sponsor or its designee.

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
15/Protocol GO29437 , Version 7PROTOCOL SYNOPSIS
TITLE: A PHA SE III, OPEN -LABEL, MULTICENTER, RA NDOMIZED 
STUDY EVA LUATING THE EFFIC ACY  AND SA FETY OF 
ATEZOLIZUM AB (MPDL32 80A, ANTIPD-L1 A NTIBODY) IN 
COM BINA TION WITH CAR BOPL ATINPACLIT AXEL OR 
ATEZOLIZUM AB IN COMB INATION WITH 
CARBOPL ATINNAB-PACLIT AXEL VERSUS 
CARBOPL ATINNAB-PACLIT AXEL IN CH EMOTHERA PY-NAIVE 
PATIENTS WITH STA GE IV SQUA MOUS NON SMALL CELL 
LUNG CA NCER
PROTOCOL NUMBER: GO29437
VERSION NUMBER: [ADDRESS_121714] NUMBER: 2014- 003208 -59
IND NUMBER: [ADDRESS_121715]: Atezolizumab (MPDL3280A, RO5541267)
PHASE: III
INDIC ATION: Squamous non small cell lung cancer
SPONSOR: F. Hoffmann -La [COMPANY_002] Ltd
Objectives
Unless otherwise specified, efficacy  objectives will be analyzed for the following two treatment 
comparisons:
Atezolizumab carboplatin nab-paclitaxel (Arm B) versus
carboplatin nabpaclitaxel (Arm C)
Atezolizumab carboplatin paclitaxel (Arm A) versus
carboplatin nabpaclitaxel (Arm C)
The term “tumor gene expression” (tGE) refers to randomized patients with a d efined level of 
expression of a PD- L1 and T -effector gene signature [CONTACT_109861], as analyzed through use 
of a centrally performed RNA -based assay.
Some efficacy endpoints will be analyzed in a population of randomized patients with a defined 
level of P D-L1 expression on tumor cells (TCs) and tumor -infiltrating immune cells (ICs) , as 
analyzed through use of a centrally performed immunohistochemistry  (IHC) test.
Efficacy Objectives
The co -primary objectives of this study are the following:
To evaluate the efficacy  of atezolizumab as measured by [CONTACT_1697] -assessed 
progression -free survival (PFS)according to Response Eva luation Criteria in Solid Tumors, 
Version 1.1 (RECIST v1.1)in the tGE population and the intent -to-treat (ITT) population
To evaluate the efficacy  of atezolizumab as measured by [CONTACT_70085] ( OS)in the ITT 
population
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
16/Protocol GO29437 , Version 7The secondary efficacy  objectives for this study are the following:
To evaluate the efficacy  of atezolizumab as measured by [CONTACT_109792]
To eva luate the efficacy  of atezolizumab as measured by [CONTACT_1697] -assessed PFS 
according to RECIST v1.1 and OS in the TC2/3 or IC2/3 population and the TC1/2/3 or 
IC1/2/3 population 
To evaluate the efficacy  of atezolizumab as measured by [CONTACT_1697] -assesse d objective 
response rate (ORR) according to RECIST v1.1 in the tGE population and the ITT
population
To evaluate the efficacy  of atezolizumab as measured by [CONTACT_1697] -assessed duration of 
response (DOR) according to RECIST v1.1 in the tGE population an d the ITT population
To evaluate the OS rate at 1 and 2 years in each treatment arm for the tGE population and 
the ITT population n
To determine the impact of atezolizumab as measured by [CONTACT_70113] (TTD) in 
patient -reported lung cancer sy mptoms of cough, dy spnea (single -item and multi -item 
subscales), chest pain, or arm/shoulder pain, using the European Organisation for the 
Research and Treatment of Cancer (EORTC) Quality -of-Life Questionnaire Core 30 
(QLQ -C30) and the supplemental lung cancer module (QLQ -LC13) in the tGE population 
and the ITT population
To determine the impact of atezolizumab as measured by [CONTACT_109793] (i.e., 
improvement or deterioration based upon presenting sy mptomatology) in patient- reported 
lung cancer sy mptom (chest pain, dyspnea, and cough) score using the Sy mptoms in Lung 
Cancer (SILC) scale s ymptom severity score inthe tGE population and the ITT population
To evaluate the efficacy  of the tr eatment regimen of atezolizumab carbo platin paclitaxel 
versus atezolizumab carboplatin nab-paclitaxel as measured by [CONTACT_1697] -assessed 
PFS according to RECIST v1. 1and OS inthe tGE population and the ITT population
Safety Objectives
The safety  objectives for this study are the following:
To evaluate the safety and tolerability of atezolizumab in each of the two treatment 
comparisons
To evaluate the incidence and titers of anti -therapeutic antibodies (ATAs) against 
atezolizumab and to explore the potential relationship of the im munogenicity response with 
pharmacokinetics, safety, and efficacy
Pharmacokinetic Objectives
The pharmacokinetic (PK) objectives for this study are the following:
To characterize the pharmacokinetics of atezolizumab when given in combination with 
carbopla tinpaclitaxel (Arm A) or with carboplatin nab-paclitaxel (Arm B)
To characterize the pharmacokinetics of carboplatin when given in combination with 
paclitaxel and atezolizumab (Arm A) or with nab-paclitaxel with and without atezolizumab 
(Arms B and C)
To characterize the pharmacokinetics of paclitaxel when given in combination with 
atezolizumab and carboplatin (Arm A)
To characterize the pharmacokinetics of nab -paclitaxel (reported as total paclitaxel) when 
given in combination with carboplatin with and without atezolizumab (Arms B and C)
Exploratory Objectives
The exploratory objectives for this study are the following:
To evaluate PFS at 6 months and at 1 year in each treatment arm
To evaluate the OS rate at 3 years in each treatment arm
Atezolizumab—F. Hoffmann-La [COMPANY_002] Ltd
17/Protocol GO29437, Version 7#To assess predictive, prognostic, and pharmacodynamic exploratory biomarkers in archival 
and/or fresh tumor tissue and blood and their association with disease status, mechanisms of resistance, and/or response to study treatment
#To evaluate the utility of biopsy at the time of apparent disease progression to distinguish 
apparent increases in tumor volume related to the immunomodulatory activity of atezolizumab (i.e., pseudoprogression/tumor-immune infiltration) from true disease progression
#To evaluate and compare patient’s health status as assessed by [CONTACT_70090] 
5Dimensions 3-Level (EQ-5D-3L) questionnaire to generate utility scores for use in 
economic models for reimbursement
#To determine the impact of atezolizumab as measured by [CONTACT_70091]-
reported outcomes of health-related quality of life, lung cancerrelated symptoms, and 
functioningas assessed by [CONTACT_20368]-C30 and LC13
Study Design
Description of Study
This is a randomized, Phase III, multicenter, open-label study (IMpower131)designed to 
evaluate the safety and efficacy of atezolizumab in combination with carboplatin ∀paclitaxel or 
with carboplatin ∀nab-paclitaxel compared with treatment with carboplatin ∀nab-paclitaxel in 
approximately 1025chemotherapy-naive patients with StageIV squamousnon !small cell lung 
cancer(NSCLC).
Tumor specimens will be prospectively tested for PD-L1 expression by a central laboratory.  
Eligible patients will be stratified by [CONTACT_4321] (male vs. female), presence of liver metastases at 
baseline (yes vs. no), and by [CONTACT_4002]-L1 tumor expression by [CONTACT_4658] (TC3 and any IC vs. TC0/1/2 and IC2/3 vs. TC0/1/2 and IC0/1) and randomized in a1:1:1 ratioto receive one of the following 
treatment regimens.
Treatment Arm A:  Atezolizumab
∀carboplatin ∀paclitaxel (Induction: four or six 21-day 
cycles); atezolizumab (Maintenance: 21-day cycle)
Treatment Arm B:  Atezolizumab ∀carboplatin ∀nab-paclitaxel (Induction: four or six 21-day 
cycles); atezolizumab (Maintenance: 21-day cycle)
Treatment Arm C:  Carboplatin ∀nab-paclitaxel (Induction: four or six 21-day cycles); best 
supportive care (Maintenance: 21-day cycle)
The number of cycles of induction treatment (four or six) will be at the discretion of the 
investigator and will be determined and documented prior to randomization.  Induction treatment 
will be administered on a 21-day cycle until the following occurs (whichever occurs first):  
1)administration of four or six cycles or 2) disease progression (Arm C) or loss of clinical benefit 
(Arms A and B) is documented. 
Following the induction phase, patients randomized to atezolizumab (Arms A and B) may 
continue treatment with atezolizumab beyond radiographic disease progression by [CONTACT_393] 
v1.1, provided they are experiencing clinical benefit as assessed by [CONTACT_093](i.e., in the 
absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by [CONTACT_093]) after an integrated assessment of radiographic data, biopsy 
results (if available), and clinical status.  Patients randomized to carboplatin ∀nab-paclitaxel 
(Arm C) will be offered best supportive care provided they have non-progressive disease.
Treatment with chemotherapy must be discontinued in all patients who exhibit evidence of 
progressive disease by [CONTACT_393] v1.1.
Patients will undergo tumor assessments at baseline and every [ADDRESS_121716] v1.1 (or loss of clinical benefit for atezolizumab-treated patients who continue treatmentwith atezolizumabafter radiographic disease progression according to 
RECIST v1.1), withdrawal of consent, study termination by [CONTACT_2728], or death, whichever occurs 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
18/Protocol GO29437 , Version 7first.  Patients who discontinue treatment for reasons other than radiographic disease 
progression per RECIST v1.1 (e.g., toxicity , symptomatic deterioration) will continue scheduled 
tumor assessments until ra diographic disease progression per RECIST v1.1 (or loss of clinical 
benefit for atezolizumab -treated patients who had continue dtreatment with atezolizumab after 
radiographic disease progression according to RECIST v1.1), withdrawal of consent, study 
termi nation by [CONTACT_2728], or death, whichever occurs first, regardless of whether patients start a 
new anti -cancer therapy.
All primary imaging data used for tumor assessment will be collected by [CONTACT_70093], independent review of response e ndpoints.  The independent reviews of the stored 
scans will be performed when requested.
For Treatment A rms A  and B only:
During treatment (induction or maintenance), patients who show evidence of clinical benefit will 
be permitted to continue atezolizumab after RECIST v1.1 for progressive disease are met if 
they meet all of the following criteria:
Evidence of clinical benefit as assessed by [CONTACT_093]
Absence of sy mptoms and signs (including worsening of laboratory values, [e.g., new or 
worsening hyp ercalcemia]) indicating unequivocal progression of disease
No decline in Eastern Cooperative Oncology Group (ECOG) performance status that can 
be attributed to disease progression
Absence of tumor progression at critical anatomical sites (e.g., leptomening eal disease) that 
cannot be managed by [CONTACT_990] -allowed medical interventions
Patients must provide written consent to acknowledge deferring other treatment options in favor 
of continuing study treatment atezolizumab at the time of initial progression
Patients in all treatment arms will undergo a mandatory tumor biops y sam ple collection, unless 
not clinically feasible as assessed and documented by [CONTACT_431], at the time of radiographic 
disease progression.  These data will be used to explore whether rad iographic findings are 
consistent with the presence of tumor.  Additionally, these data will be analyzed to evaluate the 
association between changes in tumor tissue and clinical outcome and to understand further the 
potential mechanisms of progression and resistance to atezolizumab as compared with such 
mechanisms after treatment with chemotherapy alone.  This exploratory biomarker evaluation 
will not be used for any treatment -related decisions.  Patients in Arms A and B who are unable 
to undergo biops y sam ple collection but who otherwise meet the criteria listed above may 
continue to receive atezolizumab.
Number of Patients
Approximately [ADDRESS_121717] meet all of the following criteria to be eligible for study entry:
Signed Informed Consent Form
Male or female, 18 yearsof age or older
ECOG performance status of 0 or 1
Histologically or cytologically confirmed, Stage IV squamous NSCLC (per the Union 
Internationale contre le Cancer/American Joint Committee on Cancer staging s ystem, 
7thedition).
Patients with tumors of mixed histology (squamo us and non -squamous) are eligible if 
the major histological component appears to be squamous.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
19/Protocol GO29437 , Version 7No prior treatment for Stage IV squamous NSCLC
Patients known to have a sensitizing mutation in the EGFR gene must have 
experienced disease progression (during or after treatment) or intolerance to treatment 
with one or more EGFR TKIs, such as erlotinib, gefitinib, or another EGFR TKI 
appropriate for the treatment of EGFR -mutant NSCLC.  Patients with unknown EGFR
mutation status do not require testing.
Patients kno wn to have an ALK fusion oncogene must have experienced disease 
progression (during or after treatment) or intolerance to treatment with one or more 
ALK inhibitors (i.e. crizotinib) appropriate for the treatment of NSCLC in patients having 
an ALK fusion on cogene.  Patients with unknown ALK mutation status do not require 
testing.
Patients who have received prior neo- adjuvant, adjuvant chemotherapy, radiotherapy, or 
chemoradiotherapy with curative intent for non- metastatic disease must have experienced a 
treatment -free interval of at least [ADDRESS_121718] chemotherapy, 
radiotherapy, or chemoradiotherapy.
Patients with a histor y of treated asy mptomatic CNS metastases are eligible, provided they 
meet all of the following criteria:
Only supratentorial and cerebellar metastases allowed (i.e., no metastases to midbrain, 
pons, medulla or spi[INVESTIGATOR_1831])
No ongoing requirement for corticosteroids as therapy for CNS disease
No stereotactic radiation within [ADDRESS_121719] receive 
radiation thera py and/or surgery for CNS metastases.  Following treatment, these patients may 
then be eligible without the need for an additional brain scan prior to randomization, if all other 
criteria are met.
Known PD- L1 tumor status as determined by [CONTACT_109794] a central 
laborator y on previously obtained archival tumor tissue or tissue obtained from a biops y at 
screening
A representative formalin -fixed paraffin -embedded (FFPE) tumor specimen in paraffin 
block (preferred) or 15 (or more ) unstained, freshly cut, serial sections on slides from an 
FFPE tumor specimen is required for participation in this study.  If fewer than 15 slides 
are available at baseline (but no fewer than 10), the patient may  still be eligible, upon 
discussion with the Medical Monitor.  This specimen must be accompanied by [CONTACT_109795].
Fine- needle aspi[INVESTIGATOR_1516] ( defined as samples that do not preserve tissue architecture and 
yield cell suspension and/or cell smears), brushing, cell pellet specimens (e.g., from 
pleural effusion, and lavage samples )are not acceptable.  
Tumor tissue from bone metastases that is subject to decalcification is not acceptable.
For core -needle biopsy specimens, preferably at least three cores embedded in a single 
paraffin block, should be submitted for evaluation.  
Measurable disease, as defined by [CONTACT_393] v1.1
Previously irradiated lesions can only be considered as measurable disease if disease 
progression has been unequivocally documented at that site since radiation and the 
previously irradiated lesion is not the only site of disease. 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
20/Protocol GO29437 , Version 7Adequate hematologic and end organ function, defined by [CONTACT_40843] 14 days prior to randomization:
ANC  1500 cells/ L without granulocyte colony -stimulating factor support
Lymphocyte count 500/L
Platelet count 100,000/ L without transfusion 
Hemoglobin  9.0 g/dL
Patients may be transfused to meet this criterion.
INRor aPTT 1.5upper limit of normal ( ULN)
This applies only to patients who are not receiving therapeutic anticoagulation; 
patients receiving therapeutic anticoagulation should be on a stable dose.
AST, ALT, and alkaline phosphatase 2.5ULN, with the following exceptions:
Patients with documented liver metastases:  AST and/or ALT 5ULN
Patients with documented liver or bone metastases:  alkaline phosphatase 5ULN.
Serum bilirubin 1.25ULN
Patients with known Gilbert disease who have serum bilirubin level 3ULN may  be 
enrolled .
Serum creatinine 1.5ULN
For female patients of childbearing potential, agreement (by [CONTACT_109796]/or partner) to use a 
highly effective form(s) of contraception that results in a low failure rate [ 1% per year] 
when used consistently and correctly, and to continue its use for [ADDRESS_121720] refrain from donating eggs 
during this same period.   For male patients with female partners of chi ldbearing potential, 
agreement (by [CONTACT_109796]/or partner) to use a highly effective form(s) of contraception that 
results in a low failure rate [ 1% per year] when used consistently and correctly, and to 
continue its use for [ADDRESS_121721] dose of nab -paclitaxel, paclitaxel, and/or 
carboplatin .  Such methods include combined (estrogen and progestogen containing) 
hormonal contraception, progestogen -only hormonal contraception associated with 
inhibition of ovulation together with another additional barrier method always containing a 
spermicide, intrauterine device (IUD), intrauterine hormone- releasing system (IUS), bilateral 
tubal occlusion or vasectomized partner (on the understanding that this is the only one 
partner during the whole study duratio n), and sexual abstinence.  Men must refrain from 
donating sperm during the study and for [ADDRESS_121722] dose of nab -paclitaxel , 
paclitaxel, and/or carboplatin, whichever is latest .
Oral contraception should alway s be combined with an additional c ontraceptive method 
because of a potential interaction with the study drug.  The same rules are valid for male 
patients involved in this clinical trial if they have a partner of childbirth potential.  Male 
patients must always use a condom.
Women who are n ot postmenopausal ( 12months of non -therapy -induced amenorrhea) or 
surgically sterile must have a negative serum pregnancy test result within 14 days prior to 
initiation of study drug.
Exclusion Criteria
Patients who meet any of the criteria below will be excluded from study  entry.
Cancer -Specific Exclusions
Active or untreated CNS metastases as determined by [CONTACT_109797] 
(MRI) evaluation during screening and prior radiographic assessments
Spi[INVESTIGATOR_33373]/or radiation or previously 
diagnosed and treated spi[INVESTIGATOR_70036]  2 weeks prior to randomization
Leptomeningeal disease
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
21/Protocol GO29437 , Version 7Uncontrolled tumor -related pain
Patients requ iring pain medication must be on a stable regimen at study entr y.
Symptomatic lesions amenable to palliative radiotherapy (e.g., bone metastases or 
metastases causing nerve impi[INVESTIGATOR_20804]) should be treated prior to randomization.  
Patients should be recovere d from the effects of radiation.  There is no required 
minimum recovery period.
Asymptomatic metastatic lesions whose further growth would likely cause functional 
deficits or intractable pain (e.g., epi[INVESTIGATOR_109769]) should be considered for locoregional therapy if appropriate 
prior to randomization .
Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage 
procedures (once monthly or more frequently)
Patients with indwelling catheters (e.g., PleurX) are allowed.
Uncontrolled or s ymptomatic hypercalcemia ( 1.5 mmol/L ionized calcium or Ca 12 mg/dL 
or corrected serum calcium ULN) 
Patients who are receiving denosumab prior to randomization must be w illing and 
eligible to receive a bisphosphonate instead while in the study.
Malignancies other than NSCLC within 5 years prior to randomization , with the exception of 
those with a negligible risk of metastasis or death (e.g., expected 5 -year OS 90%) trea ted 
with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, 
basal or squamous cell skin cancer, localized prostate cancer treated surgically with 
curative intent, ductal carcinoma in situ treated surgically with curative intent)
Known tumor PD -L1 expression status as determined by [CONTACT_70095] (e.g., patients whose PD -L1 expression status was determined during screening for 
entry into a study with anti PD-1 orantiPD-L1 antibodies but were not eligible are 
excluded)
General Medical Exclusions
Women who are pregnant, lactating or intending to become pregnant during the study
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or 
humanized antibodies or fusi on proteins
Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovar y 
cells or any component of the atezolizumab formulation
History of autoimmune disease, including, but not limited to, m yasthenia gravis, myositis, 
autoimmu ne hepatitis, sy stemic lupus erythematosus, rheumatoid arthritis, inflammatory  
bowel disease, vascular thrombosis associated with antiphospholipid syndrome, W egener’s 
granulomatosis, Sjögren’s syndrome, Guillain- Barré syndrome, multiple sclerosis, vasculit is, 
or glomerulonephritis
Patients with a histor y of autoimmune -related hypothy roidism on a stable dose of 
thyroid- replacement hormone are eligible for this study.
Patients with controlled T ype I diabetes mellitus on a stable dose of insulin regimen are 
eligible for this study
Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic 
manifestations only (e.g., patients with psoriatic arthritis would be excluded) are 
permitted provided that they meet the following conditions: 
Rash must cover less than 10% of body surface area (BSA)
Disease is well controlled at baseline and only requiring low potenc y topi[INVESTIGATOR_109770] 12 months (not 
requiring PUVA [psoralen plus ultraviolet A radiation], methotrexate, retinoids, 
biologic agents, oral calcineurin inhibitors, high potency or oral steroids)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
22/Protocol GO29437 , Version 7History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), 
drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on 
screening chest CT scan
History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
Positive test for HIV
All patients will be tested for HIV prior to inclusion into the study; patients who test 
positive for HIV will be excluded from the clinical study.
Patients with active hepatitis B (chronic or acute; defined as having a positive hepatitis B 
surface antigen [HBsAg] test at screening )or hepatitis C
Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined 
as the presence of hepatitis B core antibody [HBcAb] and absence of HBsAg) are 
eligible only if they are negative for HBV DNA .  
Patients positive for hepatitis C virus (HCV) antibody are eligible only if PCR is negative 
for HCV RNA.
Active tuberculosis
Severe infections within 4 weeks prior to randomization, including but not limited to 
hospi[INVESTIGATOR_33377], bacteremia, or severe pneumonia
Received therapeutic oral or IV antibiotics within 2 weeks prior to randomization
Patients receiving prophylactic antibiotics (e.g., for prevention of a urinar y tract infection 
or to prevent chronic obstructive pulmonary disease exacerbation) are eligible.
Significant cardiovascular dise ase, such as [LOCATION_001] Heart Association cardiac disease 
(Class II or greater), m yocardial infarction , or cerebrovascular accident within the 3 months 
prior to randomization, unstable arrhythmias, or unstable angina
Patients with known coronary arter y disease, congestive heart failure not meeting the 
above criteria, or left ventricular ejection fraction 50% must be on a stable medical 
regimen that is optimized in the opi[INVESTIGATOR_021], in consultation with a 
cardiologist if appropriate.
Major surgical procedure other than for diagnosis within 28 day s prior to randomization or 
anticipation of need for a major surgical procedure during the course of the study
Prior allogeneic bone marrow transplantation or solid organ transplant
Administration of a live, attenuated vaccine within 4 weeks before randomization or 
anticipation that such a live attenuated vaccine will be required during the study
Any other diseases, metabolic dysfunction, physical examination finding, or clinical 
laborator y finding giving reasonable suspi[INVESTIGATOR_1884] a disease or condition that contraindicates 
the use of an investigational drug or that may affect the interpretation of the results or 
render the patient at high risk from treatment complications
Patients with illnesses or conditions that interfere with their capacity to understand, follow 
and/or comply with study procedures
Exclusion Criteria Related to Medications
Any approved anti -cancer therapy, including hormonal therapy ,within 21 days prior to 
initiation of study treatment; the following exceptions are allowed:
TKIs approved for treatment of NSCLC discontinued 7days prior to randomization.  
The baseline scan must be obtained after discontinuation of prior TKIs.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
23/Protocol GO29437 , Version 7Treatment with any other investigational agent with therapeutic intent within 28 days prior to 
randomization
Prior treatment with CD137 agonists or immune checkpoint blockade therapi[INVESTIGATOR_014], anti PD-1, 
and anti PD-L1 therapeutic antibodies
Patients who have had prior antiCTLA -4 treatment may be enrolled, provided the 
following requirements are met:
Last dose of anti CTLA -[ADDRESS_121723] 6 weeks prior to randomization
No history of severe immune -mediated adverse effects from anti CTLA -4 (National 
Cancer Institute Common Terminology Cri teria for Adverse Events [NCI CTCAE] 
Grade 3 and 4)
Treatment with s ystemic immunostimulatory agents (including, but not limited to, IFNs, IL -2) 
within 4 weeks or five half -lives of the drug, whichever is longer, prior to randomization
Prior treatment with cancer vaccines is allowed.
Treatment with s ystemic immunosuppressive medications (including, but not limited to, 
corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti -tumor 
necrosis factor [anti -TNF] agents) within [ADDRESS_121724] received acute, low -dose (10 mg oral prednisone or equivalent) , 
systemic immunosuppressant medications may  be enrolled in the study.
The use of corticosteroi ds (10 mg oral prednisone or equivalent) for chronic 
obstructive pulmonary disease, mineralocorticoids (e.g., fludrocortisone) for patients 
with orthostatic hypotension, and low -dose supplemental corticosteroids for 
adrenocortical insufficiency is allowed.
Exclusions Related to Chemotherapy
Known history of severe allergic reactions to platinum -containing compounds or mannitol
Known sensitivity to any component of paclitaxel or nab -paclitaxel
Grade 2 peripheral neuropathy as defined by [CONTACT_4652] v4.0 criteria (paclitaxel and 
nab-paclitaxel)
Known history of severe hypersensitivity reactions to products containing CremophorEL 
(e.g., cyclosporin for injection concentrate and teniposide for injection concentrate)
Length of Study
The final PFS analysis will be conducted when all of the following criteria have been met:  
approximately [ADDRESS_121725] been enrolled into an extension study.  The Sponsor may decide to terminate the 
study at any time.  If the Sponsor decides to end the study, patients who are still receiving 
study treatment or are in survival follow -up may be offered enrollment in an extension study 
or a non -interventional study.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
24/Protocol GO29437 , Version 7Outcome Measures
Efficacy Outcome Measures
The co-primary efficacy outcome measure sfor this study arethe following:
PFS, defined as the time from randomization to the first occurrence of the disease
progression as determined by [CONTACT_26309] v1.[ADDRESS_121726] in the tGE population and ITT population
OS, defined as the time from randomization to death from any  cause in the ITT population
The secondary eff icacy  outcome measures for this study are the following:
OS in the tGE population
PFS, as determined by [CONTACT_3143] v1.1, and OS in the TC2/3 or 
IC2/3 population and the TC1/2/3 or IC1/2/3 population
Objective response, defined as partial response (PR) or complete response (CR) as 
determined by [CONTACT_3143] v1.1 in the tGE population and ITT 
population
DOR, defined as the time interval from the first occurrence of a documented objective 
response to the time o f disease progression as determined by [CONTACT_26218] v1.1, or death from any  cause, whichever occurs first in the tGE population and 
ITT population
OS rates at 1 and 2 years for the tGE population and ITT population
TTD in patient -reported lung cancer sy mptoms, defined as time from randomization to 
deterioration (10 -point change) on each of the EORTC QLQ -C30 and EORTC QLQ -LC13 
symptom subscales (cough, dyspnea [single item], dy spnea [multi -item subscale], chest 
pain, and arm/shoulder pain) in the tGE population and ITT population
Change from baseline in patient -reported lung cancer sy mptoms (cough, dyspnea, and 
chest pain) on the sy mptom severity score of the SILC scale in the tGE population and ITT 
population
PFS, as determined by [CONTACT_3143] v1.1, and OS in the two 
atezolizumab -containing arms in the tGE population and the ITT population
Safety Outcome Measures
The safety  outcome measures for this study are the following:
Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v4.0
Changes in vital signs, physical findings, and clinical laboratory results during and following 
study treatment administration
Incidence of ATA response to atezolizumab and potential correlation with PK, 
pharma codynamic, safety, and efficacy  parameters
Pharmacokinetic Outcome Measures 
The PK outcome measures for this study are the following:
Maximum observed serum atezolizumab concentration (C max) after infusion (Arms A and B)
Minimum observed serum atezolizumab concentration (C min) prior to infusion at selected 
cycles, at treatment discontinuation, and at 120 day s (30days) after the last dose of 
atezolizumab (Arms A and B)
Plasma concentrations for carboplatin (Arms A, B, and C)
Plasma concentrations for pa clitaxel (Arm A)
Plasma concentrations for nab -paclitaxel (Arms B and C)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
25/Protocol GO29437 , Version 7Exploratory Outcome Measures
The exploratory outcome measures for this study are the following:
PFS at 6 months and at 1 year
OS rate at 3 years
Status of PD- L1, immune -, and NSCLC- related and other exploratory biomarkers in 
archival and/or freshly obtained tumor tissues, and blood (or blood derivatives) collected 
before, during, or after treatment with atezolizumab or at progression and association with 
disease status and/or r esponse to atezolizumab in combination with chemotherapy
Status of tumor -infiltrating immune cells and other exploratory biomarkers in mandatory 
biopsy specimens and blood collected at progression
Utility scores of the EQ -5D-3L 
Change from baseline in pat ient-reported outcomes of health- related quality of life, lung 
cancer related sy mptoms, and functioning as assessed by [CONTACT_20368] -C30 and LC13
Investigational Medicinal Products
Test Product (Investigational Drug)
The investigational medicinal products (IMPs) for this study are atezolizumab and erlotinib.
Atezolizumab (1200 mg IV) will be administered on Day 1 of each 21 –day cycle to patients who 
are randomized to Arms A and B.
Switch maintenance treatment with erlotinib is no longer permitted.  However , patients who had 
already started switch maintenance treatment with erlotinib under previous protocol versions 
may be allowed to continue treatment with erlotinib upon discussion of the risks, potential 
benefits and alternative treatment options with the investigator.  For those patients who receive 
switch maintenance, institutions should follow the dosage and administration instructions in the 
prescribing information.
Comparator 
nab-Paclitaxel (100 mg/m2IV) will be administered on Days 1, 8, and [ADDRESS_121727] (IMP) for study purposes in countries where nab -paclitaxel is 
considered an IMP by [CONTACT_427].
Non-Investigat ional Medicinal Products
Comparator
Carboplatin will be administered by [CONTACT_109798] curve (AUC) of 6 mg/mL/min on Day 1 of each 21 -day cycle for fouror 
sixcycles during the induction phase
Paclitaxel (200 mg/m2IV) will be administered on Day [ADDRESS_121728] 
comparing Arm B versus Arm C and then comparing Arm A versus Arm C.  For each 
comparison, analyses will be conducted according to an analy sis hierarchy and an -spending 
algorithm to control for the type I error rate  and to account for an interim analysis. 
PFS is defined as the time between the date of randomization and the date of fir st documented 
disease progression or death, whichever occurs first.  Patients who have not experienced 
disease progression or died at the time of analy sis will be censored at the time of the last tumor 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
26/Protocol GO29437 , Version 7assessment.  Patients with no post- baseline tumor asse ssment will be censored at the date of 
randomization plus [ADDRESS_121729]. The HR for PFS and OS for each comparison (i.e., Arm B vs. Arm C, Arm A vs. Arm C ) will 
be estimated using a stratified Cox regression model, respectively.  Th e 95% CI for the HR will 
be provided.
The hypothesis testing will be done in the order described below: 
Comparison of Arm B versus Arm C
To control the overall type I error rate for the one -sided test at 0.025, a one -sided type I error ( ) 
of 0.003 and 0.022 (ratio of 3:22) will be allocated to PFS and OS, respectively, for the 
comparison of Arm B versus Arm C.
1.PFS in the tGE population will be tested at 0.003 (one sided).  If the estimate of the HR is 
[ADDRESS_121730] is 0.003, the null 
hypothesis will be rejected and it will be concluded that atezolizumab carboplatin nab-
paclitaxel prolongs the duration of PFS relative to control treatment in the tGE population.
2.If the null hypothesis is rejected in the tGE population (Step 1), PFS in the ITT population will 
be tested at 0.003 (one sided)
3.recycling from PFS to OS will be conducted as follows:
a.If the null hypothesis is not rejected for PFS analy sis in the ITT population (Step 2), OS 
in the ITT population will be tested at  0.022 (one sided).
b.If the null hypothesis is rejected for PFS analy sis in the ITT population (Step 2), OS in 
the ITT popu lation will be tested at  0.025 (one sided).
Comparison of Arm A versus Arm C
If the difference in OS between Arm B and Arm C in the ITT population is statistically significant 
at an of 0.022 or 0.025 (Step 3), that same will become the overall one- sided type I error 
rate for the comparison of Arm A versus Arm C, with allocated to PFS and OS at the same 
3:22 ratio (see Figure 3 in Section 6.1).   If the difference in OS between Arm B and Arm C in the 
ITT population is not statistically significant, there will be no formal comparison of Arm A versus 
Arm C for the co -primary  endpoints of PFS and OS.
1.If the difference in OS between Arm B and Arm C is statistically significant at 0.022 (one 
sided):
a.PFS in the tGE population will be tested at 0.[ZIP_CODE] (one sided).  If the estimate of 
the HR is [ADDRESS_121731] is 
0.[ZIP_CODE], the null hypothesis will be rejected and it will be concluded that 
atezolizumab carboplatin paclitaxel prolongs the duration of PFS relative to control 
treatment in the tGE population.
b.If the null hypothesis is rejected in the tGE population (Step 1a), PFS in the ITT 
population will be tested at  0.[ZIP_CODE] (one sided).
c.recycling from PFS to OS will be conducted as follows:
If the null hypothesis is not rejected in the ITT population (Step 1b), OS in the ITT 
population will be tested at 0.[ZIP_CODE] (one sided).
If the null hypothesis is rejected in the ITT population (Step 1b), OS in the ITT 
populati on will be tested at 0.022 (one sided).  
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
27/Protocol GO29437 , Version 72.If the difference in OS between Arm B and Arm C is statistically significant at 0.025 (one 
sided):
a.PFS in the tGE population will be tested at  0.003 (one sided).  If the estimate of the 
HR is  [ADDRESS_121732] is 
0.003, the null hypothesis will be rejected and it will be concluded that 
atezolizumab carboplatin paclitaxel prolongs the duration of PFS relative to control 
treatment in the tGE population.
b.If the null hypothesis is rejected in the tGE population (Step 2a), PFS in the ITT 
population will be tested at 0.003 (one sided).
c.recycling from PFS to OS will be conducted as follows:
If the null hypothesis is not rejected in the ITT population (Step 2b), OS in the ITT 
population will be tested at 0.022 (one sided).
If the null hypothesis is rejected in the ITT population (Step 2b), OS in the ITT 
population will be tested at 0.025 (one sided).   
The stratification factors will be those used during randomization (i.e., sex [male vs. female], 
presence of liver metastases at baseline [yes vs. no], and PD -L1 tumor expression by [CONTACT_4658] [TC3 
and any IC vs. TC0/1/2 and IC2/3 vs. TC0/1/2 and IC0/1 ]), as recorded in the interac tive 
voice/ Web response sy stem.
Results from an unstratified analysis will also be presented.  Kaplan- Meier methodology will be 
used to estimate median PFS and O Sfor each treatment arm, and a Kaplan -Meier curve will be 
constructed to provide a visual description of the difference between treatment arms.   The 
Brookmeyer -Crowley methodology will be used to construct the 95% CI for the median PFS and 
the median OS for each treatment arm.
Determination o f Sample Size
This study will randomize approximately 1025 patients, including approximately 513 patients in 
the tGE population, assuming a 50% prevalence with the chosen tGE cutoff.
The sample size of this study is based on the number of events required t o demonstrate 
efficacy  with regard to both PFS and OS (co-primary  endpoints) for the comparison of Arm B 
versus Arm C.
The estimate of the number of events required to demonstrate efficacy with regard to PFS in the 
comparison of Arm B versus Arm C is based on the following assumptions:
One-sided significance level of 0.003 for the comparison of Arm B versus Arm C in the tGE 
population
One-sided significance level of 0.003 for the comparison of Arm B versus Arm C in the 
ITTpopulation
97% power to detect an HR of 0.55, corresponding to an improvement in median PFS from 
6 months to 10.9 months in the tGE population
98% power to detect an HR of 0.65, corresponding to an improvement in median PFS from 
6 months to 9.2 months in the ITT populati on
No interim analyses for PFS
Dropout rate of 5% per [ADDRESS_121733] to OS in the 
comparison of Arm B versus Arm C is based on the following assumptions:
One-sided significance level of 0.022 for the comparison of Arm B versus Arm C i n the 
ITTpopulation
86% power to detect an HR of 0.75, corresponding to an improvement in median OS from 
12 months to 16 months in the ITT population
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
28/Protocol GO29437 , Version 7One interim OS analy sis performed at the time of the final PFS analysis, at which time 
approximately 76% of the total number of OS events required for the final analysis are 
expected to have occurred, as determined through use of the Lan -DeMets approximation to 
the O’Brien -Fleming boundary
Dropout rate of 5% per 24 months
With these assumptions, approximately 1025 patients in total will be enrolled into this study, 
with approximately 684 patients in each comparison (i.e., Arm B vs. Arm C, Arm A vs. Arm C).  
The final PFS analysis w ill be conducted when allof the following criteria have been met:  
approximately [ADDRESS_121734] patient is enrolled.
Interim A nalyses
There areno interim analy ses planned for PFS in this study.  An external independent Data 
Monitoring Committee (iDMC) will be set up to evaluate s afety data on an ongoing basis.  All 
summaries/analyses by [CONTACT_70097]’s review will be prepared by [CONTACT_70098] (iDCC).  Members of the iDMC will be external to the 
Sponsor and will follow a charter that outlines their roles and responsibilities.  Any outcomes of 
these safety reviews that affect study conduct will be communicated in a timely manner to the 
investigators for notification of the Institutional Review Boards (IRBs)/Ethics Committees (ECs).  
A detailed p lan will be included in the iDMC Charter.
If approximately [ADDRESS_121735] occurred in Arms B and C combined in the ITT population 
at the time of the final PFS analysis (see criteria for final PFS analysis in Section 6.1), an interim 
OS analy sis will be conducted for Arm B versus Arm C in the ITT population.  If there are 
significantly fewer than the expected 365 OS events at the final PFS analy sis, a nominal of 
0.01% (negligible impact on overall type I error rate) wil l be spent on the OS analysis at the time 
of the final PFS analysis and a second interim OS analysis will then be conducted after 
approximately [ADDRESS_121736] patient is enrolled.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
29/Protocol GO29437 , Version 7LIST OF A BBREVI ATIONS AND DEFINITIONS OF TERMS
Abbrev iation Definition
anti-HBc antibody to hepatitis B core antigen
ATA anti-therapeutic antibody
AUC area under the concentration time curve
BSC best supportive care
CL clearance
Cmax maximum observed serum concentration
Cmin minimum observed serum concentration
CR complete response
CRC colorectal cancer
CRCL creatinine clearance
CRF Case Report Form
ctDNA circulating -tumor DNA
Ctrough trough concentration
DCR disease control rate
DLT dose -limiting toxicity
DOR duration of response
EC Ethics Committee
ECOG Eastern Cooperative Oncology Group
eCRF electronic Case Report Form
EDC electronic data capture
EORTC European Organisation for Research and Treatment of Cancer
ePRO electronic PRO
EQ-5D-3L Euro QoL5 Dimensions [ADDRESS_121737] ratio
HRQoL health- related quality of life
IC tumor- infiltrating immune cell
ICH International Council for Harmonisation
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
30/Protocol GO29437 , Version 7Abbrev iation Definition
iDCC independent Data Coordinating Center
iDMC independent Data Monitoring Committee
Ig immunoglobulin
IHC immunohistochemistry
IMP Investigational Medicinal Product
IND Investigational New Drug 
IRB Institutional Review Board
IRF Independent Review Facility
ITT intent to treat
IV intravenous
IxRS interactive web/voice response system
LFT liver function test
MP Medicinal Product
MTD maximum tolerated dose
NCCN National Comprehensive Cancer Network
NCI CTCAE National Cancer Institute Common Terminology Criteria for Adverse Even ts
NGS next-generation sequencing
NIMP Non-Investigational Medicinal Product
NSCLC non small cell lung cancer
ORR objective response rate
OS overall survival
PET positron emission tomography
PFS progression -free survival
PGIS Patient Global Impression of Severity
PK pharmacokinetic
PR partial response
PRO patient -reported outcome
PVC polyvinylchloride
Q3W every 3 weeks
QLQ -C30 Quality -of-Life Questionnaire Core 30
QLQ -LC13 Quality -of-Life Questionnaire Lung Cancer Module
qRT-PCR quantitative reverse transcriptase polymerase chain reaction
RCC renal cell carcinoma
RCR [COMPANY_002] Clinical Repository
RECIST Response Evaluation Criteria in Solid Tumors
SAP Statistical Analysis Plan
SILC Symptoms in Lung Cancer
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
31/Protocol GO29437 , Version 7Abbrev iation Definition
TC tumor cell
TE thromboembolic events
tGE tumor gene expression
TIR time in response
TKI tyrosine kinase inhibitor
TNF- tumor necrosis factor 
TSH thyroid- stimulating hormone
TTD time to deterioration
TTF-1 thyroid transcription factor [ADDRESS_121738] upper limit of normal
VEGF vascular endothelial growth factor
Vss volume of distribution at steady state
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
32/Protocol GO29437 , Version 71. BACKGROUND
1.1 BACKGROUND ON LUNG C ANCER
Lung cancer remains the leading cause of cancer deaths worldwide; it is the most 
common cancer in both me n and women and accounted for approximately 13% of all 
new cancers in 2008 ( Jemal et al. 2011).  In 2012, it was estimated that there would be 
226,160 new cases of lung cancer and 160,340 lung cancer deaths in the [LOCATION_002] 
alone (Siegel et al. 2012 ). Similar data from Europe estimate that there were 
288,000 new cases of lung cancer and 253,000 deaths in 2008 ( GLOBOCAN 2008 ). 
Nonsmall cell lung cancer (NSCLC) is the predominant subtype of lung cancer, 
accounting for approximately 85% of all cases ( Molina et al. 2008; Howlader etal.2014 ).  
NSCLC can be divided into two major histologic types:  adenocarcinoma and squamous 
cell carcinoma ( Travis et al. 2011 ).  Adenocarcinoma histology accounts for more than 
half of all NSCLC, while squamous cell histol ogy accounts for approximately 25% 
(Langer et al.2010 ).  The remaining cases of NSCLC are represented by [CONTACT_70099], neuroendocrine tumors, sarcomatoid carcinoma, and poorly differentiated 
histology.
Theoverall 5 -year survival rate for advanced disease is 2% 4%, depending on 
geographic location (Cetin et al. 2011 ).  Poor prognostic factors for survival in patients 
with NSCLC include advanced stage of disease at the time of initial diagnosis, poor 
performance status, and a history of unintentiona l weight loss.  More than half of the 
patients with NSCLC are diagnosed with distant disease, which directly contributes to 
poor survival prospects.
There are recognized differences in disease characteristics between adenocarcinoma 
and squamous NSCLC.  First, squamous tumors commonly present in the central 
airways and typi[INVESTIGATOR_70038] ( Hirsch et al. 2008 ), 
whereas non- squamous tumors are more commonly located in the lung parenchyma 
distal to the central airways.  Eva luation of NSCLC tumor tissue will reveal cytological 
differences between the squamous cell type (keratinization, intracellular bridges, and 
central necrosis) and adenocarcinoma (glandular architecture).  In cases where the 
tumor sample is poorly different iated or there is limited tissue available, 
immunohistochemical markers may support the histologic diagnosis.  Thyroid 
transcription factor [ADDRESS_121739], p63, CK5/6, an d 34E12 are strongly 
expressed in squamous cell carcinoma and less frequently in adenocarcinoma 
(Travis etal.2011 ).
Genetic changes that have prognostic and/or predictive significance in NSCLC include 
mutations in the EGFR , the rearrangement in the ALK genes, and mutations in the 
KRAS gene.  The rates of these mutations differ between squamous cell carcinoma and 
adenocarcinoma.  For example, EGFR kinase domain mutations have been reported in 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
33/Protocol GO29437 , Version 710%40% of patients with adenocarcinoma NSCLC but are infrequen tly observed in 
squamous NSCLC (Herbst et al. 2008).  Similarly, the ALK fusion oncogene, recognized 
as a driver of lung tumorigenesis, is observed in approximately 7% of patients with 
adenocarcinoma but is very rare in the squamous histology (Herbst etal.2008; Langer 
et al. 2010).  In addition, KRAS mutations are very rare in squamous NSCLC, while they 
can be observed in up to 30% of cases of adenocarcinoma NSCLC (Travis etal.2011).
1.1.[ADDRESS_121740] -Line Treatment for A dvanced Non Small Cell Lung 
Cancer with an EGFR Mutation or ALK Rearrangement
Genotype- directed therapy has the potential to dramatically improve the balance of 
benefit and toxicity for selected patients with NSCLC characterized by [CONTACT_70100], including sensitizing EGFR mutations and ALK rearrangements.  
However, these mutations are more prevalent in adenocarcinoma NSCLC and are very 
rare in squamous NSCLC.  Randomized Phase III studies of gefitinib (IPASS), erlotinib 
(EURTAC), and afatinib (LUX -Lung3) showed significant improvement of PFS and 
objective response rate ( ORR) compared with platinum doublet chemotherapy (Fukuoka 
et al. 2011; Rosell etal.2012; Sequist et al. 2013; respectively).  Similarly, the ALK
inhibitor crizotinib (XALKORI®)has demonstrated efficacy in patients with NSCLC 
positive for ALK rearrangement as defined by [CONTACT_26707] (Crino et 
al. 2011; Camidge et al.2012; Shaw etal.2012; XALKORI®U.S. Package Insert [USPI]).  
Both EGFR tyrosine kinase inhibitors (TKIs) and crizotini b have been shown to be 
generally well tolerated.  
1.1.[ADDRESS_121741] evidence that chemotherapy produced a significant survival 
benefit in patients with advanced NSCLC came in 1995; a meta -analysis showed that 
platinum -based doublet chemotherapy conferred a [ADDRESS_121742] supportive care (BSC) (NSCLC Collaborative Group 1995 ).  
More recently, the European Big Lung Trial demonstrated the potential benefits of 
chemotherapy.  In this study, 725 patients with advanced NSCLC were randomly
assigned to BSC plus cisplatin -based chemotherapy or BSC alone ( Spi[INVESTIGATOR_70040]. 2004).  
Patients allocated to chemotherapy had a significantly longer median survival 
than didthose managed with BSC (8 versus 5.7months; hazard ratio [HR] 0.77, 
95% CI:0.66,0.89). 
Recently, immune checkpoint inhibitors, including PD-L1/PD -1blocking antibodies, have 
emerged as a new therapeutic option for first -line treatment of metastatic NSCLC.  Study 
KEYNOTE -024 was a Phase III, randomized, open -label study evaluating 
pembrolizumab given as monotherapy compared with platinum -based chemotherapy in 
patients who had previously untreated advanced NSCLC with PD -L1 expression on at 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
34/Protocol GO29437 , Version 7least 50% of tumo r cells.   Patients with sensitizing mutation of the EGFR gene or 
translocation of the ALK gene were excluded from this study.   In this study, median PFS 
was 10.3 months in the pembrolizumab group versus 6.0 months in the chemotherapy 
group (HR 0.50; 95% C I: 0.37 ,0.68; p<0.001).  The estimated rate of overall survival 
(OS)at 6 months was 80.2% (95% CI: 72.9 %, 85.7%) in the pembrolizumab group 
versus 72.4% (95% CI: 64.5 %, 78.9%) in the chemotherapy group; median OS was not 
reached in either group.  OSwas significantly longer in the pembrolizumab group than in 
the chemother apy group (HR 0.60; 95% CI: 0.41, 0.89; p 0.005 ) (Reck et al. 2016 ).  
On the basis of this study, pembrolizumab wasapproved for the first -line treatment of 
metastatic NSCLC in patients whose tumors have high PD -L1 expression (tumor
proportion score 50%) with no EGFR or ALK gene aberrations.
1.1.[ADDRESS_121743] of care for patients with inoperable Stage IIIB and 
Stage IV NSCLC is platinum -based chemotherapy for 4 [ADDRESS_121744] of care applies to both 
non-squamous and squamous NSCLC ( Pfister et al. 2004; D’Addario et al. 2010 ; 
DeMaininis etal.2011 ; National Comprehensive Cancer Network [NCCN] 2014 ).  
Agents that have been partnered with either cisplatin or carboplatin include the taxanes 
(paclitaxel, docetaxel), vinorelbine, gemcitabine, and pemetrexed.  Combinations of 
these drugs with platinum analogs are superior to single -agent therapy and have been 
shown to prolong survival ( Azzoli et al. 2009 ).
The Eastern Cooperative Oncology Group (ECOG) conducted a Phase III study 
(Study E1594) to compare four commonly used platinum -based doublets in patients with 
Stage IIIB/IV NSCLC who had not previously received chemotherapy 
(Schiller etal.2002 ).  Gemcitabine cisplatin, docetaxel cisplatin, 
andpaclitaxel carboplatin were compared with paclitaxel cisplatin.  N o significant 
clinical advantage of any one of the chemotherapy regimens over the others was 
observed; the median survival rates of the four treatment arms were approximately the 
same:  approximately 8 months.  T he regimen of paclitaxel carboplatin was chosen as 
the reference regimen for ECOG’s future studies because of its more favorable toxicity 
profile.
Despi [INVESTIGATOR_109771], the benefit conferred by [CONTACT_70101] -based chemotherapy regimens 
appears to have reached a plateau in the objective response rate (approximately 
15%25%) and median survival (7 11 months; see Table 1 ).
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
35/Protocol GO29437 , Version 7Table 1Randomized Phase III Studies in Patients with Previously  
Untreated NSCLC
Treatment GroupORR
(%)Median 
PFS
(months)Median OS
(months)OS HR
95% CI
Chemotherapy a
Cisplatin and paclitaxel (n 288) 21 3.4 7.8
Cisplatin and gemcitabine (n 288) 22 4.2 8.1
Cisplatin and docetaxel (n 289) 17 3.7 7.4
Carboplatin and paclitaxel (n 290) 17 3.1 8.1
Chemotherapy biologic b
Carboplatin and paclitaxel (n 444) 15 4.5 10.3
0.79
0.67 0.92Carboplatin, paclitaxel, and bevacizumab 
(n434)35 6. 2 12.3
Chemotherapy c
Cisplatin and pemetrexed, overall (n 839) 31 4.8 10.3 0.94
0.84 1.05 Cisplatin and gemcitabine, overall ( n830) 28 5.1 10.3
Cisplatin and pemetrexed, non- squamous NR 5.3 11.8 0.81
0.70 0.94 Cisplatin and gemcitabine, non -squamous NR 4.7 10.4
Cisplatin and pemetrexed, squamous NR 4.4 9.4 1.23
1.00 1.51 Cisplatin and gemcitabine, squamous NR 5.5 10.8
Chemotherapy d
Carboplatin and nab -paclitaxel, overall 
(n521)33 6.3 12.1
0.922
0.797 1.066
Carboplatin and paclitaxel, overall ( n531) 25 5.8 11.2
Carboplatin and nab -paclitaxel, 
non-squamous ( n221)26 6.9 13.1
0.950
NR Carboplatin and paclitaxel, non -squamous 
(n292)25 6.5 13.0
Carboplatin and nab -paclitaxel, squamous 
(n300)41 5.6 10.7
0.890
0.719 1.101 Carboplatin and paclitaxel, squamous 
(n229)24 5.7 9.5
Chemotherapy biologice
Cisplatin and vinorelbine (n 568) 29 4.8 10.1
0.871
0.762 0.996Cisplatin, vinorelbine, and cetuximab 
(n557)36 4.8 11.3
Atezolizumab—F. Hoffmann-La [COMPANY_002] Ltd
36/Protocol GO29437, Version 7Table 1 Randomized Phase III Studies in Patients with Previously 
Untreated NSCLC (cont.)
Treatment GroupORR
(%)Median 
PFS
(Months)Median OS
(Months)OS HR
95% CI
Immunotherapy f
Pembrolizumab, PD-L1 positive ( ∃50%) 
(n−154)45 10.3 Not 
reached 0.60
0.41!0.89 Platinum-based chemotherapi[INVESTIGATOR_014], PD-L1 
positive ( ∃50%) (n−151)[ADDRESS_121745] ratio; NRnot reported; ORRobjective response rate; OSoverall survival; 
PFSprogression-free survival.
aSchiller et al. 2002.
bSandler et al.2006.
cScagliotti et al.2008.
dSocinski et al. 2012.
ePi[INVESTIGATOR_109772] 2009.
fReck et al. 2016.
Several meta-analyses have comparedthe use of cisplatin and carboplatin as 
treatments for NSCLC.  In general, although the objective response rate was higher in patients treated with cisplatin than in those treated with carboplatin, the1-year andoverall survival rates were comparable.  When given in combination with a third-generation chemotherapy, cisplatin may result in longer survival than carboplatin (OR 30% vs.24%, respectively; Hotta et al. 2004; Ardizzoni et al. 2007), but overall benefit was quite marginal and subgroup analyses including additional, more recent studies indicate that there may be no difference between the two agents (Jiangetal.2007, Azzolietal.2007).
With regard to safety, cisplatin-based chemotherapy was associated with more severe 
nausea and vomiting and nephrotoxicity, while severe thrombocytopenia was more frequent during carboplatin-based chemotherapy (Hottaetal.2004; Ardizzonietal.2007).  The risk of treatment-related deaths was greater in the cisplatin arm, but this increase was not statisticallysignificant (Jiang et al. 2007).  
Data from a large randomized Phase III study demonstrated that patients with squamous 
NSCLC had inferior PFS and OS with the combination of pemetrexed ∀cisplatin 
compared with gemcitabine ∀cisplatin, as evidenced by [CONTACT_109799] (HRs) for both 
endpoints (PFS: HR −1.36, p−0.002; OS: HR −1.23, p−0.05) (Scagliotti et al. 2008).  
The median duration of PFS was 4.4 months in those who received cisplatin∀pemetrexed versus 5.5 months in the cisplatin ∀gemcitabine–treated patients.  
OS in the cisplatin ∀pemetrexed group was 9.4 months versus 10.8 months in the 
cisplatin∀gemcitabine group.  In addition, maintenance therapy with pemetrexed 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
37/Protocol GO29437 , Version 7produced no improvement in PFS or OS when compared with placebo in patients with 
advanced NSCLC who achieved stable disease after 4 cycles of platinum -based doublet 
therapy ( Ciuleanu et al. 2009 ).  One possible explanation for the differential benefit 
between squamous and non -squamous NSCLC with pemetrexed is the difference in th e 
protein level of thymidylate synthase (TS), the primary target of pemetrexed.  Squamous 
NSCLC tumors have higher TS levels, which may account for the decreased response to 
pemetrexed ( Ceppi [CONTACT_2297]. 2006).
Few studies have prospectively evaluated gemcitabi ne versus paclitaxel in patients with 
squamous NSCLC.  While both agents have activity in NSCLC ( Treat et al. 2010 ), a 
retrospective analysis of data generated from a large randomized Phase III clinical study 
revealed significantly different efficacy resul ts by [CONTACT_109800] ( Treat et al. 2010 ).  In 
this analysis, efficacy results were similar across three treatment regimens in patients 
with non -squamous NSCLC.  However, patients with squamous NSCLC who received 
paclitaxel carboplatin (n 61) had a med ian survival of 10.3 months (95% CI: 8.7, 12.0) 
compared with 6.6 months (95% CI: 5.1, 9.5) in patients who received 
gemcitabine carboplatin (n 67); the adjusted HR was0.73 (95% CI: 0.50, 1.07), and 
the histology -by-treatment interaction p -value was 0 .04.  Additionally, the overall 
response rate (45.9% vs.25.4%) and median time to progression (5.7 months vs. 
4.3months) was higher in patients who received paclitaxel carboplatin versus 
gemcitabine carboplatin .  From a safety perspective, the combin ation of gemcitabine 
and carboplatin was associated with significantly more Grade 34hematologic toxicity 
but less sensory neuropathy than the paclitaxel carboplatin combination.  In summary, 
the data from this analysis suggests that the combination of paclitaxel carboplatin has a 
more favorable benefit –risk profile compared with gemcitabine carboplatin in patients 
with squamous NSCLC.
A potential explanation for the difference in efficacy results by [CONTACT_109801]1 expression, which 
has been shown in both tumor cell lines and in clinical NSCLC samples to correlate with 
resistance to gemcitabine ( Gong etal.2012 ;Rosell etal.2004 ; Bepler etal.2004 ; 
Ceppi [INVESTIGATOR_109773].2006 ).  RRM1 mRNA expression levels have been shown to differ by [CONTACT_109802].  An evaluation of tissue specimens for RRM1 from 1104 patients with NSCLC 
(n678 adenocarcinoma, n 426 squamous NSCLC) suggests that the great majority of 
patients with squamous NSCLC (87%) have high RRM1 mRNA expression and, 
subsequently, may derive little benefit from gemcitabine -containing chemotherapy 
(Gandara et al. 2010 ).
1.1.4 nab-Paclitaxel Carboplatin for First- Line NSCLC
Socinski et al. ( 2012 ) conducted a Phase III randomized study evaluating the efficacy 
and safety of albumin- bound paclitaxel (nab- paclitaxel; ABRAXANE®)carboplatin 
compared with solvent -based paclitaxel carboplatin in 1052 previously untreated 
patients with NSCLC.  The primary efficacy endpoint of this study was ORR with 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
38/Protocol GO29437 , Version 7secondary endpoints of progression -free survival (PFS) and overall survival (OS).  
Patients treated with nab -paclitaxel carboplatin demonstrated a significantly improved 
ORR compared with patients treated with paclitaxel carboplatin (33% v s. 25%; 
response rate ratio [RRR] 1.31; p0.005), with patients with squamous histology 
experiencing the greatest improvement (41% vs. 24%; RRR 1.68; p0.001).  In 
patients with non -squamous histology, nab -paclitaxel carboplatin achieved a similar 
ORR as paclitaxel carboplatin ( 26% vs. 25%, respectively).  There was a comparable 
improvement in PFS (6.3 months vs. 5.8 months; HR0.902, 95% CI: 0.767 1.060) and 
OS (12.1 months vs. 11.2 months; HR0.922, 95% CI:0.797 1.066) i n patients 
treated with nab- paclitaxel carboplatin compared with paclitaxel carboplatin in the 
intent -to-treat ( ITT)population, respectively.  No clinically meaningful differences were 
seen with respect to PFS (6.9 months [nab -paclitaxel carboplatin] vs. 6.5 months 
[paclitaxel carboplatin]; HR0.933) or OS (13.1 months [nab -paclitaxel carboplatin] 
vs. 13.0 months [paclitaxel carboplatin]; HR0.950) in the non -squamous subgroups.  
A statistically non- significant improvement in OS was seen in patients with squamous 
histology (10.7 [nab-paclitaxel carboplatin] vs. 9.5 months [paclitaxel carboplatin]; 
HR0.890, 95% CI: 0.719, 1.101), with no difference in PFS observed in this 
subgroup.  On the basis of these comparable clinical results, th e regimen of nab -
paclitaxel carboplatin was approved for the treatment of NSCLC in the first -line 
setting in all histologies.  
1.1.5 Erlotinib Maintenance Therapy  for Squamous NSCLC
NCCN guidelines ( 2014 ) on chemotherapy for Stage IV NSCLC recommend that 
cytotoxic regimens consisting of two drugs should be given for no more than [ADDRESS_121746] -line cytotoxic chemotherapy at disease 
progression.  At study start , switch maintenance treatment with erlotinib in unselected 
patients could be considered for patients with stable disease or continued response to 
therapy after four to six cycles of chemotherapy (NCCN 2014 ).  This recommendation 
wasbased on the sequential Tarceva unresectable NSCLC study (SATURN), which had
shown a PFS and OS benefit after the initiation of erlotinib after induction treatment in 
patients with non -progressive disease.  The median PFS in patients receiving 
maintenance therapy with erlotinib was statistically significantly longer than in patients 
receiving placebo (12.3 vs. 11.1 weeks; HR 0.71, 95% CI: 0.62, 0.81; p 0.0001).  
Maintenance treatment with erlotinib also yielded a statistically significant yet clinically 
modest improvement in OS (12.0 vs. 11.0 months; HR 0.81, 95% CI: 0.70, 0.95; 
p0.0088).  A statistically significant improvement in PFS and OS was seen in patients 
with EGFR wild-type and EGFR mutation positive tumors ( Cappuzzo etal.2010 ).  This 
Phase III study resulted in regulatory approval (U.S. Food and Drug Administration [FDA] 
and European Medicines Agency) for erlotinib as maintenance therapy of patients with 
locally advanced or metastatic NSCLC whose disease has not progressed aft er [ADDRESS_121747] demonstrated that 
patients with advanced or recurrent (Stage IIIB) or metastatic (Stage IV) NSCLC whose 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
39/Protocol GO29437 , Version 7tumor did not harbor an EGFR -activating mutation did not achieve benefit from first -line 
maintenance therapy with erlotinib compared with placebo.  OS was not superior in 
patients randomized to receive maintenance erlotinib followed by [CONTACT_109803] (HR 1.02, 95% CI: 0.85, 1.22; 
p0.82).  In the maintenance phase, patients who received erlotinib al so did not have 
superior PFS compared with patients who received placebo (HR 0.94, 95% CI: 0.80, 
1.11; p 0.48).  This change in the benefit -risk assessment of erlotinib as switch 
maintenance therapy in patients whose tumors do not harbor an activating EGFR
mutation has led to the removal of this treatment option from this protocol.
1.2 BACKGROUND ON ATEZOLIZUMA B (MPDL3280A )
Atezolizumab (MPDL3280A) is a humanized immunoglobulin (Ig) G1 monoclonal 
antibody consisting of two heavy chains (448 amino acids) and two light chains 
(214 amino acids) and is produced in Chinese hamster ovary cells.  Atezolizumab was 
engineered to eliminate Fc -effector function via a single amino acid substitution at 
position 298 on the heavy chain, which results in a non -glycosylated antibody that has 
minimal binding to Fc receptors and prevents Fc -effector function at expected 
concentrations in humans.  Atezolizumab targets human PD-L1 and inhibits its 
interaction with its receptors, PD-1, and B7.1 (CD80, B7- 1).  Both of these interac tions 
are reported to provide inhibitory signals to T cells.
Atezolizumab is being investigated as a potential therapy against solid tumors and 
hematologic malignancies in humans. Atezolizumab is approved for the treatment of
patients with metastatic NSCLC after prior chemotherapy andfor the treatment of
patients with locally advanced or metastatic urothelial carcinoma after prior 
chemotherapy .
1.2.1 Summary  of Nonclinical Studies
The nonclinical strategy of the atezolizumab program was to demonstrate in vitro and 
invivo activity, to determine in vivo pharmacokinetic (PK) behavior, to demonstrate an 
acceptable safety profile, and to identify a Phase I starting dose.  Comprehensive 
pharmacology, PK, and toxicology evaluations were th usundertaken with atezolizumab.
The safety, pharmacokinetics, and toxicokinetics of atezolizumab were investigated in 
mice and cynomolgus monkeys to support intravenous (IV) administration and toaid 
inprojecting the appropriate starting dose in humans. Given the similar binding of 
atezolizumab for cynomolgus monkey and human PD -L1, the cynomolgus monkey was 
selected as the primary and relevant nonclinical model for understanding the safety, 
pharmacokinetics, and toxicokinetics of atezolizumab.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
40/Protocol GO29437 , Version 7Overall, the nonclinical pharmacokinetics and toxicokinetics observed for atezolizumab 
supported entry into clinical studies, including providing adequate safety factors for the 
proposed Phase I starting doses.  The results of the toxicology program were consistent
with the anticipated pharmacologic activity of downmodulating the PD -L1/PD -[ADDRESS_121748] 
and supported entry into clinical studies in patients.
Refer to the Atezolizumab Investigator’s Brochure for details on the nonclinical studies.
1.3 CLINICA L EXPERIENCE WITH ATEZOLIZUMA B
1.3.1 Ongoing Clinical Studies
Atezolizumab is currently being tested in multiple Phase I, II, and III studies, both as 
monotherapy and in combination with several anti- cancer therapi[INVESTIGATOR_014] (see the 
Atezolizumab Investigator’s Brochure for study descrip tions).  The single- agent safety 
and efficacy data that are summarized below include data from the following studies:
Study PCD4989g:  A Phase Ia, multicenter, first -in-human, open -label, 
dose- escalation study evaluating the safety, tolerability, immunogen icity, 
pharmacokinetics, exploratory pharmacodynamics, and preliminary evidence of 
biologic activity of atezolizumab administered as a single agent by [CONTACT_33433] 
3weeks ( Q3W)to patients with locally advanced or metastatic solid malignancies or 
hematologic malignancies
Study GO28753 (POPLAR):  A randomized, Phase II, open -label study assessing 
the clinical benefit of atezolizumab as a single agent versus docetaxel in patient s 
with locally advanced or metast atic NSCLC that has progressed during or fo llowing 
treatment with a platinum -containing regimen
Study GO28915 (OAK):  A randomized, Phase III, open- label study assessing the 
efficacy and safety of atezolizumab as a single agent versus docetaxel in patients 
with locally advanced or metastatic NSCLC that has progressed during or following 
treatment with a platinum -containing regimen
Study GP28328:  A Phase Ib study assessing the safety and pharmacology of 
atezolizumab in combination with bevacizumab and/or chemotherapy in patients 
with advanced solid tumors.
1.3.2 Clinical Safety
[IP_ADDRESS] Single -Agent Clinical Safety  in Patients with NSCLC in 
Study PCD4989g
Study PCD4989g, in which atezolizumab is being used as a single agent in patients with 
locally advanced or metastatic solid tumors or hematologic malignancies, p rovides the 
majority of data (with 558 safety -evaluable patients as of the data extraction date of 
11May2015) for the safety profile of atezolizumab as monotherapy.
Currently, no maximum tolerated dose (MTD), no dose -limiting toxicities (DLTs), and no 
clear dose -related trends in the incidence of adverse events have been determined.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
41/Protocol GO29437 , Version 7The safety profile of atezolizumab as a single agent is observed to be consistent across 
different indications.  The most common cancer types for these patients include NSCLC,
urothelial bladder cancer, melanoma, and renal cell carcinoma.  Safety data for NSCLC 
are also derived from Studies GO28625 (FIR) , GO28915 (OAK), and GO28753 
(POPLAR).
Adverse Events
Of the 558 patients, 520 (93.2%) patients experienced at least one adver se event, 
including 376 patients (67.4%) who experienced one treatment -related adverse event.  
Commonly reported events (reported in10% of all patients) included fatigue, decreased 
appetite, nausea, pyrexia, constipation, and cough (see Table 2 ).  
Table 2Study PCD4989g:   Adverse Events with Frequency  10% of 
Patients for A ll Grades
Adverse EventAll Grades
n (%)All Grades 
Related
n (%)Grade 3 4
n (%)Grade 34 
Related
n (%)
Any adverse event 520 (93.2) 376 (67.4) 239 (42.8) 66 (11.8)
Fatigue 192 (34.4) 115 (20.6) 13 (2.3) 6 (1.1)
Decreased appetite 142 (25.4) 62 (11.1) 4 (0.7) 0 (0.0)
Nausea 136 (24.4) 65 (11.6) 5 (0.9) 2 (0.4)
Pyrexia 117 (21.0) 63 (11.3) 2 (0.4) 0 (0.0)
Constipation 116 (20.8) 8 (1.4) 2 (0.4) 0 (0.0)
Cough 113 (20.3) 11 (2.0) 1 (0.2) 1 (0.2)
Dyspnea 112 (20.1) 18 (3.2) 18 (3.2) 4 (0.7)
Diarrhea 110 (19.7) 53 (9.5) 2 (0.4) 1 (0.2)
Anem ia 104 (18.6) 26 (4.7) 23 (4.1) 5 (0.9)
Vomiting 96 (17.2) 28 (5.0) 3 (0.5) 2 (0.4)
Asthenia 88 (15.8) 53 (9.5) 8 (1.4) 4 (0.7)
Back pain 85 (15.2) 9 (1.6) 8 (1.4) 1 (0.2)
Headache 83 (14.9) 32 (5.7) 2 (0.4) 1 (0.2)
Arthralgia 79 (14.2) 35 (6.3) 2 (0.4) 0 (0.0)
Pruritus 75 (13.4) 55 (9.9) 0 (0.0) 0 (0.0)
Rash 73 (13.1) 53 (9.5) 0 (0.0) 0 (0.0)
Abdominal pain 63 (11.3) 12 (2.2) 8 (1.4) 0 (0.0)
Insomnia 62 (11.1) 7 (1.3) 1 (0.2) 0 (0.0)
Peripheral edema 59 (10.6) 7 (1.3)  
Chills 57 (10.2) 31 (5.6) 0 (0.0) 0 (0.0)
Note:  “” refers to missing Common Terminology Criteria grade.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
42/Protocol GO29437 , Version 7Grade 3 or4adverse events (on the basis of National Cancer Institute Common 
Terminology Criteria for Adverse Events, Version 4 [NCI CTCAE v4 .0]) were reported in 
239 patients (42.8%), of which 66 (11.8%) were considered related.  Grade [ADDRESS_121749], increased gamma -glutamyl transferase (GGT), 
lymphocyte count decreased, cardiac tamponade, asthenia, autoimmune hepatitis, 
pneumonia, influenza, and hypoxia .
Refer to the Atezolizumab Investigator’s Brochure for details on adverse events 
observed in patients treated with atezolizumab.
Immune -Mediated A dverse Ev ents
Given the mechanism of action of atezolizumab, events associated with inflammation 
and/or immune- mediated adverse events have been closely monitored during the 
atezolizumab clinical program.  These include potential dermatologic, hepatic, endocrine, 
gastro intestinal, and respi[INVESTIGATOR_29343].  
Refer to the Atezolizumab Investigator’s Brochure for details on immune -mediated 
adverse events that were observed in patients treated with atezolizumab.  Guidelines for 
the management of immune- mediated adverse events are described in Section [IP_ADDRESS]. 
[IP_ADDRESS] Single -Agent Clinical Safety  in Patients with NSCLC in 
Study GO28753 ( POPLA R)
As of the 1 December 2015 data cu toff date, the Phase II Study GO28753 (POPLAR) 
included data from 277 safety -evaluable patients treated with either atezolizumab as a 
fixed dose of 1200 mg IV every 3 weeks (Q3W) (n 142) or docetaxel 75 mg/m2IV Q3 W 
(n135).   The frequency of patients in the POPLAR study who reported any adverse 
event regardless of attribution was 95.8%for the atezolizumab arm and 96.3%for the 
docetaxel arm.  A higher frequency of Grade 3or 4adverse events was observed 
among patients in the docetaxel arm ( 52.6% vs. 40.8% ), explained primarily by [CONTACT_109804]. The frequency of 
patients who discontinued treatment because of adverse events was higher in the 
docetaxel arm than in the atezolizumab arm (22.2% vs. 8.5%).  Adverse events reported 
in at least 10% of patients in either treatment arm are listed in Table 3 .
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
43/Protocol GO29437 , Version 7Table 3Study GO28753 (POPLA R):  Adverse Events Reported in at Least 
10% of Patients
No. of Patients (%)
Adverse EventAtezolizumab
(n142)Docetaxel
(n135)
Fatigue 55 (38.7) 54 (40.0)
Decreased appetite 49 (34.5) 28 (20.7)
Nausea 32 (22.5) 45 (33.3)
Cough 40 (28.2) 33 (24.4)
Dyspnea 39 (27.5) 27 (20.0)
Constipation 31 (21.8) 32 (23.7)
Diarrhea 25 (17.6) 38 (28.1)
Alopecia 3 (2.1) 52 (38.5)
Anem ia 25 (17.6) 27 (20.0)
Pyrexia 24 (16.9) 16 (11.9)
Vomiting 20 (14.1) 18 (13.3)
Asthenia 15 (10.6) 22 (16.3)
Arthralgia 22 (15.5) 12 (8.9)
Insomnia 22 (15.5) 11 (8.1)
Rash 16 (11.3) 16 (11.9)
Back pain 16 (11.3) 11 (8.1)
Myalgia 9 (6.3) 18 (13.3)
Musculoskeletal pain 19 (13.4) 7 (5.2)
Weight decreased 16 (11.3) 9 (6.7)
Hemopty sis 15 (10.6) 8 (5.9)
Pneumonia 17 (12.0) 4 (3.0)
Neuropathy peripheral 3 (2.1) 16 (11.9)
Neutropenia 2 (1.4) 17 (12.6)
For additional information, refer to the Atezolizumab Investigator’s Brochure.
[IP_ADDRESS] Single -Agent Clinical Safety  in Patients with NSCLC in the 
Study GO28915 (OA K)
As of the 7 July 2016 data cutoff date for the primary analysis ,the Phase III Study 
GO28915 (OAK )included data from 609 patients treated with atezolizumab at a fixed 
dose of 1200 mg IV Q3W and 578 patients treated with docetaxel 75 mg/m2IV Q3W.  
The frequency of patients who reported any adverse event regardless of attribution was 
94.1% for the atezolizumab arm and 96.0% forthe docetaxel arm.  A higher frequency of 
Grade 3 or 4 adverse events was observed among patients in the docetaxel arm 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
44/Protocol GO29437 , Version 7(53.6% vs. 37.3% ). The frequency of patients who discontinued treatment because of 
adverse event s was higher in the docetaxel arm than in the atezolizumab arm (18.7% 
vs. 7.6%). Table 4lists adverse events with an arm difference frequency of at least 
5percentage points.
Table 4Adverse Events in Study GO28915 (OA K) with a Between -Arm 
Difference in Frequency  of at Least 5 Percentage Points
Adverse Event Atezolizumab Docetaxel
Fatigue 26.8% 35.5%
Alopecia 0.5% 34.9%
Diarrhea 15.4% 24.4%
Anem ia 11.5% 23.5%
Nausea 17.7% 22.7%
Myalgia 6.4% 15.7%
Neutropenia 1.6% 15.6%
Peripheral edema 8.9% 14.2%
Peripheral neuropathy 3.9% 11.2%
Stom atitis 3.1% 10.9%
Febrile neutropenia 0.2% 10.7%
Dysgeusia 3.0% 10.0%
Musculoskeletal pain 10.5% 4.3%
Pruritus 8.2% 3.1%
Source: Rittmeyer et al. 2017
[IP_ADDRESS] Clinical Safety  in Combination with Bevacizumab or 
Platinum- Based Doublet Chemotherapy
Study GP28328 is a Phase Ib study of atezolizumab in combination with bevacizumab or 
cytotoxic chemotherapy in patients with multiple tumor types including NSCLC, triple 
negative breast cancer , and colorectal cancer.  As of 10 February 2015, 144 patients 
had been enrolled in this study:  39 in Arm A ( atezolizumab bevacizumab ), 36 in Arm B 
(atezolizumab bevacizumab and FOLFOX), 14 in Arm C ( atezolizumab carboplatin
and paclitaxel), 24 in Arm D (atezolizumab carboplatin and pemetrexed), 20 in Arm E 
(atezolizumab carboplatin and nab -paclitaxel), and 11 in Arm F ( atezolizumab nab
paclitaxel).  The treatment combinations have been generally well tolerated.  No DLTs 
have been reported during the dose- escalation stage in any study arm.  Patients are 
being enrolled in safety and biopsy expansion cohorts in Arms A and B as well as in 
additional arms testing atezolizumab in combination with commonly used NSCLC 
chemotherapy doublets.  
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
45/Protocol GO29437 , Version 7A total of 141 of 144 patients (97.9% ) reported at least one adverse event while 
receiving study drug.  The majority of these events were Grade [ADDRESS_121750] commonly reported adverse events across the study arms ( 10% ofpatients) 
included fatigue, nausea, diarrhea, decreased appetite, and pyrexia.   The adverse 
events were consistent with the known safety profile of each agent (atezolizumab 
monotherapy and chemotherapy).  No additive effects were observed when 
atezolizumab was administered with chemotherapy.
Table 5Study GP28328:  A ll Reported A dverse Events
ParameterArm A
(n39)
No. (%)Arm B
(n36)
No. (%)Arm C
(n14)
No. (%)Arm D
(n24)
No. (%)Arm E
(n20)
No. (%)Arm F
(n12)
No. (%)All 
Patients
(n145)
No. (%)
Any AEs 39 (100) 36 (100) 14 (100) 24 (100) 19 (95.0) 10 (83.3) 142 (97.9)
Related AEs 29 (74.4) 28 (77.8) 12 (85.7) 19 (79.2) 19 (95.0) 6 (50.0) 113 (77.9)
Grade 3 5 AEs 20 (51.3) 29 (80.6) 12 (85.7) 17 (70.8) 18 (90.0) 6 (50.0) 102 (70.3)
Related Grade 3 5 
AEs1 (2.6) 7 (19.4) 4 (28.6) 4 (16.7) 11 (55.0) 4 (33.3) 31 (21.4)
Serious AEs 14 (35.9) 15 (41.7) 5 (35.7) 10 (41.7) 8 (40.0) 3 (25.0) 55 (37.9)
Related serious AEs 0 (0) 1 (2.8) 1 (7.1) 2 (8.3) 2 (10.0) 2 (16.7) 8 (5.5)
AEs leading to 
discontinuation1 (2.6) 4 (11.1) 0 (0) 1 (4.2) 1 (5.0) 0 (0) 8 (5.6)
AEs leading to 
death (Grade 5)0 (0) 2 (2.8) 1 (7.1) 2 (8.3) 2 (10.0) 1 (8.3) 7 (4.8)
Related AEs leading to 
death (Grade 5)0 (0) 0 (0) 0 (0) 1 (4.2) 0 (0) 0 (0) 1 (0.7)
Immune -mediated AEs 12 (30.8) 28 (77.8) 8 (57.1) 11 (45.8) 11 (55.0) 2 (16.7) 72 (49.7)
AEadverse event.
All [ADDRESS_121751] frequently reported events were consistent with the overall population and
included fatigue, nausea, diarrhea, decreased appetite, and pyrexia.  There were 
36patients enrolled in Arm B, and 97% of patients reported at least one adverse event.  
The most frequently reported adverse events ( 20% of patients) included fatigue, 
pyrexia, peripheral neuropathy, neutropenia, anemia, diarrhea, decreased appetite, 
temperature intolerance, constipation, vomiting, and nausea.  
All patients who were enrolled in Arms C and D experienced an adverse event; 95% of 
patients who were enrolled in Arm E experienced an adverse event, and 83.3 % of 
patients enrolled in Arm F experienced an adverse event.  The adverse events 
commonly reported in 2 or more patients in Arms C, D, and E included anemia, 
decreased appetite, hypomagnesemia, nausea, neutrop enia, constipation, vomiting, 
fatigue, rash, cough, and diarrhea.  Adverse events commonly reported in 2 or more 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
46/Protocol GO29437 , Version 7patients in Arm F included dermatitis, upper respi[INVESTIGATOR_4416], alopecia, peripheral 
sensory neuropathy, fever, constipation, neutrophil co unt decreased, anemia, diarrhea, 
headache, nausea, and fatigue.
1.3.3 Clinical A ctivity
Anti-tumor activity, including Response Evaluation Criteria in Solid Tumors 
(RECIST) ased responses (i.e., RECIST, Version 1.1 responses), has been observed in 
patients with different tumor types treated with atezolizumab monotherapy in 
Study PCD4989g. 
Refer to the Atezolizumab Investigator’s Brochure for additional details on clinical activity 
in all patients treated to date, regardless of tumor type.
[IP_ADDRESS] Single -Agent Clinical Activity in Patients with NSCLC in 
Study PCD4989g
As of the clinical data cutoff of 2 December 2014, the efficacy evaluable population 
included 88 patients with locally advanced or metastatic NSCLC.  The median age was 
60.5 years (range 2484 years) andrepresented a heavily pre-treated patient population:  
97% of the patients had received 2 prior systemic therapi[INVESTIGATOR_014] , and 77.3% had received 
4 prior systemic therapi[INVESTIGATOR_014] .
Overall, responses were observed in 20 of 88 (22.7%) patients with NSCLC and 
included r esponses in patients with squamous and non -squamous NSCLC (4 in 
21patients and 16 in 67 patients, respectively).  A total of [ADDRESS_121752] continued to respond at the time of the clinical data cutoff.
Table 6 displays the confirmed ORR, du ration of confirmed response (DO R), and 
6-month PFS rates by [CONTACT_4002] -L1 expression for patients with NSCLC.  These results are 
based on investigator assessed RECIST v 1.1.  Analyses of tumor -infiltrating immune 
cells (IC) and tumor cells (TC) for PD -L1 expression on baseline tumor tissue from 
NSCLC patients have been performed.  Higher ORRs were associated with higher 
PD-L1 expression.
Refer to the Atezolizumab Investigator’s Brochure for additional details on clinical activity 
in patients with NSCLC treated to date.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
47/Protocol GO29437 , Version 7Table 6Patients with NSCLC in Study  PCD4989g:  Investigator -Assessed 
Confirmed Objective Response Rate by [CONTACT_70108]-L1 Expression , 
Duration of Response, and Six-Month Progression -Free Survival 
Rates (per RECIST, Version 1.1)
PD-L1 IHC 
Expression 
CategoryORR by [CONTACT_393], 
Version 1.1
n88SD
(n/N)PD
(n/N)DOR (range 
in months)6-month 
PFS 
% (95% CI)
TC3 or IC3 50.0% (11 of 22)
(95%CI: 28.22%, 
71.78%)13.6%
(3/22)31.8%
(7/22)7.16 25.26 50.0
(29.1, 70.9)
TC3 or IC2/3 37.5% (15 of 40)
(95% CI: 22.73% , 
54.2%)12.5%
(5/40)45.0%
(18/40)7.16 26.74+ 44.9
(29.4, 60.3)
TC2/3 or IC2/3 33.3% (16 of 48)
(95%CI: 20.40%, 
48.41%)22.9%
(11/48)37.5%
(18/48)7.16 26.74+ 41.6
(27.6, 55.5)
TC0/1/2 and 
IC0/1/215.5% (9 of 58)
(95%CI: 7.35%, 
27.42%)37.9%
(22/58)37.9%
(22/58)7.16 26.74+ 41.1 
(28.4, 53.8)
TC0/1/2 and 
IC0/112.5% (5 of 40)
(95%CI: 4.19%, 
26.8%)37.5%
(15/40)40.0%
(16/40)9.92 24.74 42.3
(27, 57.7)
TC0/1 and IC0/1 12.5% (4 of 32)
(95% CI: 3.51%, 
28.99%)43.8%
(14/32)34.4%
(11/32)9.92 24.74 46.7
(29.3, 64.0)
DORduration of response; IC tumor-infiltrating immune cell; IHCimmunohistochemistry ; 
NSCLC non small cell lung cancer; ORR objective response rate; PFSprogression -free 
survival; PR partial response; SD stable disease; PD progressive disease; 
RECIS TResponse Evaluation Criteria in Solid Tumors; TCtumorcell.
Notes: This table is based on a data cutoff of 02 Dec 2014 of NSCLC patients. ORR includes 
confirmed responses.  “ ” denotes a censored value.
[IP_ADDRESS] Single -Agent Clinical A ctivity in Patients with NSCLC in Study  
GO28753 (POPLA R)
The primary OS analysis in Study GO28753 (POPLAR) was conducted when 
173deaths had occurred (clinical cutoff, 8 May 2015).  Key efficacy results for the
ITTpopulation are shown in Table 7 .  Atezoli zumab showed significant improvement in
OSoverall survival compared with docetaxel in patients with advanced, previously 
treated NSCLC unselected for PD -L1 expression.   OS was 12.6 months (95% CI: 9.7, 
16.4 months ) for atezolizumab versus 9.7 months (95% CI: 8.6, 12.0 months ) for 
docetaxel (HR 0.73; 95% CI: 0.53, 0.99; p 0.04).  PFS was similar between groups 
(2.7 months with atezolizumab vs.3.0 months with docetaxel ).Objective responses 
withatezolizumab were durable, with a median duration of 14.3 months (95% CI: 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
48/Protocol GO29437 , Version 711.6 months , not estimable) compared with 7.2 months (95% CI: 5.6, 12.5 months ) for 
docetaxel (see Table 7 ) (Fehrenbacher et al. 2016 ).
Table 7Efficacy  Results in Study GO28753 (POPLA R): 
Intent -to-Treat Population
Efficacy  EndpointAtezolizumab
(n144)Docetaxel
(n143)
Overall survival
No. of deaths (%) 78 (54.2) 95 (66.4)
Median (months)
95% CI12.[ADDRESS_121753] ratio
95% CI0.73
0.53, 0.99
Progression -free survival
No. of events (%) 124 (86.1) 121 (84.6)
Median (months)
95% CI2.[ADDRESS_121754] ratio
95% CI0.94
0.72, 1.23
Objective response rate (confirmed) 14.6% 14.7%
Duration of response
Median (months)
95% CI14.3 
11.6, NE7.2
5.6, 12.5
NEnot estimable.
At the time of an updated analysis representing an additional 7 months of follow-up 
(1 December 2015 data cutoff date), 200 of 287 randomized patients (70%) had died.  
Improvement in OS benefit was observed for atezolizumab compared with docetaxel 
in the ITT population (stratified HR 0.69; 95% CI: 0.52, 0.92) (see Table 8).  The 
median OS in the ITT population was 12.6 months (95% CI: 9.7, 16.0 months) in the 
atezolizumab arm and 9.7
 months (95% CI: 8.6, 12.0 months) in the docetaxel arm.  
PFS was similar between groups (2.7 months with atezolizumab vs. 3.4 months with 
docetaxel) (
Smith et al. 2016).  
The updated OS and PFS analyses for the ITT population and by [CONTACT_4002]-L [ADDRESS_121755] PD-L 1 expression 
levels 
experienced OS similar to that in the docetaxel group (see Table 8 ).
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
49/Protocol GO29437 , Version 7Table 8Study GO28753 (POPLA R) Efficacy  Results by  [CONTACT_109791]-L1 Diagnostic Subgroup w ith Complementary  Comparison 
Subgroupi[INVESTIGATOR_14839]:  Intent -to-Treat Population
PopulationHR (95% CI) Total No. of Patients
(Atezolizumab/
Docetaxel) OS PFS
ITT 0.69 (0.52, 0.92) 0.92 (0.71, 1.20) 287 (144/143)
TC3 or IC3 0.45 (0.22, 1.95) 0.60 (0.32, 1.13) 47 (24/23)
TC2/3 or IC2/3 0.50 (0.31, 0.80) 0.71 (0.47, 1.08) 105 (50/55)
TC1/2/3 or IC1/2/3 0.59 (0.41, 0.83) 0.86 (0.63, 1.16) 195 (93/102)
TC0 and IC0 0.88 (0.55, 1.42) 1.06 (0.68, 1.67) 92 (51/41)
HRhazard ratio; IC tumor -infiltrating immune cell; ITTintent to treat; OSoverall 
survival; PFS progression -free survival; TC tumor cell.
Notes:  The data cutoff date is 1 December 2015.
The HRs are stratified for the ITT population and unstratified for the PD -L1 
expression subgroups.f
In summary, the data from Study GO28753 ( POPLAR )show that atezolizumab provides 
survival benefit compared with docetaxel in previously treated patients with NSCLC.
[IP_ADDRESS] Single -Agent Clinical A ctivity in Patients with NSCLC in Study
GO28915 (OA K)
The co -primary endpoints of Study GO28915 (OAK) were OS in all randomized patients 
(ITT population) and OS in a PD -L1selected subgroup in the primary analysis 
population (TC1/2/3 or IC1/2/3).  
At the time of the primary analysis (7 July 2016 data cutoff date), which included data 
from the first 850 randomized patie nts (425 in the atezolizumab arm and 425 in the 
docetaxel arm), the median duration of survival follow-up was 21 months and 
569patients had died.  In the ITT population, OS was significantly improved with 
atezolizumab compared with docetaxel (median OS, 13.8vs. 9.6 months; HR0.73; 95% 
CI: 0.62, 0.87; p 0.0003).  For the TC1/2/3 or IC1/2/3 subgroup, OS was also 
significantly improved with atezolizumab compared with docetaxel (median OS, 
15.7 vs.10.3 months; HR 0.74; 95% CI: 0.58, 0.93; p 0.0102).   
PFS was similar between the atezolizumab and docetaxel arms (median PFS, 
2.8vs.4months; HR 0.95; 95% CI: 0.82, 1.10).  Fifty -eight patients (14%) in the 
atezolizumab arm and 57 patients (13%) in the docetaxel arm achieved a confirmed
objective resp onse per RECIST v1.1.  Objective responses with atezolizumab were 
durable, with a median duration of 16.3 months (95% CI: 10.0 months, not estimable) in 
the atezolizumab arm compared with 6.2 months (95% CI: 4.9, 7.6 months) in the 
docetaxel arm (Rittmeyer et al. 2017 ).
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
50/Protocol GO29437 , Version [IP_ADDRESS] Clinical Efficacy  in Combination with Platinum -Based Doublet 
Chemotherapy  in Patients with NSCLC
As of the 10February [ADDRESS_121756] dose of 
atezolizumab by 10November 2014 were evaluable for efficacy ( n41).  Patients who 
were enrolled into Arms C, D, and E received 15 mg/kgatezolizumab administered Q3W
in combination with carboplatin paclitaxel , carbopla tinpemetrexed, and 
carboplatin nab-paclitaxel, respectively.  All patients had histologically or cytologically 
documented Stage IIIB, Stage IV or recurrent NSCLC and had not received prior 
chemotherapy for advanced disease.  The median age was 65 years, and 79% of 
patients had non -squamous histology.  The overall confirmed objective response rate 
per RECIST v1.1 in all three arms combined was 63% (26 of 41 patients) . The ORR 
was50% (95% CI: 16%, 84%) in Arm C ( 4partial responses [PRs] among 8patients), 
77% (95% CI: 50%, 93%) in Arm D ( 13PRs among 17patients), and 56% (95% CI: 3 0%, 
80%) in Arm E (5 PRs and 4complete responses [CRs] among 16 patients).  Patients 
with high levels of PD -L1 expression appeared to have higher response rates, but
responses were also seen in patients with lower PD- L1 expression levels (Liuet al. 
2015 ).
1.3.4 Clinical Pharmacokinetics and Immunogenicity
On the basis of available preliminary PK data (0.03 20 mg/kg), atezolizumab appeared
to show linear pharmacokinetics at doses 1 mg/kg.  For the 1 -mg/kg and 20- mg/kg 
dose groups, the mean apparent clearance (CL) and the mean volume of distribution at 
steady state (V ss) had a range of 3.11 to 4.14 mL/kg and 48.1 to 67.0 mL/kg, respectively, 
which is consistent with the expected profile of an IgG1 antibody in humans.
The development of anti -therapeutic antibodies (ATAs) has been observed in patients in 
all dose cohorts and was associated with changes in pharmacokinetics for some patients 
in the lower dose cohorts (0.3, 1, and 3 mg/kg).  The development of detectable ATAs 
has not had a significant impact on pharmacokinetics for doses from 10 to 20 mg/kg.  
Patients who were dosed at the 10 -, 15-, and 20 -mg/kg dose levels have maintained the 
expected target trough levels of d rug despi[INVESTIGATOR_33384].  To date, no clear 
relationship between the detection of ATAs and adverse events or infusion reactions has 
been observed.
1.3.5 Rationale for A tezolizumab Dosage
The fixed dose of 1200 mg (equivalent to an average body weight based dose of 
15 mg/kg) was selected on the basis of both nonclinical studies and available clinical 
data from Study PCD4989g as described below.
The target exposure for atezolizumab was projected on the basis of nonclinical tissue 
distribution data in tumor- bearing mice, target -receptor occupancy in the tumor, the 
observed atezolizumab interim pharmacokinetics in humans, and other factors. The 
target trough concentration (C trough) was projected to be 6 mg/mL on the basis of several 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
51/Protocol GO29437 , Version 7assumptions, including t he following:  1) 95% tumor -receptor saturation is needed for 
efficacy and 2) the tumor -interstitial concentration to plasma ratio is 0.30 based on tissue 
distribution data in tumor -bearing mice.
The atezolizumab dose is also informed by [CONTACT_33444], safety, 
pharmacokinetics, and immunogenicity data. Anti-tumor activity has been observed 
across doses from 1 mg/kg to 20 mg/kg. The MTD of atezolizumab was not 
reached, and no DLTs have been observed at any dose in Study PCD4989g. Currently 
available PK and ATA data suggest that the 15 -mg/kg atezolizumab Q3Wregimen (or 
fixed -dose equivalent) for Phase II and Phase III studies would be sufficient to both 
maintain C trough6g/mL and further safeguard against both interpatient variability and 
the potential effect of ATAs that could lead to subtherapeutic levels of atezolizumab 
relativ e to the 10 -mg/kg atezolizumab Q3 Wregimen (or fixed -dose equivalent).  From 
inspection of available observed C troughdata, moving further to the 20- mg/kg 
atezoliz umab Q3Wregimen does not appear to be warranted to maintain targeted C trough 
levels relative to the proposed 15- mg/kg atezolizumab Q3Wlevel. 
Simulations ( Bai et al. 2012 ) do not suggest any clinically meaningful differences in 
exposure following a fixed dose or a dose adjusted for weight.  Therefore, a fixed dose 
of 1200 mg has been selected (equivalent to an average body weight based dose 
of15mg/kg).  Selection of an every -21-day dosing interval is supported by [CONTACT_109805].
Refer to the Atezolizumab Investigator’s Brochure for details regarding nonclinical and 
clinical pharmacology of atezolizumab.
1.[ADDRESS_121757] cancer can 
result in a significant survival benefit in patients with Stage IV cancer ( Hodi etal.2010 ; 
Kantoff etal.2010 ; Chen et al. 2012 ).
PD-L1 is an extracellular protein that downregulates immune responses primarily in 
peripheral tissues through binding to its two receptors PD -1 and B7.1. PD-1 is an 
inhibitory receptor expressed on T cells following T -cell activation, which is sustained in 
states of chronic stimulation such a s in chronic infection or cancer ( Blank etal.2005 ; 
Keiretal.2008 ).  Ligation of PD -L1 with PD -1 inhibits T -cell proliferation, cytokine 
production, and cytolytic activity, leading to the functional inactivation or exhaustion of 
Tcells.  B7.1 is a molecule expressed on antigen -presenting cells and activated T cells.  
PD-L1 binding to B7.1 on T cells and antigen -presenting cells can mediate 
downregulation of immune responses, including inhibition of T- cell activation and 
cytokine production ( Butte et al. 2007 ; Yang etal.2011 ).
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
52/Protocol GO29437 , Version 7Overexpression of PD -L1 on tumor cells has been reported to impede anti -tumor 
immunity, resulting in immune evasion ( Blank and Mackensen 2007 ).  Therefore, 
interruption of the PD -L1/PD -[ADDRESS_121758] represents an attractive strate gy to reinvigorate 
tumor -specific T -cell immunity.
PD-L1 expression is prevalent in many human tumors, and elevated PD -L1 expression 
is associated with a poor prognosis in patients with NSCLC ( Mu et al. 2011).
Targeting the PD -L1 pathway with atezolizumab has demonstrated activity in patients 
with advanced malignancies and who have failed standard of care therapi[INVESTIGATOR_014].  At the time 
of Study GO29437 initiation, Study PCD4989g , aPhase Ia dose -escalation and 
expansion study of patients who were treated with atezolizumab as a single agent had 
the following clinical activity :  345 evaluable patients were dosed by 21 October 2013 
(data cutoff date as of 21 April 2014) with a minimum of 6 months of follow -up; 
62patients experienced objective responses per RECIST v1. 1 with an ORR of 18.0% 
(95% CI: 14.1% , 22.3%).  Objective responses were observed across a broad range of 
malignancies, including NSCLC, RCC, melanoma, and urothelial bladder cancer.  In 
Studies GO28753 (POPLAR) and GO2 8915 (OAK), there was significant imp rovement 
in OS with atezolizumab compared with docetaxel in patients with previously treated 
advanced NSCLC.
1.4.1 Rationale for Testing Atezolizumab in Combination with 
Carboplatin/Paclitaxel or Car boplatin/nab-Paclitaxel
Platinum -based regimens remain the stan dard first -line option for patients with locally 
advanced or metastatic NSCLC that is not harboring EGFR mutations or ALK gene 
rearrangements.  However, the survival benefit conferred by [CONTACT_70109] a plateau, with overall response rates of approximately 20% and 1 -year survival 
ranging from 31% to 36% ( Schiller et al. 2002 ), leaving considerable room f or 
improvement in outcomes.  Tumor cell killing by [CONTACT_109806] -specific T -cell immunity in this setting by [CONTACT_70121] -L1/PD -[ADDRESS_121759] 
chemotherapy alone ( Merritt etal.2003 ; Apetoh et al. 2007).  Evaluating the safety and 
efficacy of these treatment combinations in patients with NSCLC will enable future tests 
ofthis hypothesis.
Nivolumab, a fully human IgG4 PD -1 antibody, was evaluated in combination with 
platinum -based doublet therapy in PD -1unselected, chemotherapy -naive patients with 
NSCLC, and interim results were presented at ASCO 2014 ( Antonia et al. 2014).  The 
ORR for patients treated with gemcitabine cisplatin , pemetrexed cisplatin, and 
paclitaxel carboplatin in addition to 10 mg nivolumab was 33% ( n12), 47% (n 15), 
and 47% (n 15), respectively.  The median duration of response ranged from 24 weeks 
with nivolumab in combination with paclitaxel carboplatin to 45 weeks with nivolumab in 
combination with gemcitabine cisplatin.  The 1- year OS for patients treated with 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
53/Protocol GO29437 , Version 7gemcitabine cisplatin, pemetrexed cisplatin, and paclitaxel carboplatin in addition to 
10 mg nivolumab was 50%, 87%, and 60%, respectively.  Grade 3/4 treatment -related 
adverse events were reported in 45% of patients across all treatment arms with the most 
common treatment -related Grade 3/4 adverse events being pne umonitis (7%), fatigue 
(5%), and acute renal failure (5%) ( Antonia et al. 2014 ).  Although the patient numbers 
are limited, these data along with the preliminary efficacy and safety results from 
Study GP28328 offer evidence of an acceptable safety profile when combining a 
PD-L1/PD -1 inhibitor with platinum -based doublet chemotherapy in a nonPD-L1 
selected population.  Carboplatin nab-paclitaxel was approved for the first -line 
treatment of patients with NSCLC on the basis of results from the randomized Ph aseIII 
study comparing nab- paclitaxel carboplatin with solvent -based paclitaxel carboplatin.  
In nonclinical models, the combination of nab -paclitaxel atezolizumab demonstrated 
significantly greater anti -tumor activity than either agent alone.
In light of these observations, Study GO29437 is designed to evaluate whether the 
anti-tumor effect seen in atezolizumab- treated patients would translate into a statistically 
significant and clinically relevant improvement in PFS and OS when used in combination
with carboplatin nab-paclitaxel compared with carboplatin nab-paclitaxel in patients 
with squamous NSCLC.  This study will allow for the evaluation of the efficacy of 
atezolizumab in both the ITT population, as well as in patients with PD -L1selected 
tumors (defined by [CONTACT_109807] -L1 in TCs and/or ICs).  A PD -L1 
immunohistochemistry ( IHC)assay will be used to identify patients by [CONTACT_109808] -L1 
expression (see Appendix 6).
Study GO29437 will enroll patients with Stage IV squamous NSCLC who are naive to 
chemotherapy treatment and for whom the experimental arms 
(atezolizumab carboplatin paclitaxel and atezolizumab carbopla tinnab-paclitaxel) 
can represent a valuable treatment option and a reasonable benefit -risk balance.  
Patients whose tumors are known to harbor sensitizing EGFR mutations or ALK
rearrangements must have experienced disease progression or have proven intolerance 
during or after treatment with an EGFR tyrosine kinase or ALK inhibitor, respectively 
(see specific inclusion criteria in Section 4.1.1 ) before they can enroll in the study. 
In order to account for the possibility of pseudoprogression/tumor -immune infiltration (i.e., 
radiographic increase in tumor volum e due to the influx of immune cells) 
(Hales etal.2010 ) and the potential for delayed anti -tumor activity, this study will allow 
patients treated with atezolizumab to receive treatment beyond the initial apparent 
radiographic progression (see Section 3.3.5 and Section 4.6) and will use modified 
RECIST criteria (in addition to RECIST v1.1) to evaluate clinical benefit.  Because it is 
not yet possible to reliably differentiate pseudoprogression/tumor -immune infiltration 
from true tumor progression, the risk exists that some patients who are not responding to 
treatment but yet continuing to receive atezolizumab may experience further progression 
of NSCLC and delay treatment with subsequent therapi[INVESTIGATOR_33386].  
Investigators should make every effort to fully inform patients of this risk.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
54/Protocol GO29437 , Version 7Atezolizumab has been generally well tolerated (see Section 1.3.2 ); adverse events with 
potentially immune- mediated causes consistent with an immunotherapeutic agent, 
including rash, hypothyroidism, hepatitis/transaminitis, colitis, and myasthenia gravis, 
have been observed in Study PCD4989g.  To date, these events have been 
manageable with t reatment.
In summary, treatment with atezolizumab offers the potential for clinical benefit in 
patients with NSCLC, in addition to platinum -based chemotherapy.  Patients will be fully 
informed of the risk of continuing study treatment in spi[INVESTIGATOR_109774] a careful assessment of the potential benefit 
of doing so, considering radiographic data, biopsy results, and the clinical status of 
thepatient.
2. OBJECTIVES
The following objectives will be assessed in chemotherapy -naivepatients with Stage IV 
squamous NSCLC.  
2.1 EFFICA CY OBJECTIVES
Unless otherwise specified, efficacy objectives will be analyzed for the following two 
treatment comparisons:
Atezolizumab carboplatin nab-paclitaxel (Arm B) versus 
carbop latinnabpaclitaxel (Arm C)
Atezolizumab carboplatin paclitaxel (Arm A) versus carboplatin nabpaclitaxel 
(Arm C)
The term “tumor gene expression ”(tGE) refers to randomized patients with a defined 
level of expression of a PD-L1 and T -effector gene signature [CONTACT_109861] , as
analyzed through use of a centrally performed RNA -based assay.
Some efficacy endpoints will be analyzed in a population of randomized patients with a 
defined level of PD-L1 expression on TCs and ICs ,as analyzed through use of a 
centrally performed IHC test.
2.1.1 Co-Primary  Efficacy  Objectives
The co -primary objectives of this study are the following :
To evaluate the efficacy of atezolizumab as measured by [CONTACT_1697] -assessed 
PFS according to RECIST v1.1 in the tGEpopulation andtheITTpopulation
To evaluate the efficacy of atezolizumab as measured by [CONTACT_109809]
2.1.2 Secondary  Efficacy Objectives
The secondary efficacy objectives for this study are the following :
To ev aluate the efficacy of atezolizumab as measured by [CONTACT_109810] —F. Hoffmann- La [COMPANY_002] Ltd
55/Protocol GO29437 , Version 7To evaluate the efficacy of atezolizumab as measured by [CONTACT_1697] -assessed 
PFS according to RECIST v1.1 and OS in the TC2/3 or IC2/3 population andthe 
TC1/2/3 or IC1/2/3 popula tion
To evaluate the efficacy of atezolizumab as measured by [CONTACT_1697] -assessed 
ORR according to RECIST v1.1 in the tGE population and the ITTpopulation
To evaluate the efficacy of atezolizumab as measured by [CONTACT_1697] -assessed 
duration of response (DOR) according to RECIST v1.1 in the tGE population and 
the ITT population
To evaluate the OS rate at 1 and 2 years in each treatment arm for the tGE
population and the ITTpopulation
To determine the impact of atezolizumab a s measured by [CONTACT_70113] (TTD) 
in patient -reported lung cancer symptoms of cough, dyspnea (single- item and 
multi -item subscales), chest pain, or arm/shoulder pain, using the European 
Organisation for the Research and Treatment of Cancer (EORTC) Quality -of-Life 
Questionnaire Core 30 (QLQ -C30) and the supplemental lung cancer module 
(QLQ -LC13) in the tGE population and the ITT population
To determine the impact of atezolizumab as measured by [CONTACT_109793]
(i.e., improvement or deterioration based upon presenting symptomatology) in 
patient -reported lung cancer symptom (chest pain, dyspnea, and cough) score using 
the Symptoms in Lung Cancer (SILC) scale symptom severity score in the tGE 
population and the ITTpopulation
To evaluate the efficacy of the treatment regimen of 
atezolizumab carboplatin paclitaxel versus 
atezolizumab carboplatin nab-paclitaxel as measured by [CONTACT_1697] -assessed 
PFS according to RECIST v1.1 and  OS in the tGE population and the ITT 
population
2.2 SAFETY OBJECTIVES
The safety objectives for this study are the following:
To evaluate the safety and tolerability of atezolizumab in each of the two treatment 
comparisons
To evaluate the incidence and titers of ATAs against atezolizumab and to explore 
the potenti al relationship of the immunogenicity response with pharmacokinetics, 
safety, and efficacy
2.3 PHA RMA COKINETIC OBJE CTIVES
The pharmacokinetic (PK) objectives for this study are the following:
To characterize the pharmacokinetics of atezolizumab when given in combination 
with carboplatin paclitaxel (Arm A) or with carboplatin nab-paclitaxel (Arm B)
To characterize the pharmacokinetics of carboplatin when given in combination with 
paclitaxel and atezolizumab (Arm A) or with nab-paclitaxel with and without 
atezolizumab (Arms B and C)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
56/Protocol GO29437 , Version 7To characterize the pharmacokinetics of paclitaxel when given in combination with 
atezolizumab and carboplatin (Arm A)
To characterize the pharmacokinetics of nab -paclitaxel (reported as total paclitaxel)
when given in combinati on with carboplatin with and without atezolizumab (Arms B 
and C)
2.4 EXPLORA TORY OBJECTIV ES
The exploratory objectives for this study are the following:
To evaluate PFS at 6 months and at 1 year in each treatment arm
To evaluate the OS rate at 3 years in each treatment arm
To assess predictive, prognostic, and pharmacodynamic exploratory biomarkers in 
archival and/or fresh tumor tissue and blood and their association with disease 
status, mechanisms of resistance, and/or response to study treatment
To evaluate the utility of biopsy at the time of apparent disease progression to 
distinguish apparent increases in tumor volume related to the immunomodulatory 
activity of atezolizumab (i.e., pseudoprogression/tumor -immune infiltration) from true 
disease progression
To evaluate and compare patient’s health status as assessed by [CONTACT_70090] 
5Dimensions 3 -Level (EQ -5D-3L) questionnaire to generate utility scores for use in 
economic models for reimbursement
To determine the impact of atezolizumab as measured by [CONTACT_109811] -reported outcomes of health- related quality of life (HRQoL) , lung 
cancer related symptoms, and functioning as assessed by [CONTACT_20368] -C30 
and QLQ -LC13. 
3. STUDY DESIGN
3.1 DESCRIPTION OF THE S TUDY
This is a randomized, Phase III, multic enter, open -label study (IMpower131) designed to 
evaluate the safety and efficacy of atezolizumab in combination with 
carboplatin paclitaxel or with carboplatin nab-paclitaxel compared with treatment with 
carboplatin nab-paclitaxel in approximately 1025chemotherapy -naive patients with 
Stage IV squamous NSCLC.  Figure 1illustrates the study design.  The schedules of 
assessments are p rovided in Appendix 1and Appendix 2.  
Tumor specimens will be prospectively tested for PD -L1 expression by a central 
laboratory.  Eligible patients will be stratified by [CONTACT_4321] (male vs. female), presence of liver 
metastases at b aseline (yes vs. no), and by [CONTACT_4002] -L1 tumor expression by [CONTACT_4658] (TC3 and 
any IC vs. TC0/1/2 and IC2/3 vs. TC0/1/2 and IC0/1) and randomized in a 1:1:1 ratio to 
receive one of the following treatment regimens detailed in Table 9 .
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
57/Protocol GO29437 , Version 7Table 9Treatment A rms in Study GO29437
Treatment ArmInduction 
(Four or Six 21 -day Cycles)Maintenance 
(21-day Cycle)
A Atezolizumab carboplatin paclitaxel Atezolizumab
B Atezolizumab carboplatin nab-paclitaxel Atezolizumab
C Carboplatin nab-paclitaxel Best supportive care
The number of cycles of induction treatment (four or six) will be at the discretion of the 
investigator and will be determined and documented prior to randomization.  Induction 
treatment will be admi nistered on a 21 -day cycle until the following occurs (whichever 
occurs first):  1) administration of four or six cycles or 2) disease progression (Arm C) or 
loss of clinical benefit (Arms A and B) is documented. 
Following the induction phase, patients randomized to atezolizumab (Arms A and B) 
may continue treatment with atezolizumab beyond radiographic disease progression by 
[CONTACT_393] v1.1, provided they are exper iencing clinical benefit as assessed by [CONTACT_1275] (i.e., in the absence of unacceptable toxicity or symptomatic deterioration 
attributed to disease progression as determined by [CONTACT_093]) after an integrated 
assessment of radiographic data, b iopsy results (if available), and clinical status.  
Patients randomized to carboplatin nab-paclitaxel (Arm C) will be offered best 
supportive care provided they have non -progressive disease.
Treatment with chemotherapy must be discontinued in all patient s who exhibit evidence 
of progressive disease by [CONTACT_393] v1.1.
Patients will undergo tumor assessments at baseline and every [ADDRESS_121760] v1.1 (or loss of clinical benefit for 
atezolizumab- treated patients who continue treatment with atezolizumab after 
radiographic disease progression according to RECIST v1.1), withdrawal of consent, 
study termination by [CONTACT_2728], or death, whichever occurs first.  Patients who discontinue 
treatment for reasons other than radiographic disease progression per RECIST v1.1
(e.g., toxicity , symptomatic deterioration )will continue scheduled tumor assessments 
until radiographic disease progression per RECIST v1.1 (or loss of clinical benefit for 
atezolizumab- treated patients who hadcontinue dtreatment with atezolizumab after 
radiographic disease progression according to RECIST v1.1), withdrawal of consent, 
study termination by [CONTACT_2728], or death, whichever occurs first, regardless of whether 
patients start a new anti -cancer therapy.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
58/Protocol GO29437 , Version 7All primary imaging data used for tumor assessment will be collected by [CONTACT_70117], independent review of response endpoints. The independent 
reviews of the stored scans will be performed when requested.
For Treatment A rms A  and B Only
During treatment (induction or maintenance), patients who show evidence of clinical 
benefit will be permitted to continue atezolizumab after RECIST v1.1 for progressive 
disease are met if they meet all of the following criteria: 
Evidence of clinical benefit as assessed by [CONTACT_093]
Absence of symptoms and signs (including worsening of laboratory values, [e.g., 
new or worsening hypercalcemia ]) indicating unequivocal progression of disease
No decline in ECOG performance status that can be attributed to disease 
progression
Absence of tu mor progression at critical anatomical sites (e.g., leptomeningeal 
disease) that cannot be managed by [CONTACT_990] -allowed medical interventions
Patients must provide written consent to acknowledge deferring other treatment 
options in favor of continuing atezo lizumab at the time of initial progression
Patients in all treatment arms will undergo a mandatory tumor biopsy sample collection, 
unless not clinically feasible as assessed and documented by [CONTACT_431], at the time 
of radiographic disease progression.  These data will be used to explore whether
radiographic findings are consistent with the presence of tumor.  Additionally, these data 
will be analyzed to evaluate the association between changes in tumor tissue and 
clinical outcome and to understand further the potential mechanisms of progression and 
resistance to atezolizumab as compared with such mechanisms after treatment with 
chemotherapy alone.  This exploratory biomarker evaluation will not be used for any 
treatment -related decisions.  Patients in Arms A and B who are unable to undergo 
biopsy sample collection but who otherwise meet the criteria listed above may continue 
to receive atezolizumab.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
59/Protocol GO29437 , Version 7Figure 1 Study Schema
Chem otherapy -Naive Patients with Stage IV Squam ous NSCLC
(n=approx imately 1025)
Arm A:
Atezolizum ab (1200 m g IV Day 1)
+Carboplatin (AUC=6 IV Day 1)
+Paclitaxe l (200 mg/m2IV Day 1)Arm B:
Atezolizumab (1200 m g IV Day 1)
+ Carboplatin (AUC=6 I V Day 1)
+nab -Paclita xel (100 mg/m2IV 
Days 1, 8, and 15)Arm C:
Carboplatin (AUC=6 I V Day 1)
+nab- Paclita xel (100 mg/m2IV 
Days 1, 8, and 15)
Treat until 
Loss of Clinical BenefitTreat until 
Disease Progre ssion, per RECIST v 1.1
Survival Follow -Up1:1:1 Random ization
Stratificatio n Factors:
•Sex
•Liver metastase s
•PD-L1 expression (by [CONTACT_109812]-L1 status)
Induction Treatment:  Four or Six 21-Day Cycles
Maintenance Treatment:  21-Day Cycles
Arm A:
Atezolizum ab (1200 m g IV)Arm B:
Atezolizumab (1200 m g IV)Arm C:
Best Supportive Care
No Crossov er Perm itted
AUC area under the concentration time curve; IV intravenous; NSCLC non small cell lung 
cancer; RECIST v1.1 Response Evaluation Criteria in Solid Tumors, Version 1.1.
Note:  In Arm A, p atients with Asian race/ethnicity receive paclitaxel at a dose of 175 mg/m2
3.1.1 Independent Data Monitoring Committee
An independent Data Monitoring Committee (iDMC) will be used to evaluate safety 
during the study.  Unblinded safety data will be reviewed by [CONTACT_109813] a periodic 
basis, approximately every [ADDRESS_121761] patient in (FPI).  The safety 
data will include demographic data, adverse events, serious adverse events, and 
relevant laboratory data.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
60/Protocol GO29437 , Version 7The Sponsor will remain blinded to the efficacy results until the final PFS analysis for the 
primary comparisons (i.e., Arm A vs.Arm C, Arm B vs.Arm C).  All summaries and 
analyses by [CONTACT_109814] (iDCC).  Following the safety review s, the iDMC 
will provide a recommendation as to whether the st udy may continue, whether 
amendment(s) to the protocol should be implemented, or whether the study should be 
stopped.  The final decision will rest with the Sponsor.
Members of the iDMC will be external to the Sponsor and will follow a separate iDMC 
Charte r that outlines their roles and responsibilities as well as a detailed monitoring plan. 
Any outcomes of these safety or efficacy reviews that affect study conduct will be 
communicated in a timely manner to the investigators for notification of the Institu tional 
Review Boards/Ethics Committees (IRBs/ECs).
3.[ADDRESS_121762] been enrolled into an extension study. The Sponsor may decide 
to terminate the study at any time. If the Sponsor decides to end the study, patients 
who are still receiving study treatment or are in survival follow -up may be offered 
enrollment in an extension study or a non -interventional study.
3.3 RATIONA LE FOR STUDY DESIGN
3.3.1 Rationale for Testing Atezolizumab in Patients with 
PD-L1Unselected NSCLC
Despi[INVESTIGATOR_70046], the prognosis for patients with advanced 
NSCLC remains dismal, with a median OS of approximately 12.3 months 
(Sandler etal.2006 ).  Patients who re ceive second -line treatment for their disease have 
an even more limited prognosis, with a median survival duration of approximately 
89months ( Stinchcombe et al. 2008 ).  Approved therapi[INVESTIGATOR_109775] (e.g., neuropathy, febr ile neutropenia, myelosuppression, and 
alopecia) that negatively impact quality of life.  Therefore, there is a continuing need 
formore efficacious, better -tolerated treatments.
Inhibition of PD -L1/PD -1 signaling has been shown to produce durable response s in 
some patients, and expression of PD -L1 by [CONTACT_109815]/or ICs in several tumor types 
(including NSCLC) correlates with response to therapy ( Topalian et al. 2012; 
(Fehrenbacher et al. 2016).
Atezolizumab monotherapy has demonstrated clinical efficacy and is generally 
well-tolerated in patients with squamous or non -squamous NSCLC (Besse et al. 2015; 
Horn et al. 2015; Spi[INVESTIGATOR_70048]. 2015 ; Fehrenbacher et al. 2016 ).  In the second- and third -
line setting, the POPLAR study , the first randomized Phase II study of atezolizumab in 
advanced NSCLC, showed significant improvement in OSwith atezolizumab (12.6 vs .
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
61/Protocol GO29437 , Version 79.7 months; HR 0.73;95% CI: 0.53 , 0.99, p0.04) versus docetaxel (Fehrenbacher et 
al. 2016 ).In the Phase III Study GO28915 (OAK )which investigated the efficacy and 
safety of atezolizumab compared with docetaxel in patients with previously treated 
locally advanced or metastatic NSCLC, OS was significantly prolonged with 
atezolizumab (media n OS 13.8 months vs.9.6 months, HR 0.73; 95% CI :0.62, 0.87,
p=0.0003).   In patients with squamous and non -squamous disease, OS was 8.9versus 
7.7months (HR 0.73;95% CI: 0.54, 0.98 ), and 15. 6 versus 11.2months (HR 0.73;
95% CI:0.60, 0.89 ), respectively, in the atezolizumab arm compared with the docetaxel 
arm (Rittmeyer et al. 2017 ).
On the basis of promising efficacy of atezolizumab as a single agent (Study GO28753 
[POPLAR ], Study PCD4989g) , and in combination with platinum -doublet therapy 
(Study GP28328) and the safety findings from Study GP28328 indicating no additive 
toxicity of atezolizumab in combination with platinum -based chemotherapy or 
bevacizumab, this study will evaluate atezolizumab in combination with platinum -based 
chemotherapy.   Tumor -cell killing by [CONTACT_109816], and invigorating tumor -specific T -cell immunity 
in this setting by [CONTACT_70121] -L1/PD -[ADDRESS_121763] chemotherapy alone (Merritt et al. 2003; 
Apetoh etal.2007), and this may reasonably occur in tumors regardless of PD -L1 
expression.
3.3.2 Rationale for Control A rm
In this study, the control group will receive the platinum doublet of 
carboplatin nab-paclitaxel, an approved regimen in the first -line treatment of advanced 
stage NSCLC.  Patients enrolled into the experimental Arm B will receive this standard 
chemotherapy regimen in addition to atezolizumab.  The emerging safety profile of 
atezolizumab su ggests that there is minimal risk of significant additive toxicity when it is 
administered with chemotherapy and that patients will be able to receive standard 
treatment for their disease in the setting of this clinical study.  
In addition, treatment with this chemotherapy regimen does not require premedication 
with steroids.  Because the effects of corticosteroids on T -cell proliferation have the 
potential to ablate early atezolizumab- mediated anti -tumor immune activity, it is 
recommended that dexamethaso ne doses be minimized to the extent that is clinically 
feasible in patients treated with atezolizumab.  Therefore, the backbone treatment of 
carboplatin nab-paclitaxel in combination with atezolizumab is considered optimal to 
minimize the prolonged requi rement for systemic corticosteroids, and it follows that 
carboplatin nab-paclitaxel would be a logical comparator.  
In the Phase III study conducted by [CONTACT_109817]. (2012) comparing 
carboplatin paclitaxel to carboplatin nab-paclitaxel, no statist ically significant 
differences in PFS or OS was seen in patients with squamous histology.  Therefore, the 
control group of carboplatin nab-paclitaxel is considered a suitable comparator for the 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
62/Protocol GO29437 , Version 7experimental arm of carboplatin paclitaxel with atezolizum ab.  This control group will be 
instrumental in assessing the relative benefit and safety of atezolizumab in combination 
with carboplatin nab-paclitaxel compared with chemotherapy alone in the front -line 
treatment setting.
3.3.3 Rationale for Open -Label Study
An open -label study design was chosen for this study for the following reasons:  A 
blinded study would require prolonged administration of placebo during the maintenance 
phase for patients randomized to Arm C, which could pose a significant burden to 
patients. Furthermore, because of the potential for pseudoprogression in patients 
randomized to atezolizumab- containing arms, a blinded study would require the option 
that all patients continue treatment until loss of clinical benefit regardless of whether the y 
were receiving atezolizumab. In the absence of pseudoprogression, this could then 
delay subsequent treatment with approved therapi[INVESTIGATOR_109776], as well as increase the complexity of treatment decisions.
Adequate steps have been taken to ensure the validity of data in an open -label study 
design. This includes performing a sensitivity analysis to demonstrate the robustness of 
the primary endpoint, defining progression using established response evaluation criteria 
(RECIST v1.1), performing tumor assessments at the same frequency in all arms, 
adhering to protocol -defined schedules, and determining the strategy for the final 
analysis of the primary endpoint prior to database lock for the primary efficacy anal yses, 
including predefined methods for handling missing data and censoring rules. Efficacy 
analyses will only be performed at the prespecified analysis timepoints in the protocol.
3.3.[ADDRESS_121764] that OS may be a more sensitive endpoint for cancer 
immunotherapy t han PFS.  For example, in the randomized Phase II Study GO28753 
(POPLAR) in patients with advanced NSCLC, an OS benefit in the atezolizumab arm 
compared with the docetaxel arm was observed in the ITT population, with a stratified 
HR of 0.73 (95% CI: 0.53, 0.99).  PFS in the ITT population was similar between both 
treatment arms:  HR of 0.94 (95% CI: 0.72, 1.23) ( Fehrenbacher et al. 2016 ).  In addition, 
OS is the most objective and best measure of clinical benefit for patients with 
advanced/unresectable or m etastatic lung cancer.
However, given that the majority of patients in this study will likely receive subsequent 
anti-cancer therapi[INVESTIGATOR_13265]/or palliative care ( Temel et al. 2010 ) post -disease progression, 
the OS analysis may be confounded (Miller et al. 2012 ).  Therefore, PFS is being 
retained as a co- primary endpoint and crossover from the control arm to either of the 
experimental arms after the disease progression will not be permitted, with the aim of 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
63/Protocol GO29437 , Version 7preserving the study’s ability to potentially demonstrate treatment benefit of 
atezolizumab on OS.
PFS as an endpoint can reflect tumor growth and can be assessed before the 
determination of a survival benefit.  Whether an improvement in PFS represents a direct 
clinical benefit or a surrogate for clinical benefit depends on the magnitude of the effect 
and the benefit -riskprofile of the new treatment compared with available therapi[INVESTIGATOR_014] 
(Guidance forIndustry 2007 ; European Medicines Agency 2012 ).  To ensure the validity 
of investigator -assessed PFS as a co- primary endpoint, a number of measures have 
been implemented:  a substantial target magnitude of benefit (target HR of 0.65 in the 
ITT and of 0.55 in the biomarker selected tGEpopulation), and study assessments that 
will allow a robust evaluation of benefit -risk assessment (using standard RECIST to 
define progression with fixed assessment intervals that are identical in all treatment arms 
and a robust definition of PFS and prospectively defined methods to assess, quantify, 
and analyze PFS, including sensitiv ity analyses ).
New treatment modalities, such as targeted therapi[INVESTIGATOR_70050], are emerging 
as highly effective regimens that are providing improvements in patient outcomes far 
beyond what was achieved before ( Ellis et al. 2014).  In particular, im munotherapy has 
been correlated/associated with durable responses, significant prolongation of PFS, and 
improvement of quality of life.  In addition, meta -analyses have indicated that PFS can 
be considered a good measure of clinical benefit for patients wi th locally 
advanced/metastatic NSCLC ( Laporte et al. 2013 ).  
3.3.5 Rationale for A llowing Patients to Continue A tezolizumab 
Treatment until Loss of Clinical Benefit 
Conventional response criteria may not adequately assess the activity of 
immunotherapeutic agen ts because progressive disease (by [CONTACT_70125]) does not necessarily reflect therapeutic failure.  Because of the potential for 
pseudoprogression/tumor -immune infiltration, this study will allow patients randomized to 
the atezolizumab t reatment arms to remain on atezolizumab after apparent radiographic 
progression, provided the benefit -risk ratio is judged to be favorable.  Patients should be 
discontinued for unacceptable toxicity or symptomatic deterioration attributed to disease 
progre ssion as determined by [CONTACT_109818] (see Section 3.1).
3.3.[ADDRESS_121765] negative impacts on HRQoL (Hyde and 
Hyde 1974; Hopwood and Stephens 1995; Sarna etal.2004).  This is e specially true for 
studies that use PFS as the primary endpoint, where it is important to better understand 
in what regard the delay in disease progression is meaningful to patients.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
64/Protocol GO29437 , Version 7Chest pain, dyspnea, and cough have been regard ed as the most frequent and clinically 
relevant disease- related symptoms experienced by [CONTACT_70127].  The BR.21 
study (erlotinib vs. best supportive care in second -or third- line NSCLC) demonstrated 
that longer TTD in the pain, dyspnea, and cough s cales of the EORTC QLQ -C30 and 
EORTC QLQ -LC13 was consistent with superior PFS, OS, and quality -of-life benefits in 
the erlotinib arm compared with the placebo arm ( Aaronson et al. 1993 ; 
Bergman etal.1994 ; Bezjak et al. 2006 ).  Patients in the afatinib LUX -Lung [ADDRESS_121766]-line 
study also reported significant delay of TTD in lung cancer symptoms (chest pain, 
dyspnea, and cough) as measured by [CONTACT_20368] -C30 and EORTC QLQ -LC13 
(Yang etal.2013).  In this study, the validated EORTC QLQ -C30 and EORTC 
QLQ -LC13 will be used to assess HRQoL and symptom severity. 
In addition, the SILC scale will be used to assess the effect/impact of atezolizumab on 
TTD of specific lung cancer symptoms (chest pain, dyspnea, and cough) in patients with 
Stage IV, squamous NSCLC in the first -line setting.
The single -item Patient Global Impressions of Severity (PGIS) and the EQ -5D-3L 
instrument are included in the study to generate HRQoL and utility scores to confirm 
construct validity of the SILC scale and for use in economic models for reimbursement, 
respectively.  Results from the PGIS and EQ -5D-3L are not planned to be used for 
market authorization.
3.3.7 Rationale for C ollection of A rchiv al and/or Fresh 
Tumor Specimens and Evaluation of PD -L1 and T -Effector
Gene Signature
[CONTACT_109862] -L1 in tumors correlates with 
response to anti PD-1 therapy ( Topalian et al. 2012).  This correlation wasalso 
observed with atezolizumab in Studies PCD4989g (Herbst et al. 2014; Horn etal.2015) ,
GO28625 ( FIR) (Sp igel et al. 2015), GO28754 ( BIRCH) (Besse et al. 2015 ),GO28753 
(POPLAR )(Fehrenbacher et al. 2016) ,and OAK (Rittmeyer et al. 2017) .  In addition, 
POPLAR data suggest higher expression of genes related to PD -L1 andT-effector 
biology in tumor tissue is associated with improved efficacy of atezolizumab compared 
withdocetaxel ( Fehrenbacher et al. 2016 ). Similar observations have been reported for 
other PD -L1orPD-1 inhibitors (Higgs et al. 2015; Muro et al. 2015; Seiwert et al. 2015) . 
Furthermore , expression of PD -L1 on tumor -infiltrating immune cells was reported to be 
associated with expression of a T-effector gene signature ,therefore representing a 
preexisting immunity ( Fehrenbacher et al. 2016 ).
In this study, archival and/or fresh tumor specimens from patients will be prospectively 
tested for PD -L1 expression by a central laboratory during the screening period.  
Patients will be stratified by [CONTACT_4002] -L1 expression.  T he primary analysis of t his study will
evaluate the efficacy of atezolizumab in the ITT population, as well as in patients with a 
defined level of expression of aPD-L1 and T -effector gene signature (tGE population).   
On the basis of an analysis of independent cohorts of patients with NSCLC, it is 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
65/Protocol GO29437 , Version 7estimated that the primary tGE cut off for this study will identify a population 
corresponding to approximately 50% of the first -line NSCLC patient population. 
In addition to the assessment of PD -L1 status and T -effector gene signature [CONTACT_41900] ,
other exploratory markers, such as potential p redictive and prognostic markers related to 
the clinical benefit of atezolizumab, tumor immunobiology, mechanisms of resistance, or 
tumor type, may also be analyzed.  DNA and/or RNA extraction and analysis may be 
performed to enable identification of somat ic mutations by [CONTACT_109819]-generation 
sequencing (NGS )and to evaluate expression of genes (including but not limited to PD -
L1, PD -1, T-effector and others) to assess their association with efficacy and to increase 
understanding of disease pathobiology.
3.3.8 Rationale for Blood Sampling for Biomarkers
An exploratory objective of this study is to evaluate surrogate biomarkers (that may 
include circulating -tumor DNA [ctDNA], gene expression, tumor burden biomarkers, and 
others ) in blood samples.  Evaluation of b lood biomarkers may provide evidence for 
biologic activity of atezolizumab in patients with NSCLC and may allow for the 
development of blood -based biomarkers to help predict which patients may benefit from 
atezolizumab. 
In addition, potential correlations of these biomarkers with the safety and activity of 
atezolizumab will be explored.
3.3.9 Rationale for the Collection of Mandatory  Tumor Specimens 
atRadiographic Progression
Anti-tumor immune responses such as those associated with atezolizumab may result in 
objective responses that are delayed and can be preceded by [CONTACT_109820].  This initial apparent progression may occur as a result of either 
delayed anti -tumor activity and/or robust tumor -immune infiltration with a concomitant 
increase in tumor size.  In addition, lesions that would otherwise be undetectable with 
conventional imaging (i.e., micrometastatic disease) may increase in size as a result of 
these processes and be recorded as new lesions ( Hales et al. 2010 ).  
If clinic ally feasible, collection of a mandatory tumor biopsy at the time of radiographic 
progression is required in order to evaluate the utility of the biopsy in distinguishing 
pseudoprogression/tumor -immune infiltration from true progression.  Additionally, 
mechanisms relating to progression, resistance, predictive, prognostic, and 
pharmacodynamic relationships in tumor biomarkers (including, but not limited to, PD-L1, 
CD8, mutation status, and others) and efficacy will be evaluated.  DNA and/or RNA 
extraction m ay be performed to enable identification of somatic mutations, by [CONTACT_109821], that are associated with disease progression or acquired resistance to 
atezolizumab and to increase understanding of disease pathobiology.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
66/Protocol GO29437 , Version 73.4 OUTCOME MEA SURES
3.4.1 Efficacy  Outcome Measures
[IP_ADDRESS] Co-Primary  Efficacy  Outcome Measure s
The co-primary efficacy outcome measures for this study arethe following :
PFS, defined as the time from randomization to the first occurrence of the disease 
progression as determined by [CONTACT_109822] v1.[ADDRESS_121767] in the tGE population and ITT population
OS, defined as the time from randomization to death from any cause , in the ITT 
population
[IP_ADDRESS] Secondary  Efficacy Outcome Measures
The secondary efficacy outcome measures for this study are the following :
OSin the tGE population
PFS, as determined by [CONTACT_3143] v1.1 , and OS in the 
TC2/3 or IC2/3 population and the TC1/2/3 or IC1/2/3 population
Objective response, defined as PR or CR as determined by [CONTACT_70131] v1.1 in the tGE population and ITT population
DOR, defined as the time interval from the first occurrence of a documented 
objective response to the time of disease progression as determined by [CONTACT_109823] v1.1, or death from any cause, whichever occurs 
firstin the tGE population and ITT population
OS rates at 1 and 2 years for the tGE population and the ITT population
TTD in patient -reported lung cancer symptoms, def ined as time from randomization 
to deterioration (10 -point change) on each of the EORTC QLQ -C30 and EORTC 
QLQ -LC13 symptom subscales (cough, dyspnea [single item], dyspnea [multi -item 
subscale], chest pain, and arm/shoulder pain) in the tGE population and ITT
popu lation
Change from baseline in patient -reported lung cancer symptoms (cough, dyspnea, 
and chest pain) on the symptom severity score of the SILC scale in the tGE 
population and ITT population
PFS, as determined by [CONTACT_109824] T v1.1 , and OS in the 
two atezolizumab -containing arms in the tGE population and the ITT population 
3.4.2 Safety  Outcome Measures
The safety outcome measures for this study are the following:
Incidence, nature, and severity of adverse events graded according t o the 
NCICTCAE v4.0
Changes in vital signs, physical findings, and clinical laboratory results during and 
following study treatment administration
Incidence of ATA response to atezolizumab and potential correlation with PK, 
pharmacodynamic, safety, and ef ficacy parameters
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
67/Protocol GO29437 , Version 73.4.3 Pharmacokinetic Outcome Measures
The PK outcome measures for this study are the following:
Maximum observed serum atezolizumab concentration (C max) after infusion 
(Arms Aand B)
Minimum observed serum atezolizumab concentration (C min) prior to infusion at 
selected cycles, at treatment discontinuation, and at 120 days ( 30days) after the 
last dose of atezolizumab (Arms A and B)
Plasma concentrations for carboplatin (Arms A, B, and C)
Plasma concentrations for paclitaxel (Arm A)
Plasma concentrations for nab -paclitaxel (Arms B and C)
See Appendix 2for specific sample collection times.
3.4.4 Exploratory  Outcome Measures
The exploratory outcome measures for this study are the following:
PFS at 6 months and at 1 year
OS rate at 3 years
Status o f PD-L1, immune -, and NSCLC -related and other exploratory biomarkers 
in archival and/or freshly obtained tumor tissues, and blood (or blood derivatives) 
collected before, during, or after treatment with atezolizumab or at progression and 
association wit h disease status and/or response to atezolizumab in combination with 
chemotherapy
Status of tumor -infiltrating immune cells and other exploratory biomarkers in 
mandatory biopsy specimens and blood collected at progression
Utility scores of the EQ -5D-3L 
Change from baseline in patient -reported outcomes of HRQOL, lung cancer related 
symptoms, and functioning as assessed by [CONTACT_20368] -C30 and QLQ -LC13
4. MATERI ALS AND METHOD S
4.[ADDRESS_121768] meet all of the following criteria to be eligible for study entry:
Signed Informed Consent Form
Male or female, 18 years of age or older
ECOG performance status of 0 or 1 (see Appendix 10)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
68/Protocol GO29437 , Version 7Histologically or cytologically confirmed, Stage IV squamous NSCLC (per the Union 
Internationale contre le Cancer/American Joint Committee on Cancer staging 
system, 7th edition; Detterbeck et al. 2009 ; see Appendix 3)
Patients with tumors of mixed histology (squamous and non -squamous) are 
eligible if the major histological component appears to be squamous.
No prior treatment for Stage IV squamous NSCLC
Patients known to have a sensitizing mutation in the EGFR gene must have 
experienced disease progr ession (during or after treatment) or intolerance to 
treatment with one or more EGFR TKIs, such as erlotinib, gefitinib, or another 
EGFR TKI appropriate for the treatment of EGFR -mutant NSCLC .  Patients with 
unknown EGFR mutation status do not require test ing.
Patients known to have an ALK fusion oncogene must have experienced 
disease progression (during or after treatment) or intolerance to treatment with 
one or more ALK inhibitors (i.e. ,crizotinib) appropriate for the treatment of 
NSCLC in patients havin g an ALK fusion oncogene .  Patients with unknown 
ALK mutation status do not require testing.
Patients who have received prior neo -adjuvant, adjuvant chemotherapy, 
radiotherapy, or chemoradiotherapy with curative intent for non -metastatic disease 
must have experienced a treatment -free interval of at least [ADDRESS_121769] chemotherapy, radiotherapy, or chemoradiotherapy.
Patients with a history of treated asymptomatic CNS metastases are eligible, 
provided they meet all of the follow ing criteria:
Only supratentorial and cerebellar metastases allowed (i.e., no metastases to 
midbrain, pons, medulla, or spi[INVESTIGATOR_1831])
No ongoing requirement for corticosteroids as therapy for CNS disease
No stereotactic radiation within [ADDRESS_121770] receive radiation therapy and/or surgery for CNS metastases.  Following 
treatment, these patients may then be eligible without the need for an additional 
brain scan prior to randomization, if all other criteria are met.
Known PD-L1 tumor status as determined by [CONTACT_109794] a central 
laboratory on previously obtained archival tumor tissue or tissue obtained from a 
biopsy at screening. See Section [IP_ADDRESS].
A representative formalin- fixed paraffin -embedded (FFPE) tumor specimen in 
paraffin block (preferred) or 15 (or more ) unstained, freshly cut, serial sections
on slides from an FFPE tumor specimen is requi redfor participation in this 
study.  If fewer than 15 slides are available at baseline (but no fewer than 10), 
the patient may still be eligible, upon discussion with the Medical Monitor.  This 
specimen must be accompanied by [CONTACT_109825].
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
69/Protocol GO29437 , Version 7Fine-needle aspi[INVESTIGATOR_1516] (defined as samples that do not preserve tissue 
architecture and yield cell suspension and/or cell smears), brushing, cell pellet 
specimens (e.g., from pleural effusion, and lavage samples )are not acceptable.  
Tumor tissue from bone metastases that is subject to decalcification is not 
acceptable.  
For core -needle biopsy specimens, preferably at least three cores embedded in 
a single paraffin block, should be submitted for evaluation.  
Measurable disease, as de fined by [CONTACT_393] v1.1
Previously irradiated lesions can only be considered as measurable disease if 
disease progression has been unequivocally documented at that site since 
radiation and the previously irradiated lesion is not the only site of disease.
Adeq uate hematologic and end organ function, defined by [CONTACT_40855] 14 days prior to randomization:
ANC 1500 cells/ L without granulocyte colony -stimulating factor support
Lymphocyte count 500/ L
Platelet count 100,000/ L without transfusion 
Hemoglobin 9.0 g/dL
Patients may betransfused to meet this criterion.
INR or aPTT 1.5upper limit of normal ( ULN)
This applies only to patients who are not receiving therapeutic 
anticoagulation; patients receiving therapeutic anticoagulation should be 
ona stable dose.
AST, ALT, and alkaline phosphatase 2.5ULN, with the following exceptions:
Patients with documented liver metasta ses:  AST and/or ALT 5ULN
Patients with documented liver or bone metastases:  alkaline phosphatase 
5ULN.
Serum bilirubin 1.25ULN
Patients with known Gilbert disease who have serum bilirubin level 
3ULN may be enrolled
Serum c reatinine 1.5ULN
For female patients of childbearing potential, agreement (by [CONTACT_109796]/or partner) 
to use a highly effective form(s) of contraception that results in a low failure rate (1% 
per year )when used consistently and correctly, and to continue its use for 5months 
after the last dose of atezolizumab ,for [ADDRESS_121771] 
refrain f rom donating eggs during this same period.  For male patients with female 
partners of childbearing potential, agreement (by [CONTACT_109796]/or partner) to use a 
highly effective form(s) of contraception that results in a low failure rate (1% per 
year)when u sed consistently and correctly, and to continue its use for 6 months 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
70/Protocol GO29437 , Version 7after the last dose of nab -paclitaxel, paclitaxel, and/or carboplatin .  Such methods 
include combined (estrogen and progestogen containing) hormonal contraception, 
progestogen -only hormon al contraception associated with inhibition of ovulation 
together with another additional barrier method always containing a spermicide, 
intrauterine device (IUD), intrauterine hormone- releasing system (IUS), bilateral 
tubal occlusion or vasectomized partn er (on the understanding that this is the only 
one partner during the whole study duration), and sexual abstinence.  Men must 
refrain from donating sperm during the study and for [ADDRESS_121772] dose of 
nab-paclitaxel , paclitaxel, and/or carboplati n, whichever is latest .
Oral contraception should always be combined with an additional contraceptive 
method because of a potential interaction with the study drug.  The same rules are 
valid for male patients involved in this clinical trial if they have a partner of 
childbearing potential.  Male patients must always use a condom.
Women who are not postmenopausal ( 12months of non therapy induced 
amenorrhea) or surgically sterile must have a negative serum pregnancy test result 
within 14 days prior to initiation of study drug.
4.1.2 Exclusion Criteria
Patients who meet any of the following criteria will be excluded from study entry.
[IP_ADDRESS] Cancer- Specific Exclusions
Active or untreated CNS metastases as determined by [CONTACT_109826]
Spi[INVESTIGATOR_33373]/or radiation or 
previously diagnosed and treated spi[INVESTIGATOR_33395] 2 weeks prior to randomizatio n
Leptomeningeal disease
Uncontrolled tumor -related pain
Patients requiring pain medication must be on a stable regimen at study entry.
Symptomatic lesions amenable to palliative radiotherapy (e.g., bone 
metastases or metastases causing nerve impi[INVESTIGATOR_20804]) should be treated prior 
to randomization.  Patients should be recovered from the effects of radiation.  
There is no required minimum recovery period.
Asymptomatic metastatic lesions whose further growth would likely cause 
functional deficits or intractable pain (e.g., epi[INVESTIGATOR_70052]) should be considered 
forlocoregional therapy if appropriate prior to randomization .
Uncontrolled pleural effusion, pericardial effusion, or ascites requiring r ecurrent 
drainage procedures (once monthly or more frequently)
Patients with indwelling catheters (e.g., PleurX®) are allowed.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
71/Protocol GO29437 , Version 7Uncontrolled or symptomatic hypercalcemia ( 1.5 mmol/L ionized calcium or 
Ca12 mg/dL or corrected serum calcium ULN) 
Patients who are receiving denosumab prior to randomization must be willing 
and eligible to receive a bisphosphonate instead while in the study.
Malignancies other than NSCLC within 5 years prior to randomization , with the 
exception of those with a negligible r isk of metastasis or death (e.g., expected 
5-year OS 90%) treated with expected curative outcome (such as adequately 
treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized 
prostate cancer treated surgically with curative i ntent, ductal carcinoma in situ 
treated surgically with curative intent)
Known tumor PD -L1 expression status as determined by [CONTACT_70133] (e.g., patients whose PD -L1 expression status was determined 
during screening for entry i nto a study with anti PD-1 or anti PD-L1 antibodies but 
were not eligible are excluded)
[IP_ADDRESS] General Medical Exclusions
Women who are pregnant, lactating or intending to become pregnant during 
thestudy
History of severe allergic, anaphylactic, or other hypers ensitivity reactions 
tochimeric or humanized antibodies or fusion proteins
Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese 
hamster ovary cells or any component of the atezolizumab formulation
History of autoimmune disease, incl uding, but not limited to, myasthenia gravis, 
myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, 
inflammatory bowel disease, vascular thrombosis associated with antiphospholipid 
syndrome, W egener’s granulomatosis, Sjögren’s syndrome, Guillain -Barré 
syndrome, multiple sclerosis, vasculitis, or glomerulonephritis (see Appendix 12for 
a more comprehensive list of autoimmune diseases)
Patients with a history of autoimmune -related hypothyroidism on a stable dose 
of thyroid -replacement hormone are eligible for this study.
Patients with controlled Type 1 diabetes mellitus on a stable dose of insulin 
regimen are eligible for this study.
Patients with eczema, psoriasis, or lichen simplex chronicus of vitiligo with 
dermatologic manifestations only (e.g., patients with psoriatic arthritis would be 
excluded) are permitted provided that they meet the following conditio ns:
Rash must cover less than 10% of body surface area (BSA).
Disease is well controlled at baseline and only requires low -potency 
topi[INVESTIGATOR_8826].
No acute exacerbations of underlying condition within the previous 
12months (not requiring PUVA [psoralen plus ultraviolet A radiation], 
methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, 
high-potency or oral steroids)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
72/Protocol GO29437 , Version 7History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis 
obliterans), drug -induced pneumonitis, idiopathic pneumonitis, or evidence of active 
pneumonitis on screening chest CT scan
History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
Positive test for HIV
All patients will be tested for HIV prior to inclusion into the stud y; patients who 
test positive for HIV will be excluded from the clinical study.
Patients with active hepatitis B (chronic or acute; defined as having a positive 
hepatitis B surface antigen [HBsAg] test at screening) or hepatitis C
Patients with past hepati tis B virus (HBV) infection or resolved HBV infection 
(defined as the presence of hepatitis B core antibody [HBcAb] and absence of 
HBsAg) are eligible only if they are negative for HBV DNA .  Patients who are 
positive for hepatitis C virus (HCV) antibody ar e eligible only if PCR is negative 
for HCV RNA.
Active tuberculosis
Severe infections within 4 weeks prior to randomization , including, but not limited to, 
hospi[INVESTIGATOR_33377], bacteremia, or severe pneumonia
Received therapeutic oral or IV antibiotics within 2 weeks prior to randomization
Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract 
infection or to prevent chronic obstructive pulmonary disease exacerbation) are 
eligible.
Significant cardiov ascular disease, such as [LOCATION_001] Heart Association cardiac 
disease (Class II or greater), myocardial infarction, or cerebrovascular accident
within the 3 months prior to randomization, unstable arrhythmias, or unstable angina
Patients with known coronary artery disease, congestive heart failure not 
meeting the above criteria, or left ventricular ejection fraction 50% must be on 
a stable medical regimen that is optimized in the opi[INVESTIGATOR_33398], in consultation with a cardiologist if appr opriate.
Major surgical procedure other than for diagnosis within 28 days prior to 
randomization or anticipation of need for a major surgical procedure during the 
course of the study
Prior allogeneic bone marrow transplantation or solid organ transplant
Administration of a live, attenuated vaccine within 4 weeks before randomization or 
anticipation that such a live attenuated vaccine will be required during the study
Any other diseases, metabolic dysfunction, physical examination finding, or clinical 
laboratory finding giving reasonable suspi[INVESTIGATOR_1884] a disease or condition that 
contraindicates the use of an investigational drug or that may affect the 
interpretation of the results or render the patient at high risk from treatment 
complications
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
73/Protocol GO29437 , Version 7Patients with il lnesses or conditions that interfere with their capacity to understand, 
follow and/or comply with study procedures
[IP_ADDRESS] Exclusion Criteria Related to Medications
Any approved anti -cancer therapy, including hormonal therapy ,within 21 days prior 
to initiation o f study treatment; the following exceptions are allowed:
TKIs approved for treatment of NSCLC discontinued 7days prior to 
randomization.  The baseline scan must be obtained after discontinuation of 
prior TKIs.
Treatment with any other investigational agent with therapeutic intent within 28 days 
prior to randomization
Prior treatment with CD137 agonists or immune checkpoint blockade therapi[INVESTIGATOR_014], 
antiPD-1, and anti PD-L1 therapeutic antibodies
Patients who have had prior anti CTLA-4 treatment may be enrolled, provided 
the following requirements are met:
Last dose of anti CTLA-[ADDRESS_121773] 6 weeks prior to randomization
No history of severe immune- mediated adverse effects from anti CTLA-4 
(NCI CTCAE Grades 3 and 4)
Treatment with systemic immunostimulatory agents (including, but not limited to, 
IFNs, IL -2) within 4 weeks or five half -lives of the drug, whichever is longer, prior to 
randomization
Prior treatment with cancer vaccines is allowed.
Treatment with systemic immunosuppressive medic ations (including, but not limited 
to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and 
anti-tumor necrosis factor [anti -TNF] agents) within [ADDRESS_121774] received acute, low -dose (10mg o ral prednisone or 
equivalent) , systemic immunosuppressant medications may be enrolled in the 
study.
The use of corticosteroids (10 mg oral prednisone or equivalent) for chronic 
obstructive pulmonary disease, mineralocorticoids (e.g., fludrocortisone) for
patients with orthostatic hypotension, and low -dose supplemental 
corticosteroids for adrenocortical insufficiency is allowed.
[IP_ADDRESS] Exclusions Related to Chemotherapy
Known history of severe allergic reactions to platinum -containing compounds 
ormannitol
Known sensitivity to any component of paclitaxel or nab -paclitaxel
Grade 2 peripheral neuropathy as defined by [CONTACT_4652] v4.0 (paclitaxel and 
nab-paclitaxel)
Known history of severe hypersensitivity reactions to products containing 
Cremophor®EL (e.g., cyclos porin for injection concentrate and teniposide for 
injection concentrate)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
74/Protocol GO29437 , Version 74.2 METHOD OF TREA TMENT ASSIGNMENT A ND BLIND ING 
This is an open -label study.
After written informed consent has been obtained and eligibility has been established, 
the study site will enter demographic and baseline characteristics in the interactive 
voice/W eb response system (IxRS).  For patients who are eligible for enrollment, the 
study site will obtain the patient’s randomization number and treatment assignment from 
the IxRS.  The num ber of cycles of induction treatment (four or six) will be determined by 
[CONTACT_70134].
Randomization to one of the three treatment arms will occur in a 1:1:1 ratio.  
Permuted- block randomization will be applied to ensure a balanced assignment to each 
treatment arm.  Randomization will be stratified by [CONTACT_4868]:
Sex (male vs. female)
Presence of liver metastases at baseline (yes vs. no)
PD-L1 expression by [CONTACT_4658] (TC3 and any IC vs. TC0/1/2 and IC2/3 vs. T C0/1/2 and 
IC0/1) (see Section 6.4.1 )
Patients should receive their first dose of study drug on the day of randomization if 
possible.   If this is not possible, the first dose should occur within 5 days after 
randomization.
4.3 STUDY TRE ATMENT
4.3.1 Formulation, Packaging, and Handling
[IP_ADDRESS] Atezolizumab (MPDL3280A )
The atezolizumab (MPDL3280A) drug product is provided as a sterile liquid in a 
single -use, 20 -mL glass vial.  The vial is designed to deliver 20 mL (1200 mg) of 
atezolizumab solution but may contain more than the stated volume to enable delivery 
ofthe entire 20 -mL volume.  
For further details on the formulation and handling of atezolizuma b, see the Pharmacy 
Manual and Investigator’s Brochure.
[IP_ADDRESS] Carboplatin, Paclitaxel, and n ab-Paclitaxel
Carboplatin and paclitaxel will be obtained in commercially available formulations .  
nab-Paclitaxel will be supplied to the sites by [CONTACT_1034].  For count ries in which the 
Sponsor is required to provide all study drugs, including standard -of-care drugs, 
carboplatin and paclitaxel will be provided by [CONTACT_109827]. 
For information on the formulation, packaging, and handling of carboplatin , paclitaxe l, 
and nab- paclitaxel, see the prescribing information for each drug.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
75/Protocol GO29437 , Version [IP_ADDRESS] Erlotinib
Switch maintenance to erlotinib is no longer permitted.  However, patients who had 
already started switch maintenance treatment with erlotinib under previous protocol 
versions may be allowed to continue treatment with erlotinib upon discussion of the risks, 
potential benefits, and alternative treatment options with the investigator.   Because 
erlotinib is considered an investigational medicinal produc t(IMP), erlotinib will be 
provided by [CONTACT_109828].   For information 
on the formulation and packaging and handling of erlotinib, see the prescribing 
information.
4.3.[ADDRESS_121775] of four or six cycles of chemotherapy; 
atezolizumab, paclitaxel, and carboplatin will be administered on Day 1 of each 21 -day 
cycle.  nab -Paclitaxel will be administered on Days 1, 8, and 15 of each 21 -day cycle.  
The Day 1 order of drug admini stration is as follows:
Arm A:  Atezolizumab paclitaxel carboplatin
Arm B:   Atezolizumab nab
-paclitaxel carboplatin
Arm C:   nab
-Paclitaxel carboplatin
During the induction phase, a chemotherapy cycle counts toward the prespecified 
number of induction chemotherapy cycles (four or six) as long as at least one 
chemotherapy component has been administered at least once during a 21- day cycle.  
Cycles in which no chemotherapy component is given do not count toward the 
prespecified number of induction chemotherapy cycles.  Additional guidance is provided 
in Appendix 15
.
Patients who experience no further clinical benefit (for patients enrolled into Arms A or B, 
see Section 3.1for definitio n) or disease progression (for patients enrolled into Arm C) at 
any time during the induction phase will discontinue all study treatment.  In the absence 
of the above criteria, after the [ADDRESS_121776] supportive care until disease progression.  
During treatment (induction or maintenance), patients randomized to Arms A or B who 
show evidence of clinic al benefit will be permitted to continue atezolizumab after 
RECIST v1.[ADDRESS_121777] of care and manufacturer’s instruction.  Table 10lists the 
suggested premedication for induction treatment for patients randomized to Arm A and 
Table 11lists the suggested infusion times for treatment administration during the 
induction and maintenance phases.  
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
76/Protocol GO29437 , Version 7Chemotherapy infusion times may be adapted in ac cordance with local standard of care 
in lieu of the suggested infusion times specified in Table 11and Section [IP_ADDRESS].  
Chemotherapy dose modifications are allowed only to address toxicities (see 
Section [IP_ADDRESS] and Section 5.1.9 for guidelines).  The investigator may use discretion in 
modifying or accelerating the chemotherapy dose modification, depending on the 
severity of toxicity and an assessment of the risk vers us benefit for the patient, with the 
goal of maximizing patient compliance and access to supportive care.
Table 10Suggested Premedication for Induction Treatment for A rmA
Premedication Dose/Route Timing
Before paclitaxel 
treatment in Arm ADexamethasone 20 mg PO 12 and 6 hours before 
paclitaxel (or per standard of 
care at treating institution)
Diphenhydramine 
(orequivalent)50 mg IV 30–60 minutes before 
paclitaxel
Cimetidine (or 
ranitidine) (or 
equivalent)300 mg 
(or50mg) IV 
(orequivalent)30–60 minutes before 
paclitaxel
IVintravenous; PO oral.
Note:  Prophylactic anti -emetics and hydration should be administered as per the local 
standard of care and manufacturer’s instruction. 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
77/Protocol GO29437 , Version 7Table 11Treatment Regimen and Order of Administration for 
AllTreatment Arms
Agent (1) Atezolizumab (2) Paclitaxel OR nab -Paclitaxel (3) Carboplatin
Dose and 
administration 
route1200 mg IV Paclitaxel
200mg/m2IVanab-Paclitaxelb
100mg/m2IVAUC 6 IVe
Infusion rate Over 60 ( 15) min 
(for the first 
infusion); 
30(10)min for 
subsequent 
infusions if 
toleratedOver 180 
minutescOver 30 
minutesdOver 
approximately 
1530mine
Frequenc y Day 1 of every 21 day s (and Day s 8 and 15 for nab -paclitaxel )
Induction 
Phase
(fouror six
Cycles)A x x x
B x x x
C x x
Maintenance 
PhaseA x
B x
C
AUC area under the concentration time curve; IV intravenous.
a Patients of Asian race/ethnicity: 175 mg/m2 IV
bOn Day s8 and 15, nab -paclitaxel will be administered alone over 30 minutes .
cSee Section [IP_ADDRESS] for more details on paclitaxel dosing.
dSee Section [IP_ADDRESS] for more details on nab -paclitaxel dosing.
eSee Section [IP_ADDRESS] for details on dose calculation of carboplatin.
Guidelines for dose modification and treatment interruption or discontinuation for 
carboplatin, paclitaxel, and nab- paclitaxel are provided in Section 5.1.7 , Section 5.1.9 , 
and Section 5.1.10 .
[IP_ADDRESS] Atezolizumab
Patients randomized to atezolizumab will receive 1200 mg of atezolizu mab administered 
by [CONTACT_33433] 21 days in a monitored setting where there is immediate access to 
trained personnel and adequate equipment/medicine to manage potentially serious 
reactions.  
Atezolizumab infusions will be administered per the instructions outlined in Table 12.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
78/Protocol GO29437 , Version 7Table 12Administration of First and Subsequent Infusions 
ofAtezolizumab
First Infu sion Subsequent Infusions
Nopremedication administered for 
atezolizumab specifically is permitted 
Record patient’s vital signs ( pulse rate, 
respi[INVESTIGATOR_13521] y rate, blood pressure, and 
temperature) within 60 min before starting 
infusion.
Infuse atezolizumab (1200 mg in a 250 mL 
0.9% NaCl IV infusion bag) over 60 ( 15) 
min.
If clinically indicated, record patient’s vital 
signs ( pulse rate, respi[INVESTIGATOR_697], blood 
pressure, and temperature) during the 
infusion at 15 min, 30 min, 45 min, and 
60min (5-min windows are allowed for all 
timepoints).
If clinically indicated ,record patient’s vital 
signs ( pulse rate, respi[INVESTIGATOR_697], blood 
pressure, and temperature) at 30 min ( 10 
min) after the infusion.
Patients will be informed about the possibility 
of delayed post-infusion s ymptoms and 
instructed to contact [CONTACT_109829].If patient experienced infusion -related 
reaction during any previous infusion, 
premedication with antihistamines may be 
administered for C ycles  2 at the discretion 
of the treating physician .
Record patient’s vital signs ( pulse rate, 
respi[INVESTIGATOR_13521] y rate, blood pressure, and 
temperature) within 60 min before starting 
infusion.
If the patient tolerated the first infusion well 
without infusion -associated adverse events, 
the second infusion may be delivered over 
30(10) min.
If no reaction occurs, subsequent infusions 
may be delivered over 30 ( 10) minutes.
Continue to record vital signs within 
60minutes before starting infusion.  
Record vital signs during and after the 
infusion, if clinically indicated.
If the patient had an infusion -related 
reaction during the previous infusion, the 
subsequent infusion must be delivered over 
60(15) min.
Record patient’s vital signs ( pulse rate, 
respi[INVESTIGATOR_697], blood pres sure, and 
temperature) every 15 ( 5) minutes
during the infusion if clinically indicated or 
patient experienced sy mptoms during the 
previous infusion. 
Record patient’s vital signs ( pulse rate, 
respi[INVESTIGATOR_13521] y rate, blood pressure, and 
temperature) 30 min ( 10 min) after the 
infusion if clinically indicated or patient 
experienced s ymptoms during previous 
infusion.
Dose modifications to atezolizumab are not permitted.  Guidelines for treatment 
interruption or discontinuation and the management of specific ad verse events are 
provided in Sections [IP_ADDRESS], [IP_ADDRESS] , and 5.1.8 .
Refer to the Pharmacy Manual for detailed instructions on drug preparation, storage, and 
administration.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
79/Protocol GO29437 , Version [IP_ADDRESS] Paclitaxel, n ab-Paclitaxel ,and Carboplatin
Paclitaxel
Ingeneral, paclitaxel will be administered intravenously at a dose of 200 mg/m2over 
3hours followed by [CONTACT_104124]. Patients of Asian race/ethnicity will have a lower 
starting dose of paclitaxel at 175 mg/m2 intravenously over 3 hours. The lower starting 
dose of paclitaxel is based on a higher overall incidence of hematologic toxicities in 
patients from Asian countries compared with those from non- Asian countries , as
observed during safety review of this study by [CONTACT_68200] .The term "Asian race/ethnicity "
refers to a pan -ethnic/racial group that includes diverse populations who either live or 
have ancestral origins in East Asia, Southeast Asia, or South Asia. The appl icability of 
such term in a particular patient will be at the discretion of the treating investigator and 
should be based on the patient’s clinical characteristics and country of origin.
Paclitaxel Injection must be diluted prior to infusion.  Paclitaxel s hould be diluted in 0.9% 
Sodium Chloride Injection, USP; 5% Dextrose Injection, USP; 5% Dextrose and 
0.9% Sodium Chloride Injection, USP; or 5% Dextrose in Ringer’s Injection to a final 
concentration of 0.3 to 1.2 mg/mL. 
Contact [CONTACT_109830].  Paclitaxel should be administered 
through an in- line filter with a microporous membrane not greater than 0.22 m.  Use of 
filter devices such as IVEX -2®filters, which incorporate short inlet and outlet PVC -coated 
tubing, has not resulted in significant leaching of bis(2 -ethylhexyl)phthalate (DEHP).
Sites should follow their institutional standard ofcare for determining the paclitaxel dose
adjustments i n the event of patient weight changes .  For paclitaxel infusion, exceptions 
to the infusion time of 3hours will be allowed for sites that have an institutional policy of 
infusing paclitaxel more quickly (over 90 minutes) or more slowly (up to [ADDRESS_121778] infusion).
nab-Paclitaxel
nab-Paclitaxel injection must be diluted prior to infusion.  nab -Paclitaxel should be 
diluted in 0.9% Sodium Chloride Injection to a final concentration of 5 mg/mL.  Sites 
should follow their institutional standard of ca re for determining nab- paclitaxel dose 
adjustments in the event of patient weight changes.  The infusion site should be closely 
monitored for possible infiltration during drug administration.  Limiting the infusion of 
nab-paclitaxel to 30 minutes, as direc ted, reduces the likelihood of infusion -related 
reactions.  Following administration, the intravenous line should be flushed with sodium 
chloride 9 mg/mL (0.9%) solution for injection to ensure administration of the complete 
dose, according to local practi ce.
See the prescribing information for nab -paclitaxel for more information.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
80/Protocol GO29437 , Version 7Carboplatin
Carboplatin should be administered by [CONTACT_16228], immediately after the completion of 
paclitaxel or nab- paclitaxel administration, over 15 30minutes to achieve an initial target 
area under the concentration time curve (AUC) of 6mg/mL/min (Calvert formula dosing) 
and with standard anti -emetics per local practice guidelines.  
The carboplatin dose of AUC 6 will be calculated using the Calvert formula 
(Calvert etal.1989 ):
Calvert Formula
Total Dose (mg) (target AUC) (glomerular filtration rate [GFR] 25)
NOTE:  The GFR used in the Calvert formula to calculate AUC -based dosing should 
not exceed 125 mL/min. 
For the purposes of this protocol, the GFR is considered to be equivalent to the 
creatinine clearance (CRCL).  The CRCL is calculated by [CONTACT_109831] ( 1976 ) using the following formula:
CRCL (140age) (wt)(0.85 if female)72Scr
Where: CRCL creatinine clearance in mL/min
agepatient's age in years 
wtpatient’s weight in kg
Scr serum creatinine in mg/dL
NOTE:  For patients with an abnormally low serum creatinine level, estimate GFR using 
a minimum creatinine level of 0.8 mg/dL or cap the estimated GFR at 125 mL/min.
If a patient’s GFR is estimated based on serum creatinine measurements by [CONTACT_70138], the FDA recommends that physicians consider 
cappi[INVESTIGATOR_109777] (AUC) to avoid potential toxicity 
due to overdosing. Based on the Calvert formula described in the carboplatin label, the 
maximum doses can be calculated as follows:
Maximum carboplatin dose (mg) target AUC (mg min/mL) (GFR 25 mL/min)
The maximum dose is based on a GFR estimate that is capped at 125 mL/min for 
patients with normal renal function.  No higher estimated GFR values should be used.
For a target AUC6, the maximum dose is 6 150900 mg.
For a target AUC 5, the maximum dose is 5 150750 mg.
For a target AUC 4, the maximum dose is 4 150600 mg.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
81/Protocol GO29437 , Version 7Refer to the FDA’s communication regarding carboplatin dosing using the following URL 
for more details:
http://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacc o/cder/
ucm228974.htm.
[IP_ADDRESS] Erlotinib
Switch maintenance treatment with erlotinib is no longer permitted.  However, patients 
who had already started switch maintenance treatment with erlotinib under previous 
protocol versions may be allowed to continue treatment with erlotinib upon discussion of 
the risks, potential benefits and alternative treatment options with the investigator .  For 
those patients who receive switch maintenance, institutions should follow the dosage 
and administration instructions in the erlotinib prescribing information.   
4.3.3 Additional Required Medication
[IP_ADDRESS] Prophy lactic Measures for Carboplatin
Carboplatin is considered moderately to highly emetogenic.  Therefore, appropriate 
anti-emetic medication should be given prior to initiation of c hemotherapy according to 
the local practice and standard of care. 
[IP_ADDRESS] Premedication for Paclitaxel
All patients should be premedicated prior to paclitaxel administration to prevent severe 
hypersensitivity reactions.  Prior to receiving paclitaxel, all patient s will receive either the 
institutional standard ofcare or the following premedication: 
Dexamethasone 20 mg orally approximately 12 hours prior and 6 hours prior to the 
paclitaxel infusion
Patients may be treated with dexamethasone 10 20mg IV within 1 hour prior to 
paclitaxel infusion if the patient did not take the oral dexamethasone.
Diphenhydramine 50 mg IV (or equivalent) 30 60 minutes prior to paclitaxel infusion
Cimetidine 300 mg IV or ranitidine 50 mg IV (or equivalent) 30 [ADDRESS_121779] or an IMP.  IMPs requi red for completion of this study will be provided by [CONTACT_109832] —F. Hoffmann- La [COMPANY_002] Ltd
82/Protocol GO29437 , Version 7Sponsor if required by [CONTACT_109833].   The Sponsor or appointed 
designee will supply other medicinal products in accordance with local regulations.  
The study site will acknowledge receipt of the IMPs using IxRS to confirm shipment 
condition and content.  Any damaged shipments will be replaced.
IMPs will either be disposed of at the study site according to the study site’s institutional 
standard operating procedure or returned to the Sponsor with the appropriate 
documentation.  The site’s method of IMP destruction must be agreed to by [CONTACT_1034].  
The site must obtain written authorization from the Sponsor before any IMP is destroyed, 
and IMP destruction must be documented on the appropriate form.
Accurate records of all IMPs received at, dispensed from, returned to, and disposed of 
by [CONTACT_25729].
4.3.[ADDRESS_121780], available 
at the following W eb site:
http://www.roche.com/policy_continued_access_to_investigational_medicines.pdf
These analyses may be conducted prior to completion of the study.  
4.4 CONCOMITA NT THERA PY
Concomitant therapy includes any medication (e.g., prescription drugs, over -the-counter 
drugs, herbal or homeopathic remedies, nutritional supplements) used by a patient from 
7days prior to screening until the treatment discontinuation visit.  All such medications 
should be reported to the investigator. 
4.4.1 Permitted Therapy  
Premedication with antihistamines may be administered for any atezolizumab infusions 
after Cycle 1.
The following therapi[INVESTIGATOR_70056]:
Oral contraceptives
Hormone -replacement therapy
Prophylactic or therapeutic anticoagulation therapy (such as low molecular weight 
heparin or warfarin at a stable dose level)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
83/Protocol GO29437 , Version 7Palliative radiotherapy (e.g., treatment of known bony metastases) provided it does 
not interfere with the assessment of tumor target lesions (e.g., the lesion being 
irradiated is not the only site of disease, as that would render the patient not 
evaluable for response by [CONTACT_33461] v1.1)
It is not a requirement to withhold atezolizumab during palliative radiotherapy.
Inactive influenza vaccinations 
Megastrol administered as an appetite stimulant 
Corticosteroids (10mg oral prednisone or equivalent) for chronic obstructive 
pulmonary disease
Mineralocorticoids (e.g., fludrocortisone) 
Low-dose corticosteroids for patients with orthostatic hypotension or adrenocortical 
insufficiency
Switch maintenance therapy with erlotinib is no longer permitted.  However, patien ts who 
had already started treatment with erlotinib under previous protocol versions may be 
allowed to continue treatment with erlotinib upon discussion of the risks, the potential 
benefits, and alternative treatment options with the investigator.   Investi gators should 
follow the dosage and administration instructions in the prescribing information for 
erlotinib.   
In general, investigators should manage a patient’s care with supportive therapi[INVESTIGATOR_40801], as per local standards.  Patients wh o experience infusion- associated 
symptoms may be treated symptomatically with acetaminophen, ibuprofen, 
diphenhydramine, and/or famotidine or another H 2-receptor antagonist, as per standard 
practice (for sites outside the [LOCATION_002], equivalent medicati ons may be substituted 
perlocal practice).  Serious infusion -associated events manifested by [CONTACT_27926], 
hypotension, wheezing, bronchospasm, tachycardia, reduced oxygen saturation, or 
respi[INVESTIGATOR_109778] 
(e.g., supplemental oxygen and 2-adrenergic agonists; see Appendix 11). 
All concomitant medications must be recorded on the appropriate Concomitant 
Medications electronic Case Report Form (eCRF).  Erlotinib use will be recorded on a 
separate Erlotinib Administ ration eCRF.
4.4.2 Cautionary  Therapy for A tezolizumab -Treated Patients
Systemic corticosteroids and TNF -inhibitors may attenuate potential beneficial 
immunologic effects of treatment with atezolizumab.  Therefore, in situations where 
systemic corticosteroids or TNF- inhibitors would be routinely administered, alternatives, 
including antihistamines, should be considered first by [CONTACT_1963].  If the 
alternatives are not feasible, systemic corticosteroids and TNF -inhibitors may be 
administered at t he discretion of the treating physician except in the case of patients for 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
84/Protocol GO29437 , Version 7whom CT scans with contrast are contraindicated (i.e., patients with contrast allergy or 
impaired renal clearance) (see also Section 4.4.3 ).
Systemic corticosteroids are recommended with caution at the discretion of the treating 
physician for the treatment of specific adverse events when associated with 
atezolizu mab therapy.  Guidelines for the management of immune- mediated adverse 
events are described in Section 5.1.8 .
4.4.3 Prohibited Therapy
Any c oncomitant therapy intended for the treatment of cancer, whether health 
authority approved or experimental, is prohibited for various time periods prior to 
starting study treatment, depending on the anti -cancer agent (see Section 4.1.2 ), and 
during study treatment until disease progression is documented and thepatient has 
discontinued study treatment.  This includes, but is not limited to, chemotherapy, 
hormonal therapy, immunotherapy, radiotherapy, non-approved experimental agents, or 
herbal therapy (unless otherwise noted) .
The following medications are prohi bited while in the study, unless otherwise noted:
Denosumab; patients who are receiving denosumab prior to enrollment must be 
willing and eligible to receive a bisphosphonate instead while in the study 
Any live, attenuated vaccine (e.g., FluMist®) within [ADDRESS_121781] atezolizumab dose (for patients 
randomized to atezolizumab).
Use of steroids to premedicate patients for whom CT scans with contrast are 
contraindicated (i.e., patients wit h contrast allergy or impaired renal clearance); in 
such patients, non- contrast CT of the chest and non -contrast CT or MRI scans of 
the abdomen and pelvis should be performed. 
The concomitant use of herbal therapi[INVESTIGATOR_109779], 
safety profiles, and potential drug -drug interactions are generally unknown.  However, 
their use for patients in the study is allowed at the discretion of the investigator , provided 
that there are no known interactions with any study treatment .  Asnoted above, herbal 
therapi[INVESTIGATOR_109780].
4.[ADDRESS_121782] be performed and documented for each patient.
Patients should be assessed for toxic ity prior to each dose; dosing will occur only if the 
clinical assessment and local laboratory test values are acceptable.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
85/Protocol GO29437 , Version 74.5.[ADDRESS_121783] a 
biopsy of the progressing lesion (if clinically feasible) and to acknowledge deferring other
treatment options available to them in favor of continuing treatment with atezolizumab.
4.5.2 Medical History  and Demographic Data
Medical history includes clinically significant diseases, surger ies, cancer history 
(including prior cancer therapi[INVESTIGATOR_26649]), reproductive status, smoking history, 
and all medications (e.g., prescription drugs, over -the-counter drugs, herbal or 
homeopathic remedies, nutritional supplements) used by [CONTACT_25701] 7 days prior 
to the screening visit. 
NSCLC cancer history will include prior cancer therapi[INVESTIGATOR_014], procedures, and an 
assessment of tumor mutational status (e.g., sensitizing EGFR mutation, ALK
fusion status).
Demographic data will include age, sex, a nd self -reported race/ethnicity.
4.5.3 Physical Examinations
A complete physical examination should include an evaluation of the head, eyes, ears, 
nose, and throat, and the cardiovascular, dermatological, musculoskeletal, respi[INVESTIGATOR_696], 
gastrointestinal, genitouri nary, and neurological systems.  Any abnormality identified at 
baseline should be recorded on the General Medical History and Baseline Conditions 
eCRF.
At subsequent visits (or as clinically indicated), limited, symptom -directed physical 
examinations should be performed.  Changes from baseline abnormalities should be 
recorded in patient notes.  New orworsened clinically significant abnormalities should be 
recorded as adverse events on the Adverse Event eCRF.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
86/Protocol GO29437 , Version 74.5.4 Vital Signs
Vital signs will include measurements of temperature, pulse rate, respi[INVESTIGATOR_697], and 
systolic and diastolic blood pressures while the patient is in a seated position.
Vital signs will be measured and recorded as described in Table 13.
For all sites in Argentina, pulse oximetry to measure hypoxia will be performed at every 
visit.  These data will not be recorded.
Table 13Vital Sign Measurements at Cy cle 1 and All Subsequent Cy cles
Cycle 1
Treatment Arm Timepoints
Arms A and B  Within 60 minutes prior to atezolizumab infusion
 During (every 15 [5]minutes) the atezolizumab
infusion and within 30 (10) m inutes after 
atezolizumab infusion if clinically indicated
 Within 30 (10)minutes after carboplatin infusion
Arm C  Within 60 minutes prior to nab-paclitaxel infusion
 Within 30 (10)minutes after carboplatin infusion
Subsequent Cycles
Treatment Arm Timepoints
Arms A and B Within 60 minutes prior to atezolizumab infusion
 During (every 15 [5]minutes) the atezolizumab
infusion and within 30 (10) m inutes after 
atezolizumab infusion if clinically indicated or 
symptoms occurred during prior infusion
Arm C Within 60 minutes prior to nab -paclitaxel infusion
 During infusion if clinically indicated or sy mptoms 
occurred during prior infusion
 Within 30 ( 10) m inutes after carboplatin infusion if 
clinically indicated or if sy mptoms occurred during the 
prior infusion
For patients in the atezolizumab ar m, also refer to Table 12.
4.5.[ADDRESS_121784] scans (with oral/IV contrast unless 
contr aindicated) or MRIs of the chest and abdomen.  A CT or MRI scan of the pelvis is 
required at screening and as clinically indicated or as per local standard of care at 
subsequent response evaluations.  A spi[INVESTIGATOR_70058] a requirement.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
87/Protocol GO29437 , Version 7A CT (with contrast if not contraindicated) or MRI scan of the head must be done at 
screening to exclude CNS metastasis.  An MRI scan of the brain is required to confirm or 
refute the diagnosis of CNS metastases at baseline in the event of an equivocal scan.  
Patients with active or untreated CNS metastases are not eligible for the study 
(see Section [IP_ADDRESS]).
If a CT scan for tumor assessment is performed in a positron emission tomography 
(PET)/CT scanner, the CT acquisition must be consistent with the standards for 
afull-contrast diagnostic CT scan.
Bone scans and CT scans of the neck should also be performed if clini cally indicated.  At 
theinvestigator’s discretion, other methods of assessment of measurable disease as per 
RECIST v1.[ADDRESS_121785] be documented at screening and re- assessed at each subsequent 
tumor evaluation .  Patients with a history of irradiated brain metastases at screening are 
not required to undergo imaging brain scans at subsequent tumor evaluations, unless 
scans are clinically indicated.   The same radiographic procedure used to assess disease 
sites at screening should be used throughout the study (e.g., the same contrast protocol 
for CT scans).  Re sponse will be assessed by [CONTACT_3143] v1.[ADDRESS_121786] for atezolizumab -containing treatment arms (Arms A and B) and 
only according to RECI ST v1.1 for carboplatin nab-paclitaxel treatment arm (Arm C).  
Assessments should be performed by [CONTACT_22960], if possible, to ensure internal 
consistency across visits.  Results must be reviewed by [CONTACT_109834].
Tumor assessments should occur every 6 weeks ( 7 days) for 48weeks following 
Cycle 1, Day 1 and then, after completion of the W eek48 tumor assessment , every 
9weeks ( 7 days) ,regardless of treatment delays until radiographic disease 
progression per RECIST v1.1 ( or loss of clinical benefit for patients assigned to 
atezolizumab who continue treatment beyond disease progression according to 
RECIST v1.1), withdrawal of consent, death, or study termination by [CONTACT_1034], 
whichever occurs first.
Patients who discontinue treatment for reasons other than radiographic disease 
progression per RECIST v1.1 (e.g., toxicity, symptomatic deterioration) will continue 
scheduled tumor assessments until radiographic disease progression per RECIST v1.1 
(or loss of clinical benefit for atezolizumab -treated patients who hadcontinue dtreatment
with atezolizumab after radiographic disease progression according to RECIST v1.1), 
withdrawal of consent, study termination by [CONTACT_2728], or death, whichever occurs first.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
88/Protocol GO29437 , Version 7Patients who start a new anti -cancer therapy in the absence of radiographic disease 
progression per RECIST v1.[ADDRESS_121787].  Patients who are treated with 
atezolizumab who continue to experience clinical benefit, despi[INVESTIGATOR_40803], will continu e tumor assessments as per the schedule listed 
above.  
Scans will be submitted to an IRF.
4.5.6 Laboratory  Assessments and Biomarker Samples
Samples for the following laboratory tests will be sent to the study site's local laboratory 
for analysis:
Hematology (C BC, including RBC count, hemoglobin, hematocrit, W BC count with 
differential [neutrophils, eosinophils, lymphocytes, monocytes, basophils, and other 
cells], and platelet count)
Serum chemistries (glucose, BUN or urea, creatinine, sodium, potassium, 
magnesi um, chloride, bicarbonate or total CO 2, calcium, phosphorus, total bilirubin, 
ALT, AST, alkaline phosphatase, LDH, total protein, and albumin)
Coagulation (aPTT or INR)
Serum pregnancy test for women of childbearing potential, including women who 
have had a tubal ligation; urine pregnancy tests will be performed on Day [ADDRESS_121788].
Childbearing potential is defined as not having undergone surgical sterilization, 
hysterectomy, and/or bilateral oophorectomy, or not being postmenopausal 
(12 months of amenorrhea). 
Urinalysis (specific gravity, pH, glucose, protein, ketones, and blood) ; dipstick
permitted
Thyro id-function testing (thyroid- stimulating hormone [TSH], free T3, free T4)
Total T3 to be tested only at sites where free T3 testing is not performed.
HBV serology:  hepatitis B surface antigen (HBsAg), antibodies against HBsAg, total 
hepatitis B core antib ody (HBcAb)
HBV DNA test must be performed prior to randomization if patient has a 
negative serology for HBsAg and a positive serology for HBcAb.   The HBV DNA 
test must be negative.
HCV serology:  hepatitis C virus antibody (anti -HCV)
HCV RNA testmust be performed prior to randomization if the patient tests 
positive for anti -HCV .
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
89/Protocol GO29437 , Version 7HIV testing
All patients will be tested for HIV prior to inclusion into the study and 
HIV-positive patients will be excluded from the clinical study.
A central laboratory will coordinate the sample collection of tissue and blood samples for 
research -related testing at central laboratories or by [CONTACT_1034]. Instruction manuals 
and supply kits will be provided for all central laboratory assessments.  Sa mples for the 
following laboratory tests will be sent to one or several central laboratories or to the 
Sponsor for analysis:  
ATA assays (all atezolizumab -treated patients)
Serum samples will be assayed for the presence of ATAs to atezolizumab with 
use of validated immunoassays.  Accompanying PK samples will be collected 
at the same timepoints.
PK assay
Blood samples for PK assessments will be obtained according to the schedule 
in Appendix 2.  
Serum samples will be assayed for atezolizumab concentration with use of a 
validated immunoassay.
At select edsites, a subset of 20 patients in each arm will undergo the additional 
PK assessments fo r carboplatin and paclitaxel (Arm A) and carboplatin and 
nab-paclitaxel (Arms B and C). 
Plasma carboplatin, paclitaxel, and nab -paclitaxel (reported as total paclitaxel) 
concentrations will be assayed using validated methods.
Biomarker assays in blood sam ples
Blood samples will be obtained for biomarker evaluation (including but not 
limited to biomarkers that are related to NSCLC or tumor immune biology) from 
all eligible patients according to the schedule in Appendix 2.  Samples will be 
processed to obtain plasma and serum for the determination of changes in 
blood -based biomarkers (e.g., ctDNA, cytokines ).  W hole blood samples may 
be processed to obtain their derivatives (e.g., RNA and DNA) and evaluated for 
immune -related, tumor typerelated , and other exploratory biomarkers (e.g., 
alterations in gene expression or single nucleotide polymorphisms). 
For patients who consent to the opt ional collection of samples for the [COMPANY_002] Clinical 
Repository (RCR), any leftover material from the above sample collection will be 
stored and used for exploratory analyses as indicated in Section 4.5.11 .  For 
patients who consent to RCR optional future research on their whole blood samples 
collected at screening but are determined to be ineligible for study participation, 
these samples and their derivatives (e.g., DNA, RNA, protein) may be used for 
future development of biomarker and/or diagnostic tests as indicated in 
Section 4.5.11.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
90/Protocol GO29437 , Version 74.5.7 Tumor Tissue Samples
[IP_ADDRESS] Archival and Freshly  Collected Tumor Tissue Samples for 
Screening
Representative tumor specimens in paraffin blocks (preferred) or 15 ( or more) freshly cut,
serial unstained sections on slides, with an associated p athology report, must be 
submitted at screening for determination of PD -L1 status prior to study randomization.  If 
fewer than 15 slides are available at baseline (but no fewer than 10), the patient may still 
be eligible, upon discussion with the Medical M onitor.   In addition, expression of PD-L1 
and T -effector gene signature [CONTACT_109863]. Exploratory biomarkers (including, but 
not limited to, markers related to immune or NSCLC biology, such as T -cell markers or 
non-inherited biomarkers identified through NGS on extracted DNA and/or RNA) may
also be evaluated. The biomarkers will be identified by [CONTACT_4658], quantitative reverse 
transcriptase -polymerase chain reaction (qRT -PCR), NGS, and/or other methods.
Tumor tissue should be of good quality based on total and viable tumor content (sites 
will be informed if the quality of the submitted specimen is inadequate to determine 
tumor PD -L1 status). 
An archival tumor specimen should be submitted if available.  I f an archival specimen is 
not available, the patient may still be eligible, with the assumption that the patient is 
willing to consent to and undergo a pre -treatment biopsy or resection of the tumor.  
For freshly collected biopsy specimens, acceptable sam ples include all those outlined 
below, provided there is a minimum of 50 viable tumor cells that preserve cellular 
context and tissue architecture regardless of needle gauge or retrieval method:
Core -needle biopsies for deep tumor tissue.  At least three c ores, embedded into a 
single paraffin block, should be submitted for evaluation.
Excisional, incisional, punch, or forceps biopsies for cutaneous, subcutaneous, or 
mucosal lesions 
Tumor tissue resections
Fine-needle aspi[INVESTIGATOR_1516] (defined as samples that do not preserve tissue architecture and 
yield cell suspension and/or cell smears), brushing, cell pellets (e.g., from pleural 
effusion), and lavage samples are not acceptable.
Tumor tissue from bone metastases that is subject to decalcification is not accept able.
For archival samples, the remaining tumor tissue block for all patients enrolled will be 
returned to the site upon request or 18 months after final closure of the study database, 
whichever is sooner.  Tissue samples from patients who are deemed ineli gible to enroll 
in the study will be returned no later than 6 weeks after eligibility determination.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
91/Protocol GO29437 , Version [IP_ADDRESS] Tumor Samples at the Time of Radiographic Progression
Patients in all treatment arms will undergo a mandatory tumor biopsy to obtain a tumor 
sample, unless not clinically feasible, at the time of radiographic disease progression 
(within 40 days of radiographic progression or prior to start of the next anti -cancer 
treatment, whichever is sooner).
Acceptable samples include :
Core -needle biopsies for deep tumo r tissue; at least three cores, embedded into a 
single paraffin block, should be submitted for evaluation.
Excisional, incisional, punch, or forceps biopsies for cutaneous, subcutaneous, 
ormucosal lesions
Tumor tissue resection
The status of immune -related and tumor type related, and other exploratory biomarkers 
(including, but not limited to, T -cell markers and non -inherited biomarkers identified 
through NGS on extracted DNA and/or RNA) in tumor tissue samples may be evaluated.
NGS may be performed by [CONTACT_33430]. If performed by [CONTACT_33430], 
the investigator can obtain results from the samples collected at the time of disease 
progression in the form of an NGS report, which is available upon request directly from 
Foundation Medicine. The investigator may share and discuss the results with the 
patient, unless the patient chooses otherwise. The Foundation Medicine NGS assay 
has not been cleared or approved by [CONTACT_941] U.S. Food and Drug Administration; results 
from these investigational tests should not be used to guide future treatment decisions.
[IP_ADDRESS] Tumor Samples at Other Timepoints
If a patient undergoes a medically indicated procedure (e.g., bronchoscopy, 
esophagogastroduodenoscopy, colonoscopy) any time during the course of the study 
that has the likelihood of yielding tumor tissue, any remaining samples or a portion of the 
sample not necessary for medical diagnosis (leftover tumor tissue) may be obtained 
forexploratory analysis.
Patients with additional tissue samples from procedures perform ed at different times 
during the course of their study participation (during treatment and during survival 
follow -up) who have signed the [COMPANY_002] Clinical Repository (RCR) optional consent will be 
requested (but not required) to also submit these optional fr eshsamples for central 
testing.  Tumor tissue samples collected at the time of clinical events (e.g., clinical 
response) are preferred.   Tissue samples obtained at multiple times for individual 
patients will greatly contribute to an improved understanding of the dynamics of PD -L1 
expression and relationship with intervening anti -cancer therapy.  
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
92/Protocol GO29437 , Version [IP_ADDRESS] Use and Storage of Remaining Samples from 
Study -Related Procedures
Unless the patient gives specific consent for his or her leftover samples to be stored for 
optional exploratory research (se e Section 4.5.11 ), biological samples will be destroyed 
when the final Clinical Study Report has been completed, with th e following exceptions:
Serum samples collected for PK or immunogenicity analysis may be needed for 
additional immunogenicity characterization and PK and immunogenicity assay 
development and validation; therefore, these samples will be destroyed no later t han 
5 years after the final Clinical Study Report has been completed, or earlier 
depending on local regulations.
Blood and tumor tissue samples collected for biomarker research will be destroyed 
no later than [ADDRESS_121789] ATAs at multiple 
timepoints before, during, and after treatment with atezolizumab (see Appendix 1and 
Appendix 2for the schedule).  The immunogenicity evaluation will utilize a risk -based 
immunogenicity strategy ( Rosenberg and Worobec 2004 ; Koren et al. 2008) to 
characterize ATA responses to atezolizumab in support of the clinical development 
program.  This tiered strategy may include an assessment of whether detected 
ATA responses correlate with relevant clinical endpoints.  Implementation of ATA 
characterization assays will depend on the safety profile and clinical immunogenicity 
data.
4.5.[ADDRESS_121790] review, sign, and date all ECG 
tracings.  Paper copi[INVESTIGATOR_26650]'s permanent 
study file at the site.  Any morphologic waveform changes or other ECG abnormalities 
must be documented on the eCRF.
4.5.10 Patient -Reported Ou tcomes
PRO data will be collected via the EORTC QLQ -C30, the EORTC QLQ -LC13, SILC, 
PGIS, and EQ -5D-3L to more fully characterize the clinical profile of atezolizumab.  
The questionnaires will be translated as required in the local language.  To ensure 
instrument validity and that data standards meet health authority requirements, 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
93/Protocol GO29437 , Version 7questionnaires scheduled for administration during a clinic visit will be completed in their 
entirety by [CONTACT_40873] -PRO assessments and the 
administration of study treatment. 
Patients will use an electronic PRO ( ePRO )device to capture PRO data.  The ePRO 
device and/or instructions for completing the PRO questionnaires electronically will be 
provided by [CONTACT_6649].  The data will be tra nsmitted via a prespecified 
transmission method (e.g., W eb or wireless) automatically after entry to a centralized 
database at the ePRO vendor.  The data can be accessed by [CONTACT_109835].  
The EORTC QLQ -C30 (see Appendix 7) is a validated and reliable self -report measure 
(Aaronson etal.1993 ; Fitzsimmons etal.1999 ) that consists of 30 questions th at assess 
five aspects of patient functioning (physical, emotional, role, cognitive, and social), three 
symptom scales (fatigue, nausea and vomiting, pain), global health/quality of life, and six 
single items (dyspnea, insomnia, appetite loss, constipation , diarrhea, and financial 
difficulties).  Scale scores can be obtained for the multi -item scales.  The EORTC 
QLQ -C30 module takes approximately 15 minutes to complete.  This questionnaire will 
be completed on the ePRO tablet at each scheduled cycle visit d uring the treatment 
induction phase and then according to the tumor assessment schedule during the 
treatment maintenance phase.  During survival follow -up, the questionnaire will be 
completed at 3months and 6 months following disease progression (or loss of clinical 
benefit for atezolizumab -treated patients who continue treatment after radiographic 
disease progression according to RECIST v1.1).  
The EORTC QLQ -LC13 (see Appendix 8) module incorporates one multiple -item scale 
to assess dyspnea and a series of single items assessing pain, coughing, sore mouth, 
dysphagia, peripheral neuropathy, alopecia, and hemoptysis.  TheEORTC QLQ -LC13 
module takes approximately 15 minutes to complete.  This questionnaire will be 
completed on the ePRO tablet at each scheduled cycle visit during the treatment 
induction phase and then according to the tumor assessment schedule during the
treatment maintenance phase.  During survival follow -up, the questionnaire will be 
completed at 3months and 6 months following disease progression (or loss of clinical 
benefit for atezolizumab -treated patients who continue treatment after radiographic 
disease progression according to RECIST v1.1).  
The SILC scale will be used to assess patient -reported severity of lung cancer 
symptoms (chest pain, dyspnea, and cough). The SILC scale is a [ADDRESS_121791] pain with a symptom severity score. This questionnaire will be completed 
using an ePRO device at the patient’s home on a weekly basis, then during survival 
follow -up every month for 6 months following dis ease progression (or loss of clinical 
benefit for atezolizumab -treated patients who continue treatment after radiographic 
disease progression according to RECIST v1.1).  
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
94/Protocol GO29437 , Version 7The EQ -5D-3L is a generic, preference -based health utility measure with questions 
about mobility, self -care, usual activities, pain/discomfort, and anxiety/depression that is 
used to build a composite of the patient’s health status (see Appendix 9).  The EQ -5D-3L 
will be utilized in this study for economic modeling.  This questionnaire will be completed 
on the ePRO tablet at each scheduled cycle visit during the treatment induction phase 
and then according to the tumor assessment schedule during the treatment maintenance 
phase.  During survival follow -up, the questionnaire will be completed for at 3 months 
and 6 months following disease progression (or loss of clinical benefit for 
atezolizumab- treated patients who continue treatment afte r radiographic disease 
progression according to RECIST v1.1).  
The PGIS consists of a single question used to assess patient global impression of 
disease severity.  This question will be completed on the ePRO tablet at each scheduled
cycle visit during the treatment induction phase and then according to the tumor 
assessment schedule during the treatment maintenance phase .The PGIS is not 
required during survival follow -up.
Patients who discontinue study treatment for any reason other than progressive 
diseaseor loss of clinical benefit will complete the EORTC QLQ -C30, EORTC 
QLQ -LC13, PGIS, and EQ -5D-3L at each tumor assessment visit and will complete the 
SILC at home on a weekly basis, until radiographic disease progression per 
RECIST v1.1 (or loss of clinical benefit for atezolizumab -treated patients who had
continued treatment with atezolizumab after radiographic disease progression) as 
determined by [CONTACT_093] (unless the patient withdraws consent or the Sponsor 
terminates the study).
The Spons or will not derive adverse events reports from PRO data.  However, any PRO 
responses suggestive of a possible adverse event that are identified during site review of 
the PRO data should be reported as outlined in Section [IP_ADDRESS].
Patients whose native language is not available on the ePRO device or who are deemed 
by [CONTACT_109836].
4.5.11 Samples for [COMPANY_002] Clinical Repository
[IP_ADDRESS] Overview  of the [COMPANY_002] Clinical Repository
The RCR is a centrally administered group of facilities used for the long -term storage of 
human biologic specimens, including body fluids, solid tissues, and derivatives thereof 
(e.g., DNA, RNA, proteins, peptides).  The collection and analysis of RCR specimens will 
facilitate the rational design of new pharmaceutical agents and the development of 
diagnostic tests, which may allow for individualized drug therapy for patients in the future.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
95/Protocol GO29437 , Version 7Specimens for the RCR will be collected from patients who give specific consent to 
participate in this optional research.  RCR specimens will be used to achieve th e 
following objectives:
To study the association of biomarkers with efficacy, adverse events, or disease 
progression
To increase knowledge and understanding of disease biology
To study drug response, including drug effects and the processes of drug absorption 
and disposition
To develop biomarker or diagnostic assays and establish the performance 
characteristics of these assays
[IP_ADDRESS] Approval by [CONTACT_109837]'s IRB/EC and, if applicable, an appropriate regulatory body.  
If a site has not been granted approval for RCR sampling, this section of the protocol 
(Section 4.5.11 ) will not be applicable at that site.
[IP_ADDRESS] Sample Collection
The following samples may be collected for patients who have signed the RCR optional 
consent:
Optional fresh biopsy samples
Leftover tumor tissue samples
Remaining fluids (serum, plasma, blood cell derivatives) after study -related tests 
have been performed 
Remaining FFPE tissue (with the exception of arch ival FFPE blocks, which will be 
returned to sites) after study -related tests have been performed
Whole blood samples collected at screening (for screen -fail patients only )
The following sample will be used for identification of genetic (inherited) biomark ers:
Whole blood sample for DNA extraction (6 mL) (see Appendix 1and Appendix 2)
For all samples, dates of consent should be recorded on the associated RCR page of 
the eCRF.  For sampling procedures, storage conditions, and shipment instructions, see 
the laboratory manu al.  
RCR specimens will be destroyed no later than 15 years after the date of final closure of 
the associated clinical database.  The RCR storage period will be in accordance with the 
IRB/EC -approved Informed Consent Form and applicable laws (e.g., health authority 
requirements).
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
96/Protocol GO29437 , Version 7The dynamic biomarker specimens will be subject to the confidentiality standards 
described in Section 8.4.  The genetic biomarker specimens collected for the RCR will 
undergo additional processes to ensure confidentiality as described below.
[IP_ADDRESS] Confidentiality
Given the sensitive nature of genetic data, [COMPANY_002] has implemented additional processes 
to ensure patient confidentialit y for RCR specimens and associated data.  Upon receipt 
by [CONTACT_25736], each specimen is “double -coded” by [CONTACT_70144] a new independent number.  Data generated from the use of these 
specimens and all clinical data transferr ed from the clinical database and considered 
relevant are also labeled with this same independent number.  A “linking key” between 
the patient identification number and this new independent number is stored in a secure 
database system.  Access to the linki ng key is restricted to authorized individuals and is 
monitored by [CONTACT_25738].  Legitimate operational reasons for accessing the linking key are 
documented in a standard operating procedure.  Access to the linking key for any other 
reason requires written approval from the Pharma Repository Governance Committee 
and [COMPANY_002]'s Legal Department, as applicable.
Data generated from RCR specimens must be available for inspection upon request by 
[CONTACT_25735], and [COMPANY_002] mo nitors, 
representatives, and collaborators, as appropriate.
Patient medical information associated with RCR specimens is confidential and may be 
disclosed to third parties only as permitted by [CONTACT_25734] (or separate 
authorization for use and disclosure of personal health information) signed by [CONTACT_102], 
unless permitted or required by [CONTACT_2371].
Data derived from RCR specimen analysis on individual patients will generally not be 
provided to study investigators unless a request for research use is granted.  The 
aggregate results of any research conducted using RCR specimens will be available in 
accordance with the effective [COMPANY_002] policy on study data publication.
Any inventions and resulting patents, improvements, and/or know -how originating from
the use of the RCR data will become and remain the exclusive and unburdened property 
of [COMPANY_002], except where agreed otherwise.
[IP_ADDRESS] Consent to Participate in the [COMPANY_002] Clinical Repository
The Informed Consent Form will contain a separate section that addresses participation 
in the RCR.  The investigator or authorized designee will explain to each patient the 
objectives, methods, and potential hazards of participation in the RCR.  Patients will be 
told that they are free to refuse to participate and may withdraw their specimens at any 
time and for any reason during the storage period.  A separate, specific signature [CONTACT_20030] a patient’s agreement to provide optional RCR specimens.  
Patients who decline to participate will not provide a separate signature.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
97/Protocol GO29437 , Version 7The investigator should document whether or not the patient has given consent to 
participate by [CONTACT_26806].
In the event of an RCR participant's death or loss of competence, the participant’s 
specim ens and data will continue to be used as part of the RCR research.
[IP_ADDRESS] Withdrawal from the [COMPANY_002] Clinical Repository
Patients who give consent to provide RCR specimens have the right to withdraw their 
specimens from the RCR at any time for any reason.  If a pa tient wishes to withdraw 
consent to the testing of his or her specimens, the investigator must inform the Medical 
Monitor in writing of the patient’s wishes through use of the RCR Subject W ithdrawal 
Form and, if the study is ongoing, must enter the date of withdrawal on the RCR 
Research Sample W ithdrawal of Informed Consent eCRF.  A patient's withdrawal from 
Study GO2943 7does not, by [CONTACT_5071], constitute withdrawal of specimens from the RCR.  
Likewise, a patient’s withdrawal from the RCR does not constitute withdrawal from Study 
GO2943 7.
If a patient wishes to withdraw consent to the testing of his or her specimens after 
closure of the site, the investigator must inform the Sponsor by [CONTACT_70146] :
global_rcr -[EMAIL_1377]
[IP_ADDRESS] Monitoring and Oversight
RCR specimens will be tracked in a manner consistent with Good Clinical Practice by a 
quality -controlled, auditable, and appropriately validated laboratory information 
management system, to ensure compliance with data confidentiality as well as 
adherence to authorized use of specimens as specified in this protocol and in the 
Informed Consent Form.  Monitors and auditors will have direct access to appropriate 
parts of records relating to patient part icipation in the RCR for the purposes of verifying 
the data provided to [COMPANY_002].  The site will permit monitoring, audits, IRB/EC review, and 
health authority inspections by [CONTACT_70148].
4.5.12 Timing of A ssessments
[IP_ADDRESS] Screening and Baseline A ssessments
Screening tests and evaluations will be performed within [ADDRESS_121792] -of-care tests or examinations performed prior toobtaining informed 
consent and within 28 days prior to Cycle 1, Day 1, may be used; such tests do not need 
to be repeated for screening. 
See Appendix 1for the schedule of scree ning assessments and Appendix 2for the 
schedule of PK, ATA, and biomarker sampling.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
98/Protocol GO29437 , Version [IP_ADDRESS] Assessments during Treatment
All visits must occur 3 days from the scheduled date unless otherwise noted 
(see Appendix 1).All assessments will be performed on the day of the specified visit 
unless a time window is specified.  Assessments scheduled on the day of study 
treatment administration (Day 1) of each cycle should be performed prior to study 
treatment infusion unless otherwise noted.
Patients who are randomized to Arm C who had started erlotinib switch maintenance 
after the induction phase (allowed under previous protocol versions), will continue with 
cycle visits as outlined in Appendix 1for the maintenance phase until erlotinib treatment 
termination, disease progression, withdrawal of consent, death, or study termination by 
[CONTACT_1034], whichever occurs first. 
Patients who are randomized to Arm C who receive BSC after the induction phase are 
not required to continue with cycle visits.  Their treatment discontinuation visit will take 
place when patients discontinue BSC .
If scheduled dosing and study assessments are precluded because of a holiday, 
weekend, or other event, then dosing may be postponed to the soonest following date, 
with subsequent dosing continuing on a 21-day schedule.  If treatment was postponed 
for fewer than 3 days, the patient can resume the original schedule.
After completion of the induction phase one of three cycles may be delayed by 1 week 
(28 days instead of 21 days for one cycle) to allow for vacations/holidays.   Following the 
delay, the next cycle must be delivered 21 days from the previous dose administration:  
two consecutive 28 cycles are not permitted.  If a dose modification is required due to 
toxicity, refer to Section 5.1.
Tumor assessments should occur every 6 weeks ( 7 days) for 48 weeks following 
Cycle 1, Day 1 and every 9 weeks ( 7 days) after the completion of the Week [ADDRESS_121793] v1.1 ( or loss of clinical benefit for patients who continue treatment with 
atezolizumab after disease progression according to RECIST v1.1 for Arms A and B 
only), withdrawal of consent, death, or study termination by [CONTACT_1034], whichever 
occurs first.   Patients who discontinue treatment for reasons other than radiographic 
disease progression per RECIST v1.1 (e.g., toxicity, symptomatic deterioration) will 
continue scheduled tumor assessments until radiographic disease progression per 
RECIST v1.1 (or loss of clinical benefit for atezolizumab -treated patients who had 
continued treatment with atezolizumab beyond radiographic disease progression per 
RECIST v1.1) , withdrawal of co nsent, death, or study termination by [CONTACT_2728], whichever 
occurs first.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
99/Protocol GO29437 , Version 7The following assessments may be performed 96hours before Day 1 of each cycle:  
ECOG performance status
Limited physical examination
Local laboratory tests
Screening assessments performed [ADDRESS_121794] be performed prior to nab -paclitaxel infusions also on 
Day8 and Day 15.
See Appendix 1for the schedule of assessments performed during the treatment period 
and Appendix 2for the schedule of PK, pharmacodynamic, ATA, and biomarker 
sampling.
[IP_ADDRESS] Assessments at Study Drug Discontinuation Visit
When a patient discontinues all study treatment (including erlotinib swit ch maintenance 
for patients randomized to Arm C who receive erlotinib switch maintenance allowed 
under previous versions of this protocol) regardless of the reason fordiscontinuation , the 
patient will be asked to return to the clinic within 30 days after the treatment for a study 
drug discontinuation visit.  The visit at which the decision is made to discontinue 
treatment (e.g., loss of clinical benefit is confirmed) may be used as the study -drug 
discontinuation visit. The treatment discontinuation visit for patients in Arm C 
who receive best supportive care will take place when patients discontinue best 
supportive care.
See Appendix 1and Appendix 2for the schedule of follow -up assessments.
[IP_ADDRESS] Follow -Up A ssessments
After the study drug discontinuation visit, adverse even ts should be followed as outlined 
in Section 5.3.1 .
For patients who discontinue study treatment (including chemotherapy induction and
erlotinib switch maintenance for patients who are randomized to Arm C and receive 
erlotinib switch maintenance allowed under previous protocol versions ) for any reason 
other than radiographic disease progression per RECIST v1.1, tumor assessments 
should c ontinue at the same frequency as would have been followed had the patient 
remained on study treatment until radiographic disease progression (or loss of clinical 
benefit for patients treated with atezolizumab who hadcontinued treatment with 
atezolizumab after disease progression according to RECIST v1.1), withdrawal of 
consent, death, or study termination by [CONTACT_1034] , whichever occurs first .  
Patients who start a new anti -cancer therapy in the absence of radiographic disease 
progression per RECIST v1.1 should continue tumor assessments according to the 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
100/Protocol GO29437 , Version 7protocol schedule of response assessments until radiographic disease progression per 
RECIST v1.[ADDRESS_121795].
Follow -up data collection will also include ePROs ( theSILC will be completed monthly 
only for the first 6 months after disease progression [or loss of clinical benefit for 
atezolizumab-treated p atients who had continued treatment with atezolizumab after 
radiogra phic disease progression according to RECIST v1.1 ] using an ePRO device at 
the patient’s home and EORTC QLQ -C30, EORTC QLQ -LC13, and EQ -5D-3L will be 
completed 3 and 6 months after disease progression [or loss of clinical benefit [for 
atezolizumab- treated patients who continue treatment after disease progression 
according to RECIST v1.1 ] at the site using the ePRO tablet), study treatment related
adverse events (including serious adverse events), subsequent anti -cancer therapi[INVESTIGATOR_014], 
and date and cause of death.  Patients who discontinue study treatment for any reason 
other than progressive disease or loss of clinical benefit will complete the EORTC QLQ -
C30, EORTC QLQ -LC13, PGIS, and EQ -5D-3L at each tumor assessment visit and will 
complete the SILC at home on a weekly basis, until radiographic disease progression 
per RECIST v1.1 (or loss of clinical benefit for atezolizumab -treated patients who had
continued treatment with atezolizumab after radiographic disease progression according 
to RECIST v1.1 ) as determined by [CONTACT_093] (unless the patient withdraws consent 
or the Sponsor terminates the study).
Adverse events will be foll owed as described in Section 5.5.
Survival follow -up information will be collected via telephone calls, patient medical 
records, and/or clinic visits every [ADDRESS_121796]. All patients will be 
periodically contact[CONTACT_70149] -cancer therapy information unless the 
patient requests to be withdrawn from the study (this request must be documented in the 
source documents and signed by [CONTACT_093]).   If the patient withdraws from study, 
the study staff may use a public information source (e.g., county records) when 
permissible, to obtain information about survival sta tus only.
See Appendix 1and Appendix 2for the schedule of follow -up assessments.
[IP_ADDRESS] Assessments at Unplanned Visits
Assessments for unscheduled visits related to a patient’s underlying NSCLC, study drug, 
or adverse event should be performed as clinically indicated and enter ed into 
Unscheduled Visit eCRFs.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
101/Protocol GO29437 , Version 74.[ADDRESS_121797] the right to voluntarily withdraw from the study at any time for any reason.  
In addition, the investigator has the right to withdraw a patient from the study at any time.  
Reasons for withdrawal from the study may include, but are not limited to, the following:
Patient withdrawal of consent at any time
Any medical condition that the investigator or Sponsor determines may jeopardize 
thepatient’s safety if he or she continues in the study
Investigator or Sponsor determines it is in the best interest of the patient
Patient non -compliance
Every effort should be made to obtain information on patients who withdraw from the 
study.  The primary reason for withdrawal from the study should be documented on the 
appropriate eCRF.  However, patients will not be followed for any reason after consent 
has been withdrawn.  Patients who withdraw from the study will not be replaced.
4.6.[ADDRESS_121798] discontinue study treatment if they experience any of the following:
Symptomatic deterioration attributed to disease progression as determined by [CONTACT_40876], biopsy result s, and 
clinical status
Intolerable toxicity related to atezolizumab, including development of an 
immune -mediated adverse event determined by [CONTACT_70150]’s potential response to therapy and severity of the event
Intolerable toxicity related to other components of study treatment
If one component of study treatment is discontinued permanently due to tolerability 
concerns, the patient may continue with other components of study treatment until 
disease progression (or loss of clinical benefit for atezolizumab- treated patients who 
continue treatment after disease progression according to RECIST v1.1) if agreed 
upon by [CONTACT_70151]
Any medical condition that may jeopardize the patient’s safety if he or she continues 
on study treatment
Use of another non protocol -specified anti-cancer therapy (see Section 4.4.3 )
Pregnancy
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
102/Protocol GO29437 , Version 7Radiographic disease progression per RECIST v1.1 
Exception for atezolizumab treatment:  patients randomized to atezolizumab 
treatment will be permitted to continue atezolizumab after RECIST v1.1 for 
progressive disease are met if they meet all of the foll owing criteria ( see Figure 2for 
schematic representation):
Evidence of clinical benefit as assessed by [CONTACT_33470] (including worsening of laboratory values 
[e.g., new or worsening hypercalcemia]) indicating unequivocal progression of 
disease
No decline in ECOG performance status 
Absence of tumor progression at critical anatomical sites (e.g., leptomeni ngeal 
disease) that cannot be readily managed and stabilized by [CONTACT_990] -allowed 
medical interventions prior to repeat dosing
Patients must provide written consent to acknowledge deferring any standard 
treatment options that may exist in favor of continuing atezolizumab treatment 
at the time of initial progression
A mandatory biopsy sample collection, unless not clinically feasible as 
assessed by [CONTACT_473], at the site of local or metastatic progression
The primary reason for study treatment discontinuation should be documented on the 
appropriate eCRF.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
103/Protocol GO29437 , Version 7Figure 2 Criteria for Continuing A tezolizumab in the Presence of 
Increased Radiographic Tumor Size (A tezolizumab A rms)
Radiographic Progressi on accordi ng to RECI ST v 1.1.
Patien ts Must Provide the Fol lowing:
•Signed Informed Consent Form (s)
•Tissue Biop sy Unless Not Clinically Feasib le
Atezolizumab  May Be Continued, Provided All of the Fol lowing 
Criteria Are Met:
•Evidence of Clinical Benefit, as Assessed  by [CONTACT_109838]
•No Signs/Symptoms Indicatin g Unequivocal  Disease Progression
•No Decline in ECOG PS A ttributed to Disease Prog ression
•No Tumor Growth at Critical  Sites
Conti nue Treatment Until Evidence of 
Loss of Cl inical Benefi t
Survival Follow-UpAtezolizumab -Treated  Patients Only
ECOG PSEastern Cooperative Oncology Group performance status; ICF Informed Consent 
Form ; RECIST v1.1 Response Evaluation Criteria in Solid Tumors, Version 1.1
4.6.3 Study and Site Discontinuation
The Sponsor has the right to terminate this study at any time.  Reasons for terminating 
the study may include, but are not limited to, the following:
The incidence or severity of adverse events in this or other studies indicates a 
potential health hazard to patients
Patient enrollment is unsatisfactory
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
104/Protocol GO29437 , Version 7The Sponsor will notify the investigator if the Sponsor decides to discontinue the study.  
The Sponsor has the right to close a site at any time.  Reasons for closing a site may 
include, but are not limited to, the following:
Excessively slow recruitment
Poor protocol adherence
Inaccurate or incomplete data recording
Non-compliance with the International Council for Harmonisation (ICH) guideline for 
Good Clinical Practice
No study activity (i.e., all patients have completed and all obligations have 
been fulfilled)
5. ASSESSMENT OF SA FETY
The following information is based on results from nonclinical and clinical studies and 
published data on similar molecules.
5.1 SAFETY PLA N
Measures will be taken to ensure the safety of patients participating in this study, 
including the use of stringent inclusion and exclusion criteria (see Section 4.1.1 and 
Section 4.1.2 ) and close monitoring (as indicated below and in Section 4.5).  
SeeSection 5.3(Methods and Timing for Capturing and Assessing Safety Parameters ) 
for complete details regarding safety reporting for this study.  
Administration of atezolizumab will be performed in a setting with emergency medical 
facilities and staff who are trained to monitor for and respond to medical emergencies.  
All serious adverse events and adverse events of special interest will be recorded during 
the study and for up to [ADDRESS_121799] dose of study treatment (inclusive of 
erlotinib switch maintenance for patients randomized to Arm C who receive erlotinib 
switch maintenance allowed under previous versions of this prot ocol) or until initiation of 
new systemic anti-cancer therapy after the last dose of study treatment , whichever 
occurs first.  All other adverse events will be recorded during the study and for up to 
30days after the last dose of study treatment (inclusiv e of erlotinib switch maintenance 
for patients who are randomized to Arm C who receive erlotinib switch maintenance 
allowed under previous protocol versions) or until initiation of new systemic anti-cancer 
therapy after the last dose of study treatment , whichever occurs first.  
After the adverse event reporting period , all deaths should continue to  be reported.  In 
addition, the Sponsor should be notified if the investigator becomes aware of any serious 
adverse event or adverse event of special interest t hat is believed to be related to prior 
exposure to study treatment (see Section 5.6).  The potential safety issues anticipated in 
this trial, as well as measures intended to avoid or minimize such toxicities, are outlined 
in the following sections.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
105/Protocol GO29437 , Version 75.1.1 Risks A ssociated with A tezolizumab
The PD -L1/PD -[ADDRESS_121800] is involved in peripheral tolerance; therefore, such therapy 
may increase the risk of immune -media ted adverse events, specifically the induction or 
enhancement of autoimmune conditions.  Adverse events with potentially 
immune -mediated causes, including rash, hypothyroidism, hepatitis/transaminitis, colitis, 
pneumonitis, myositis, and myasthenia gravis, have been observed in the Phase Ia 
Study PCD4989g.  For further details regarding clinical safety, including a detailed 
description of anticipated safety risks for atezolizumab, see the Atezolizumab
Investigator’s Brochure.
Although most immune -mediated a dverse events observed with immunomodulatory 
agents have been mild and self -limiting, such events should be recognized early and 
treated promptly to avoid potential major complications ( Di Giacomo et al. 2010). 
Suggested workup procedures for suspected im mune -mediated adverse events are 
provided in Section 6 (Guidance for the Investigator) of the Atezolizumab Investigator’s 
Brochure . 
5.1.[ADDRESS_121801] 
(LFT) elevations, injection site reactions, and cardiovascular effects such as hypotension, 
bradycardia, hypertension, arrhythmias, other ECG abnormalities, syncope, and venous 
thrombosis.
For mor e details regarding the safety profile of paclitaxel, refer to the prescribing 
information for paclitaxel .
5.1.[ADDRESS_121802] -marketing experience, nab -paclitaxel has been associated 
with alopecia, myelosuppression (neutropenia, anemia, thrombocytopenia), peripheral 
neuropathy, cranial nerve palsies, hypersensitivity reactions, pneumonitis, 
gastrointestinal events (i.e., nausea, vomiting, diarrhea), myalgia, anthralgia, 
cardiotoxicity (myocardial disorders, car diac failure, angina, tachycardia, ventricular 
arrhythmia), cystoid macular edema, Stevens -Johnson syndrome/toxic epi[INVESTIGATOR_109781] —F. Hoffmann- La [COMPANY_002] Ltd
106/Protocol GO29437 , Version 7necrolysis, sepsis, drug -induced lupus erythematous, infusion- site 
reactions/extravasation, hepatic toxicity (drug -induced liver inj ury), acute renal failure, 
and hemolytic -uremic syndrome.
Patients will be monitored for nab -paclitaxel related adverse events, including 
hematologic, gastrointestinal, and hepatic toxicities and peripheral neuropathy.
For more details regarding the safety profile of nab -paclitaxel, refer to the prescribing 
information for nab -paclitaxel.
5.1.[ADDRESS_121803] 
adverse events were Grade 1 or 2 in severity and were manageable without intervention.  
In general, rash manifests as a mild or moderate erythematous and papulopustular rash 
and may occur or worsen in sun -expo sed areas.  For patients who are exposed to the 
sun, protective clothing, and/or the use of sunscreen (e.g., mineral -containing) may be 
advisable.
For more details regarding the safety profile of erlotinib, refer to the prescribing 
information for erlotinib.
5.1.6 General Plan to Manage Safety Concerns
[IP_ADDRESS] Monitoring
Safety will be evaluated in this study through the monitoring of all serious and 
non-serious adverse events defined and graded according to NCI CTCAE v4.0.  Patients 
will be assessed for safety ( including laboratory values) according to the schedule in 
Appendix 1.  Laboratory values must be reviewed prior to each infusion.
Genera l safety assessments will include serial interval histories, physical examinations, 
and specific laboratory studies, including serum chemistries and blood counts 
(see Appendix 1and Appendix 2for the list and timing of study assessments).
During the study, patients will be closely monitored for the development of any signs or 
symptoms of autoimmune conditions and infection.
Allserious adverse events and protocol -defined events of special interest 
(see Section 5.2.2and Section 5.2.3 ) will be reported in an expedited fashion.  In 
addition, the iDMC and Medical Monitor will review and evaluate observed adverse 
events on a regular basis.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
108/Protocol GO29437 , Version 7safety and efficacy as specified in Section 5.2.[ADDRESS_121804] dose until steroids are 
discontinued or reduced to prednis one dose (or dose equivalent) 10mg/day .  The 
acceptable length of interruption will depend on agreement between the investigator and 
the Medical Monitor.
5.1.8 Management of A tezolizumab -Specific A dverse Ev ents
Management of systemic immune activation is pres ented below.  Refer to the 
Atezolizumab Investigator’s Brochure for details on management of atezolizumab -
specific adverse events . 
Refer to Appendix 11for precautions for anaphylaxis.
Refer to Section [IP_ADDRESS] and Table 22for management of pulmonary events and 
pneumonitis when atezolizumab and nab -paclitaxel are administered together, or when 
nab-paclitaxel is administered without atezolizumab.
Systemic Immune A ctivation
Systemic immune activation is a rare condition characterized by [CONTACT_33471].  Given the mechanism of action of atezolizumab, systemic immune activation 
is considered a potential risk when given in combination with other immunomodulating 
agents.  Systemic immune activation should be included in the differential diagnosis for 
patients who, in the absence of an alternate etiology, develop a sepsis -like syndrome 
after administration of atezolizumab, and the initial evaluation should include the
following:
CBC with peripheral smear
PT, PTT, fibrinogen, and D -dimer
Ferritin
Triglycerides
AST, ALT, and total bilirubin
LDH
Complete neurologic and abdominal examination (assess for hepatosplenomegaly)
If systemic immune activation is still suspected after the initial evaluation, contact [CONTACT_33472].
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
109/Protocol GO29437 , Version 75.1.9 Carboplatin and Paclitaxel Dose Modification and Management 
of Specific A dverse Events
Dose reductions, holds, and discontinuations for each study drug may be made as
outlined below. The investigator may use discretion in modifying or accelerating the 
dose modification guidelines described below, depending on the severity of toxicity and 
an assessment of the risk versus benefit for the patient, with the goal of maximi zing 
patient compliance and access to supportive care.
When a treatment cycle is delayed or interrupted because of toxicity resulting from either 
component of the regimen, all study treatment should generally be withheld and 
resumed together to remain sync hronized.  However, if it is anticipated that 
chemotherapy will be delayed by 2 weeks, then atezolizumab should be given without 
the chemotherapy if there is no contraindication; this should be discussed with the 
Medical Monitor prior to re -initiating th erapy.
Investigators should be vigilant and alert to early and overt signs of 
myelosuppression/infection/febrile neutropenia so that these complications can be 
promptly and appropriately managed.  Patients should be made aware of these signs 
and encouraged to seek medical attention at the earliest opportunity.
Dose modifications of carboplatin and paclitaxel are allowed as described in the 
following sections.
[IP_ADDRESS] Hematologic Toxicity
At the start of each cycle, the ANC must be 1500 cells/ Land the platelet count must 
be 100,000/ L.  Treatment may be delayed for up to [ADDRESS_121805] dose to 
allow sufficient time for recovery.  Growth factors may be used in lieu of a dose reduction 
for neutropenic fever or Grade 4 neutropenia in acco rdance with ASCO and NCCN 
guidelines ( Smith et al. 2006; NCCN 2014 ).  Upon recovery, dose adjustments at the 
start of a subsequent cycle will be based on the lowest platelet and neutrophil values 
from the previous cycle (see Table 14and Table 15).
Table 14Dosing Based on A NC and Febrile Neutropenia —Paclitaxel and 
Carboplatin
Dose of Paclitaxel and Carboplatin
ANC (Day 1 of Each Cycle)
1500 cells/ L 1500 cells/ L
Febrile neutropenia
(regardless of duration)0 Paclitaxel 150 mg/m2
Carboplatin AUC 4.5
ANC absolute neutrophil count; AUC area under the concentration time curve .
Table 15summarizes dose modifications based on platelet count.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
110/Protocol GO29437 , Version 7Table 15Dosing Based on Nadir Platelet Count— Paclitaxel and 
Carboplatin
Nadir of Last CourseDose of Paclitaxel and Carboplatin
Platelets (Day 1 of Each Cycle)
100,000/ L 100,000/ L
25,000/ Lor 
50,000/ Lwith bleeding 
or requiring transfusion0 Paclitaxel 150 mg/m2
Carboplatin AUC 4.5
AUC area under the concentration time curve .
All dose reductions for the first epi[INVESTIGATOR_109782] 
(platelet count 25,000/ L or 50,000 cells/ L with bleeding or that requires transfusion) 
arepermanent.  If a second epi[INVESTIGATOR_109783], another 25% dose reduction of carboplatin and paclitaxel is 
recommended .  Patients who require a third dose reduction will immediately discontinue 
chemotherapy.
In the event that dose adjustments are needed for both ANC and pl atelets, patients are 
to receive the lower dose.
Treatment should be delayed for up to 3 weeks until the Day 1 ANC is 1500 cells/ L 
and the platelet count is 100,000/ L.  However, if the counts have not recovered within 
3weeks, the patient’s chemotherapy will be dose reduced, withheld until adequate 
neutrophil recovery, or discontinued, according to physician judgment and local standard 
practice.  If chemotherapy is wi thheld longer than 63days from the last dose, all 
chemotherapy should be discontinued. 
Investigators should be vigilant and alert to early and overt signs of myelosuppression, 
infection or febrile neutropenia so that these complications can be promptly a nd 
appropriately managed.  Patients should be made aware of these signs and encouraged 
to seek medical attention at the earliest opportunity. 
If chemotherapy must be withheld because of hematologic toxicity, full blood counts 
(including differential W BC) should be obtained weekly until the counts reach the lower 
limits for treatment as outlined.  The treatment schedule will then proceed in the usual 
sequence.
No dose reductions will be made for anemia.  Patients should be supported per the 
treating physici an’s institution’s guidelines.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
111/Protocol GO29437 , Version [IP_ADDRESS] Gastrointestinal Toxicity
For Grade 3 or 4 gastrointestinal toxicities, treatment should be delayed until resolution 
to less than or equal to the patient’s baseline value.  Dose reductions at the start of the 
subsequent cycle will be based on gastrointestinal toxicities from the dose administered 
in the preceding cycle.  Table 16provides the relevant dose ad justments for 
gastrointestinal toxicities.
Table 16Carboplatin and Paclitaxel Dose Modification Based on 
Gastrointestinal Toxicities in the Preceding Cy cle
ToxicityAdjusted 
Carboplatin Dose 
as % of Previous 
DoseaAdjusted Paclita xel
Dose as % of 
Previous Dose
Diarrhea Grade 3 or 4b75% 75%
Oral mucositis/stomatitis Grade 3 or 4 75% 75%
Nausea/vomiting Grade 3 or 4 75% 75%
AUC area under the concentration time curve .
aIf deemed appropriate by [CONTACT_1963], adjust carboplatin dose to the specified 
percentage of the previous AUC.
bAnd per investigator discretion.
Nausea and/or vomiting should be controlled with adequate anti -emetics.  If Grade 3 or 
4nausea/vomiting occurs despi[INVESTIGATOR_70061] -emetics, the dose should be reduced 
by 25% for the next course.  If tolerated, the dose should be increased back to 100% 
assoon as possible.
If, on Day 1 of any treatment cycle, the patient has oral mucositis/stomatitis, the 
treatment should be withheld until the oral mucositis/stomatitis is cleared.  If the oral 
mucositis/stomatitis has not resolved to a Grade 1 or 0in 3weeks, the patient’s 
chemotherapy will be discontinued.  If acute Grade 3 oral mucositis occurs at any time, a 
75% dose should be given when the ora l mucositis has resolved to a Grade 1 or 0 .  This 
is a permanent dose reduction.
[IP_ADDRESS] Hepatic Toxicity  (Paclitaxel Only )
No dose adjustment is required in patients with mild hepatic impairment.  For patients 
who develop hepatic toxicity, paclitaxel dose should be withheld until LFTs resolve to 
Grade 1prior to subsequent dosing.  If paclitaxel is withheld because of hepatic toxicity, 
carboplatin should also be withheld and administered when the paclitaxel is resumed.  
The recommendations for paclitaxel dose r eduction based on elevated LFTs are 
provided in Table 17.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
112/Protocol GO29437 , Version 7Table 17Dose Modifications for Paclitaxel for Hepatic Toxicity
SGOT (AST) 
Levels Bilirubin LevelsPaclitaxel Reduction from 
Starting Dose
10ULN AND 1.25ULN No change
10ULN AND 1.26–2.0ULN 25%
10ULN AND 2.01–5.0ULN 50%
10ULN OR 5.0ULN Discontinue paclitaxela
ULNupper limit of normal.
Note:  Recommendations for paclitaxel dose adjustments are extrapolated from 
dose adjustments for patients with hepatic impairment at baseline.
aPatients with AST 10ULN or bilirubin 5.0ULN were excluded from clinical 
studi es for lung cancer.
If paclitaxel is withheld, hepatic values must recover to Grade 1 within 3 weeks or the 
patient’s paclitaxel treatment will be discontinued.  No dose reductions for carboplatin 
will be made for hepatic toxicity.
The investigator should make all efforts to exclude malignant disease progression as a 
cause of liver enzyme derangement.  All study treatment must be discontinued if the 
disease under investigation has progressed.
[IP_ADDRESS] Cardiovascular Toxicity  (Paclitaxel Only)
Cardiac rhythm disturbances have occurred infrequently in patients treated with 
paclitaxel in clinical studies; however, most patients were asymptomatic, and cardiac 
monitoring is not required.  Transient asymptomatic bradycardia has been noted in as 
many as 29% of patients.  More significant atrioventricular block has rarely been noted.  
Cardiac events should be managed as follows:
Asymptomatic bradycardia:  no treatment required
Symptomatic arrhythmia during infusion:  Stop paclitaxel infusion, manage 
arrhythmia according to standard practice.  Paclitaxel treatment will be discontinued. 
Chest pain and/or symptomatic hypotension ( 90/60 mmHg or requires fluid 
replacement):  Stop paclitaxel infusion.  Perform an ECG.  Give IV 
diphenphydramine and dexameth asone if hypersensitivity is considered.  
Also consider epi[INVESTIGATOR_109784].  Paclitaxel treatment will be discontinued, and cardiovascular support 
should be given as appropriate.  If appropriate, the advice of a cardiologist should 
also be sought.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
113/Protocol GO29437 , Version [IP_ADDRESS] Neurologic Toxicity  (Paclitaxel Only )
The dose of paclitaxel should be modified as follows for sensory neuropathy. 
Table 18Paclitaxel Dose Modification for Neurologic Toxicity
Toxici ty Paclitaxel Dose Modification
Grade 0 None
Grade 1 None
Grade 2 Withhold treatment until patient recovers to Grade 1 
toxicity, then resume treatment at a 25% reduction.
Grade 3 or worse Withhold treatment until patient recovers to Grade 1 
toxicity, then resume treatment at a 50% reduction.
Dose modifications made for neurotoxicity are permanent.  If recovery to Grade 1 toxicity 
does not occur within 3 weeks, the patient’s paclitaxel treatment will be discontinued.
[IP_ADDRESS] Allergic Reaction/Hypersensitivity (Paclitaxel Only )
CAUTION:   Patients who had a mild to moderate hypersensitivity reaction have been 
successfully rechallenged, but the administration of prophylactic medication (see below) 
and intensive monitoring of vital signs is recommended.
Mild sympt oms:  Complete paclitaxel infusion.  Supervise at bedside.  No treatment 
required.
Moderate symptoms :  Stop paclitaxel infusion.  Give IV diphenhydramine 25 50mg 
and IV dexamethasone 10 mg.  Resume paclitaxel infusion after recovery of 
symptoms at a low r ate, 20 mL/hr for 15 minutes, then 40 mL/hr for 15 minutes, then 
if no further symptoms, at full -dose rate until infusion is complete.  If symptoms recur, 
stop paclitaxel infusion.  Paclitaxel treatment will be discontinued.
Severe life -threatening symptom s:  Stop paclitaxel infusion.  Give IV 
diphenhydramine and dexamethasone as above.  Add epi[INVESTIGATOR_109785].  Paclitaxel treatment will be discontinued.
Moderate or severe hypersensitivity reactions should be recorded as an adverse event.
[IP_ADDRESS] Other Toxicities
For any Grade 3 or 4 toxicities not mentioned above, carboplatin or paclitaxel should be 
withheld until the patient recovers completely or to Grade 1 toxicity.  The treatment 
should then be resumed at 75% dose (permanent dose reduc tion) for Grade 3 toxicities 
and 50% of dose (permanent dose reduction) for Grade 4 toxicities.  If recovery to 
Grade 1 toxicity does not occur within 3 weeks, the patient’s chemotherapy will be 
discontinued.  For Grade 1 and 2 toxicities, no dose reductio n should be made.
For guidelines on the dosing of other study drugs when carboplatin or paclitaxel are
withheld , see Section [IP_ADDRESS] .
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
114/Protocol GO29437 , Version 75.1.10 Carboplatin and n ab-Paclitaxel Dose Modification and 
Management of Specific A dverse Events
Dose reductions, holds, and discontinuations for each study drug may be made as 
outlined below.
The investigator may use discretion in modifying or accelerating the dose modification 
guidelines described below, depending on the severity of toxicity and an assessment of 
the risk versus benefit for the patient, with the goal of maximizing patient compliance and 
access to supportive care.
When a treatment cycle is delayed or interrupted because of toxicity resulting from either 
component of the regimen, all study drugs should generally be withheld and resumed 
together to remain synchronized.  However, if it is anticipated that chemotherapy will be 
delayed by 2 weeks, then atezolizumab should be given without the chemotherapy if 
there is no contraindication; this should be discussed with the Medical Monitor prior to 
re-initiating therapy.
Investigators should be vigilant and alert to early and overt signs of 
myelosuppression/infection/febrile neutropenia so that these complications can be 
promptly and appropriately managed.  Patients should be made aware of these signs 
and encouraged to seek medical attention at the earliest opportunity.
Dose modifications of carboplatin and nab -paclitaxel are allowed as described in the 
following sections.
[IP_ADDRESS] Hematologic Toxicity
In general , ANC must be 1500 cells/ Landplatelet count must be 100,000/ Lon 
Day1 of each cycle.  When nab-p aclitaxel is administered on Day 1, it should not be 
administered on Days 8 or 15 of the cycle unless ANC 500 cells/ Land platelet 
count 50,000/ L.  
In certain situations, a cycle may begin with the administration of atezolizumab alone 
(without nab- paclitaxel on Day 1).  If Day 1 of a cycle begi ns with only atezolizumab but 
without the administration of nab -paclitaxel due to low platelet or ANC levels, 
nab
-paclitaxel should not be administered subsequently within that cycle until 
ANC 1500 cells/ L and platelet count 100,000/ L.  If the delay in re-starting 
nab-paclitaxel is 7 days (i.e., counts do not recover until Day 15), dosing should be 
resumed with applicable reductions according to the criteria in Table 19.  
If the start of a cycle is delayed (i.e., both atezolizumab and nab -paclitaxel are withheld) 
for low counts, postpone Day [ADDRESS_121806] 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
115/Protocol GO29437 , Version 7recovered to permissible levels.  W hen dosing resumes, the carboplatin and 
nab-paclitaxel doses should be permanently reduced as outlined in Table 19.
Table 19nab-Paclitaxel and Carboplatin Permanent Dose Reductions 
Based on Nadir A bsolute Neutrophil Count and Platelets
Hematologic Toxic ity OccurrenceWeekly 
nab-Paclitaxel 
Dose (mg/m2)Every -
3-Week 
Carboplatin Dose 
(AUC mg min/mL)
Neutropenic fever ( nadir ANC
500 cells /L with fever 38°C)
OR
Delay of next scheduled dose by
7days for nadir 
ANC 1500 cells/ L
OR
Nadir ANC 500/L for7daysFirst [ADDRESS_121807] Discontinue treatment
Nadir p latelet count 50,000/ L First 75 4.5
Second Discontinue treatment
ANC absolute neutrophil count ;AUC area under the concentration time curve .
[IP_ADDRESS] Gastrointestinal Toxicity
For Grade 3 or 4 gastrointestinal toxicities, treatment should be delayed until resolution 
to less than or equal to the patient’s baseline value.  Dose reductions at the start of the 
subsequent cycle will be based on gastrointestinal toxicities fr om the dose administered 
in the preceding cycle.  Table 20provides the relevant dose adjustments for 
gastrointestinal toxicities.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
116/Protocol GO29437 , Version 7Table 20Carboplatin and nab -Paclitaxel Dose Modification Based on 
Gastrointestinal Toxicities in the Preceding Cy cle
Toxicity OccurrenceAdjusted 
Carboplatin
Dose as % of 
Previous DoseaAdjusted 
nab-Paclitaxel
Dose as % of 
Previous Dose
Grade 3 diarrhea
OR
Grade 3 
mucositis/stomatitis
OR
Grade 3 or 4 
nausea/vomitingFirst 75% 75%
Second 50% 50%
Third Discontinue treatment
Grade 4 oral 
mucositis/stomatitisNA Discontinue treatment
Grade 4 diarrhea NA Discontinue treatment
AUC area under the concentration time curve .
aIf deemed appropriate by [CONTACT_1963], adjust carboplatin dose 
to the specified percentage of the previous AUC.
Nausea and/or vomiting should be controlled with adequate anti -emetics.  If Grade 3 or 4 
nausea/vomiting occurs in spi[INVESTIGATOR_109786] -emetics, the dose should be reduced by 25% for 
the next and subsequent courses.
If, on Day 1 of any treatment cycle, the patient has oral mucositis/stomatitis, the 
treatment should be withheld until the oral mucositi s/stomatitis is cleared.  If the oral 
mucositis/stomatitis has not cleared in 3 weeks, the patient’s chemotherapy will be 
discontinued.  See Table 20for additional details on dose reductions.  Dose reductions 
listed are permanent.
[IP_ADDRESS] Neurological Toxicity
nab-Paclitaxel and carboplatin should be withheld for Grade 34 peripheral neuropathy.  
nab-Paclitaxel and carboplatin may be resumed at reduced doses (see Table 21) when 
peripheral neuropathy recovers to Grade 1 or completely resolves. 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
117/Protocol GO29437 , Version 7Table 21nab-Paclitaxel and Carboplatin Permanent Dose Reductions for 
Neurological Toxicity
Adverse Reaction OccurrenceWeekly nab-Paclitaxel 
Dose (mg/m2)Every -3-Week 
Carboplatin 
Dose (AUC 
mgmin/mL)
Grade [ADDRESS_121808] Discontinue treatment
AUC area under the concentration time curve .
[IP_ADDRESS] Hepatic Toxicity  (nab -Paclitaxel Only )
For patients with no hepatic metastases at baseline who develop severe enzyme 
elevations during study treatment (ALT and/or AST 5ULN or total bilirubin 3ULN), 
study treatment should be interrupted, hepatic toxicity must resolve to baseline levels 
prior to dosing.  If nab -paclitaxel is withheld because of hepatic toxicity, carboplatin 
should also be withheld and administered when the nab -paclitaxel is resu med.  If 
nab-paclitaxel is withheld, hepatic values must recover to baseline levels within 3 weeks 
or the patient’s nab -paclitaxel treatment will be discontinued.  No dose reductions for 
carboplatin will be made for hepatic toxicity.
For patients with mild hepatic impairment (total bilirubin 1 to 1.5ULN and 
ALT/AST 5ULN), no dose adjustments are required.  Treat with the same doses as 
patients with normal hepatic function.
If moderate to severe hepatic elevations (total bilirubin 1.55.0ULN or ALT and/or 
AST 5 10ULN) occur at any time, the nab -paclitaxel dose should be permanently 
reduced to 80% of the starting dose (i.e., to 80 mg/m2).  nab -Paclitaxel will be 
discontinued for patients with total bilirubin 5ULN or AST 10ULN.
The investigator should make all efforts to exclude malignant disease progression as a 
cause of liver enzyme derangement.  All study treatment must be discontinued if the 
disease under investigation has progressed.
[IP_ADDRESS] Pulmonary  Events and Pneumonitis:  A tezolizumab with 
nab-Paclitaxel, or nab -Paclitaxel with or without Atezolizumab
Note:  W hen atezolizumab is administered without nab -paclitaxel, refer to the 
Atezolizumab Investigator’s Brochure for management of pulmonary events, including 
pneumonitis. 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
118/Protocol GO29437 , Version 7Atezol izumab
Dyspnea, cough, fatigue, hypoxia, pneumonitis, and pulmonary infiltrates have been 
associated with the administration of atezolizumab and have primarily been 
observed in patients with underlying NSCLC.
Mild to moderate events of pneumonitis have be en reported with atezolizumab.  All 
pulmonary events should be thoroughly evaluated for other commonly reported 
etiologies, such as pneumonia or infection, lymphangitic carcinomatosis, pulmonary 
embolism, heart failure, chronic obstructive pulmonary diseas e, or pulmonary 
hypertension:
Measurement of oxygen saturation (i.e., arterial blood gas)
High-resolution CT scan of the chest
Bronchoscopy with bronchoalveolar lavage and biopsy
Pulmonary function tests (diffusion capacity of the lung for carbon monoxide [DL CO])
Pulmonary function testing with a pulmonary embolism protocol
Patients will be assessed for pulmonary signs and symptoms throughout the study and 
will also have CT scans of the chest at every tumor assessment.  See Table 22for 
management guidelines for pulmonary events and pneumonitis.
nab-Paclitaxel 
Interstitial pneumonitis has been observed in 1% of patients with nab- paclitaxel 
monotherapy and 4% with the use of nab- paclitaxel in combination with gemcitabine.  
Patients should be monitored closely for signs and symptoms of pneumonitis. 
nab-paclitaxel should be permanently discontinued upon rul ing out infectious etiology 
and making a diagnosis of pneumonitis.  Promptly initiate appropriate treatment and 
supportive measures.
Infections should be ruled out with routine microbiological and/or immunologic methods.
After ruling out an infectious etiology, IV high -dose corticosteroid therapy should be 
instituted without delay, with appropriate premedication and secondary pathogen 
coverage.  Patients with an added immunological component may also require immune 
modulation with azathioprine or cyclophosphamide.
Table 22details the management of pulmonary events/pneumonitis when atezolizumab 
and nab- paclitaxel are administered together, or when nab -paclitaxel is administered 
alone.
Note: When atezolizumab is administered alone, refer to the Atezolizumab Investigator’s 
Brochure for management of pulmonary events, including pneumonitis.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
119/Protocol GO29437 , Version 7Table 22Management Guidelines for Pneumonit is:  A tezolizumab w ith 
nab-Paclitaxel, or nab -Paclitaxel with or without Atezolizumab
SeverityAtezolizumab
(in Combination with nab -Paclitaxel)nab-Paclitaxel
(with or without Atezolizumab)
Grade 1Withhold atezolizumab with close 
monitoring.
Resume when event improves to Grade 0.
Re-evaluate on serial imaging.
Consider pulmonary consultation.Permanently discontinue 
nab-paclitaxel.
After ruling out infection, 
start high -dose IV 
corticosteroids with 
appropriate premedication 
and secondar y pathogen 
coverage.
Grade 2Withhold atezolizumab.
Pulm onary and infectious disease 
consultation with consideration for 
bronchoscopy/BAL.
Start 60 mg prednisone or equivalent per 
day.
When im proves to Grade 0 or Grade 1, then 
taper steroids over 1 month.
Atezolizumab may  be resumed if the event 
improves to Grade [ADDRESS_121809] been 
reduced to the equivalent of oral prednisone 
10mg daily or less.
Treat as Grade 34if recurrent epi[INVESTIGATOR_109787].Permanently discontinue 
nab-paclitaxel.
After ruling out infection, 
start high -dose IV 
corticosteroids with 
appropriate premedication 
and secondar y pathogen 
coverage.
Grade 
3or4Permanently discontinue atezolizumab and 
contact [CONTACT_1689].
Bronchoscopy/BAL is recommended.
Start 60 mg prednisone or equivalent per 
day.
Taper steroids over 1 month after 
symptoms improve to Grade 0 or Grade 1.
If not improving after 48 hours or worsening, 
add additional immunosuppression (e.g., 
infliximab, cyclophosphamide, I VIg, or 
mycophenolate mofetil).Permanently discontinue 
nab-paclitaxel.
After ruling out infection, 
start high -dose IV 
corticosteroids with 
appropriate premedication 
and secondar y pathogen 
coverage.
BALbroncho -alveolar lavage; Ig immunoglobulin; IV intravenous.
[IP_ADDRESS] Other Toxicities
For any Grade 3 or 4 toxicity not mentioned above, carboplatin or nab -paclitaxel should 
be withheld until the patient recovers completely or to Grade 1 toxicity.  nab-Paclitaxel 
and carboplatin may be resumed at reduced dos es (see Table 23) when toxicity 
recovers to Grade 1 or completely resolves .  If recovery to Grade 1 toxicity does not 
occur within 3 weeks, the patient’s chemotherapy will be discontinued.  For Grade 1 and 
2 toxicities, no dose reduction should be made.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
120/Protocol GO29437 , Version 7Table 23nab-Paclitaxel and Carboplatin Permanent Dose Reductions for 
Non- Hematologic, Non -Gastrointestinal, Non- Neurologic, and 
Non- Hepatic Toxicity
Adverse Reaction OccurrenceWeekly nab-Paclitaxel 
Dose (mg/m2)Every 3 -Week 
Carboplatin Dose 
(AUC mg min/mL)
Grade [ADDRESS_121810] Discontinue treatment
AUC area under the concentration time curve; GI gastrointestinal .
For guidelines on the dosing of other study drugs when carboplatin or nab -paclitaxel are 
withheld, see Section 5.1.[ADDRESS_121811] been associated with each agent 
separately (e.g., hepatotoxicity, skin, and gastrointestinal toxicity) may not be 
unambiguous when the agents are administered together.  It is theoretically possible that 
allergic or inflam matory adverse events associated with these chemotherapeutic agents 
(e.g., hepatotoxicity) could be exacerbated by [CONTACT_109839]. 
Toxicities should initially be managed according to the recommendations in 
Section [IP_ADDRESS] to Section 5.1.10, with dose holds and modifications (if applicable) 
applied to the component of the study drug judged to be the primary cause.  For severe 
(Grade 3) or persistent Grade [ADDRESS_121812] dose 
(see Section [IP_ADDRESS]).  Exceptions require Medial Monitor approval.  Prompt symptoma tic 
management is appropriate for mild immune -mediated adverse events.  In severe cases, 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
121/Protocol GO29437 , Version 7immune -mediated toxicities may be acutely managed with topi[INVESTIGATOR_11930],
systemic corticosteroids, or TNF-inhibitors.  These cases should be discussed with the 
Medical Monitor.
5.[ADDRESS_121813]; measurement of 
protocol -specified safety laboratory assessments; measurement of protocol -specified 
vital signs; and other protocol -specified tests that are deemed critical to the safety 
evaluation of the study.
Certain types of events require immediate reporting to the Sponsor, as outlined in 
Section 5.4.
5.2.[ADDRESS_121814], regardless of causal attribution.  An adverse event can 
therefore be any of the following:
Any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a medicinal product, 
whether or not considered related to the medicinal product
Any new disease or exacerbation of an existing disease (a worsening in the 
character, frequency, or severity of a known condition), except as described in 
Section [IP_ADDRESS]
Recurrence of an intermittent medical condition (e.g., headache) not present at 
baseline
Any deterioration in a laboratory value or other clinical test (e.g., ECG, X -ray) that is 
associated with symptoms or leads to a change in study treatment or concomitant 
treatment or discontinuation from study drug
Adverse events that are related to a protocol -mandated intervention, including those 
that occur prior to assignment of study treatment (e.g., screening invasive 
procedures such as biopsies)
5.2.2 Serious A dverse Events (Immediately  Reportable to 
theSponsor)
A serious adverse event is any adverse event that meets any of the following criteria:
Is fatal (i.e., the adverse event actually causes or leads to death)
Is life threatening (i.e., the adverse event, in the view of the investigator, places the 
patient at immediate risk of death)
This does not include any adverse event that had it occurred in a more severe 
form or was allowed to continue might have caused death.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
122/Protocol GO29437 , Version 7Requires or prolongs inpatient hospi[INVESTIGATOR_059] (see Section [IP_ADDRESS])
Results in persistent or significant disability/incapacity (i.e., the adverse event 
results in substantial disruption of the patient’s ability to conduct normal life 
functions)
Results in a congenital anomaly/birth defect in a neonate/infant born to a mother 
exposed to study drug
Is asignificant medical event in the investigator's judgment (e.g., may jeopardize the 
patient or may require medical/surgical intervention to prevent one of the outcomes 
listed above)
The terms “severe” and “serious” are notsynonymous.  Severity refers to the intensity of 
an adverse event (e.g., rated as mild, moderate, or severe, or according to NCI CTCAE; 
see Section 5.3.3 ); the event itself may be of relatively minor medical significance (such 
as severe headache without any further findings).
Severity and seriousness need to be independently assessed for each adverse event 
recorded on the eCRF.
Serious adverse events are required to b e reported by [CONTACT_25741] (i.e., no more than 24 hours after learning of the event; see Section 5.4.2 for 
reporting instructions).
5.2.[ADDRESS_121815] (Immediately  Reportable to 
the Sponsor)
Adverse events of special interest are required to be reported by [CONTACT_33473] (i.e., no more than 24 hours after learni ng of the event; see 
Section 5.4.2 for reporting instructions).  Adverse events of special interest for this study 
include the followi ng:
Confirmed treatment -emergent autoimmune conditions:
Pneumonitis
Hypoxia or dyspnea Grade 3
Colitis
Endocrinopathies:  diabetes mellitus, pancreatitis, or adrenal insufficiency
Vasculitis
Hepatitis
Transaminitis:  Grade 2(AST or ALT3ULN and bilirubin 2ULN) OR 
AST/ALT 10ULN
Systemic lupus erythematosus
Guillain -Barré syndrome
Skin reactions:  vitiligo, pemphigoid
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
123/Protocol GO29437 , Version 7Events suggestive of hypersensitivity, cytokine release, influenza -like illness, 
systemic inflammatory response system (SIRS), or infusion- reaction syndromes
Cases of potential drug- induced liver injury that include an elevated ALT or AST in 
combination with either an elevated bilirubin or clinical jaundice, as defined by [CONTACT_25742]’s 
law (see Section [IP_ADDRESS]).
Suspected transmission of an infectious agent by [CONTACT_5257], as defined below
Any organism, virus, or infectious particle (e.g., prion protei n-transmitting 
transmissible spongiform encephalopathy), pathogenic or non -pathogenic, is 
considered an infectious agent.  A transmission of an infectious agent may be 
suspected from clinical symptoms or laboratory findings that indicate an infection 
in a patient who was exposed to a medicinal product.  This term applies only
when a contamination of the study drug is suspected.
5.3 METHODS A ND TIMING F OR CA PTURING A ND ASSESSING 
SAFETY PARAMETERS
The investigator is responsible for ensuring that all adverse eve nts (see Section 5.2.1 for 
definition) are recorded on the Adverse Event eCRF and reported to the Sponsor in 
accordance with instructi ons provided in this section and in Sections 5.45.6.
For each adverse event recorded on the Adverse Event eCRF, the investigator will make 
an assessment of seriousness (see Section 5.2.2 for seriousness criteria), severity (see 
Section 5.3.3 ), and causality (see Section 5.3.4 ).  
5.3.[ADDRESS_121816].  All 
adverse events, whether reported by [CONTACT_25743], will be 
recorded in the patient’s medical record and on the Adverse Event eCRF.
After informe d consent has been obtained but prior to initiation of study drug, only 
serious adverse events caused by a protocol -mandated intervention (e.g., invasive 
procedures such as biopsies, discontinuation of medications) should be reported (see 
Section 5.4.2 for instructions for reporting serious adverse events).
After initiation of study treatment , allserious adverse events and adverse event s of 
special interest, regardless of relationship to study treatment , will be reported until 
90days after the last dose of study treatment (inclusive of erlotinib switch maintenance 
for patients randomized to Arm C who received switch maintenance with er lotinib under 
previous protocol versions ) or until initiation of new systemic anti-cancer therapy after 
the last dose of study treatment , whichever occurs first.  All other adverse events, 
regardless of relationship to study treatment, will be reported unt il [ADDRESS_121817] 
dose of study treatment (inclusive of erlotinib switch maintenance for patients 
randomized to Arm C who received switch maintenance with erlotinib under previous 
protocol versions ) or until initiation of new systemic anti-cancer therapy after the last 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
124/Protocol GO29437 , Version 7dose of study treatment , whichever occurs first.  Instructions for reporting adverse 
events that occur after the adverse event reporting period are provided in Section 5.6.
5.3.2 Eliciting A dverse Ev ent Information
A consistent methodology of non -directive questioning should be adopted for eliciting 
adverse event information at all patient evaluation timepoints.  Example s of non -directive 
questions include the following:
“How have you felt since your last clinic visit?”
“Have you had any new or changed health problems since you were last here?”
5.3.3 Assessment of Severity  of A dverse Events
The adverse event severity grading scale for the NCI CTCAE v4.0 will be used for 
assessing adverse event severity.  Table 24will be used for assessing severity for 
adverse events that are not specifically listed in the NCI CTCAE.
Table 24Adverse Event Severity Grading Scale for Events Not Specifically  
Listed in NCI CTCA E
Grade Severity
1 Mild; as ymptomatic or mild symptoms; clinical or diagnostic observations only; or 
intervention not indicated
2 Moderate; minimal, local, or non -invasive intervention indicated; or limiting 
age-appropriate instrumental activities of daily livinga
3 Severe or medically significant, but not immediately life -threatening; hospi[INVESTIGATOR_12342]; disabling; or limiting self-care activities 
of daily livingb, c
4 Life-threatening consequences or urgent intervention indicatedd
5 Death related to adverse eventd
NCI CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events .
Note:  Based on the most recent version of NCI CTCAE v4.0, which can be found at:  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
aInstrumental activities of daily living refer to preparing meals, shoppi[INVESTIGATOR_19640], using the telephone, managing money, etc.
bExamples of self -care activities o f daily living include bathing, dressing and undressing, 
feeding oneself, using the toilet, and taking medications, as performed by [CONTACT_25744].
cIf an event is assessed as a “significant medical event,” it must be reported as a serious
adverse event (see Section 5.4.2 for reporting instructions), per the definition of serious 
adverse event in Section 5.2.[ADDRESS_121818] be reported as serious adverse events (see Section 5.4.2 for 
reporting instructions), per the definition of serious adverse event in Section 5.2.2 .
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
125/Protocol GO29437 , Version 75.3.4 Assessment of Causality  of Adverse Events
Investigators should use their knowledge of the patient, the circumstances surrounding 
the event, and an evaluation of any potential alternative causes to determine whether or 
not an adverse event is considered to be related to the study drug, indicating "yes" or 
"no" accordingly.  The following guidance should be taken into consideration:
Temporal relationship of event onset to the initiation of study drug
Course of the event, considering es pecially the effects of dose reduction, 
discontinuation of study drug, or reintroduction of study drug (as applicable)
Known association of the event with the study drug or with similar treatments
Known association of the event with the disease under study
Presence of risk factors in the patient or use of concomitant medications known to 
increase the occurrence of the event
Presence of non treatment -related factors that are known to be associated with the 
occurrence of the event
For patients receiving combination therapy, causality will be assessed individually for 
each protocol -mandated therapy.
5.3.[ADDRESS_121819] medical terminology/concepts when recording adverse 
events on the Adverse Event eCRF.  Avoid colloquialisms and abbreviations.
Only one adverse event term should be recorded in the event field on the Adverse 
Event eCRF.
[IP_ADDRESS] Diagnosis versus Signs and Sy mptoms
For all adverse events, a diagnosis (if known) rather than individual signs and symptoms 
should be recorded on the Adverse Event eCRF (e.g., record only liver failure or 
hepatitis rather than jaundice, asterixis, and elevated transaminases).  However, if a 
constellation of signs and/or symptoms cannot be medically characterized as a s ingle 
diagnosis or syndrome at the time of reporting, each individual event should be recorded 
on the Adverse Event eCRF.  If a diagnosis is subsequently established, all previously 
reported adverse events based on signs and symptoms should be nullified an d replaced 
by [CONTACT_25746], with a starting date that 
corresponds to the starting date of the first symptom of the eventual diagnosis.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
126/Protocol GO29437 , Version [IP_ADDRESS] Adverse Events That A re Secondary  to Other Events
In general, adverse events that are secondary to other events (e.g., cascade events or 
clinical sequelae) should be identified by [CONTACT_5252], with the exception of 
severe or serious secondary events.  A medically significant secondary adverse event 
that is separated in time f rom the initiating event should be recorded as an independent 
event on the Adverse Event eCRF.  For example:
If vomiting results in mild dehydration with no additional treatment in a healthy adult, 
only vomiting should be reported on the eCRF.
If vomiting results in severe dehydration, both events should be reported separately 
on the eCRF.
If a severe gastrointestinal hemorrhage leads to renal failure, both events should be 
reported separately on the eCRF.
If dizziness leads to a fall and consequent fractur e, all three events should be 
reported separately on the eCRF.
If neutropenia is accompanied by [CONTACT_25747], both events should be reported 
separately on the eCRF.
All adverse events should be recorded separately on the Adverse Event eCRF if it is 
unclea r as to whether the events are associated.
[IP_ADDRESS] Persistent or Recurrent A dverse Events
A persistent adverse event is one that extends continuously, without resolution, between 
patient evaluation timepoints.  Such events should only be recorded once on the 
Adver se Event eCRF.  The initial severity (intensity) of the event will be recorded at the 
time the event is first reported.  If a persistent adverse event becomes more severe, the 
most extreme intensity should also be recorded on the Adverse Event eCRF.  If th e 
event becomes serious, it should be reported to the Sponsor immediately (i.e., no more 
than 24 hours after learning that the event became serious; see Section 5.4.2 for 
reporting instructions).  The Adverse Event eCRF should be updated by [CONTACT_70156] "non -serious" to "serious," providing the date that the event became serious, 
and completing all data fields related to serio us adverse events.
A recurrent adverse event is one that resolves between patient evaluation timepoints 
and subsequently recurs.  Each recurrence of an adverse event should be recorded as a 
separate event on the Adverse Event eCRF.
[IP_ADDRESS] Abnormal Laboratory Valu es
Not every laboratory abnormality qualifies as an adverse event.  A laboratory test result 
must be reported as an adverse event if it is a change from baseline and meets any of 
the following criteria:
Is accompanied by [CONTACT_4659]
Results in a chan ge in study treatment (e.g., dosage modification, treatment 
interruption, or treatment discontinuation)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
127/Protocol GO29437 , Version 7Results in a medical intervention (e.g., potassium supplementation for hypokalemia) 
or a change in concomitant therapy
Is clinically significant in the investigator’s judgment 
It is the investigator’s responsibility to review all laboratory findings.  Medical and 
scientific judgment should be exercised in deciding whether an isolated laboratory 
abnormality should be classified as an adverse event.
If a clinically significant laboratory abnormality is a sign of a disease or syndrome 
(e.g., alkaline phosphatase and bilirubin 5 ULN associated with cholestasis), only the 
diagnosis (i.e., cholestasis) should be recorded on the Adverse Event eCRF.
If a clinically significant laboratory abnormality is not a sign of a disease or syndrome, 
the abnormality itself should be recorded on the Adverse Event eCRF, along with a 
descriptor indicating if the test result is above or below the normal range (e.g., “elev ated 
potassium,” as opposed to “abnormal potassium”).  If the laboratory abnormality can be 
characterized by a precise clinical term per standard definitions, the clinical term should 
be recorded as the adverse event.  For example, an elevated serum potass ium level of 
7.0 mEq/L should be recorded as “hyperkalemia.”
Observations of the same clinically significant laboratory abnormality from visit to visit 
should not be repeatedly recorded on the Adverse Event eCRF, unless the etiology 
changes.  The initial s everity of the event should be recorded, and the severity or 
seriousness should be updated any time the event worsens.
[IP_ADDRESS] Abnormal Vital Sign Values
Not every vital sign abnormality qualifies as an adverse event.  A vital sign result must 
be reported as an adverse event if it is a change from baseline and meets any of the 
following criteria:
Is accompanied by [CONTACT_4659]
Results in a change in study treatment (e.g., dosage modification, treatment 
interruption, or treatment discontinuation)
Results in a m edical intervention or a change in concomitant therapy
Is clinically significant in the investigator’s judgment 
It is the investigator’s responsibility to review all vital sign findings.  Medical and scientific 
judgment should be exercised in deciding wh ether an isolated vital sign abnormality 
should be classified as an adverse event.
If a clinically significant vital sign abnormality is a sign of a disease or syndrome 
(e.g., high blood pressure), only the diagnosis (i.e., hypertension) should be recorded on 
the Adverse Event eCRF.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
128/Protocol GO29437 , Version 7Observations of the same clinically significant vital sign abnormality from visit to visit 
should not be repeatedly recorded on the Adverse Event eCRF, unless the etiology 
changes.  The initial severity of the event should be re corded, and the severity or 
seriousness should be updated any time the event worsens.
[IP_ADDRESS] Abnormal Liver Function Tests
The finding of an elevated ALT or AST ( 3baseline value) in combination with either 
an elevated total bilirubin ( 2ULN) or clinical jaundice in the absence of cholestasis or 
other causes of hyperbilirubinemia is considered to be an indicator of severe liver injury.  
Therefore, investigators must report as an adverse event the occurrence of either of the 
following:
Treatment -emergent AL T or AST 3baseline value in combination with total 
bilirubin 2ULN (of which 35% is direct bilirubin)
Treatment -emergent ALT or AST 3baseline value in combination with 
clinical jaundice
The most appropriate diagnosis or (if a diagnosis cannot be established) the abnormal 
laboratory values should be recorded on the Adverse Event eCRF (see Section [IP_ADDRESS]) 
and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of 
the event), either as a serious adverse event or anadverse event of special interest (see 
Section 5.4.2 ).
[IP_ADDRESS] Deaths
For this protocol, mortality is an efficacy endpoint.  Deaths that occur during the 
protocol -specified adverse event reporting period (see Section 5.3.1 ) that are attributed 
by [CONTACT_109840].  All other deaths occurring during the adverse ev ent reporting 
period, regardless of relationship to study drug, must be recorded on the Adverse Event 
eCRF and immediately reported to the Sponsor (see Section 5.4.2 ).  The iDMC will 
monitor the frequency of deaths from all causes.
Death should be considered an outcome and not a distinct event.  The event or condition 
that caused or contributed to the fatal outcome should be recorded as the single medical 
concept on the Adverse Event eCRF.  Generally, only one such event should be 
reported.  If the cause of death is unknown and cannot be ascertained at the time of 
reporting, “unexplained death” should be recorded on the Adverse Event eCRF.  If the 
cause of death later becomes available (e.g., after autopsy), “unexplained death” should
be replaced by [CONTACT_25749].   The term "sudden death" should not be 
used unless combined with the presumed cause of death (e.g., "sudden cardiac death").
During survival follow -up, deaths attributed to progression of NSCLC should be reco rded 
on the Study Discontinuation eCRF. 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
129/Protocol GO29437 , Version [IP_ADDRESS] Preexisting Medical Conditions
A preexisting medical condition is one that is present at the screening visit for this study.  
Such conditions should be recorded on the General Medical History and Baseline 
Conditions eCRF.
A preexisting medical condition should be recorded as an adverse event only if the 
frequency, severity, or character of the condition worsens during the study.  W hen 
recording such events on the Adverse Event eCRF, it is important to convey the conc ept 
that the preexisting condition has changed by [CONTACT_9672] 
(e.g., “more frequent headaches”).
[IP_ADDRESS] Worsening of NSCLC
Events that are clearly consistent with the expected pattern of progression of the 
underlying disease should not be recorded as adverse events.  These data will be 
captured as efficacy assessment data only.  In most cases, the expected pattern of 
progression will be based on RECIST.  In rare cases, the determination of clinical 
progression will be based on symptomat ic deterioration.  However, every effort should 
be made to document progression through use of objective criteria.  If there is any 
uncertainty as to whether an event is due to disease progression, it should be reported 
as an adverse event.
[IP_ADDRESS] Hospi[INVESTIGATOR_26663] (i.e., in -patient admission to a hospi[INVESTIGATOR_307]) 
or prolonged hospi[INVESTIGATOR_25676] a serious adverse 
event (per the definition of serious adverse even t in Section 5.2.2 ), except as outlined 
below.
An event that leads to hospi[INVESTIGATOR_26664] a serious adverse event:
Hospi[INVESTIGATOR_25678]
Planned hospi[INVESTIGATOR_33402] (e.g., for study drug administration or 
to perform an efficacy measurement for the study)
Hospi[INVESTIGATOR_272] a preex isting condition, provided that all of the following criteria 
aremet:
The hospi[INVESTIGATOR_33403].
The patient has not experienced an adverse event.
Hospi[INVESTIGATOR_33404] —F. Hoffmann- La [COMPANY_002] Ltd
130/Protocol GO29437 , Version 7An event that leads to hospi[INVESTIGATOR_33405] a serious adverse event, but should be repor ted as an adverse event 
instead:
Hospi[INVESTIGATOR_25682]
[IP_ADDRESS] Adverse Events A ssociated with an Overdose or Error in 
Drug Administration
Study overdose is the accidental or intentional use of a drug in an amount higher than 
the dose being studied.  An overdose or incorrect administration of study treatment is not 
itself an adverse event, but it may result in an adverse event.  All adverse e vents 
associated with an overdose or incorrect administration of study drug should be 
recorded on the Study Drug Administration eCRF.  
All adverse events associated with an overdose or incorrect administration of study drug 
should be recorded on the Adver se Event eCRF.  If the associated adverse event fulfills 
seriousness criteria, the event should be reported to the Sponsor immediately (i.e., no 
more than 24 hours after learning of the event; see Section 5.4.2 ).
[IP_ADDRESS] Patient -Reported Outcome Data
Adverse event reports will not be derived from PRO data and safety analyses will not be 
performed using PRO data.   However, if any PRO responses su ggestive of a possible 
adverse event are identified during site review of the PRO data, the investigator will 
determine whether the criteria for an adverse event have been met and, if so, will report 
the event on the Adverse Event eCRF.
5.[ADDRESS_121820] report 
such events to the Sponsor immediately; under no circumstances should reporting take 
place more than [ADDRESS_121821] report to the Sponsor within 24 hours after learning 
of the event, regardless of relationship to study drug:
Serious adverse events
Adverse events of special interest
Pregnancies
The investigator must report new significant follow -up information for these events to the 
Sponsor immediately (i.e., no more than 24 hours after becoming aware of the 
information).  New significant information includes the following:
New signs or symptoms or a change in the diagnosis
Significant new diagnostic test results
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
131/Protocol GO29437 , Version 7Change in causality based on new information
Change in the event’s outcome, includin g recovery
Additional narrative information on the clinical course of the event
Investigators must also comply with local requirements for reporting serious adverse 
events to the local health authority and IRB/EC.
5.4.[ADDRESS_121822] Information 
Medical Monitor: , M.D. (Primary)
Telephone No.:
Mobile Telephone No.:
Medical Monitor: , M.D. Ph. D. (Secondary)
Telephone No.:
Mobile Telephone No.:
To ensure the safety of study patients, an Emergency Medical Call Center Help Desk will 
access the [COMPANY_002] Medical Emergency List, escalate emergency medical calls, provide 
medical translation service (if necessary), connect the investigat or with a [COMPANY_002] Medical 
Monitor, and track all calls.  The Emergency Medical Call Center Help Desk will be 
available [ADDRESS_121823]
[IP_ADDRESS] Events That Occur prior to Study  Drug Initiation
After informed consent has been obtained but prior to initiation of study drug, only 
serious adverse events caused by a protocol -mandated intervention should be reported.  
The Serious Adverse Event/Adverse Event of Special Interest Reporting Form provided 
to investigators should be completed and submitted to [COMPANY_002] or its designee 
immediately (i.e., no more than 24 hours after learning of the event), either by [CONTACT_40879].
[IP_ADDRESS] Events That Occur after Study  Drug Initiation
After initiation of study drug, serious adverse events and adverse events of special 
interest will be reported until [ADDRESS_121824] dose of study treatment (inclusive of 
erlotinib switch maintenance for patients who were randomized to Arm C who receive d
switch maintenance with erlotin ib under previous protocol versions ) or until initiation of 
new systemic anti-cancer therapy after the last dose of study treatment , whichever 

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
132/Protocol GO29437 , Version 7occurs first.  All other adverse events, regardless of relationship to study drug, will be 
reported until [ADDRESS_121825] dose of study treatment (inclusive of erlotinib switch 
maintenance for patients who are randomized to Arm C who receive dswitch 
maintenance with erlotinib under previous protocol versions ) or until initiation of new 
systemic anti-cancer therapy after the last dose of study treatment , whichever occurs 
first.
Investigators should record all case details that can be gathered immediately (i.e., within 
24 hours after learning of the event) on the Adverse Event eCRF and submit the report 
via the e lectronic data capture (EDC) system.  A report will be generated and sent to 
[COMPANY_002] Safety Risk Management by [CONTACT_27950].
In the event that the EDC system is unavailable, the Serious Adverse Event / Adverse 
Event of Special Interest Reporting Form provi ded to investigators should be completed 
and submitted to [COMPANY_002] or its designee immediately (i.e., no more than 24 hours after 
learning of the event), either by [CONTACT_109841] i nvestigators.  Once the EDC system is 
available, all information will need to be entered and submitted via the EDC system.  
Instructions for reporting adverse events that occur after the adverse event reporting 
period are provided in Section 5.6.
5.4.3 Reporting Requirements for Pregnancies
[IP_ADDRESS] Pregnancies in Female Patients
Female patients of childbearing potential will be instructed to immediat ely inform the 
investigator if they become pregnant during the study or within [ADDRESS_121826] dose of paclitaxel .  A Clinical Trial Pregnancy Reporting Form should be 
completed and submitted to the Sponsor or its designee immediately (i.e., no more than 
24hours after learning of the pregnancy) , either by [CONTACT_109842] e mail address provided to investigators .  
Pregnancy should not be recorded on the Adverse Event eCRF.  The investigator should 
discontinue study drug and counsel the patient, discussing the risks of the pregnancy 
and the possible effects on the f etus.  Monitoring of the patient should continue until 
conclusion of the pregnancy.  Any serious adverse events associated with the 
pregnancy (e.g., an event in the fetus, an event in the mother during or after the 
pregnancy, or a congenital anomaly/birth defect in the child) should be reported on the 
Adverse Event eCRF.   In addition, the investigator will submit a Clinical Trial Pregnancy 
Reporting Form when updated information on the course and outcome of the pregnancy 
becomes available.
[IP_ADDRESS] Pregnancies in Fe male Partners of Male Patients 
Male patients will be instructed through the Informed Consent Form to immediately 
inform the investigator if their partner becomes pregnant during the study or within 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
133/Protocol GO29437 , Version 76months after the last dose of nab -paclitaxel, paclitaxe l, and/or carboplatin.  A Clinical 
Trial Pregnancy Reporting Form should be completed and submitted to the Sponsor or 
its designee immediately (i.e., no more than 24 hours after learning of the pregnancy) , 
either by [CONTACT_109843] f orm with use of the fax number or 
email address provided to investigators.   Attempts should be made to collect and report 
details of the course and outcome of any pregnancy in the partner of a male patient 
exposed to study drug.  When permitted by [CONTACT_3899] e, the pregnant partner would need to 
sign an Authorization for Use and Disclosure of Pregnancy Health Information to allow 
for follow -up on her pregnancy.  If the authorization has been signed, the investigator 
should submit a Clinical Trial Pregnancy Rep orting Form when updated information on 
the course and outcome of the pregnancy becomes available.   An investigator who is 
contact[CONTACT_109844], to support an informed 
decision in cooperation with the treating physician and/or obstetrician.
[IP_ADDRESS] Abortions
A spontaneous abortion should be classified as a serious adverse event (as the Sponsor 
considers abortions to be medically significant), recorded on the Adverse Event eCRF, 
and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of 
the event; see Section 5.4.2 ).
If a therapeutic or elective abortion was performed because of an underlying maternal 
or embryofetal toxicity, the toxicity should be classified as a serious adverse event, 
recorded on the Adverse Event eCRF, and reported to the Sponso r immediately (i.e., no 
more than 24 hours after learning of the event; see Section 5.4.2).   A therapeutic or 
elective abortion perfo rmed for reasons other than an underlying maternal or 
embryofetal toxicity is not considered an adverse event.
All abortions should be reported as pregnancy outcomes on the paper Clinical Trial 
Pregnancy Reporting Form.  
[IP_ADDRESS] Congenital A nomalies/Birth Defects
Any congenital anomaly/birth defect in a child born to a female patient exposed to study 
drug or the female partner of a male patient exposed to study drug should be classified 
as a serious adverse event, recorded on the Adverse Event eCRF, and reported t o the 
Sponsor immediately (i.e., no more than 24 hours after learning of the event; see 
Section 5.4.2 ).
5.[ADDRESS_121827] to 
follow -up, or the patient withdraws consent.  Every effort should be made to follow all 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
134/Protocol GO29437 , Version 7serious adverse events considered to be related to study drug or study -related procedures 
until a final outcome can be reported.
During the study period, resolution of adverse events (with dates) should be documented 
on the Adverse Event eCRF and in the patient’s medical record to facilitate source data 
verification.  If, after follow -up, return to baseline status or stabilization cannot be 
established, an explanation should be recorded on the Adverse Eve nt eCRF. 
All pregnancies reported during the study should be followed until pregnancy outcome.  
If the EDC system is not available at the time of pregnancy outcome, follow reporting 
instructions provided in Section [IP_ADDRESS] .
5.5.[ADDRESS_121828], and pregnancies, the 
Sponsor or a designee may follow up by [CONTACT_756], fax, electronic mail, and/or a 
monitoring visit to obtain additional case details and outcome information (e.g., from 
hospi[INVESTIGATOR_8838], consultant reports, autopsy reports) in order to perform 
an independent medical assessment of the reported case.
5.6 ADVERSE EVENTS THA T OCCUR AFTER THE A DVERSE 
EVENT REPORTING PERI OD
After the end of the adverse event reporting period (as defined in Section 5.3.1 ),all 
deaths should be reported through use of the Study Discontinuation eCRF.  In addition, 
if the investigator becomes aware of a serious adverse event or adverse event of special 
interest that is believed to be related to prior exposure to study treatmen t, the event 
should be reported through use of the Adverse Event eCRF.  
However, if the EDC system is not available, the investigator should report these events 
directly to the Sponsor or its designee, either by [CONTACT_109845] r Clinical Trial Serious Adverse Event/Adverse Event of Special Interest Reporting 
Form using the fax number or email address provided to investigators.
5.[ADDRESS_121829] experience to identify and expeditiously 
communicate possible new safety findings to investigators, IRBs, ECs, and applic able 
health authorities based on applicable legislation.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
135/Protocol GO29437 , Version 7To determine reporting requirements for single adverse event cases, the Sponsor will 
assess the expectedness of these events using the following as a reference:
Atezolizumab Investigator's Brochure
Tarceva(erlotinib) Summary of Product Characteristics (SmPC)/Local Label
Abraxane®(nab-paclitaxel) Summary of Product Characteristics (SmPC)/Local
Label
The Sponsor will compare the severity of each event and the cumulative event 
frequency reported for the study with the severity and frequency reported in the 
applicable reference document.
Reporting requirements will also be based on the investigator's assessment of causality 
and seriousness, with allowance for upgrading by [CONTACT_25753].
An iDMC will monitor safety data during the study.  An aggregate report of any clinically 
relevant imbalances that do not favor the test product will be submitted to health 
authorities.
6. STATISTICA L CONSIDER ATIONS AND ANAL YSIS PLAN
This is a randomized Phase III, multicenter, open -label study designed to evaluate the 
safety and efficacy of atezolizumab in combination with either carboplatin paclitaxel 
orcarboplatin nab-paclitaxel as compared with treatment with 
carboplatin nab-paclitaxel in approximately [ADDRESS_121830] -line setting. 
Efficacy analyses will be performed in one or more populations (tGE, ITT, TC2/3 or IC2/3, 
or TC1/2/3 or IC1/2/3), with patients grouped according to the treatment assigned at 
randomizat ion, regardless of whether they received any assigned study treatment.
Safety analyses will be performed on all randomized patients who received any amount 
of any components of protocol treatments, with patients grouped according to whether 
any full or pa rtial dose of atezolizumab was received.   Specifically, for patients 
randomized to Arm C, if atezolizumab was received by [CONTACT_86966], the patients will be 
grouped with Arm B for safety analyses.
6.[ADDRESS_121831] comparing Arm B versus Arm C and then 
comparing Arm A versus Arm C as shown in  the in the -spending algorithm (see 
Figure 3).  For each comparison, analyses will be conducted according to the

-spending algorithm to control for the type I error rate  and to account for an interim OS 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
137/Protocol GO29437 , Version 7The sample size of this study is based on the number of events required to demonstrate 
efficacy with regard to both PFS and OS (co-primary endpoints) for the comparison of 
Arm B versus Arm C .
The estimate of the number of events required to demonstrate efficacy with regard to 
PFS in the comparison of Arm B versus Arm C isbased on the following assumptions:
One-sided significance level of 0.003 for the comparison of Arm B versus Arm C in 
the tGE population
One-sided significance level of 0.003 for the comparison of Arm B versus Arm C in 
the ITT population
97% power to detect an HR of 0.55, corresponding to an improvement in median 
PFS from 6 months to 10.9 months in the tGE population
98% power to detect an HR of 0.65, corresponding to an improvement in median 
PFS from 6 months to 9.2 months in the ITT population
No interim analysis for PFS
Dropout rate of 5% per [ADDRESS_121832] to OS
in the comparison of Arm B versus Arm C isbased on the following assumptions:
One-sided significance level of 0.022 for the comparison of Arm B versus Arm C in 
the ITT population
86% powe r to detect an HR of 0.75, corresponding to an improvement in median 
OS from 12 months to 16 months in the ITT population
One interim OS analysis performed at the time of the final PFS analysis, at which 
time approximately 76% of the total number of OS eve nts required for the final 
analysis are expected to have occurred ,as determined through use of the Lan -
DeMets approximation to the O’Brien- Fleming boundary
Dropout rate of 5% per [ADDRESS_121833] to 
PFS and OS in the comparison of Arm A versus Arm C is based on assumptions similar 
to those outlined above for Arm B versus Arm C.
With these assumptions, approximately 1025 patients in total will be enrolled into this 
study, with approximately 684 patients in each comparison (i.e., Arm B vs. Arm C, Arm A 
vs. Arm C).  The final PFS analysis will be conducted when allof the following criteria 
have been met:  approximately [ADDRESS_121834] patien t is enrolled.  These numbers of events would allow for a minimum 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
138/Protocol GO29437 , Version 7detectable difference corresponding to an HR of approximately 0.[ADDRESS_121835] to inclusion/exclusion criteria, will be reported and summarized by [CONTACT_109846].
6.3 SUMMA RIES OF TREA TMENT GROUP COMP ARAB ILITY
Demographic characteristics, such as age, sex, race/ethnicity, and baseline disease 
characteristics (e.g., ECOG performance status), will be summarized by [CONTACT_109847].  Descriptive statistics (mean, median, 
standard deviation, and range) will be presented for continuous data, and frequencies 
and percentages will be presented for categorical data.
Baseline measurements are the last available data obtained prior to the patient rece iving 
the first dose of any component of protocol treatments. 
6.[ADDRESS_121836] one interim OS analysis will be 
performed (see Section 6.8.1 ).
PFS is defined as the time between the date of randomization and the date of first 
documented disease progression or death, whichever occurs first.  Patients who have 
not experienced disease progression or died at the time of analysis will be censored 
atthe time of the last tumor assessment.  Patients with no post -baseline tumor 
assessment will be censored at the date of randomization plus [ADDRESS_121837] known to be alive.  Data for patients who do 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
140/Protocol GO29437 , Version 7b.If the null hypothesis is rejected for PFS analysis in the ITT population (Step 2),
OS in the ITT population will be tested at 0.025 (one sided).
Comparison of Arm A versus Arm C
If the difference in OS between Arm B and Arm C in the ITT population is statistically 
significant at an of 0.022 or 0.025 (Step 3), that same will become the overall 
one-s ided type I error rate for the comparison of Arm A versus Arm C, with  allocated 
to PFS and OS at the same 3:22 ratio (see Figure 3 in Section 6.1). If the difference in 
OS between Arm B and Arm C in the ITT population is not statistically significant, there 
will 
be no formal  comparison of Arm A versus Arm C for the co-p rimary endpoints of 
PFS and OS.
1.If the difference in OS between Arm B and Arm C is statistically significant at
0.022 (one sided):
a.PFS in the tGE population will be tested at 0.[ZIP_CODE] (one sided).  If the
estimate of the HR is [ADDRESS_121838] is 0.[ZIP_CODE], the null hypothesis will be rejected and it will
be concluded that atezolizumab carboplatin paclitaxel prolongs the duration of
PFS relative to control treatment in the tGE population.
b.If the null hypothesis is rejected in the tGE population (Step 1a), PFS in the ITT
population will be tested at 0.[ZIP_CODE] (one sided).
c.recycling from PFS to OS will be conducted as follows:
If the null hypothesis is not rejected in the ITT population (Step 1b), OS in
the ITT population will be tested at 0.[ZIP_CODE] (one sided).
If the null hypothesis is rejec ted in the ITT population (Step 1b), OS in the
ITT population will be tested at 0.022 (one sided).
2.If the difference in OS between Arm B and Arm C is statistically significant at
0.025 (one sided):
a.PFS in the tGE population will be tested at 0.003 (one sided).  If the estimate
of the HR is [ADDRESS_121839] is 0.003, the null hypothesis will be rejected and it will be concluded
that atezolizumab carboplatin paclitaxel prolongs the duration of PFS relative
to control treatment in the tGE population.
b.If the null hypothesis is rejected in the tGE population (Step 2a), PFS in the ITT
population will be tested at 
0.003 (one sided).
c.recycling from PFS to OS wil l be conducted as follows:
If the null hypothesis is not rejected in the ITT population (Step 2b), OS in
the ITT population will be tested at 0.022 (one sided).
If the null hypothesis is rejected in the ITT population (Step 2b), OS in the
ITT popula tion will be tested at 0.025 (one sided).
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
141/Protocol GO29437 , Version 7Details on the hypothesis testing will be provided in the SAP. On the basis of emerging 
external data, the testing strategy may be modified to improve the efficiency of the 
design. Should this occur, modif ications to the testing strategy will be documented in the 
SAP prior to any unblinding of the data.
6.4.2 Secondary  Efficacy Endpoints
[IP_ADDRESS] Progression -Free Survival and O verall Survivalin Secondary  
Populations
PFS will be analyzed in the TC2/3 or IC2/3 population andtheTC1/2/3 or IC1/2/3 
population, through use of the same methods described for the primary PFS analysis 
(see Section 6.4.1 ). 
OS will be analyzed in the tGE population, the TC2/3 or IC2/3 population, and the 
TC1/2/3 or IC1/2/3 population, through use of the same methods described for the 
primary OS analysis (see Section 6.4.1 ).  
[IP_ADDRESS] Objective Response Rate
An objective response is defined as either an unconfirmed CR or a PR, as determined 
by [CONTACT_3143] v1.1.  Patients not meeting these criteria, 
including patients without any post -baseline tumor assessment, will be considered 
non-responders.
ORR is defined as the proportion of patients who had an objective response.  ORR will 
be analyzed in the tGE population and the ITT population.  Patients must have 
measurable disease at baseline to be included in the analysis.  An estimate of ORR and 
its 95% CI will be calculated using the Clopper -Pearson method for each treatment arm.  
CIs for the di fference in ORRs between the two arms will be determined using the 
normal approximation to the binomial distribution.  The ORR will be compared between 
the two arms using the stratified Mantel -Haenszel test.  The stratification factors of this 
analysis wil l be the same as described in Section 6.4.1 .
[IP_ADDRESS] Duration of Response
DOR will be analyzed in the tGE population and in the ITT population.   DOR will be 
assessed in patients who had an objective response as determined by [CONTACT_70131] v1.1.  DOR is defined as the time interval from the date of the first 
occurrence of a complete or partial response (whichever status is recorded first) until 
thefirst date that progressive disease or death is documented, whichever occurs first.  
Patients who have not progressed and who have not died at the time of analysis will 
becensored at the time of last tumor assessment da te.  If no tumor assessments were 
performed after the date of the first occurrence of a complete or partial response, DOR 
will be censored at the date of the first occurrence of a complete or partial response 
plus 1 day.  
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
142/Protocol GO29437 , Version 7DOR is based on a non -randomized subset of patients (specifically, patients who 
achieved an objective response); therefore, formal hypothesis testing will not be 
performed for this endpoint.  Comparisons between treatment arms will be made for 
descriptive purposes.  The methodologies deta iled for the PFS analysis will be used for 
the DOR analysis.
[IP_ADDRESS] Overall Survival Rate at Landmark Timepoints
OS rate at 1 and 2 years will be analyzed in the tGE population and the ITT population.  
The OS rates at 1 and 2 years will be estimated using Kaplan -Meier methodology for 
each treatment arm, along with 95% CIs calculated using the standard error derived 
from Greenwood’s formula.  The 95% CI for the difference in OS rates between the two 
treatment arms will be estimated using the normal approximation me thod.
[IP_ADDRESS] Patient -Reported Outcomes
TTD in lung cancer symptoms as determined by [CONTACT_109848].
TTD using EORTC is defined as the time from baseline to the first time the patient’s 
score shows a 10-point increase above baseline in any of the following EORTC 
transformed symptom subscale scores (whichever comes first):  cough, dyspnea (single 
item), dyspnea (multi -item subscale), chest pain, or arm/shoulder pain.  A 10-point 
change in the symptoms subscale score is perceived by [CONTACT_109849] 
(Osoba et al. 1998).
Change from baseline per SILC scale will be analyzed in patients with a baseline and a 
post-baseline PRO assessment.
Further details regarding all PRO analyses will be described in the Statistical Analysis 
Plan (SAP) .
6.4.[ADDRESS_121840] -baseline tumor 
assessment is available, PFS will be censored at the date of randomization plus 1 day.  
Data for patients with a PFS event who missed two or more scheduled assessments 
immediately prior to the PFS event will be handled as described in the sensitivity 
analysis in Section [IP_ADDRESS].
For objective response, patients without any post -baseline assessment will be 
considered non -responders.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
143/Protocol GO29437 , Version 7For OS, data for patients who are not reported as having died will be analyzed as 
censored observations on the date they were last known to be alive.  If no post -baseline 
data are available, OS will be censored at the date of ran domization plus [ADDRESS_121841] study drug dose will be summarized by [CONTACT_26736].  In 
addition, serious adverse events, severe adverse events ( Grade 3), adverse events of 
special interest, and adverse events leading to study drug discontinuation or interruption 
will be summarized accordingly.  Multiple occurrences of the same event will be counted 
once at the maxim um severity.
Laboratory data with values outside the normal ranges will be identified.  In addition, 
selected laboratory data will be summarized by [CONTACT_70165].
Changes in vital signs will be summarized by [CONTACT_2939].
Deaths reported during the study treatment period and those reported during the 
follow -up period after treatment completion/discontinuation will be summarized by 
[CONTACT_2939].
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
144/Protocol GO29437 , Version 76.6 PHA RMA COKINETIC A NALYSES
PK samples will be collected in this study as outlined in Appendix 2.  Atezolizumab 
serum concentration data (C minand C max) will be tabulated and summarized.  Descriptive 
statistics will include means, medians, ra nges, and standard deviations, as appropriate.
Plasma concentrations of carboplatin, paclitaxel, and nab -paclitaxel (reported as total 
paclitaxel) will be collected in this study as outlined in Appendix 2.  The concentrations of 
carboplatin, paclitaxel, and nab- paclitaxel (reported as total paclitaxel) will be 
summarized using descriptive statistics as described above.
Additional PK analyses will be conducted, as appropriate, based on the availability 
ofdata.
6.7 EXPLORA TORY ANALYSES
6.7.1 Exploratory  Analyses of Progression -Free Survival
[IP_ADDRESS] Progression -Free Survival Rate at Landmark Timepoints
The PFS rate at various timepoints (e.g., 6 months and at 1 year after randomization)
will be estimated by [CONTACT_8761]- Meier methodology for each treatment arm, with 95% 
CIs calculated using Greenwood’s formula.  The 95% CIs for the difference in PFS rates 
between the two treatment arms (i.e., Arm A vs. Arm CandArm B vs. Arm C) will be 
estimated using the normal approximation method.
[IP_ADDRESS] Non Protocol -Specified Anti-Cancer Therapy
The impact of non protocol -specified anti-cancer therapy on PFS will be assessed 
depending on the number of patients who receive non -protocol -specified anti -cancer
therapy before a PFS event.  If 5% of patients received non protocol -specified
anti-cancer therapy before a PFS event in any treatment arm, a sensitivity analysis will 
be performed for the comparisons between the two treatment arms (i.e., Arm A vs. 
Arm C and Arm B vs. Arm C) in which data for patients who receive non protocol -
specified anti -cancer therapy before a PFS event will be censored at the last tumor 
assessment date before receipt of non protocol -specified anti-cancer therapy.
[IP_ADDRESS] Subgroup A nalysis
To assess the consistency of the study results in subgroups defined by [CONTACT_70166] 
(e.g., age, sex, and race/ethnicity), baseline prognostic characteristics (e.g., ECOG 
performance status, presence of liver metastases at baseline), and PD -L1 tumor 
expression status, the duration of PFS in these subgroups will be examined.  Summaries 
of PFS, including unstratified HRs estimated from Cox proportional hazards models and 
Kaplan -Meier estimates of median PFS, will be produced separately for each level of the 
categorical variables for the comparisons between two treatment arms (i.e., Arm A vs.
Arm C and Arm B vs.Arm C) ( Lewis and Clarke 2001 ).
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
145/Protocol GO29437 , Version [IP_ADDRESS] Sensitivity Analyses 
Sensitivity analyses will be performed to evaluate the potentia l impact of missing 
scheduled tumor assessments on the primary analysis of PFS, as determined by [CONTACT_70167] a PFS event imputation rule.  The following two imputation rules will 
be considered:
If a patient missed two or more scheduled tumor assessments immediately prior to 
the date of the PFS event according to RECIST v1.1, the patient will be censored at 
the last tumor assessment prior to the first of these missed visits .
If a patient missed two or more scheduled tumor assessments immediately prior to 
the date of the PFS event according to RECIST v1.1, the patient will be counted as 
having progressed on the date of the first of these missing assessments.
The imputation rule will be applied to patients in alltreatment arms.  Statistical 
methodologies that are analogous to those used in the primary analysis of PFS as 
specified in Section 6.4.1 will be used for this sensitivity analysis.
6.7.2 Exploratory  Analyses of Overall Survival
[IP_ADDRESS] Loss to Follow -up
The impact of loss to follow -up on OS will be assessed depending on the number of 
patients who are lost to follow -up.  If 5% of patients are lost to follow -upfor OS in either 
treatment arm, a sensitivity analysis will be performed for the comparisons between two 
treatment arms (i.e., Arm A vs. Arm C and Arm B vs. Arm C) in which patients who are 
lost to follow -up will be considered as having died at the last d ate they were known to be 
alive.
[IP_ADDRESS] Subgroup A nalysis
To assess the consistency of the study results in subgroups defined by [CONTACT_70166] 
(e.g., age, sex, and race/ethnicity), baseline prognostic characteristics (e.g., ECOG 
performance status, presence of liver metastases at baseline), and PD -L1 tumor 
express ion status, the duration of OS in these subgroups will be examined.  Summaries 
of survival, including unstratified HRs estimated from Cox proportional hazards models 
and Kaplan -Meier estimates of median survival time, will be produced separately for 
each l evel of the categorical variables for the comparisons between two treatment arms 
(i.e., Arm A vs.Arm C and Arm B vs.Arm C) ( Lewis andClarke 2001 ).
[IP_ADDRESS] Overall Survival Rate at Three -Year Landmark
The methodologies for landmark OS analysis that are outlined in Section [IP_ADDRESS] will 
beused.
[IP_ADDRESS] Milestone Overall Survival A nalysis
To assess the effect of long -term survival and delayed clinical e ffects, a milestone OS 
analysis will be conducted ( Chen 2015 ).  The milestone OS is an OS endpoint with 
cross- sectional assessment at a pre -specified timepoint.  The milestone OS analysis will 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
146/Protocol GO29437 , Version 7be performed using the same methods as those specified for the primary OS analysis, 
and the specific definition of milestone will be documented in the SAP.
6.7.3 Exploratory  Biomarker A nalysis 
Exploratory biomarker analyses will be performed in an effort to understand the 
association of these markers with study drug response, including efficacy and/or adverse 
events.  The tumor biomarkers include, but are not limited to, PD -L1 and CD8, as 
defined by [CONTACT_4658], qRT- PCR, or other methods.  Additional pharmacodynamic analyses will 
be conducted as appropriate.
6.7.[ADDRESS_121842] -baseline PRO 
assessment.
Compliance rates will be summarized by [CONTACT_109850].  Reasons for 
non-completion will be summarized if available. 
6.8 INTERIM A NALYSES
6.8.1 Planned Interim A nalysis
There areno interim analyses planned for PFS in this study.  An external iDMC will be 
set up to evaluate safety data on an ongoing basis.  All summaries/analyses by 
[CONTACT_70097]’s review will be prepared by [CONTACT_70168].  Members of the 
iDMC will be external to the Sponsor and will follow a charter that outlines their roles and 
responsibilities.  Any outcomes of these safety reviews that affect study conduct will be 
communicated in a timely manner to the investigators for notification of the IRBs/ECs.  A 
detailed plan will be included in the iDMC Charter.
If approximately [ADDRESS_121843] occurred in Arms B and C combined in the ITT 
population at the time of the final PFS analysis (see criteria for final PFS analysis in 
Section 6.1), an interim OS analysis will be conducted for Arm B versus Arm C in the ITT 
population.  If there are significantly fewer than the expected 365 OS events at t he final 
PFS analysis, a nominal of 0.01 %(negligible impact on overall type I error rate) will be 
spent on the OS analysis at the time of the final PFS analysis and a second interim OS 
analysis will then be conducted after approximately 365 OS events ha veoccurred.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
148/Protocol GO29437 , Version 7Table 26Analysis Timing and Stoppi[INVESTIGATOR_109788] :  Arm A vs. A rmC
A.  Boundaries if difference in OS between A rm B and A rm C in the ITT population 
was statistically  significant at 0.022.
Analysis TimingStoppi[INVESTIGATOR_109789] y:  HR (p -value)
If 0.[ZIP_CODE] If 0.022
Interim OS analy sisHR0.775
(p0.0075)HR0.780
(p0.0088)
Final OS analy sisHR0.824
(p0.0171)HR0.828
(p0.0194)
HRhazard ratio; ITT intent to treat; OS overall survival. 
Note:  values and p -values are one -sided.  The p -value will be used to claim crossing of a 
boundar y.
B.  Boundaries if difference in OS between A rm B and A rm C in the ITT population 
was statistically  significant at 0.025.
Analysis TimingStoppi[INVESTIGATOR_109789] y:  HR (p -value)
If 0.022 If 0.025
Interim OS analy sisHR0.780
(p0.0088)HR0.785
(p0.0104)
Final OS analy sisHR0.828
(p0.0194)HR0.832
(p0.0219)
HRhazard ratio; ITT intent to treat; OS overall survival. 
Note:  values and p -values are one -sided.  The p -value will be used to claim crossing of a 
boundar y.
6.8.[ADDRESS_121844] the optional interim analysis, along with the rationale, timing, 
and statistical details for the analysis, will be documented in the Stat istical Analysis Plan 
(SAP), and the SAP will be submitted to relevant health authorities at least [ADDRESS_121845] of the interim analysis.  The iDMC Charter will document potential 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
149/Protocol GO29437 , Version 7recommendations the iDMC can make to the Sponsor as a result of the analysis 
(e.g., stop the study for positive efficacy, stop the study for futility), and the iDMC Charter 
will also be made available to relevant health authorities.
7. DATA COLLECTION A ND MANAGEMENT
7.[ADDRESS_121846] data clarification from the sites, which the sites 
will resolve electronically in the EDC system.
The Sponsor will produce an EDC Study Specification document that describes the 
quality checking to be performed on the data.  Central laborato ry data will be sent 
directly to the Sponsor, using the Sponsor’s standard procedures to handle and process 
the electronic transfer of these data.
eCRFs and correction documentation will be maintained in the EDC system’s audit trail.  
System backups for da ta stored by [CONTACT_40892]’s standard procedures.
7.[ADDRESS_121847] that is attributable, secure, and accurate, in compliance with U.S. FDA regulations 
for electronic records (21 Code of Federal Regulations, Part 11).  The data will be 
transmitted to a centralized database at the eP RO vendor.  The data from the ePRO 
devices are available for view access only via secure access to a W eb portal provided 
by [CONTACT_70170].  Only identified and trained users may view the data, and their 
actions become part of the audit trail.  The Sponso r will have view access only.  Regular 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
150/Protocol GO29437 , Version 7data transfers will occur from the centralized database at the vendor to the database at 
the Sponsor.
Once the study is complete, the ePRO data, audit trail, and study and system 
documentation will be archived.  The S ponsor will receive all data entered by [CONTACT_70171] e -diary and tablet device and all the study documentation.
Details regarding patient reported data and the electronic device are available in the 
Study Reference Manual.  System backups for data stored by [CONTACT_70172]’s standard procedures.
7.4 SOURCE DA TA DOCUMENT ATION
Study monitors will perform ongoing source data verification to confirm that critical 
protocol data (i.e., source data) entered into the eCRFs by [CONTACT_26831], complete, and verifiable from source documents. 
Source documents (paper or electronic) are those in which patient data are recorded 
and documented for the first time.  They include, but are not limited to, hospi[INVESTIGATOR_1097], 
clinical and office charts, laboratory notes, memoranda, patient -reported outcomes, 
evaluation checklists, pharmacy dispensing records, recorded data from automated 
instruments, copi[INVESTIGATOR_26671], microfiche, photographic negatives, microfilm or magnetic media, X -rays, 
patient files, and records kept at pharmacies, laboratories, and medico- technical 
departments involved in a clinical study.
Before study initiation, the types of source documents that are to be generated will be 
clearly defined in the Trial Monitoring Plan.  This includes any protocol data to be 
entered directly into the eCRFs (i.e., no prior written or electronic record of the data) and 
considered source data.
Source documents that are required to verify the validity and completeness of data 
entered into the eCRFs must not be obliterated or destroyed and must be retained per 
the policy for retention of records described in Sect ion7.6.
To facilitate source data verification, the investigators and institutions must provide the 
Sponsor direct access to applica ble source documents and reports for study -related 
monitoring, Sponsor audits, and IRB/EC review.  The study site must also allow 
inspection by [CONTACT_25756].
7.5 USE OF COMPUTERIZED SYSTEMS
When clinical observations are entered directly into a study site’s computerized medical 
record system (i.e., in lieu of original hardcopy records), the electronic record can serve 
as the source document if the system has been validated in accordance with health 
authority requirements pertaining to computeri zed systems used in clinical research.  An 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
151/Protocol GO29437 , Version 7acceptable computerized data collection system allows preservation of the original entry 
of data.  If original data are modified, the system should maintain a viewable audit trail 
that shows the original data as w ell as the reason for the change, the name [CONTACT_40916], and the date of the change.
7.[ADDRESS_121848] to local regulations.  
No records may be disposed of without the written approval of the Sponsor.  W ritten 
notification should be provided to the Sponsor pr ior to transferring any records to 
another party or moving them to another location.
[COMPANY_002] will retain study data for 25 years after the final Clinical Study Report has been 
completed or for the length of time required by [CONTACT_109851], whichever is longer.
8. ETHICA L CONSIDERA TIONS
8.1 COMPLIA NCE WITH LA WSAND REGULATIONS
This study will be conducted in full conformance with the ICH E6 guideline for Good 
Clinical Practice and the principles of the Declaration of Helsinki, or the laws and 
regulations of the country in which the research is conducted, whichever affords the 
greater protection to the individual.  The study will comply with the requirements of the 
ICH E2A guideline (Clinical Safety Data Management:  Definitions and Stand ards for 
Expedited Reporting).  Studies conducted in the [LOCATION_002] or under a U.S. 
Investigational New Drug (IND) Application will comply with U.S. FDA regulations and 
applicable local, state, and federal laws.  Studies conducted in the European Union or 
European Economic Area will comply with the E.U. Clinical Trial Directive (2001/20/EC).
8.2 INFORMED CONSENT
The Sponsor’s sample Informed Consent Form will be provided to each site.  If 
applicable, it will be provided in a certified translation of the local language.  The 
Sponsor or its designee must review and approve any proposed deviations from the 
Sponsor's sample Informed Consent Forms or any alternate consent forms proposed by 
[CONTACT_779] (collectively, the “Consent Forms”) before IRB/EC submission. The final 
IRB/EC -approved Consent Forms must be provided to the Sponsor for health authority 
submission purposes according to local requirements.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
152/Protocol GO29437 , Version 7The Informed Consent Form will contain a separate section that addresses the use of 
remaining samples for optional exploratory research.  The investigator or authorized 
designee will explain to each patient the objectives of the exploratory research.  Patients 
will be told that they are free to refuse to participate and may withdraw their specimens 
at any time an d for any reason during the storage period.  A separate, specific signature 
[CONTACT_22862] a patient's agreement to allow any remaining specimens to 
be used for exploratory research.  Patients who decline to participate will not provide a 
separate signature.
The Informed Consent Form will also contain the following additional signature [CONTACT_1787]:
A signature [CONTACT_70197], if approved by [CONTACT_47806], to continue treatment beyond initial radiographic d isease 
progression per RECIST v1.[ADDRESS_121849] be si gned and dated by [CONTACT_12718]’s legally 
authorized representative before his or her participation in the study.  The case history or 
clinical records for each patient shall document the informed consent process and that 
written informed cons ent was obtained prior to participation in the study.
The Consent Forms should be revised whenever there are changes to study procedures 
or when new information becomes available that may affect the willingness of the patient 
to participate.  The final rev ised IRB/EC -approved Consent Forms must be provided to 
the Sponsor for health authority submission purposes.
Patients must be re -consented to the most current version of the Consent Forms (or to a 
significant new information/findings addendum in accordance with applicable laws and 
IRB/EC policy) during their participation in the study.  For any updated or revised 
Consent Forms, the case history or clinical records for each patient shall document the 
informed consent process and that written informed consent was obtained using the 
updated/revised Consent Forms for continued participation in the study.
A copy of each signed Consent Form must be provided to the patient or the patient’s 
legally authorized representative.  All signed and dated Consent Forms must remain in 
each patient’s study file or in the site file and must be available for verification by [CONTACT_33483].
For sites in the [LOCATION_002], each Consent Form may also include patient authorization 
to allow use and disclosure of personal h ealth information in compliance with the U.S. 
Health Insurance Portability and Accountability Act (HIPAA) of 1996.  If the site utilizes a 
separate Authorization Form for patient authorization for use and disclosure of personal 
health information under the HIPAA regulations, the review, approval, and other 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
153/Protocol GO29437 , Version 7processes outlined above apply except that IRB review and approval may not be 
required per study site policies.
8.[ADDRESS_121850] be submitted to the IRB/EC by [CONTACT_9532] [INVESTIGATOR_25684]/EC before the study is initiated.  
Inaddition, any patient recruitment materia ls must be approved by [CONTACT_1201]/EC. 
The Principal Investigator [INVESTIGATOR_25685]/EC annually or more frequently in accordance with the requirements, 
policies, and procedures established by [CONTACT_1201]/EC.  Investigators are also responsible 
for promptly informing the IRB/EC of any protocol amendments (see Section 9.6).
In ad dition to the requirements for reporting all adverse events to the Sponsor, 
investigators must comply with requirements for reporting serious adverse events to the 
local health authority and IRB/EC.  Investigators may receive written IND safety reports 
or other safety -related communications from the Sponsor.  Investigators are responsible 
for ensuring that such reports are reviewed and processed in accordance with health 
authority requirements and the policies and procedures established by [CONTACT_11577]/EC, and
archived in the site’s study file. 
8.[ADDRESS_121851] parties only as permitted by [CONTACT_25734] (or separate 
authorization for use and disclo sure of personal health information) signed by [CONTACT_102], 
unless permitted or required by [CONTACT_2371].
Medical information may be given to a patient’s personal physician or other appropriate 
medical personnel responsible for the patient’s welfare, for treatment purposes.
Data generated by [CONTACT_26832] U.S. FDA and other national and local health authorities, Sponsor 
monitors, representatives, and collaborators, and the IRB/EC for each study sit e, as 
appropriate.
8.5 FINA NCIA L DISCLOSURE
Investigators will provide the Sponsor with sufficient, accurate financial information in 
accordance with local regulations to allow the Sponsor to submit complete and accurate 
financial certification or disclosure s tatements to the appropriate health authorities.  
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
154/Protocol GO29437 , Version 7Investigators are responsible for providing information on financial interests during the 
course of the study and for [ADDRESS_121852] of 
the study to be fully documented, including but not limited to the protocol, protocol 
amendments, Informed Consent Forms, and documentation of IRB/E C and 
governmental approval.  In addition, at the end of the study, the investigator will receive 
the patient data, including an audit trail containing a complete record of all changes to 
data.
9.[ADDRESS_121853] on patient safety and 
data integrity to the Sponsor and to the IRB/EC in accordance with established IRB/EC 
policies and procedures.   The Sponsor or a designee will review all protocol deviations 
and assess whether any represent a serious breach of Good Clinical Practice guidelines 
and require reporting to health authorities.  As per the Sponsor's standard operating 
procedures, prospective requests to deviate from the protocol, including requests to 
waive protocol eligibility criteria, are not allowed.
9.3 SITE INSPECTIONS
Site visits will be conducted by [CONTACT_26833], patients’ medical records, and eCRFs.  The investigator will 
permit national and local health authorities, Sponsor monitors, representatives, and 
collaborators, and the IRBs/ECs to inspect facilities and records relevant to this study.
9.4 ADMINISTRA TIVE STRUC TURE
This study will be sponsored and managed by F. Hoffmann -La [COMPANY_002] Ltd.  
Approximately 310 sites globally will participate in the study and approximately 
1025 patients will be randomized.
Randomization will occur through an IxRS.  Central facilities will be used for study 
assess ments throughout the study (e.g., specified laboratory tests and PK analyses).  
Accredited local laboratories will be used for routine monitoring; local laboratory ranges 
will be collected.
9.5 PUBLICA TION OF DATA  AND PROTECTION OF 
TRADESECRETS
Regardless of the outcome of a study, the Sponsor is dedicated to openly providing 
information on the study to healthcare professionals and to the public, both at scientific 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
155/Protocol GO29437 , Version 7congresses and in peer -reviewed journals. The Sponsor will comply with all 
requirements for publication of study results.  For more information, refer to the [COMPANY_002] 
Global Policy on Sharing of Clinical Trials Data at the following W eb site:
http:// www.roche.com/roche_global_polic y_on_sharing_of_clinical_study_information.pdf
The results of this stud y may be published or presented at scientific congresses.  For all 
clinical studies in patients involving an IMP for which a marketing authorization 
application has been filed or approved in any country, the Sponsor aims to submit a 
journal manuscript repo rting primary clinical study results within [ADDRESS_121854] editorial and ethical practice, the Sponsor will generally 
support publication of multicenter studies only in their entirety and not as individual 
center data.  In this case, a coordinating investigator [INVESTIGATOR_9231].
Authorship will be determined by [CONTACT_109852]’ authorship requirements.  Any formal publication 
of the study in which contribution of Sponsor personnel exceeded that of conv entional 
monitoring will be considered as a joint publication by [CONTACT_26834].
Any inventions and resulting patents, improvements, and/or know -how originating from 
the use of data from this study will become and re main the exclusive and unburdened 
property of the Sponsor, except where agreed otherwise.
9.6 PROTOCOL A MENDMENTS
Any protocol amendments will be prepared by [CONTACT_1034].  Protocol amendments will 
be submitted to the IRB/EC and to regulatory authorities in acc ordance with local 
regulatory requirements.
Approval must be obtained from the IRB/EC and regulatory authorities (as locally 
required) before implementation of any changes, except for changes necessary to 
eliminate an immediate hazard to patients or change s that involve logistical or 
administrative aspects only (e.g., change in Medical Monitor or contact [CONTACT_3031]).
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
156/Protocol GO29437 , Version 710. REFERENCES
Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research 
and Treatment of Cancer QLQ -C30: a quality -of-life instrument for use in 
international clinical trials in oncology. J Natl Cancer Inst 1993;85:365 76.
Amit O, Mannino F, Stone AM, et al. Blinded independent central review of progression 
in cancer clinical trials: results from a meta -analysis. Eur J Cancer 2011;47:1772 8. 
doi: 10.1016/j.ejca.2011.02.013. Epub: 21March 2011.
Antonia SJ, Brahmer JR, Gettinger S, et al.  Nivolumab (anti -PD-1; BMS -936558, 
ONO- 4538) in combination with platinum -based doublet chemotherapy (PT -DC) in 
advanced non -small cell lung cancer (NSCLC). J Clin Oncol 2014;32:abstract 8113.
Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll -like receptor 4- dependent contribution of 
the immune system to anti -cancer chemotherapy and radiotherapy. Nat Med 
2007;13:1050 9.
Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin versus carboplatin -based chemotherapy in 
first-line treatment of advanced non small cell lung cancer: an individual patient 
data meta- analysis. J Natl Cancer Inst 2007;99:847 57.
Azzoli CG, Baker Jr S, Temin S, et al. American Society of Clinical Oncology Clinical 
Practice Guideline update on chemotherapy for Stage IV non small -cell lung 
cancer. J Clin Oncol 2009;27:6251 66.
Azzoli CG, Kris MG, Pfister DG. Cisplatin versus carboplatin for patients with metastatic 
non small -cell lung cancer an old rivalry renewed. J Natl Cancer Inst 
2007:99:828 9.
Bai S, Jorga K, Xin Y, et al. A guide to rational dosing of monoclonal antibodies. Clin 
Pharmacokinet 2012;51:119 35.
Bepler G, Kusmartseva I, Sharma S, et al. RRM1 modulated in vitro and in vivo efficacy 
of gemcitabine and platinum in non small -cell lung cancer. J Clin Oncol 
2006; 24:4731 7.
Bergman B, Aaronson NK, Ahmedzai S, et al. The EORTC QLQ -LC13: a modular 
supplement to the EORTC Core Quality of Life Questionnaire (QLQ -C30) for u se in 
lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 
1994;30A:635 42.
Besse B, Johnson M, Janne PA, et al. Phase II, single -arm trial (BIRCH) of atezolizumab 
as first -line or subsequent therapy for locally advanced or metastatic 
PD-L1selected non small cell lung cancer (NSCLC) [abstract]. Eur J Cancer 
2015;51(Suppl 3):S717 18.
Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated 
with erlotinib: quality of life analysis of the National C ancer Institute of Canada 
Clinical Trials Group Study BR21. J Clin Oncol 2006;24:3831 7.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
157/Protocol GO29437 , Version 7Blank C, Gajewski TF, Mackensen A. Interaction of PD -L1 on tumor cells with PD -1 on 
tumor -specific T cells as a mechanism of immune evasion: implications for tumor 
immunotherapy. Cancer Immunol Immunother 2005;54:307 14.
Blank C, Mackensen A. Contribution of the PD -L1/PD -[ADDRESS_121855] to T -cell exhaustion: 
anupdate on implications for chronic infections and tumor evasion. Cancer 
Immunol Immunother 2007;56:739 45.
Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics 
1982;38:29 41.
Burman CF, Sonesson C, Guilbaud O, et al. A recycling framework for the construction
of Bonferroni -based multiple tests. Stat Med 2009;28:739 61.
Butte MJ, Keir M E, Phamduy TB. Programmed death ligand 1 interacts specifically with 
the B7 -1 costimulatory molecule to inhibit T cell responses. Immunity 
2007;27:111 22.
Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation 
of a simple formula based on renal function. JClinOncol 1989;7:1748 56.
Camidge DR, Bang Y, Kwak EL, et al. Activity and safety of crizotinib in patients with 
ALK-positive non -small cell lung cancer: updated res ults from a Phase I study. 
Lancet Oncol 2012;13:1011 9.
Cappuzzo F, Ciuleanu T, Stelmakh L, et al. and the SATURN Investigators. Erlotinib as 
maintenance treatment in advanced non small -cell lung cancer: a multicentre, 
randomised, placebo -controlled phase 3 study. Lancet Oncol 2010;11:521 9.
Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared 
with other histotypes shows higher messenger RNA and protein levels for 
thymidylate synthase. Cancer 2006;107:1589 96.
Cetin K, Ettinge r DS, Hei YJ, et al. Survival by [CONTACT_33485], Epi[INVESTIGATOR_33407]. Clin Epi[INVESTIGATOR_5541] 2011;3:139 48.
Chen DS, Irving BA, Hodi FS. Molecular pathways: next -generat ion 
immunotherapy inhibiting programmed death -ligand 1 and programmed death -1. 
ClinCancer Res 2012;18:6580 7.
Chen TT. Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint 
Inhibitors. J Natl Cancer Inst 2015;107: djv156.
Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best 
supportive care versus placebo plus best supportive care for non -small -cell lung 
cancer: a randomised, double -blind, phase 3 study. Lancet 2009;374:1432 40.
Cockcroft D W, Gault MH. Prediction of creatinine clearance from serum creatinine. 
Nephron 1976;16:31 41.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
158/Protocol GO29437 , Version 7Crino L, Kim D, Riely GJ, et al. Initial Phase II results with crizotinib in advanced 
ALK-positive non -small cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol 
2011;29:abstr act 7514.
D’Addario G, Fruh M, Reck M, et al. Metastatic non -small -cell lung cancer: ESMO 
Clinical Practice Guidelines for diagnosis, treatment and follow -up. Ann Oncol 
2010;21:v115 9.
De Marinis F, Rossi A, Di Maio M, et al. Treatment of advanced non smal l-cell lung 
cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines. 
Lung Cancer 2011;73:1 10.
Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest 
2009;136:260 71.
Di Giacomo AM, Biagioli M, Maio M. Th e emerging toxicity profiles of anti CTLA -4
antibodies across clinical indications. Semin Oncol 2010;37:499 507.
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid 
tumours: revised RECIST guideline (version 1.1). EurJCancer 2009;45:228 47.
Ellis LM, Bernstein DS, Voest EE, et al. American Society of Clinical Oncology 
perspective: raising the bar for clinical trials by [CONTACT_70179]. J Clin Oncol 2014;32:1277 80.
European Medicines Agency. Guideline on the evaluation of anti -cancer medicinal 
products in man. EMA/CHPM/205/95/Rev.4 (December 2012). 
[FDA] U.S. Food and Drug Administration. Clinical trial endpoints for the approval of 
non small cell lung cancer drugs and biologics: guidance for industry. Fed Regist 
2015;80:[ZIP_CODE] 7.
Fehrenbacher L, Spi[INVESTIGATOR_20116] A, Ballinger M, et al., for the POPLAR Study Group. 
Atezolizumab versus docetaxel for patients with previously treated non -small -cell 
lung cancer (POPLAR): a multicentr e, open -label, phase 2 randomised controlled 
trial. Lancet 9 March 2016;1 10. (Epub ahead of print.)
Fitzsimmons D, Johnson CD, George S, et al. Development of a disease specific quality 
of life (QoL) questionnaire module to supplement the EORTC core cancer QoL 
questionnaire, the QLQ -C30 in patients with pancreatic cancer. EORTC Study 
Group on Quality of Life. Eur J Cancer 1999;35:939 41.
Fukuoka M, W u YL, Thongprasert S, et al. Biomarker analyses and final overall survival 
results from a Phase III, ra ndomized, open -label, first -line study of gefitinib versus 
carboplatin/paclitaxel in clinically selected patients with advanced non small -cell 
lung cancer in Asia (IPASS). J Clin Oncol 2011;29:2866 74.
Gandara D.R., Grimminger P.P., Mack P.C., et al. Histology -and gender -related 
associations of ERCC1, RRM1, and TS biomarkers in 1,802 patients with NSCLC: 
Implications for therapy. J Clin Oncol (Meeting Abstracts) 2010;28:7513.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
159/Protocol GO29437 , Version 7GLOBOCAN 2008. Estimated cancer incidence: mortality, prevalence and 
disability -adjusted life years (DALYs) worldwide in 2008.  Available at: 
http://globocan.iarc.fr/factsheets/ cancers /lung.asp.
Gong W, Zhang X, Wu J, et al. RRM1 expression and clinical outcome of 
gemcitabine- containing chemotherapy for advanced non small -cell lung cancer: a 
meta -analysis. Lung Cancer 2012:75;374 80.
Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and 
Biologics; May 2007.
Hales RK, Banchereau J, Ribas A, et al. Assessing oncologic benefit in clinical trials of 
immunot herapy agents. Ann Oncol 2010;21:1944 51.
Herbst RS, Baas P, Kim D W, et al. Pembrolizumab versus docetaxel for previously 
treated, PD -L1-positive, advanced non -small -cell lungcancer (KEYNOTE -010): a 
randomized controlled trial Lancet 2016; 387:1540 50. 
doi:10.1016/S0140 -6736(15)[ZIP_CODE] -7. Epub: [ADDRESS_121856] RS, Heymach JV, Lippman SM. Lung Cancer. N Engl J Med 2008;359:1367 80.
Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the 
anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563 67.
Higgs B W, Robbins PB, Blake- Haskins JA, et al. High tumoral IFN mRNA, PD -L1 
protein, and combined IFN mRNA/PD -L1 protein expression associates with 
response to durvalumab (anti -PD-L1) monotherapy in NSCLC patients. Eur J 
Cancer 2015;51(Suppl 3):S717.
Hirsch FR, Spreafico A, Novello S, et al. The prognostic and predictive role of histology 
in advanced non small cell lung cancer: a literature review. J Thorac Oncol 
2008;3:1468 81.
Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipi[INVESTIGATOR_33410]. N Engl J Med 2010;363:711 23.
Hopwood P, Stephens RJ. Symptoms at pr esentation for treatment in patients with lung 
cancer: implications for the evaluation of palliative treatment. The Medical 
Research Council (MRC) Lung Cancer W orking Party. Br J Cancer 1995;71:633 6.
Horn L, Spi[INVESTIGATOR_43942], Gettinger SN, et al. Clinical activi ty, safety and predictive biomarkers 
of the engineered antibody MPDL3280A (anti -PDL1) in non small cell lung cancer 
(NSCLC): update from a phase Ia study. J Clin Oncol 2015;33(suppl):abstr 8029. 
[[ZIP_CODE]].
Hotta K, Matsuo K, Ueoka H, et al. Meta -analysis of randomized clinical trials comparing 
cisplatin to carboplatin in patients with advanced non- small cell lung cancer. J Clin 
Oncol 2004;22:3852 9.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
160/Protocol GO29437 , Version 7Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975 2011, 
National Cancer Institute. Be thesda, MD, http://seer.cancer.gov/csr/1975_2011/, 
based on November [ADDRESS_121857] 1974;65:299 306.
Jemal A, Bray F, Center MM, et al. Glob al Cancer Statistics. CA Cancer 
JClin2011;61:69 90.
Jiang J, Liang X, Zhou, et al. A meta -analysis of randomized controlled trials comparing 
carboplatin- based to cisplatin -based chemotherapy in advanced non small cell 
lung cancer. Lung Cancer 2007;57:348 58.
Kantoff P W, Higano CS, Shore ND, et al. Sipuleucel -T immunotherapy for 
castration -resistant prostate cancer. N Engl J Med 2010;363:411 22.
Keir ME, Butte MJ, Freeman GJ, et al. PD -1 and its ligands in tolerance and immunity. 
Annual Rev Immunol 2008;26:677 704.
Koren E, Smith H W, Shores E, et al. Recommendations on risk -based strategies for 
detection and characterization of antibodies against biotechnology products. 
JImmuno Methods 2008;333:1 9.
Langer CJ, Besse B, Gualberto A, et al. The evolving role of histology in the 
management of advanced non small -cell lung cancer. J Clin Oncol 
2010;28:5311 20.
Laporte S, Squifflet P, Baroux N, et al. Prediction of survival benefits from 
progression -free survival benefits in advanced non small cell lung cancer: 
evidence from a meta -analysis of 2334 patients from 5 randomized trials. BMJ 
Open 2013;3:1 6.
Lewis S, Clarke M. Forest plots: trying to see the wood and the trees. BMJ 
2001;322:1479 80.
Liu SV, Powderly JD, Camidge DR, et al. Safety and efficacy of MPDL3280A (anti-PDL1) 
in combination with platinum -based doublet chemotherapy in patients with 
advanced non small cell lung cancer. J Clin Oncol 2015;33(suppl), abstr 8030.
Merritt RE, Mahtabifard A, Yamada RE, et al. Cisplatin augments cytotoxic 
T-lymphocyte -mediated antitumor immunity in poorly immunogenic murine lung 
cancer. J Thorac Cardiovasc Surg 2003;126:1609 17.
Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, 
metastatic non small -cell lung cancer aft er failure of erlotinib, gefitinib, or both, 
and one or two lines of chemotherapy (LUX -Lung 1): a phase 2b/3 randomised trial. 
Lancet Oncol 2012;12:528 38.
Molina JR, Yang P, Cassivi SD, et al. Nonsmall cell lung cancer: epi[INVESTIGATOR_623], risk 
factors, treatm ent, and survivorship. Mayo Clin Proc 2008;83:584 94.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
161/Protocol GO29437 , Version 7Mu C- Y, Huang J- A, Chen Y et al. High expression of PD -L1 in lung cancer may 
contribute to poor prognosis and tumor cells immune escape through suppressing 
tumor infiltrating dendritic cells maturation. Med Oncol 2011;28:682 8.
Muro K, Bang Y -J, Shankaran V, et al. Relationship between PD -L1 expression and 
clinical outcomes in patients (Pts) with advanced gastric cancer treated with the 
anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK -3475) in 
KEYNOTE -012. [abstract] . J Clin Oncol 2015;33(suppl 3; abstr 3) .
National Comprehensive Cancer Network®(NCCN®). Guidelines for non -small cell lung 
cancer 2014.
NonSmall Cell Lung Cancer Collaborative Group. Chemotherapy in non -small cell lung 
cancer: a meta -analysis using updated data on individual patients from 
52randomised clinical trials. BMJ 1995;311:899 909.
Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in 
health- related quality -of-life scores. J Clin Oncol 1998;16:139 44.
Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology 
treatment of unresectable non -small -cell lung cancer guideline: update 2003. JClin 
Oncol 2004;22:330– 53.
Pi[INVESTIGATOR_70041] R, Pereira JR, Szczesna A, et al. Cetuximab plus chemothera py in patients with 
advanced non -small -cell lung cancer (FLEX): an open -label randomised Phase III 
trial. Lancet 2009 ;373:1525 31.
Reck M, Rodríguez -Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy 
for PD -L1-Positive Non -Small -Cell Lung Cancer. N Engl J Med. [ADDRESS_121858] 8. [Epub 
ahead of print].
Rittmeyer A, Barlesi F, W aterkamp D, et al. Atezolizumab versus docetaxel in patients 
with previously treated non -small cell lung cancer (OAK): a phase 3, open -label, 
multicentre randomised controlled trial. Lancet 2017;389:255 65. doi :  
10.1016/S0140 -6736(16)[ADDRESS_121859]-line treatment for European patients with advanced EGFR mutation -positive 
non-small -cell lung cancer (EURTAC): a multicentre, open -label, randomised 
phase 3 trial. Lancet Oncol 2012;13:239 46. 
Rosell R, Danenberg KD, Alberola V, et al. Ribonucleotide reductase messenger RNA 
expression and survival in gemcitabine/cisplatin -treated a dvanced non -small cell 
lung cancer patients. Clin Cancer Res 2004;10:1318 –25.
Rosenberg AS, W orobec AS. A risk -based approach to immunogenicity concerns of 
therapeutic protein products. BioPharm Intl 2004; Nov:2226;Dec:34 42.
Sandler A, Gray R, Perry MC, et al. Paclitaxel –carboplatin alone or with bevacizumab for 
non– small -cell lung cancer. N Engl J Med 2006;355:2542 50.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
162/Protocol GO29437 , Version 7Sarna L, Evangelista L, Tashkin D, et al. Impact of respi[INVESTIGATOR_70071] -term survivors of non-small cell lung cancer. 
Chest 2004;125:439 45.
Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus 
gemcitabine with cisplatin plus pemetrexed in chemotherapy -naive patients with 
advanced -stage non– small -cell lung cancer. J Clin Oncol. 2008;26:3543– 51.
Schiller JH, Harrington D, Belani CP, et al. Eastern Cooperative Oncology Group. 
Comparison of four chemotherapy regimens for advanced non– small -cell lung 
cancer. NEngl J Med 2002;346:92 8.
Seiwert TY, Haddad RI, Gupta S, et al. Antitumor activity and safety of pembrolizumab in 
patients (pts) with advanced squamous cell carcinoma of the head and neck 
(SCCHN): preliminary results from KEYNOTE -012 expansion cohort [abstract]. J 
Clin Oncol 2015; 33(suppl; abstr LBA6008) .
Sequist LV, Yang JC -H, Yamamo N, et al. Phase III Study of Afatinib or Cisplatin Plus 
Pemetrexed in Patients W ith Metastatic Lung Adenocarcinoma W ith EGFR 
Mutations. J Clin Oncol 2013;31:3327 38.
Shaw AT, Engelman JA. Ceritinib in ALK-rearranged non -small -cell lung cancer. N Engl 
J Med; 2014;370: 25379.
Shaw AT, Kim D W, Nakagawa K, et al. Phase III study of crizotinib versus pemetrexed 
or docetaxel in patients with advanced ALK -positive non -small cell lung cancer 
(NSCLC). European Society of Medical Oncology Meeting 2012:abstract LBA1 PR.
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 
2012;62:10 29.
Smith DA, Vansteenkiste JF, Fehrenbacher L, et al. Updated survival and biomarker 
analyses of a randomized phase II study of atezolizumab vs docetaxel in 2L/3L 
NSCLC (POPLAR)[abstract]. J Clin Oncol 2016;34(suppl):abstr 9082
Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the 
use of white blood cell growth factors: an evidence -based clinical practice 
guideline. J Clin Oncol 2006;24:3187 205.
Socinski MA, Bondarenki I, Karaseva NA, et al. Weekly nab -paclitaxel in combination 
with carboplatin versus solvent -based paclitaxel plus carboplatin as first -line 
therapy in patients with advanced non -small -cell lung cancer: final results of a 
phase III trial. J Clin Oncol 2012;30:2055 62.
Spi[INVESTIGATOR_43942], Chaft JE, Gettinger SN, et al. Clinical activity and safety from a phase II 
study (FIR) of MPDL3280A (anti -PDL1) in PD -L1selected patients with non small 
cell lung cancer (NSCLC). J Clin Oncol. 2015;33(suppl; abstr 8028).
Spi[INVESTIGATOR_26189], Rudd RM, Souhami RL, et al. Chemotherapy versus supportive care in 
advanced non -small cell lung cancer: improved survival without detriment to quality 
of life. Thorax 2004;59:828 –36.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
163/Protocol GO29437 , Version 7Stinchcombe TE, Socinski MA. Maintenance therapy in advanced non -small cell lung 
cancer: current status and future implications. J Thorac Oncol 2011;6:174 82.
Stinchcombe TE, Socinski MA, Lee CB, et al. Considerations for second -line therapy 
ofnon-small cell lung cancer. Oncologist 2008;13:128 36.
TARCEVA®(erlotinib) tablets, for oral use, Genentec h, Inc. 2015 [cited 21 Jul 2015] 
Available from http://www.gene.com/download/pdf/tarceva_prescribing.pdf.
TAXOTERE®(docetaxel) Injection Concentrate Summary of Product Characteristics, 
Aventis Pharma S.A. [Cited 21 Jul 2015]. Available from: 
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/000073/W C500035264.pdf.
Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with 
metastatic non -small -cell lung cancer. N Engl J Med 2010;363:733 42.
Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of 
antiPD-1 antibody in cancer. N Engl J Med 2012;366:2443 54.
Travis W D, Brambilla E, Noguchi M, et al. International association for the study of lung 
cancer/american thoracic soci ety/european respi[INVESTIGATOR_33411]. JThorac Oncol 
2011;6:244– 85.
Treat JA, Gonin R, Socinski MA, et al. A randomized, phase III multicenter trial of 
gemcitabine in combination with carbop latin or paclitaxel versus paclitaxel plus 
carboplatin in patients with advanced or metastatic non -small -cell lung cancer. Ann 
Oncol 2010;21:540– 7.
Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy 
activity in solid tumors : immune -related response criteria. Clin Can Res 
2009;15:7412 20.
XALKORI®(crizotinib) Package Insert, [COMPANY_007].
Yang J, Riella LV, Chock S. The novel costimulatory programmed death ligand 1/B7.[ADDRESS_121860] is functional in inhibiting alloimmune responses in v ivo. J Immunol 
2011;187:1113 9.
Yang JC, Hirsh V, Schuler M, et al. Symptom control and quality of life in LUX -Lung 3: a 
phase III study of afatinib versus pemetrexed and cisplatin as first -line treatment 
afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma 
with EGFR mutations. JClin Oncol 2013;3 1:3342 50.
ZYKADIA (ceritinib) Package Insert, [COMPANY_001].
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
164/Protocol GO29437 , Version 7Appendix 1
Schedule of A ssessments
ProcedureScreening All Treatment Cy cles aTreatment 
Discontinuation
Visit Survival Follow -Up 
Days – 28
to –1Induction Phase
(Cycles 1 to 4 
or 6)Maintenance 
Phase[ADDRESS_121861] Dose of 
Study TreatmentEvery 3 Months 
after Disease 
Progression or Loss 
of Clinical BenefitEvery 21 days
(3 Days) bEvery 21 days
(3 Days) 
Informed consent x
Tumor tissue specimen for PD -L1 testing 
(15FFPE slides required; blocks preferred) c
Fresh or archival tissue can be usedx
Demographic data x
Medical histor y and baseline conditions x
NSCLC cancer history x
Vital signsdx x x x
Weight x x x x
Height x
Complete physical examination x
Limited physical examination ex x x
ECOG performance status x x x x
12-Lead ECG x x fx fx f
Hematologygx x x x
Serum chem istryhx x x x
Appendix 1
Schedule of A ssessments (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
165/Protocol GO29437 , Version 7ProcedureScreening All Treatment Cy cles aTreatment 
Discontinuation
Visit Survival Follow -Up 
Days – 28
to –1Induction Phase
(Cycles 1 to 4 
or 6)Maintenance 
Phase[ADDRESS_121862] Dose of 
Study TreatmentEvery 3 Months 
after Disease 
Progression or Loss 
of Clinical BenefitEvery 21 days
(3 Days) bEvery 21 days
(3 Days) 
Coagulation test (aPTT or INR) x x
Pregnancy test (women of childbearing- potential 
ONLY)xixjxjxjxy
TSH, freeT3, free T4kx xkxkx
HIV, HBV, HCV serologylx
Urinalysismx x x x
Determination of duration of induction treatment x
Induction treatment administration
(Arm A: Atezolizumab carboplatin paclitaxel
Arm B: Atezolizumab carboplatin nab-paclitaxel
Arm C: Carboplatin nab-paclitaxel)xn
Maintenance treatment administration
Arm A: Atezolizumab
Arm B: Atezolizumab
Arm C: Best supportive care oxn
Tumor response assessment xpxqxqxr
Serum samplefor ATA assessment x x x 120 ( 30)days 
Appendix 1
Schedule of A ssessments (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
166/Protocol GO29437 , Version 7ProcedureScreening All Treatment Cy cles aTreatment 
Discontinuation
Visit Survival Follow -Up 
Days – 28
to –1Induction Phase
(Cycles 1 to 4 
or 6)Maintenance 
Phase[ADDRESS_121863] Dose of 
Study TreatmentEvery 3 Months 
after Disease 
Progression or Loss 
of Clinical BenefitEvery 21 days
(3 Days) bEvery 21 days
(3 Days) 
(atezolizumab -treated patients only)safter last dose
Serum samplefor PK sampling
(atezolizumab -treated patients only)sx x x120 ( 30)days 
after last dose
Carboplatin, paclitaxel, and nab -paclitaxel PK 
sampling as applicable (20 patients per arm)sx
Blood samples for PD bio markers s
x x x x120 ( 30)days 
after last dose
Optional blood for DNA extraction 
(RCR only) s, tx
Informed consent to continue treatment beyond 
radiographic progression (atezolizumab -treated 
patients only)At time of radiographic progression
Tumor biopsy At time of radiographic progressionu
Optional tumor biops y at other timepoints 
(RCR only)Any tim e during study treatment or during survival follow -up
Adverse eventsvx x x xv
Appendix 1
Schedule of A ssessments (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
167/Protocol GO29437 , Version 7ProcedureScreening All Treatment Cy cles aTreatment 
Discontinuation
Visit Survival Follow -Up 
Days – 28
to –1Induction Phase
(Cycles 1 to 4 
or 6)Maintenance 
Phase[ADDRESS_121864] Dose of 
Study TreatmentEvery 3 Months 
after Disease 
Progression or Loss 
of Clinical BenefitEvery 21 days
(3 Days) bEvery 21 days
(3 Days) 
Concomitant medications From  7 days 
before 
screeningx x x
Patient- reported outcomeswxwx wx w
Survival and anti -cancer therapy follow -up xx
ATAanti-therapeutic antibody; BSC best supportive care; ECOG Eastern Cooperative Oncology Group; EORTC European Organization for 
Research and Treatment of Cancer; EQ -5D-3LEuro QoL5 Dimensions 3 -Level Version; FFPE formalin -fixed paraffin -embedded; HBcAb hepatitis 
B core antibody; HBV hepatitis B virus; HCV hepatitis C virus; ICF Informed Consent Form; IV intravenous; QLQ -LC13 Lung Cancer module; 
NSCLC non small cell lung cancer; PD pharmacodynamic; PD -L1programmed death ligand 1; PGIS Patient Global Impression of Severity; 
PKpharmacokinetic; QLQ -C30Qualit y-of-Life Questionnaire Core 30; SILC Symptoms in Lung Cancer; EQ -5D-3 Level version; 
TSHthyroid-stimulating hormone.
Note:  For patients who are randomized to Arm C who receive erlotinib switch maintenance allowed under previous protocol versions , patients will 
continue with cycle visits at the same frequency as those patients randomized to Arms A and B until disease progression, with drawal of consent, 
death, or study termination by [CONTACT_1034], whichever occurs first.
aAssessments should be performed before study drug infusion unless otherwise noted. 
bExcept for Cycle 1, Day 1, which must be performed within 5 days after the patient is randomized. In addition, ECOG performance status, limited 
physical examination, and local laborator y tests may be performed  96 hours before Day 1 of each cycle as specified in Section [IP_ADDRESS] .  
Screening assessmen ts performed 96 hours before Cycle 1, Day 1, do not need to be repeated for Cycle 1 Day 1.
Appendix 1
Schedule of A ssessments (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
168/Protocol GO29437 , Version 7cIf a representative FFPE tumor specimen in paraffin block (preferred) or 15 (or more) unstained, freshly cut, serial sections on slides from an FFPE 
tumor specimen are not available for PD -L1 testing, contact [CONTACT_109853].  
Fine- needle aspi[INVESTIGATOR_1516] ( defined as samples that do not preserve tissue architecture and yiel d cell suspension and/or cell smears ), brushing, cell 
pellets from pleural effusion, and lavage samples are NOT acceptable.  For core needle biopsy specimens, at least three cores should be 
submitted for evaluation .  Retrieval of archival tumor sample may  occur outside the 28 -day screening period p rior to enrollment.  See 
Section [IP_ADDRESS] and the inclusion criteria in Section 4.1.1 . 
dVital signs include pulse rate, respi[INVESTIGATOR_697], blood pressures, and temperature.  Vital signs should be recorded as described in Section 4.5.4 .  
Forall sites in Argentina, pulse oximetry  will be performed at ever y visit; these data will not be recorded.
eSymptom-directed phy sical examinations; see Section 4.5.3 for details.
fECG recordings will be obtained when clinically indicated.
gHematology consists of CBC, including RBC count, hemoglobin, hematocrit, W BC count with differential (neutrophils, ly mphocytes, eosinophils, 
monocy tes, basophils, and other cells), and platelet count.  Hematology tests must be performed prior to Day 1 infusions and for nab -paclita xel 
administration, also prior to Day 8 and Day 15 infusions.   See Section [IP_ADDRESS] (Table 19) for dose modifications due to hematological toxicities.
hSerum chemistry  includes BUN, creatinine, sodium, potassium, magnesium, chloride, bicarbonate or total CO 2, calcium, phosphorus, glucose, 
total bilirubin, ALT, AST, alkaline phosphatase, LDH, total protein, and albumin.  See Section [IP_ADDRESS] (Table 23) for dose modifications due to 
serum chemistry  toxicities.
iSerum pregnanc y test within 14 day s before Cycle 1, Day 1.
jUrine pregnancy tests; if aurine pregnanc y test is positive, it must be confirmed by a serum pregnancy test.
kThyroid-function testing (thyroid -stimulating hormone, free T3, free T4) collected at C ycle 1, Day 1, and every fourth cycle thereafter.   Total T3 to 
be tested only at sites where free T3 testing cannot be performed.
lAll patients will be tested for HIV prior to the inclusion into the study and HIV -positive patients will be excluded from the clinical study. Patients with 
active hepatitis B (chronic or acute; defined as having a positive HBsAg test result at screening) will be excluded from the study.  Patients wi th past 
or resolved HBV infection (defined as the presence of HBcAb and absence of HBsAg) are eligible only if their HBV DNA test i s negative .  Patients 
with HCV will be excluded from the study; patients who test positive for HCV antibody are eligible only if polymerase chain r eaction is negative for 
HCV RNA.
mUrinalysis by [CONTACT_5230] (specific gravity, pH, glucose, protein, ketones, a nd blood).
nFor atezolizumab, the initial dose will be delivered over 60 ( 15) minutes.  If the first infusion is well tolerated, all subsequent infusions may be 
delivered over 30 ( 10)minutes.  For carboplatin, paclitaxel, and nab -paclitaxel, study dr ug will be administered according to the local prescribing 
information , including premedication with steroids (see Section 4.3.2 ).
Appendix 1
Schedule of A ssessments (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
169/Protocol GO29437 , Version 7oOnly patients who are already receiving switch maintenance therapy with erlotinib, permitted under previous protocol versions , may  be allowed to 
remain on treatment with erlotinib after d iscussion of the risks, potential benefits, and alternative treatment options with the investigator.
pCT scans (with oral/IV contrast unless contraindicated) or MRI of the chest and abdomen.  A CT or MRI scan of the pelvis is required at screening 
and as clinically indicated or as per local standard of care at subsequent response evaluations.  A CT (with contrast) or MRI scan o f the head must 
be done at screening to evaluate CNS metastasis in all patients.  See Section 4.5.5 for details.
qPerform every 6 weeks ( 7 day s) (approximately every two cycles) for 48 weeks following C ycle 1, Day 1, and then, after completion of the 
Week48 tum or assessment, every 9 weeks ( 7 day s)regardless of treatment delays, until radiographic disease progression (loss of clinical 
benefit for patients assigned to atezolizumab who continue treatment after disease progression according to RECIST v1.1), wit hdrawal of consent, 
death, or study termination by [CONTACT_1034], whichever occurs first.  See Section 4.5.[ADDRESS_121865] v1.1 (e.g., toxicity, s ymptomatic 
deterioration , tumor assessmen ts will continue at the same frequency as would have been followed if the patient had remained on study treatment 
until radiographic disease progression (loss of clinical benefit for patients treated with atezolizumab who continue treatmen t after disease 
progression according to RECIST v1.1), withdrawal of consent, death, or study termination by [CONTACT_1034], whichever occurs fir st, even if patient 
starts another anti -cancer therapy after study treatment discontinuation.
sSee Appendix 2for the detailed schedule.
tThe optional RCR whole blood sample requires an additional informed consent and can be collected at any time during the course o f the study.
uMandator y tum or biopsy at radiographic disease progression, if clinically feasible, within [ADDRESS_121866] dose of study treatment (inclusive of erlotinib switch maintenance for patients who are randomized to Arm C who receive switch maintenance 
allowed under previous protocol versions ) or initiation of new systemic anti-cancer therapy after last dose of study treatment .  All other adverse 
events, regardless of relationship to study drug, will be reported unti l [ADDRESS_121867] dose of study treatment (inclusive of erlotinib switch 
maintenance for patients who are randomized to Arm C who receive switch maintenance allowed under previous protocol versions ) or initiation of 
new sy stemic anti-cancer therapy after last dose of study treatment .  After this period, ,all deaths should continue to be reported.  In addition, the 
Sponsor should be notified if the investigator becomes aware of any serious adverse event or adverse event of special interes t that is be lieved to 
be related to prior exposure to study treatment (see Section 5.6).
Appendix 1
Schedule of A ssessments (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
170/Protocol GO29437 , Version 7wEORTC QLQ -C30, EORTC QLQ -LC13, PGIS, and EQ -5D-3L questionnaires wil l be completed by [CONTACT_109854](s).  SILC will be completed using an ePRO device at the patient’s 
home on a weekly basis.  During survival follow -up, the EORTC QLQ -C30, EORTC QLQ -LC13, and EQ -5D-3L will be completed at [ADDRESS_121868] v1.1 (or loss of clinical benefit for atezolizumab -treated patients 
who hadcontinue dtreatment with atezolizumab after radiographic disease progression) as determined by [CONTACT_093] (unless the patient 
withdraws consent or the Sponsor terminates the study). Study  personnel should review all questionnaires for completeness before the patient 
leaves the investig ational site. Patients whose native language is not available in the ePRO device or who are deemed by [CONTACT_109855].
xSurvival follo w-up information will be collected via telephone calls, patient medical records, and/or clinic visits every [ADDRESS_121869].  All patients will be perio dically contact[CONTACT_109856] -cancer therapy information unless the patient requests to be withdrawn from follow -up (this request must be documented in the source 
documents and signed by [CONTACT_093]).  If the patient withdraws from the s tudy, study staff may use a public information source (e.g., county 
records when permissible, to obtain information about survival status only. 
yFor Argentina sites only: A urine pregnanc y test is required monthly until [ADDRESS_121870] dose of study treatment.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
171/Protocol GO29437 , Version 7Appendix 2
Schedule of Pharmacokinetic, Pharmacody namic, Biomarker, 
and A nti-Therapeutic A ntibody  Assessments
Study Visit TimeArm A 
(Atezolizumab 
Carboplatin 
Paclitaxel)Arm B
(Atezolizumab 
Carboplatin 
nab-Paclitaxel)Arm C
(Carboplatin 
nab-Paclitaxel)
Screening N/A BiomarkersbBiomarkersbBiomarkersb
Cycle 1, Day 1ePredose 
(same day as 
treatment 
administration) Atezolizumab ATA
Atezolizumab 
pharmacokinetics
Carboplatin 
pharmacokineticsa
Paclitaxel 
pharmacokineticsa
BiomarkersdAtezolizumab ATA
Atezolizumab 
pharmacokinetics
Carboplatin 
pharmacokineticsa
nab-Paclitaxel 
pharmacokineticsa
BiomarkersdCarboplatin 
pharmacokinetics a
nab-Paclitaxel 
pharmacokineticsa
Biomarkersd
30 min ( 10 min) 
after end of 
atezolizumab 
infusionAtezolizumab 
pharmacokineticsAtezolizumab 
pharmacokinetics
510 min before the 
end of paclitaxel 
infusionaPaclitaxel 
pharmacokineticsa
1 hour after the end 
of paclitaxel 
infusionaPaclitaxel 
pharmacokineticsa
510 min before the 
end of nab -paclitaxel 
infusion anab-Paclitaxel 
pharmacokineticsanab-Paclitaxel 
pharmacokineticsa
1 hour after the end 
of nab -paclitaxel 
infusionanab-Paclitaxel 
pharmacokineticsanab-Paclitaxel 
pharmacokineticsa
510min before the 
end of carboplatin 
infusionaCarboplatin 
pharmacokineticsaCarboplatin 
pharmacokineticsaCarboplatin 
pharmacokineticsa
1 hour after the end 
of carboplatin 
infusionaCarboplatin 
pharmacokineticsaCarboplatin 
pharmacokineticsaCarboplatin 
pharmacokineticsa
Cycle 2, Day 1 
(3days)Predose 
(same day as 
treatment 
administration)Atezolizumab ATA
Atezolizumab 
pharmacokinetics
BiomarkersdAtezolizumab ATA
Atezolizumab 
pharmacokinetics
BiomarkersdBiomarkersd
Appendix 2
Schedule of Pharmacokinetic, Pharmacody namic, Biomarker, 
and A TA Assessments (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
172/Protocol GO29437 , Version 7Study Visit TimeArm A 
(Atezolizumab 
Carboplatin 
Paclitaxel)Arm B
(Atezolizumab 
Carboplatin 
nab-Paclitaxel)Arm C
(Carboplatin 
nab-Paclitaxel)
Cycle 3, Day 1 
(3 days)Predose 
(same day as 
treatment 
administration)Atezolizumab ATA
Atezolizumab 
pharmacokinetics
Carboplatin 
pharmacokineticsa
Paclitaxel 
pharmacokineticsa
BiomarkersdAtezolizumab ATA
Atezolizumab 
pharmacokinetics
Carboplatin 
pharmacokineticsa
nab-Paclitaxel 
pharmacokineticsa
BiomarkersdBiomarkersd
Carboplatin 
pharmacokineticsa
nab-Paclitaxel 
pharmacokineticsa
Biomarkersd
30 min ( 10 min) 
after end of 
atezolizumab 
infusionAtezolizumab 
pharmacokineticsAtezolizumab 
pharmacokinetics
510 min before the 
end of paclitaxel 
infusion aPaclitaxel 
pharmacokineticsa
1 hour after the end 
of paclitaxel infusionaPaclitaxel 
pharmacokineticsa
510 min before the 
end of nab -paclitaxel 
infusion anab-Paclitaxel 
pharmacokineticsanab-Paclitaxel 
pharmacokineticsa
1 hour after the end 
of nab -paclitaxel 
infusion anab-Paclitaxel 
pharmacokineticsanab-Paclitaxel 
pharmacokineticsa
510 min before the 
end of carboplatin 
infusion aCarboplatin 
pharmacokineticsaCarboplatin 
pharmacokineticsaCarboplatin 
pharmacokineticsa
1 hour after the end 
of carboplatin 
infusionaCarboplatin 
pharmacokineticsaCarboplatin 
pharmacokineticsaCarboplatin 
pharmacokineticsa
Cycles 4, 8, 
and 16, Day 1 
(3days)Predose 
(same day as 
treatment 
administration)Atezolizumab ATA
Atezolizumab 
pharmacokinetics
BiomarkersdAtezolizumab ATA
Atezolizumab 
pharmacokinetics
BiomarkersdBiomarkersd
After Cycle 16, 
every eighth 
cycle, Day 1 
(3days)Predose 
(same day as 
treatment 
administration)Atezolizumab ATA
Atezolizumab 
pharmacokinetics
BiomarkersdAtezolizumab ATA
Atezolizumab 
pharmacokinetics
BiomarkersdBiomarkersd
Appendix 2
Schedule of Pharmacokinetic, Pharmacody namic, Biomarker, 
and A TA Assessments (cont.)
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
173/Protocol GO29437 , Version 7Study Visit TimeArm A 
(Atezolizumab 
Carboplatin 
Paclitaxel)Arm B
(Atezolizumab 
Carboplatin 
nab-Paclitaxel)Arm C
(Carboplatin 
nab-Paclitaxel)
At time of fresh 
biopsy 
(on-treatment, 
or at 
progression, 
including during 
follow -up)At visit BiomarkersdBiomarkersdBiomarkersd
Treatment 
discontinuation 
visitAt visit Atezolizumab ATA
Atezolizumab 
pharmacokinetics
BiomarkersdAtezolizumab ATA
Atezolizumab 
pharmacokinetics
BiomarkersdBiomarkersd
120[ADDRESS_121871] dose 
of atezolizumabAt visit Atezolizumab ATA
Atezolizumab 
pharmacokinetics
BiomarkersdAtezolizumab ATA
Atezolizumab 
pharmacokinetics
Biomarkersd
Any time point 
during study 
(RCR consent 
required)Optional RCR 
blood (DNA 
extraction)cOptional RCR blood 
(DNA extraction) cOptional RCR blood 
(DNA extraction )c
ATAanti-therapeutic antibody; PKpharmacokinetic; RCR [COMPANY_002] Clinical Repository .
Note:  Serum PK samples for atezolizumab and plasma PK samples for carboplatin, paclitaxel, 
and nab -paclitaxel.
aTwenty patients in each treatment arm will undergo the additional PK assessments for 
carboplatin, paclitaxel, and nab -paclitaxel, where applicable.
bWhole blood for biomarkers.
cThe optional RCR blood sample (for DNA extraction) requires an additional informed consent 
and can be collected at any time during the course of the study.
dPlasma and serum for biomarkers.
eBiom arker sampling before Cycle 1, Day [ADDRESS_121872] dose of steroids.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
174/Protocol GO29437 , Version 7Appendix 3
American Joint Committee on Cancer 
Non Small Cell Lung Cancer Staging, 7th Edition

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
175/Protocol GO29437 , Version 7Appendix 3
American Joint Committee on Cancer 
Non Small Cell Lung Cancer Staging, 7th Edition (cont.)
Reference:  Lung. In: Edge S, By[CONTACT_3238], Compton CC, et al., editors. AJCC cancer staging 
Manual, Seventh Edition. Chicago: Springer, 2010:267 –70.

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
176/Protocol GO29437 , Version 7Appendix 4
Response Evaluation Criteria in Solid Tumors: 
Modified Excerpt from Original Publication
Selected sections from the Response Evaluation Criteria in Solid Tumors (R ECIST), 
Version 1.11are presented below, with slight modifications and the addition of 
explanatory text as needed for clarity.2
MEA SURA BILITY OF TUM OR AT BASELINE
DEFINITIONS
At baseline, tumor lesions/lymph nodes will be categorized measurable or 
non-measurable as follows.
a.Measurable Tumor Lesions
Tumor Lesions.   Tumor lesions must be accurately measured in at least one dimension 
(longest diameter in the plane of measurement is to be recorded) with a minimum size of:
[ADDRESS_121873] or MRI scan (CT/MRI scan slice thickness/interval no greater 
than 5mm)
10-mm caliper measurement by [CONTACT_12148] (lesions that cannot be 
accurately measured with calipers should be recorded as non- measurable)
[ADDRESS_121874] be 15 mm in the short axis when assessed by [CONTACT_70182] (CT scan 
slice thickness recommended to be no greater than 5 mm).  At baseline and in follow -up, 
only the short axis will be measured and f ollowed.  See also notes below on “Baseline 
Documentation of Target and Non -Target Lesions” for information on lymph node 
measurement.
b.Non- Measurable Tumor Lesions
Non-measurable tumor lesions encompass small lesions (longest diameter 10 mm or 
pathological lymph nodes with 10 to 15 mm short axis), as well as truly 
non-measurable lesions.  Lesions considered truly non -measurable include  
leptomeningeal disease, ascites, pleural or pericardial effusion, inflammatory breast 
disease, lymphangitic involvement of skin or lung, peritoneal spread, and abdominal 
masses/abdominal organomegaly identified by [CONTACT_33486].
                                           
1Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: 
Revised RECIST guideline (Version 1.1). Eur J Cancer 2009; 45:22847.
2For consistenc ywithin this document, the section numbers and cross -references to other 
sections within the article have been deleted and minor formatting changes have been made.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
177/Protocol GO29437 , Version 7Appendix 4
Response Evaluation Criteria in Solid Tumors: 
Modified Excerpt from Original Publication (cont.)
c.Special Considerations Regarding Lesion Measurability
Bone lesions, cystic lesions, and lesions previously treated with local therapy require 
particular comment, as outlined below.
Bone lesions:
Bone scan, positr on emission tomography (PET) scan, or plain films are not 
considered adequate imaging techniques to measure bone lesions.  However, these 
techniques can be used to confirm the presence or disappearance of bone lesions.
Lytic bone lesions or mixed lytic -blastic lesions, with identifiable soft tissue 
components , that can be evaluated by [CONTACT_12783] -sectional imaging techniques such 
asCTor MRI can be considered measurable lesions if the soft tissue component 
meets the definition of measurability described above.
Blastic bone lesions are non- measurable.
Cystic lesions:
Lesions that meet the criteria for radiographically defined simple cysts should not be 
considered malignant lesions (neither measurable nor non- measurable) since they 
are, by [CONTACT_108], simple cysts .
Cystic lesions thought to represent cystic metastases can be considered 
measurable lesions if they meet the definition of measurability described above.  
However, if non -cystic lesions are present in the same patient, these are preferred 
for selection as target lesions.
Lesions with prior local treatment:
Tumor lesions situated in a previously irradiated area or in an area subjected to 
other loco -regional therapy are usually not considered measurable unless there has 
been demonstrated progression in the lesion.  Study protocols should detail the 
conditions under which such lesions would be considered measurable.
TARGET LESIONS:  SPE CIFICA TIONS BY [CONTACT_109857]
a.Measurement of Lesions
All measurements should be recorded in metric notation, using calipers if clinically 
assessed.  All baseline evaluations should be performed as close as possible to the 
treatment start and never more than 4 weeks before the beginning of the treatment.
b.Method of Assessment
The same method of assessment and the same technique should be used to 
characterize each identified and reported lesion at baseline and during study.  
Imaging -based evaluation should always be the preferred option.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
178/Protocol GO29437 , Version 7Appendix 4
Response Evaluation Criteria in Solid Tumors: 
Modified Excerpt f rom Original Publication (cont.)
Clinical Lesions.   Clinical lesions will be considered measurable only when they are 
superficial and 10 mm in diameter as assessed using calipers (e.g., skin nodules).
Chest X -Ray.   Chest CT is preferred over chest X -ray, particularly when progression is 
an important endpoint, since CT is more sensitive than X -ray, particularly in identifying 
new lesions.  However, lesions on chest X -ray may be considered measurable if they 
are clearly defined and surrounded by [CONTACT_109858].
CT, MRI.   CT is the best currently available and reproducible method to measure lesions 
selected for response assessment.  This guideline has defined measurability of lesions 
on CT scan on the basis of the assumption that CT slice thickness is [ADDRESS_121875] scans with 
intravenous (IV) contrast because of allergy or renal insufficiency, the decision as to 
whether a non- contrast CT or MRI (without IV contrast) will be used to evaluate the 
patient at baseline and during the study should be guided by [CONTACT_33488].  For patients who develop 
contraindications to contrast after baseline contrast CT is done, the decision as to 
whether non- contrast CT or MRI (enhanced or non -enhanced) will be performed should 
also be based on the tumor type and the anatomic location of the disease and should be 
optimized to allow for comparison with the prior studies if possible.  Each case should be 
discussed with the radiologist to determine if substitution of these other approaches is 
poss ible and, if not, the patient should be considered not evaluable from that point 
forward.  Care must be taken in measurement of target lesions on a different modality 
and interpretation of non -target disease or new lesions since the same lesion may 
appear to have a different size using a new modality.
Ultrasound.   Ultrasound is not useful in assessment of lesion size and should not be 
used as a method of measurement.
Endoscopy , Laparoscopy , Tumor Markers, Cy tology , Histology .  The utilization of 
these techn iques for objective tumor evaluation cannot generally be advised.
TUMOR RESPONSE EVA LUATION
ASSESSMENT OF OVERA LL TUMOR BURDEN A ND 
MEA SURA BLE DISEA SE
To assess objective response or future progression, it is necessary to estimate the 
overall tumor burden at baseline and to use this as a comparator for subsequent 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
179/Protocol GO29437 , Version 7Appendix 4
Response Evaluation Criteria in Solid Tumors: 
Modified Excerpt from Original Publication (cont.)
measurements.  Measurable disease is defined by [CONTACT_109859] e lesion, as detailed above.
BASELINE DOCUMENTA TION OF TA RGET A ND NON -TARGET LESIONS
When more than one measurable lesion is present at baseline, all lesions up to a 
maximum of five lesions total (and a maximum of two lesions per organ) representative 
of all involved organs should be identified as target lesions and will berecorded and 
measured at baseline.  This means in instances where patients have only one or two 
organ sites involved, a maximum of two lesions (one site) and fourlesions (two sites), 
respectively, will be recorded.  Other lesions (albeit measurable) in those organs will be 
recorded as non-target lesions (even if the size is 10mm by [CONTACT_3610]).
Target lesions should be selected on the basis of their size (lesions with the longest 
diamete r) and be representative of all involved organs but, additionally, should lend 
themselves to reproducible repeated measurements .  It may be the case that, on 
occasion, the largest lesion does not lend itself to reproducible measurement, in which 
circumstan ce the next largest lesion that can be measured reproducibly should be 
selected.
Lymph nodes merit special mention since they are normal anatomical structures that 
may be visible by [CONTACT_33490].  As noted above, pathological 
nodes that are defined as measurable and may be identified as target lesions must meet 
the criterion of a short axis of [ADDRESS_121876] in which the image is obtained (for CT scan, this 
is almost always the axial plane; for MRI the plane of acquisitio n may be axial, sagittal, 
or coronal).  The smaller of these measures is the short axis.  For example, an 
abdominal node that is reported as being 20 mm30 mm has a short axis of 20 mm and 
qualifies as a malignant, measurable node.  In this example, 20 m m should be recorded 
as the node measurement.  All other pathological nodes (those with short axis 10 mm 
but 15mm) should be considered non- target lesions.  Nodes that have a short axis 
10 mm are considered non -pathological and should not be recorded or followed.
Lesions irradiated within 3 weeks prior to Cycle 1 Day 1 may not be counted as target 
lesions.
A sum of the diameters (longest for non -nodal lesions, short axis for nodal lesions) for all 
target lesions will be calculated and reported as the baseline sum of diameters.  If lymph 
nodes are to be included in the sum, then, as noted above, only the short axis is added 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
180/Protocol GO29437 , Version 7Appendix 4
Response Evaluation Criteria in Solid Tumors: 
Modified Excerpt from Original Publication (cont.)
into the sum.  The baseline sum of diameters will be used as a reference to further 
characterize any objective tumor regression in the measurable dimension of the disease.
All other lesions (or sites of disease), including pathological lymph nodes, should be 
identified as n on-target lesions and should also be recorded at baseline.  Measurements 
are not required and these lesions should be followed as “present,” “absent,” or in rare 
cases “unequivocal progression.”
In addition, it is possible to record multiple non- target les ions involving the same organ 
as a single item on the Case Report Form (CRF) (e.g., “multiple enlarged pelvic lymph 
nodes” or “multiple liver metastases”).
RESPONSE CRITERIA
a.Evaluation of Target Lesions
This section provides the definitions of the criteria used to determine objective tumor 
response for target lesions.
Complete response (CR):  disappearance of all target lesions
Any pathological lymph nodes (whether target or non -target) must have 
reduction in short axis to 10 mm.
Partial response (PR):  at least a 30% decrease in the sum of diameters of target 
lesions, taking as reference the baseline sum of diameters
Progressive disease (PD):  at least a 20% increase in the sum of diameters of target 
lesions, taking as reference the smallest sum o n study (nadir), including baseline
In addition to the relative increase of 20%, the sum must also demonstrate 
anabsolute increase of at least 5 mm.
The appearance of one or more new lesions is also considered progression.
Stable disease (SD):  neither su fficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as reference the smallest sum on study
b.Special Notes on the A ssessment of Target Lesions
Lymph Nodes.   Lymph nodes identified as target lesions should always have th eactual 
short axis measurement recorded (measured in the same anatomical plane as the 
baseline examination), even if the nodes regress to 10 mm on study.  This means that 
when lymph nodes are included as target lesions, the sum of lesions may not be zer o 
even if CR criteria are met since a normal lymph node is defined as having a short axis 
10mm.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
181/Protocol GO29437 , Version 7Appendix 4
Response Evaluation Criteria in Solid Tumors: 
Modified Excerpt from Original Publication (cont.)
Target Lesions That Become Too Small to Measure.   While on study, all lesions 
(nodal and non -nodal) recorded at baseline should have their actual measurements 
recorded at each subsequent evaluation, even when very small (e.g., 2 mm).  However, 
sometimes lesions or lymph nodes that are recorded a s target lesions at baseline 
become so faint on CT scan that the radiologist may not feel comfortable assigning an 
exact measure and may report them as being too small to measure.  W hen this occurs, it 
is important that a value be recorded on the CRF as fo llows:
If it is the opi[INVESTIGATOR_26191], 
themeasurement should be recorded as 0 mm.
If the lesion is believed to be present and is faintly seen but too small to measure, a 
default value of 5 mm should be assig ned and BML (below measurable limit) should 
be ticked.  (Note:  It is less likely that this rulewill be used for lymph nodes since 
they usually have a definable size when normal and are frequently surrounded by 
[CONTACT_12156]; however, ifa lymph node is believed to be 
present and is faintly seen but too small to measure, a default value of 5 mm should 
beassigned in this circumstance as well and BML should also be ticked.)
To reiterate, however, if the radiologist is able to provide a n actual measure, that should 
be recorded, even if it is below [ADDRESS_121877] diameter for the coalesced lesion.
c.Evaluation of Non -Target Lesions
This section provides the definitions of the criteria used to determine the tu mor response 
for the group of non -target lesions.  Although some non -target lesions may actually be 
measurable, they need not be measured and, instead, should be assessed only 
qualitatively at the timepoints specified in the protocol.
CR:  disappearance of all non -target lesions and (if applicable) normalization of 
tumor marker level)
All lymph nodes must be non- pathological in size ( 10 mm short axis).
Non-CR/Non -PD:  persistence of one or more non- target lesion(s) and/or (if 
applicable) maintenance of tu mor marker level above the normal limits
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
182/Protocol GO29437 , Version 7Appendix 4
Response Evaluation Criteria in Solid Tumors: 
Modified Excerpt from Original Publication (cont.)
PD:  unequivocal progression of existing non -target lesions
The appearance of one or more new lesions is also considered progression.
d.Special Notes on A ssessment of Progression of Non -Target Disease
When the Patient A lso Has Measurable Disease.   In this setting, to achieve 
unequivocal progression on the basis of the non -target disease, there must be an overall 
level of substantial worsening in non -target disease in a magnitude that, even in the 
presence of SD or PR in target disease, the overall tumor burden has increased 
sufficiently to merit discontinuation of therapy.  A modest increase in the size of one or 
more non -target lesions is usually not sufficient to qualify for unequivocal progression 
status.  The designation of overall progression solely on the basis of change in 
non-target disease in the face of SD or PR of target disease will therefore be extremely 
rare.
When the Patient Has Only  Non -Measurable Disease.   This circumstance arises in 
some Phase III studies when it is not a criterion of study entry to have measurable 
disease.  The same general concepts apply here as noted above; however, in th is 
instance, there is no measurable disease assessment to factor into the interpretation of 
an increase in non -measurable disease burden.  Because worsening in non -target 
disease cannot be easily quantified (by [CONTACT_108]:  if all lesions are truly non -measurable), 
auseful test that can be applied when assessing patients for unequivocal progression 
isto consider if the increase in overall disease burden based on the change in 
non-measurable disease is comparable in magnitude to the increase that would be 
required to declare PD for measurable disease; that is, an increase in tumor burden 
representing an additional 73% increase in volume (which is equivalent to a 
20% increase in diameter in a measurable lesion).  Examples include an increase in 
apleural eff usion from “trace” to “large” or an increase in lymphangitic disease from 
localized to widespread or may be described in protocols as “sufficient to require a 
change in therapy.”  If unequivocal progression is seen, the patient should be considered 
to have had overall PD at that point.  Although it would be ideal to have objective criteria 
toapply to non -measurable disease, the very nature of that disease makes it impossible 
todo so; therefore, the increase must be substantial.
e.New Lesions
The appearance of new malignant lesions denotes disease progression; therefore, some
comments on detection of new lesions are important.  There are no specific criteria for 
theidentification of new radiographic lesions; however, the finding of a new lesion 
should be unequivocal, that is, not attributable to differences in scanning technique, 
change in imaging modality, or findings thought to represent something other than tumor 
(for example, some “new” bone lesions may be simply healing or flare of preexisting 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
183/Protocol GO29437 , Version 7Append ix4
Response Evaluation Criteria in Solid Tumors: 
Modified Excerpt from Original Publication (cont.)
lesions).  This is particularly important when the patient’s baseline lesions show PR or 
CR.  For example, necrosis of a liver lesion may be reported on a CT scan report as a
“new” cystic lesion, which it is not.
A lesion identified during the study in an anatomical location that was not scanned at 
baseline is considered a new lesion and will indicate disease progression.
If a new lesion is equivocal, f or example because of its small size, continued therapy and 
follow -up evaluation will clarify if it represents truly new disease.  If repeat scans confirm 
there is definitely a new lesion, then progression should be declared using the date of 
the initial scan.
EVALUATION OF RESPON SE
a.Timepoint Response ( Overall Response)
It is assumed that at each protocol -specified timepoint, a response assessment occurs.  
Table [ADDRESS_121878] non- measurable (therefore non -target) disease only, Table 2 is to 
be used.
Table 1 Timepoint Response:  Patients with Target Lesions
(with o r without Non -Target Lesions)
Target Lesions Non-Target Lesions New Lesions Overall Response
CR CR No CR
CR Non-CR/non -PD No PR
CR Not evaluated No PR
PR Non-PD or not all 
evaluatedNo PR
SD Non-PD or not 
allevaluatedNo SD
Not all evaluated Non-PD No NE
PD Any Yes or no PD
Any PD Yes or no PD
Any Any Yes PD
CRcomplete response; NE not evaluable; PD progressive disease; 
PRpartial response; SD stable disease.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
184/Protocol GO29437 , Version 7Appendix 4
Response Evaluation Criteria in Solid Tumors: 
Modified Excerpt from Original Publication (cont.)
Table 2 Timepoint Response:  Patients with Non- Target 
Lesions Only
Non-Target Lesions New Lesions Overall Response
CR No CR
Non-CR/non -PD No Non-CR/non -PDa
Not all evaluated No NE
Unequivocal PD Yes or no PD
Any Yes PD
CRcomplete response; NE not evaluable; PD progressive disease.
a“Non -CR/non -PD” is preferred over “stable disease” for non -target 
disease since stable disease is increasingly used as an endpoint for 
assessment of efficacy  in some studies; thus, assigning “stable disease” 
when no lesions can be measured is not advised.
b.Missing A ssessments and Not -Evaluable Designation
When no imaging/measurement is done at all at a particular timepoint, the patient is not 
evaluable at that timepoint.  If only a subset of lesion measurements are made at an 
assessment, usually the case is also considered not evaluable at that timepoint, unless a 
convincing argument can be made that the contribution of the individual missing lesion(s) 
would no t change the assigned timepoint response.  This would be most likely to happen 
in the case of PD.  For example, if a patient had a baseline sum of [ADDRESS_121879] 
a sum of 80 mm; the patient will have achieved PD status, regardless of the contribution 
of the missing lesion.
If one or more target lesions were not assessed either because the scan was not done 
or the scan could not be assessed because of poor image quality or obstructed view, the 
response for target lesions should be “unable to assess” since the patient is not 
evaluable.  Similarly, if one or more non -target lesions are not assessed, the response 
for non -target lesions should be “unable to assess” except whe re there is clear 
progression.  Overall response would be “unable to assess” if either the target response 
or the non -target response is “unable to assess,” except where this is clear evidence of 
progression as this equates with the case being not evaluabl e at that timepoint.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
185/Protocol GO29437 , Version 7Appendix 4
Response Evaluation Criteria in Solid Tumors: 
Modified Excerpt from Original Publication (cont.)
Table [ADDRESS_121880] Overall Response
CR CR CR
CR PR SD, PD, or PRa
CR SD SD, provided minimum duration for SD 
was met; otherwise, PD
CR PD SD, provided minimum duration for SD 
was met; otherwise, PD
CR NE SD, provided minimum duration for SD 
was met; otherwise, NE
PR CR PR
PR PR PR
PR SD SD
PR PD SD, provided minimum duration for SD 
was met; otherwise, PD
PR NE SD, provided minimum duration for SD 
was met; otherwise, NE
NE NE NE
CRcomplete response; NE not evaluable; PD progressive disease; PR partial response; 
SDstable disease.
aIf a CR is truly met at the first timepoint, any disease seen at a subsequent timepoint, 
even disease meeting PR criteria relative to baseline, qualifies as PD at that point 
(since disease must have reappeared after CR).  Best response would depend on whether 
the minimum duration for SD was met.  However, sometimes CR may  be claimed when 
subsequent scans suggest small lesions were likely still present and in fact the patient had 
PR, not CR, at the first timepoint.  Under these circumstances, the original CR should be 
changed to PR and the best response is PR.
c.Special Notes on Response A ssessment
When nodal disease is included in the sum of target lesions and the nodes decrease to 
“normal” size ( 10 mm), they may still have a measurement reported on scans.  This 
measurement should be recorded even though the nodes are normal in order not to 
overstate progression should it be based on increase in size of the nodes.  As noted 
earlier , this means that patients with CR may not have a total sum of “zero” on the CRF.
Patients with a global deterioration of health status requiring discontinuation of treatment 
without objective evidence of disease progression at that time should be reported as 
“symptomatic deterioration.”  Every effort should be made to document objective 
progression even after discontinuation of treatment.  Symptomatic deterioration is not a 
descriptor of an objective response; it is a reason for stoppi[INVESTIGATOR_12003].
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
186/Protocol GO29437 , Version 7Appendix 4
Response Evaluation Criteria in Solid Tumors: 
Modified Excerpt from Original Publication (cont.)
The objective response status of such patients is to be determined by [CONTACT_77058]- target disease as shown in Tables 1 3.
For equivocal findings of progression (e.g., very small and uncertain new lesions; cystic 
changes or necrosis in existing lesions), treatment may continue until the next scheduled 
assessment.  If at the next sche duled assessment progression is confirmed, the date of 
progression should be the earlier date when progression was suspected.
If a patient undergoes an excisional biopsy or other appropriate approach (e.g., multiple 
passes with large core needle) of a new lesion or an existing solitary progressive lesion 
that following serial sectioning and pathological examination reveals no evidence of 
malignancy (e.g., inflammatory cells, fibrosis, etc.), then the new lesion or solitary 
progressive lesion will not consti tute disease progression.
In studies for which patients with advanced disease are eligible (i.e., primary disease still 
or partially present), the primary tumor should also be captured as a target or non -target 
lesion, as appropriate.  This is to avoid an incorrect assessment of CR if the primary 
tumor is still present but not evaluated as a target or non -target lesion.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
187/Protocol GO29437 , Version 7Appendix [ADDRESS_121881] been 
developed that account for the possible appearance of new lesions and allow 
radiological progression to be confirmed at a subsequent assessment.
Modified Response Evaluation Criteria in Solid Tumors (RECIST) is derived from 
RECIST, Version 1.1 (v1.1) conventions3and immune -related response criteria4(irRC).  
When not otherwise specified, RECIST v1.[ADDRESS_121882] v1.1:  Summary of Changes
RECIST v1.[ADDRESS_121883] instance of 20% 
increase in the sum of 
diam eters or unequivocal 
progression in non -target 
diseaseDetermined only on the basis 
of measurable disease
RECIST Response Evaluation Criteria in Solid Tumors.
A. DEFINITIONS OF MEA SURABLE/NON -MEA SURA BLE LESIONS
All measurable and non -measurable lesions should be assessed at Screening and at the 
protocol -specified tumor assessment timepoints.  Additional assessments may be 
performed, as clinically indicated for suspi[INVESTIGATOR_55519].  
                                           
3Eisenhauer et al. Eur J Cancer 2009;45: 228 47; Topalian et al. N E ngl J Med
2012;366:2443 54;and W olchok et al., Clin C an Res 2009;15:7412 20.
4Wolchok et al. Clin C an Res 2009;15:7412 20; Nishino et al. J Immunother Can 2014;2:17; 
Nishino et al. Clin Can Res 2013;19: 393643.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
188/Protocol GO29437 , Version 7Appendix 5
Modified Resp onse Evaluation Criteria in Solid Tumors (cont.)
A.[ADDRESS_121884] one dimension 
(longest diameter in the plane of measurement is to be recorded) with a minimum size 
as follows:
10 mm by [CONTACT_20420] (CT) or magnetic resonance imaging (MRI) scan 
(CT/MRI scan slice thickness/interval no greater than 5 mm)
10-mm caliper measurement by [CONTACT_12148] (lesions that cannot be 
accurately measured with calipers should be record ed as non- measurable)
Malignant Lymph Nodes.  To be considered pathologically enlarged and measurable, 
alymph node must be [ADDRESS_121885] scan (CT scan 
slice thickness recommended to be no greater than 5 mm).  At baseline a nd follow -up, 
only the short axis will be measured and followed.
A.2 NON- MEASURA BLE L ESIONS
Non-measurable tumor lesions encompass small lesions (longest diameter 10mmor 
pathological lymph nodes with short axis 10 but 15 mm), as well as truly 
non-measurable lesions.  Lesions considered truly non -measurable include 
leptomeningeal disease, ascites, pleural or pericardial effusion, inflammatory breast 
disease, lymphangitic involvement of skin or lung, peritoneal spread, and abdominal 
mass/abdominal or ganomegaly identified by [CONTACT_70187].
A.3 SPECIA L CONSIDERA TIONS REG ARDING LESION 
MEA SURA BILITY
Bone lesions, cystic lesions, and lesions previously treated with local therapy require 
particular comment, as outlined below.
Bone Lesions
Bone scan, positron emission tomography (PET) scan, or plain films are not considered 
adequate imaging techniques for measuring bone lesions.  However, these techniques 
can be used to confirm the presence or disappearance of bone lesions.
Lytic bone lesions or mixed lytic –blastic lesions, with identifiable soft tissue components, 
that can be evaluated by [CONTACT_12783] -sectional imaging techniques such as CT or MRI can be 
considered as measurable lesions if the soft tissue component meets the definition of 
measurability described above.
Blastic bone lesions are non -measurable.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
189/Protocol GO29437 , Version 7Appendix 5
Modified Response Evaluation Criteria in Solid Tumors (cont.)
Cystic Lesions
Lesions that meet the criteria for radiographically defined simple cysts should not be 
considered as malignant lesions (neither measurable nor non -measurable) since they 
are, by [CONTACT_108], simple cysts.
Cystic lesions thought to represent cystic metastases can be considered as measurable 
lesions, if they m eet the definition of measurability described above.  However, if 
non-cystic lesions are present in the same patient, these are preferred for selection as 
target lesions.
Lesions with Prior Local Treatment
Tumor lesions situated in a previously irradiated area or in an area subjected to other 
loco-regional therapy are usually not considered measurable unless there has been 
demonstrated progression in the lesion.  Study protocols should detail the conditions 
under which such lesions would be considered measu rable.
B. TUMOR RESPONSE EVA LUATION
B.1 DEFINITIONS OF T ARGET/NON -TARGET LESIONS
Target Lesions
When more than one measurable lesion is present at baseline, all lesions up to a 
maximum of five lesions total (and a maximum of two lesions per organ) representat ive 
of all involved organs should be identified as target lesions and will be recorded and 
measured at baseline.  This means that, for instances in which patients have only one 
ortwo organ sites involved, a maximum of two lesions (one site) and four lesions 
(two sites), respectively, will be recorded.  Other lesions (albeit measurable) in those 
organs will be recorded as non-target lesions (even if the size is 10mm by [CONTACT_3610]).
Target lesions should be selected on the basis of their size (lesions with t he longest 
diameter) and be representative of all involved organs, but in addition, should lend 
themselves to reproducible repeated measurements .  It may be the case that, on 
occasion, the largest lesion does not lend itself to reproducible measurement, in which 
circumstance, the next largest lesion that can be measured reproducibly should be 
selected.
Lymph nodes merit special mention since they are normal anatomical structures 
thatmay be visible by [CONTACT_33490].  As noted above, 
pathological nodes that are defined as measurable and may be identified as target 
lesions must meet the criterion of a short axis of [ADDRESS_121886] scan.  Only the short 
axis of these nodes will contribute to the baseline sum.  The short axis of the node is the 
diameter normally used by [CONTACT_48861] a node is involved by [CONTACT_70188].  
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
190/Protocol GO29437 , Version 7Appendix 5
Modified Response Evaluation Criteria in Solid Tumors (cont.)
Nodal size is normally reported as two dimensions in the plane in which the image is 
obtained (for CT, this is almost always the axial plane; for MRI, the plane of acquisition 
may be axial, sagittal, or coronal).  The smaller of these measures is the short axis.  For 
example, an abdominal node that is reported as being 20 mm30 mm has a shor t axis 
of 20mm and qualifies as a malignant, measurable node.  In this example, 20 mm 
should be recorded as the node measurement.  All other pathological nodes (those with 
short axis 10 mm but 15mm) should be considered non -target lesions.  Nodes tha t 
have a short axis of 10 mm are considered non- pathological and should not be 
recorded or followed.
Lesions irradiated within 3 weeks prior to Cycle 1, Day 1, may not be counted as target 
lesions.
Non- Target Lesions
All other lesions (or sites of diseas e), including pathological lymph nodes, should be 
identified as non -target lesions and should also be recorded at baseline.  Measurements 
are not required.
It is possible to record multiple non- target lesions involving the same organ as a single 
item on the Case Report Form (CRF) (e.g., “multiple enlarged pelvic lymph nodes” or 
“multiple liver metastases”).
After baseline, changes in non -target lesions will contribute only in the assessment 
ofcomplete response (i.e., a complete response is attained only with the complete 
disappearance of all tumor lesions, including non -target lesions) and will not be used 
toassess progressive disease.
New Lesions
During the study, all new lesions identified and recorded after baseline must be 
assessed at all tumor assessment timepoints.  New lesions will also be evaluated for 
measurability with use of the same criteria applied to prospective target lesions at 
basel ine per RECIST, (e.g., non lymph node lesions must be 10mm; see note for new 
lymph node lesions below).  Up to a maximum of five new lesions total (and a maximum 
of two lesions per organ), all with measurements at all timepoints, can be included in the 
tumor response evaluation.  New lesion types that would not qualify as target lesions per 
RECIST cannot be included in the tumor response evaluation.
New lesions that are not measurable at first appearance but meet measurability criteria 
at a subsequent tim epoint will be measured from that point on and contribute to the sum 
of longest diameters (SLD), if the maximum number of 5 measurable new lesions being 
followed has not been reached. 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
191/Protocol GO29437 , Version 7Appendix 5
Modified Response Evaluation Criteria in Solid Tumors (cont .)
B.2 CALCULA TION OF S UM OF THE DIA METERS
A sum of the diameters (longest for non -nodal lesions, short axis for nodal lesions) for all 
target lesions will be calculated as a measure of tumor burden.
The sum of the diameters is calculated at baseline and a t each tumor assessment for 
the purpose of classification of tumor responses.
Sum of the Diameters at Baseline :  The sum of the diameters for all target lesions 
identified at baseline prior to treatment on Day 1.
Sum of the Diameters at Tumor A ssessment :  For every on -study tumor assessment 
collected per protocol or as clinically indicated the sum of the diameters at tumor 
assessment will be calculated using tumor imaging scans.  All target lesions selected at 
baseline and up to five new measurable lesions (with a maximum of two new lesions per 
organ) that have emerged after baseline will contribute to the sum of the diameters at 
tumor assessment.  Hence, each net percentage change in tumor burden per 
assessment with use of modified RECIST accounts for the size and growth kinetics of 
both old and new lesions as they appear.
Note:  In the case of new lymph nodes, RECIST v1.1 criteria for measurability 
(equivalent to baseline target lesion selection) will be followed.  That is, if at first 
appearance the short axis of a new lymph node lesion 15 mm, it will be considered a 
measureable new lesion and will be tracked and included in the SLD.  Thereafter, the 
lymph node lesion will be measured at subsequent timepoints and measurements will be 
included in the SLD, even if the short axis diameter decreases to 15 mm 
(oreven 10mm).  However, if it subsequently decreases to 10 mm, and all other 
lesions are no longer detectable (or have also decreased to a short axis diameter of  10 
mm if lymph nodes), then a response assessment of CR may be assigned.
If at first appearance the short axis of a new lymph node is 10 mm and 15 mm, the 
lymph node will not be considered measurable but will still be considered a new lesion. It 
will not be included in the SLD unless it subsequently becomes measurable (short axis 
diameter 15 mm).
The appearance of new lymph nodes with diameter 10 mm should not be considered 
pathological and not considered a new lesion.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
192/Protocol GO29437 , Version 7Appendix 5
Modified Response Evaluation Criteria in Solid Tumors (cont.)
B.[ADDRESS_121887] measurable disease at baseline.
Complete Response (CR) :  Disappearance of all target and non -target lesions.  Lymph 
nodes that shrink to 10 mm short ax is are considered normal.
Partial Response (PR) :  At least a 30% decrease in the sum of the diameters of all 
target and all new measurable lesions, taking as reference the baseline sum of 
diameters, in the absence of CR.
Note: the appearance of new measura ble lesions is factored into the overall tumor 
burden, but does not automatically qualify as progressive disease until the sum of the 
diameters increases by 20% when compared with the sum of the diameters at nadir.
Stable Disease (SD) :  Neither sufficien t shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as reference the smallest sum of the diameters while 
on study.
Progressive Disease (PD) :  At least a 20% increase in the sum of diameters of all 
target and selected new measura ble lesions, taking as reference the smallest sum on 
study (nadir SLD; this includes the baseline sum if that is the smallest on study).  In 
addition to the relative increase of 20%, the sum must also demonstrate an absolute 
increase of at least [ADDRESS_121888] tumor response.
Missing A ssessments and Not Evaluable Designation
When no imaging/measurement is done at all at a particular timepoint, the patient is 
considered not evaluable (NE) at that timepoint.  If only a subset of lesion 
measurements are made at an assessment, usually the case is also considered NE at 
that timepoi nt, unless a convincing argument can be made that the contribution of the 
individual missing lesion(s) would not change the assigned timepoint response.  This 
would only happen in the case of PD.  For example, if a patient had a baseline sum of 
50mm with three measured lesions and at follow -up only two lesions were assessed but 
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
193/Protocol GO29437 , Version 7Appendix 5
Modified Response Evaluation Criteria in Solid Tumors (cont.)
those gave a sum of [ADDRESS_121889] Timepoint Response Definitions
% Change in Sum of the DiametersaNon-Target Lesion 
Response 
AssessmentOverall Modified RECIST 
Timepoint Response
100% from baselinebCR CR
100% from baselinebNon-CR or not all 
evaluatedPR
30% from  baseline Any PR
30% to 20% Any SD
Not all evaluated Any NE
20%from  nadir SLD Any PD
CRcomplete response; NEnot evaluable; PD progressive disease; PR partial 
response; RECIST Response Evaluation Criteria in Solid Tumors; SD stable disease; 
SLDsum of the longest diameter.
aPercent change in sum of the diameters (including measurable new lesions when 
present).
bWhen lymph nodes are included as target lesions, the % change in the s um of the 
diam eters may not be 100% even if complete response criteria are met, because a 
normal ly mph node is defined as having a short axis of  10 mm.  Any pathological 
lymph nodes (whether target or non -target) must have reduction in short axis to 10
mm in order to meet the definition of CR.
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
194/Protocol GO29437 , Version 7Appendix 6
AntiPD-L1 Immunohistochemistry
OVERVIEW
The Ventana antiPD-L1 (SP142) rabbit monoclonal primary antibody 
Immunohistochemistry (IHC) assay will be used to determine 
programmed death -ligand 1 (PD -L1) IHC status.  The anti PD-L1 (SP142) rabbit 
monoclonal antibody IHC assay is currently being developed by [CONTACT_70189] a companion diagnostic to atezolizumab.  For Study GO29437, the 
antiPD-L1 (SP142) IHC assay will be used for investigational purposes only.
The Ventana anti PD-L1 (SP142) rabbit monoclonal primary antibody is intended for 
laboratory use in the semi -quantitative immunohistochemical assessment of the PD -L1 
protein in formalin -fixed, paraffin -embedded non small cell lung carcinoma (NSCLC) 
tissue stained on a Ventana BenchMark ULTRA automated slide stainer.  It is indicated 
as an aid in the selection of patients with NSCLC with locally advanced or metastatic 
disease who might benefit from treatment with atezolizumab.
This assay is for investigational use only.  The performance characteristics of this 
product have not been established.
DEVICE DESCRIPTION
The Ventana antiPD-L1 (SP142) rabbit monoclonal primary antibody is a pre -dilute, 
ready -to-use antibody product optimized for use with the Ventana Medical Systems 
OptiView DAB IHC Detection Kit and the OptiView Amplification Kit on Ventana Medical 
Systems automated BenchMark ULTRA platforms.  One 5- mL dispenser of anti PD-L1 
(SP142) rabbit monoclonal primary antibody contains approximately 36 g of rabbit 
monoclonal antibody directed against the PD -L1 protein and contains sufficient reagent 
for 50 tests.  The reagents and the IHC procedure are optimized for use on the 
BenchMark U LTRA automated slide stainer, utilizing Ventana System Software (VSS). 
SCORING SYSTEM
PD-L1 staining with anti PD-L1 (SP142) rabbit monoclonal primary antibody in NSCLC 
can be observed in both tumor cells (TCs) and tumor -infiltrating immune cells (ICs).
Details of the criteria for PD -L1 diagnostic assessment are described in the IDI 
document.
Atezolizumab —F.Hoffmann- La [COMPANY_002] Ltd
195/Protocol GO29437 , Version 7Appendix 7
EORTC QLQ -C30

Atezolizumab —F.Hoffmann- La [COMPANY_002] Ltd
196/Protocol GO29437 , Version 7Appendix 7
EORTC QLQ -C30 (cont.)

Atezolizumab —F.Hoffmann- La [COMPANY_002] Ltd
197/Protocol GO29437 , Version 7Appendix 8
EORTC QLQ -LC13

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
199/Protocol GO29437 , Version 7Appendix 9
EQ-5D -3L(cont.)

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
200/Protocol GO29437 , Version 7Appendix 9
EQ-5D -3L(cont.)

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
201/Protocol GO29437 , Version 7Appendix 10
Eastern Cooperative Oncology  Group Performance Status Scale
Grade Description
0 Fully active, able to carry on all predisease performance without restriction
1 Restricted in physically  strenuous activity but ambulatory and able to carry 
out work of a light or sedentary nature; e.g., light housework or office work
2 Ambulator y and capable of all self -care but unable to carry out any work 
activities; up and about 50% of waking hours
3 Capable of only limited self -care, confined to a bed or chair 50% of 
waking hours
4 Completely disabled; cannot carry on any self -care; totally confined to 
bed or chair
5 Dead
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
202/Protocol GO29437 , Version 7Appendix 11
Anaphy laxis Precautions
EQUIPMENT NEEDED
Tourniquet
Oxygen
Epi[INVESTIGATOR_33414], intravenous, and/or endotracheal use in accordance 
with standard practice
Antihistamines
Corticosteroids
Intravenous infusion solutions, tubing, catheters, and tape
PROCEDURES
Inthe event of a suspected anaphylactic reaction during study drug infusion, 
thefollowing procedures should be performed:
Stop the study drug infusion.
Apply a tourniquet proximal to the injection site to slow systemic absorption of study 
drug.  Do not obs truct arterial flow in the limb.
Maintain an adequate airway.
Administer antihistamines, epi[INVESTIGATOR_238], or other medications as required by [CONTACT_27964].
Continue to observe the patient and document observations
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
203/Protocol GO29437 , Version 7Appendix 12
Preexisting A utoimmune Diseases
Patients should be carefully questioned regarding their history of acquired or congenital 
immune deficiencies or autoimmune disease.  Patients with any history of immune 
deficiencies or autoimmune disease listed in the table below are excluded from 
participating in the study.  Possible exceptions to this exclusion could be patients w ith a 
medical history of such entities as atopic disease or childhood arthralgias where the 
clinical suspi[INVESTIGATOR_33415].  Patients with a history of autoimmune -
related hypothyroidism on a stable dose of thyroid replacement hormone may b e eligible 
for this study.  In addition, transient autoimmune manifestations of an acute infectious 
disease that resolved upon treatment of the infectious agent are not excluded 
(e.g., acute Lyme arthritis).  Contact [CONTACT_109860].
Autoimmune Diseases andImmune Deficiencies
Acute disseminated
encephalomyelitis
Addison’s disease
Ankylosing spondylitis
Antiphospholipid antibody syndrome
Aplastic anemia
Autoimmune hemolytic anemia
Autoimmune hepatitis
Autoimmune hypoparathyroidism
Autoimmune hypophysitis
Autoimmune myocarditis
Autoimmune oophoritis
Autoimmune orchitis
Autoimmune thrombocytopenic 
purpura
Behcet’s disease
Bullous pemphigold
Chronic fatigue syndrome
Chronic inflammatory demyelinating 
polyneuropathy
Chung -Strauss syndrome
Crohn’s disease 
Derm atomyositis
Diabetes mellitus type 1Dysautonomia
Epi[INVESTIGATOR_33416]’s syndrome
Graves’ disease
Guillain -Barré syndrome
Hashimoto’s disease
IgA nephropathy
Inflammatory bowel disease
Interstitial cystitis
Kaw asaki’s disease
Lambert -Eaton myasthenia 
syndrome
Lupus erythematosus
Lyme disease -chronic
Meniere’s syndrome
Mooren’s ulcer
Morphea
Multiple sclerosis
Myasthenia gravis
Neuromyotonia
Opsoclonus myoclonus 
syndromeOptic neuritis
Ord’s thyroiditis
Pemphigus
Pernicious anemia
Polyarteritis nodusa
Polyarthritis
Polyglandular autoimmune 
syndrome
Primary biliary cirrhosis
Psoriasis
Reiter’s syndrome
Rheumatoid arthritis
Sarcoidosis
Scleroderma
Sjögren’s syndrome
Stiff-Person syndrome
Takayasu’s arteritis
Ulcerative colitis
Vitiligo
Vogt -Kovanagi -Harada 
disease
Wegener’s granulomatosis
Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
204/Protocol GO29437 , Version 7Appendix 13
Symptoms in Lung Cancer

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
205/Protocol GO29437 , Version 7Appendix 13
Symptoms in Lung Cancer (cont.)

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
206/Protocol GO29437 , Version 7Appendix 13
Symptoms in Lung Cancer (cont.)

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
207/Protocol GO29437 , Version 7Appendix 14
Patient Global Impression of Severit y

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
208/Protocol GO29437 , Version 7Appendix [ADDRESS_121890] the total number of 
induction chemotherapy cycles.  For example, if four cycles of induction ch emotherapy 
were planned, but no component of chemotherapy could be administered during 
Cycle 4, Cycle 5 counts as the fourth cycle of induction chemotherapy (as shown below). 
All chemotherapy components may be withheld for up to a maximum of [ADDRESS_121891] cycle, all chemotherapy should be 
permanently discontinued.
Within a 4 -cycle induction regimen, chemotherapy may be paused for a total of two 
consecutive or non -consecutive cycles before chem otherapy should be permanently 
discontinued.  W ithin a 6 -cycle induction regimen, chemotherapy may be paused for a

Atezolizumab —F. Hoffmann- La [COMPANY_002] Ltd
209/Protocol GO29437 , Version 7Appendix 15
Additional Guidance on Chemotherapy  Administration (cont.)
total of two consecutive or a total of three non- consecutive cycles before chemotherapy 
should be permanently discontinued.
The recommended time window for administration of all study treatment components 
within a cycle is [ADDRESS_121892] component of 
study treatment would be more than 3 days, the remaining components should be 
delayed until the next cycle and the chemotherapy induction cycle considered not done 
(Arm A), or carboplatin should be delayed un til Day 1 of the next cycle and 
nab-paclitaxel administered on Day 8 and/or Day 15 of the current cycle if there is no 
contraindication (Arms B and C).
If it is anticipated that a component of study treatment cannot be administered, it is 
recommended to delay all study treatment for up to [ADDRESS_121893] the site on how to open the appropriate visits and electronic Case Report Form 
(eCRF) so that the site can then record the interruption and reintroduction accordingly on 
the eCRF.